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Abstract 
Background: Early and effective treatment of inflammatory arthritis (IA) is essential 
to preserve patients’ functional ability and prevent joint damage. Recent strategies 
for optimising care have included implementing treatment-to-target management 
and utilising ultrasound to guide treatment decisions. The 2010 ACR/EULAR 
rheumatoid arthritis (RA) classification criteria were also recently developed with the 
aim of facilitating the study of early IA. 
Aims: To determine the phenotype, management and outcomes of patients with 
early IA, defined using the 2010 RA criteria, in clinical practice. Specific objectives 
were to risk stratify patients according to future disease severity, determine their 
response to treatment and assess the potential utility of ultrasound within a 
treatment-to-target strategy. 
Methods: An audit and a prospective longitudinal observational study were 
conducted in patients attending the Leeds Early Arthritis Clinic. Patients were 
classified as undifferentiated arthritis (UA) or RA according to the 2010 RA criteria 
at baseline. Logistic regression methods were used to identify baseline predictors of 
outcome and treatment response. 
Results: Ultrasound detectable synovitis at baseline was independently associated 
with a higher rate of methotrexate use, persistence of IA and development of new 
ultrasound erosions at one year in patients with UA and RA, as well as progression 
from UA to RA in the subset of patients with UA at baseline. A lack of concordance 
was observed between clinical and ultrasound-determined remission in RA patients 
receiving treatment-to-target management. In this sub-group, objective baseline 
measures of disease were predictive of imaging remission in comparison to the 
predominantly subjective parameters, which were predictive of clinical remission. 
Conclusions: This verifies the value of ultrasound as a prognostic tool in the risk 
stratification of patients with early IA, over and above the clinical application of the 
2010 RA criteria and clinical assessments. It supports future research in the use of 
ultrasound within a treatment-to-target strategy. 
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 : Introduction Chapter 1
Over the past decade the management of early inflammatory arthritis (IA), and 
consequently the prospects for patients, has advanced dramatically. Early, effective 
therapy with tight monitoring towards a pre-defined target (clinical remission or at 
least low disease activity) is now recognised to be of key importance in patients at 
risk of persistent disease/rheumatoid arthritis (RA) (Smolen et al., 2010; Singh et 
al., 2012; Singh et al., 2016; Smolen et al., 2016; Combe et al., 2017; Smolen et al., 
2017). With a range of conventional disease-modifying anti-rheumatic drugs 
(DMARDs) and biologic therapies now available, remission is a realistic target for 
treatment. This has led to a changing perception of RA from that of a frequently 
progressive and chronic disease towards a readily treatable and potentially even 
curable or preventable condition. However, none of these drugs are universally 
effective and some patients prove to have severe disease resistant to several of 
these therapies.  
 
The 2010 ACR/EULAR RA classification criteria are now available to aid the prompt 
diagnosis, management and study of patients with RA at an early stage in their 
disease (Aletaha, D. et al., 2010). Furthermore, ultrasound is becoming increasingly 
used in clinical practice, both as a tool to guide diagnosis and in directing treatment 
decisions in patients with IA (Colebatch et al., 2013; D'Agostino, M.A. et al., 2016).  
 
A literature review was undertaken to identify gaps in the existing research of 
patients with early IA, relevant to the management of patients in a contemporary 
clinical practice setting (Chapter 2). Pubmed was used to search for English 
language articles concerning four main areas of recent research in patients with 
early IA (including patients with undifferentiated arthritis, UA, and/or RA). These are 
displayed in Table 1, along with the selection criteria used to identify articles for 
review. References of the selected papers were also searched to identify additional, 
relevant articles. Literature searches were initially conducted in 2012 and were last 
updated in October 2016. Subsequently, a central hypothesis, aims and objectives 
for this research were devised (Chapter 3) and study methods were established 
(Chapter 4). Results, pertaining to the relevant objectives, and their implications for 
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future clinical practice and research, are presented and discussed in Chapters 5-9, 
and summarised in the final discussion (Chapter 10). 
 
 Literature searches conducted for review. Table 1.
Research Area Selection Criteria 
Section 
of 
Thesis 
Performance of the 2010 
ACR/EULAR RA 
classification criteria 
Cohort studies evaluating outcomes in 
patients with early IA, classified using the 
2010 ACR/EULAR RA criteria.  
Excluding historic cohorts in which 
anti-citrullinated peptide antibody (ACPA) 
testing (a factor with high weighting in the 
new criteria) was not available. 
2.1 
Risk stratification for 
future disease 
progression/severity 
Prospective, longitudinal studies conducted 
in patients with early IA. Studies were 
restricted to those in which patients were 
disease-modifying anti-rheumatic drug 
(DMARD)-naïve, enrolled after 1990 (since 
availability of modern day DMARDs 
including methotrexate) and investigating 
baseline clinical, laboratory or imaging 
characteristics widely available in clinical 
practice (i.e. excluding studies restricted to 
hand bone densitometry, magnetic 
resonance imaging [MRI] and experimental 
serological or synovial biomarkers).  
Due to the volume of literature available in 
patients with RA, studies exclusive to these 
patients which were restricted to univariable 
analyses were excluded. 
2.2 
Effectiveness of 
ultrasound for use as a 
clinical tool 
Articles reporting aspects of validity and/or 
the discriminative ability of ultrasound in 
detecting ultrasound pathology relevant to 
IA, i.e. synovitis, tendon abnormalities and 
bone erosions.  
2.3 
Efficacy of treatment 
strategies 
Observational and intervention studies in 
patients with early IA reporting patient 
outcomes according to specific treatment 
strategies. Due to the volume of literature 
available in patients with RA, studies 
exclusive to these patients were restricted to 
randomised controlled trials and other 
intervention studies with a strict treatment 
protocol, including treatments and treatment 
dosing schedules in frequent use in current 
daily practice. 
2.4 
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 : Literature Review Chapter 2
2.1 What is Inflammatory Arthritis and How is it Classified? 
Inflammatory arthritis is an arthropathy primarily caused by an inflammatory 
process, as distinct from arthritis caused by a degenerative process (for example 
with aging, repetitive use or trauma). Its hallmark, synovitis, manifests as joint pain, 
stiffness (particularly in the morning or after inactivity) and swelling. There are 
several causes of IA including infection, crystal deposition disease, and 
autoimmune or autoinflammatory diseases including RA, connective tissue 
diseases and spondyloarthropathies (including ankylosing spondylitis, psoriatic 
arthritis and reactive arthritis). This thesis focuses on RA and undifferentiated 
arthritis (UA, inflammatory arthritis not explained by any other specific disease 
category). 
 
2.1.1 Rheumatoid Arthritis 
Rheumatoid arthritis is characterised by persistent synovial inflammation, usually 
affecting multiple small joints in a symmetrical distribution. Persistent synovitis is 
associated with erosive joint damage (van der Heijde et al., 1995) and may lead to 
significant long-term disability (Yelin et al., 1987; Scott et al., 2000). It is a systemic 
autoimmune disorder that is associated with extra-articular complications, 
co-morbidity and excess mortality; primarily driven by increased cardiovascular 
disease due to atherosclerosis (Agca et al., 2016).  
 
2.1.1.1 Prevalence and Incidence 
Rheumatoid arthritis is the commonest cause of IA with a prevalence of 
approximately 1% (Symmons et al., 2002). Annual incidence rates across Northern 
Europe are estimated to be of the order of 20-40/100,000 (Söderlin et al., 2002; 
Savolainen et al., 2003; Pedersen et al., 2009; Humphreys et al., 2013). 
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2.1.1.2 Aetiology and Pathogenesis: Seropositive versus Seronegative 
disease 
The pathogenesis of RA is understood to be quite heterogeneous. In particular, 
serological status appears to differentiate patients into distinct disease subsets.  
 
Rheumatoid factor (RF) is an autoantibody detectable in the serum of 
approximately 60% of patients with RA (Miller et al., 2015; Ajeganova et al., 2016). 
It is directed against the constant fragment of immunoglobulin (Ig) G. Rheumatoid 
factor and IgG may combine to form immune complexes which may contribute to 
the disease process. However, its presence is not specific to RA, occurring in 
approximately 10% of healthy individuals and at higher frequencies in other 
autoimmune connective tissue diseases and chronic infections. Hence, 
investigations into the presence of other autoantibodies in RA have led to the 
development of new serological tests which include the detection of anti-cyclic 
citrullinated peptide antibodies (ACPAs). These are present in approximately 
two-thirds of patients with established RA (Nielen et al., 2004; Demoruelle et al., 
2013), but have a high specificity of around 95% (Nishimura et al., 2007) 
 
Genetic differences between seropositive and seronegative patients have been 
observed. The shared epitope alleles HLA-DRB1*01, DRB1*04, and DRB1*10 
(which code a for a sequence of five amino acids in HLA-DRβ1 chains) are 
associated with increased risk of ACPA-positive RA (Huizinga et al., 2005; van der 
Helm-van Mil et al., 2006; Ding et al., 2009), whereas association of DRB1*03 with 
ACPA-negative disease has been described (Irigoyen et al., 2005; Verpoort et al., 
2005). A further 31 genetic risk loci have been identified amongst seropositive 
patients (Stahl et al., 2010), whilst association of ACPA-negative RA with a single 
locus (IRF5) has been reported (Sigurdsson et al., 2007).  
 
Smoking is recognised as a risk factor in the aetiology of ACPA-positive RA but not 
in ACPA-negative disease, via interaction with the shared epitope region of 
HLA-DRβ1 chains (Klareskog et al., 2006; Too et al., 2012). It has been 
hypothesised that smoking contributes to the production of citrullinated antigens 
which bind with shared epitope (Hill et al., 2003), leading to the activation of T cells 
(Law et al., 2012) and subsequent generation of ACPAs by B cells.  
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Interesting histological and immunological differences have also been observed. In 
patients with established RA undergoing therapeutic arthroscopic lavage of an 
inflamed knee joint, synovial analysis demonstrated greater infiltration of 
lymphocytes in ACPA-positive (n=34) versus ACPA-negative (n=23) patients (van 
Oosterhout et al., 2008). There was also significantly less fibrosis and less 
hypertrophy of the synovial lining layer. Of note, this was a heterogeneous patient 
group; disease durations and previous treatments were variable, which included the 
prior use of tumour necrosis factor (TNF)-inhibitors in 17 patients. Significant clinical 
differences between ACPA groups were also apparent, with lower disease activity 
scores (DAS) and a high proportion of males being observed amongst the 
ACPA-negative group.  
 
Immunological differences have been implicated in early IA. In Birmingham, 
synovial fluid was aspirated from a knee or ankle joint in 36 patients with very early 
IA, with symptoms for less than three months (Raza et al., 2005b). A distinct 
cytokine profile, with elevated levels of T cell, stromal cell and macrophage related 
cytokines, was observed in eight patients who fulfilled 1987 ACR RA criteria over 
the following 18 months (seven of whom were RF and ACPA positive) in 
comparison to the remaining 28 patients who did not develop RA (only one of whom 
was ACPA positive), the majority of whom had resolving or persistent UA. In Leeds, 
a cross-sectional analysis of peripheral blood samples from 60 patients with early 
IA (with symptoms for less than one year, 25 of whom were fulfilling 1987 ACR RA 
criteria) identified differences in T cell populations, and levels of cytokines involved 
in T cell differentiation, between ACPA-positive and ACPA-negative individuals 
(Cuthbert et al., 2010). Patients with ACPA-positivity had lower concentrations of 
naїve and regulatory T cells and higher numbers of cytokine-activated T cells, in 
comparison to ACPA-negative patients in whom T cell profiles appeared similar to 
healthy controls. However, disease activity may have been a substantial 
confounder: C-reactive protein (CRP) level was associated with the concentration of 
cytokine-activated T cells and there was a trend towards higher CRP in patients 
with ACPA positive disease. Larger studies in well-defined patient cohorts are 
needed to further discern any pathological differences.  
 
Further evidence for a divergence in pathogenesis is provided by clinical data 
illustrating disparity of response to treatments including rituximab and possibly 
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methotrexate. Data from clinical trials and registries illustrate superior rates of 
response to rituximab (B-cell depleting therapy) in patients who are seropositive for 
RF and/or ACPA (Emery et al., 2006; Cohen et al., 2007; Isaacs et al., 2009; 
Strangfeld et al., 2009; Van Vollenhoven et al., 2009a; Mease et al., 2010; Sellam 
et al., 2010; Tak et al., 2011). Studies suggesting a divergence in the response to 
methotrexate are discussed further in section 2.4.2.4 (van Dongen et al., 2007; 
Wevers-de Boer, K. V. C. et al., 2012; Nam et al., 2014b). 
 
2.1.1.3 Classification Criteria for Rheumatoid Arthritis 
 1987 ACR RA Classification Criteria 
Until recently, the 1987 American College of Rheumatology (ACR) RA criteria were 
widely used in research to identify patients with RA (Arnett et al., 1988). They were 
originally developed to differentiate patients with established RA from other types of 
established arthritis. They stipulate a minimum duration of symptoms of six weeks 
and include consequences of chronic inflammation (rheumatoid nodules and 
radiographic changes) as two of the seven criteria. Meta-analyses have 
demonstrated they have poor sensitivity and specificity in identifying patients with 
early RA versus expert opinion (Banal et al., 2009).  
 
 2010 ACR/EULAR RA Classification Criteria 
The importance of early, aggressive treatment pushed the need for new 
classification criteria to facilitate the diagnosis, management and study of patients 
with early RA. The 2010 ACR/European League Against Rheumatism (EULAR) RA 
criteria were developed with the aim of classifying patients at risk of persistent IA. 
Data from patient cohorts and expert opinion was utilised to determine a set of 
criteria that would identify patients likely to require methotrexate as an indicator of 
persistence and severity (Aletaha, D. et al., 2010). To fulfil the criteria patients with 
at least one clinically swollen joint are required to score at least six points or 
demonstrate definite erosive disease, defined by the presence of typical 
radiographic erosion affecting at least three of the following joints: proximal 
interphalangeal (PIP), metacarpophalangeal (MCP), wrist or metatarsophalangeal 
(MTP) joints (van der Heijde et al., 2013).  
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 Performance of the 2010 ACR/EULAR RA Classification Criteria 
The new criteria have been retrospectively applied to early IA patient cohorts. 
Improved sensitivity of the 2010 ACR/EULAR criteria, in comparison to the 1987 
ACR criteria, has been demonstrated for various outcomes including the need for 
methotrexate, the need for DMARDs, expert opinion of RA, persistent IA and 
erosive disease (Table 2). However, specificity estimates indicate there is a risk of 
misclassification of a proportion of patients as RA under the criteria, highlighting the 
need for further study of prognostic factors in this patient group. Of note, the 
majority of studies were published prior to the formulation of the EULAR definition 
of erosive disease; hence, the 2010 criteria were most frequently applied 
considering a score of at least six points as the sole criterion for a definition of RA.
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 Cohort studies evaluating performance of the 2010 ACR/EULAR RA criteria.  Table 2.
Excludes historical cohorts in which ACPA testing (a factor with high weighting in the new criteria) was not available. 
Study 
Population 
 
Years of 
patient 
recruitment 
n Inclusion Criterion Study Design Outcomes 
2010  
Criteria 
1987 
Criteria R
e
fe
re
n
c
e
 
S
e
n
s
it
iv
it
y
(%
) 
S
p
e
c
if
ic
it
y
 
(%
) 
P
P
V
 
(%
) 
N
P
V
 
(%
) 
S
e
n
s
it
iv
it
y
 
(%
) 
S
p
e
c
if
ic
it
y
(%
) 
Leiden 
(Netherlands) 
1993-2009 2258  Symptoms <2 yrs 
 ‘Arthritis’ ≥1 joint 
Prospective 
(2010 criteria applied 
retrospectively) 
MTX use 1 yr;  
DMARD use 1 yr;  
Persistent arthritis (absence of 
sustained DMARD-free 
remission) 5 yrs 
88; 
79; 
77 
54; 
68; 
56 
- - 61; 
54;  
53 
74; 
87; 
75 
(v
a
n
 d
e
r 
L
in
d
e
n
 e
t 
a
l., 2
0
1
1
) 
Brittany 
(France, 
multicentre) 
1995-1997 270  Symptoms <1 yr 
 Clinical swelling 
with tenderness or 
reduced ROM 
Prospective 
(2010 criteria applied 
retrospectively) 
RA (expert opinion) 2 yrs with 
use of DMARD or steroid 
58 
 
86 71 
 
78 64 
 
80 (V
a
ra
c
h
e
 
e
t a
l., 
2
0
1
1
) 
Jyväskylä 
(Finland) 
 
1997-1999 221  ‘Recent onset’ 
(median symptoms 
6 mths) 
 ‘Synovitis’ 
 Excluded non-RA 
diagnoses 
Patient invite to 10 
year follow-up visit 
(2010 criteria applied 
retrospectively) 
Erosive disease at 10 years 87 
 
44 
 
68 
 
72 70 
 
 
47 (M
ä
k
in
e
n
 e
t 
a
l., 2
0
1
3
) 
France 
(multicentre) 
1998-2002 310  Symptoms <6mths 
 Swelling >4wks 
 ≥2 swollen joints 
 Excluded non-RA 
diagnoses 
Prospective  
(2010 criteria applied 
retrospectively) 
RA (expert opinion) at 6 yrs; 
Erosive (EULAR definition*) at 
2 yrs 
84*; 
100* 
71*; 
36* 
85*; 
11* 
70*; 
100
* 
78; 
100 
64; 
39 
(L
e
 L
o
ë
t e
t 
a
l., 2
0
1
5
) 
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Amsterdam 
(Netherlands) 
2000 
onwards 
455  Symptoms <2 yrs  
 DMARD-naïve 
Prospective 
(2010 criteria applied 
retrospectively) 
MTX use 1 yr;  
RA (expert opinion) at 1 yr;  
Erosive disease at 3 yrs 
85; 
90; 
91 
50; 
48; 
21 
86; 
79; 
22 
49; 
69; 
91 
- 
 
- (B
rits
e
m
m
e
r 
e
t a
l., 2
0
1
1
) 
Nagasaki 
(Japan) 
2001 
onwards 
166  UA** <6mths 
duration 
 Excluded 1987 
ACR RA and 
non-RA diagnoses 
Prospective 
(2010 criteria applied 
retrospectively) 
DMARD start over 1 yr; 
1987 ACR RA criteria at 1 yr 
62; 
61 
83; 
78 
83; 
76 
61; 
63 
- - (T
a
m
a
i e
t 
a
l., 2
0
1
4
) 
Seville (Spain) 2002-2006 201  Swelling ≥4 wks 
and ≤1 yr 
 ≥2 swollen joints 
 Excluded non-RA 
diagnoses 
Prospective 
(2010 criteria applied 
retrospectively) 
MTX use within 1 yr; 
DMARD start over 1 yr; 
RA (expert opinion) over 1 yr  
80; 
75; 
87 
62; 
73; 
73 
90; 
98; 
91 
43; 
14; 
64 
58; 
56; 
69; 
64; 
91; 
94 
(R
e
n
e
s
e
s
 
e
t a
l., 
2
0
1
2
) 
Amsterdam 
(Netherlands) 
2002-2010 301  Symptoms <1 yr 
 Clinical arthritis by 
expert opinion 
Prospective 
(2010 criteria applied 
retrospectively) 
1987 ACR RA criteria at 2 yrs 83 
 
76 
 
77 
 
91 - - (d
e
 H
a
ir 
e
t a
l., 
2
0
1
2
) 
SAVE 
(international, 
multicentre 
study) 
2004-2006 303  Symptoms ≤16 wks 
 ‘Arthritis’ ≤1 joint 
Prospective study,  
all patients receiving 
120mg 
methylprednisolone 
IM or placebo 
(2010 criteria applied 
retrospectively) 
DMARD start over 1 yr; 
RA (expert opinion) over 1 yr 
80; 
85 
63; 
64 
71; 
68 
73; 
82 
55; 
65 
76; 
80 
(B
ilia
v
s
k
a
 e
t 
a
l., 2
0
1
3
) 
REACH 
(Netherlands, 
multicentre) 
2004-2008 231†  Symptoms <1 yr 
 Clinical swelling or 
pain/reduced ROM 
in ≥2 joints with ≥2 
other factors†† 
Prospective 
(2010 criteria applied 
retrospectively) 
MTX use 1 yr;  
Persistent arthritis (synovitis 
present or DMARD use) 1 yr 
74; 
69  
 
66; 
72 
76; 
87 
 
63; 
46 
- - (A
lv
e
s
 e
t 
a
l., 2
0
1
1
) 
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Umea 
(Sweden) 
2004-2009 313  Symptoms <1 yr 
 Synovitis ≥1 joint 
(excluding DIPs, 
1
st
 CMCs and 1
st
 
MTPs) 
 Excluded non-RA 
diagnoses 
Retrospective  
(2010 criteria applied 
retrospectively) 
MTX use within 1 yr; 
RA (expert opinion) at 1 yr 
84; 
91 
54; 
65 
- - 68; 
72 
79; 
83 
(B
e
rg
lin
 a
n
d
 
D
a
h
lq
v
is
t, 
2
0
1
3
) 
Christchurch 
(New 
Zealand) 
2004-2010 79  Symptoms <1 yr 
 ≥1 swollen joint 
 Excluded non-RA 
diagnoses 
Prospective 
(2010 criteria applied 
retrospectively) 
DMARD use at 2 yrs; 
Erosive disease at 2 yrs 
79; 
88 
83; 
33 
98; 
31 
29; 
88 
- - (R
a
ja
 e
t 
a
l., 2
0
1
2
) 
Tokyo (Japan) 
 
2009-2010 82  Any symptom 
duration (mean 
18 wks) 
 Clinical swelling 
 Excluded non-RA 
diagnoses 
Retrospective 
(2010 criteria applied 
retrospectively) 
RA (expert opinion) over follow-
up (at least 3 mths follow-up) 
74 
 
71 
 
93 
 
36 47 
 
93 (K
a
n
e
k
o
 e
t 
a
l., 2
0
1
1
) 
Birmingham 
(UK)  
Not stated 205  Symptoms <3 mths  
 Clinical swelling 
 Excluded if later 
fulfilled non-RA 
diagnosis 
Prospective 
(2010 criteria applied 
retrospectively) 
MTX use 1.5 yrs;  
DMARD use 1.5 yrs 
68; 
62 
72; 
78 
57; 
75 
81; 
66 
42; 
38 
88; 
93 
(C
a
d
e
r e
t 
a
l., 2
0
1
1
) 
PPV: positive predictive value, NPV: negative predictive value, MTX: methotrexate, ROM: range of movement, SAVE: Stop arthritis very early, IM: intra-muscular, REACH: 
Rotterdam early arthritis cohort, DIP: distal interphalangeal joint, CMC: carpometacarpal joint. 
*Patients fulfilling the EULAR definition for erosive disease considered as fulfilling the criteria regardless of clinical score (typical radiographic erosion in ≥3 joints) (van der Heijde 
et al., 2013). 
**Includes 13 patients without clinical joint swelling and 2 patients with typical radiographic erosion. 
†Excludes patients from the REACH cohort whose data were used in phase 1 of development of the 2010 criteria. 
††Morning stiffness for more than 1 hour; unable to clench a fist in the morning; pain when shaking someone’s hand; pins and needles in the fingers; difficulties wearing rings or 
shoes; a family history of RA; unexplained fatigue for less than 1 year. 
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2.1.2 Undifferentiated Arthritis 
This term is used to categorise patients with IA in whom it is not possible to 
establish a specific diagnosis. Historically UA has been defined as IA not fulfilling 
1987 ACR RA criteria, or criteria for other rheumatic diseases. Outcomes within this 
patient group are wide-ranging, varying from self-limiting disease to erosive RA. 
Studies demonstrate 14-53% of patients with UA may progress to RA (defined by 
non-fulfilment and fulfilment of 1987 ACR criteria, respectively) over one to three 
years (Quinn et al., 2003; Caro-Oleas et al., 2008; van Der Helm-van Mil et al., 
2008; Salaffi et al., 2010; de Rooy et al., 2011; Tamai et al., 2014). Differences in 
the rate of progression across these studies may be, at least in part, due to 
differences in inclusion criteria.  
 
Differences between patients with UA defined by non-fulfilment of 1987 ACR RA 
criteria and UA defined by non-fulfilment of 2010 ACR/EULAR RA criteria have 
been demonstrated in the Leiden early IA cohort (Krabben et al., 2012). The latter 
UA group had milder disease characteristics at baseline and superior outcomes 
including a higher rate of sustained remission over 7 years; rates were 46% in 
patients with non-fulfilment of 2010 criteria (n=776) versus 34% in patients with 
non-fulfilment of 1987 criteria (n=1166) (HR [hazard ratio] 1.5, 95% confidence 
interval [CI] 1.2-1.7).  
 
Despite milder disease characteristics, UA defined by non-fulfilment of the 2010 
criteria is not a benign condition. In a UK study, 10% of such patients with very 
early disease (symptoms for less than three months) progressed to fulfil 2010 
ACR/EULAR RA criteria over 18 months (Cader et al., 2011). Of patients fulfilling 
neither 2010 ACR/EULAR criteria nor 1987 ACR RA criteria, 10% and 21% of 
patients progressed to fulfil the 2010 and 1987 criteria, respectively. In a Japanese 
cohort, a rate of progression to 1987 ACR RA of 32% was observed over one year, 
in a similarly defined UA group but with symptoms for up to six months (Tamai et 
al., 2014).  
 
The other studies displayed in Table 2 also indicate that there is a proportion of 
patients with UA, not fulfilling 2010 ACR/EULAR RA criteria, who are destined to 
require DMARDs (including methotrexate), develop persistent disease and receive 
a diagnosis of RA by their physician. The potential for these patients to benefit from 
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early intervention (discussed further in section 2.4.2) emphasises the need to 
identify these at risk patients early. 
 
2.2 Predicting Prognosis in Patients with Early Inflammatory 
Arthritis 
Summaries of the studies identified and reviewed are presented in Tables 3 to 7 
(see Table 1 for selection criteria). When available, results of multivariable analyses 
are presented preferentially (demonstrating independently predictive 
characteristics). The main findings are summarised with respect to the main 
outcomes assessed in section 2.2.2, below. 
 
The prognostic value of the majority of predictive factors identified seems plausible 
and results are largely consistent across studies. Differences in treatment regimens 
as well as other study methods may have contributed to some of the variation in 
results observed across studies. Generally, later cohorts are more likely to have 
included more aggressive treatment strategies, in line with the increasing 
awareness of the importance of such an approach in optimising patient outcomes. 
The strengths and limitations of study methods in respect to the areas of patient 
selection, outcomes assessed and statistical methods are discussed below.  
 
2.2.1 Populations 
The majority of studies selected patients from early arthritis clinics (EACs) in 
secondary or tertiary care settings. Implications of this include the potential for 
exclusion of patients with short, self-limiting episodes of IA. However, this is not the 
main population of interest and inclusion of such patients (for example post-viral 
illnesses) may introduce difficulty in the interpretation of results. Indeed, eligibility 
criteria for several studies include a minimum duration for symptoms.  
 
In the Norfolk Arthritis Register, in which patients with at least four weeks of 
symptoms were recruited from primary care, 73% of patients were referred to 
hospital over three years (Harrison and Symmons, 2000). However, since the time 
of this study there has been increasing awareness of the importance of early 
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diagnosis and several guidelines have been published emphasising the need for 
early referral (Luqmani et al., 2006; www.nice.org.uk, 2009). Therefore, restricting 
the population to secondary/tertiary care in more recent studies seems reasonable. 
 
 Prognosis in patients with UA, RA and non-RA (Table 3) 
It may be argued that to enable the application of results to all patients with early IA, 
it may be inappropriate to exclude specific diagnoses. Classification criteria 
(including 1987 ACR RA criteria) have been shown to have a low sensitivity and 
specificity in early IA cohorts (Banal et al., 2009) and it is plausible that an initial 
physician impression at presentation may be revised at a later date, perhaps with 
the exception of clearly identifiable cases of crystal arthropathy or culture-positive 
infective or reactive arthritis. However, it may be difficult to draw meaningful 
conclusions from studies which allow for inclusion of such a variable patient 
population.  
 
 Prognosis in patients with UA and RA (Table 4) 
Studies excluding non-RA diagnoses provide more consistency in patient selection. 
Hence, their results may be easier to interpret and more translatable into daily 
practice. Most studies included patients with swelling of at least two joints. These 
studies often reported that a substantial proportion of their patients fulfilled 1987 
ACR criteria for RA at baseline. This perhaps explains the poor outcomes observed 
in these studies (Bukhari et al., 2002). Therefore, results of a number of these 
studies may not be applicable to a proportion of patients with UA initially presenting 
with monoarthritis. 
 
 Prognosis in patients with UA (Table 5) 
Historically UA has been defined as IA not fulfilling 1987 ACR RA criteria or criteria 
for other rheumatic diseases. These studies therefore potentially include patients 
who would now be classifiable as RA according to the 2010 ACR/EULAR RA 
criteria. The definition of ‘arthritis’ also varied considerably across these studies, 
although joint swelling was a requisite for inclusion in the majority of studies. In 
2011, a multinational expert group (the 3E initiative) agreed a definition of UA of at 
least one swollen joint and no clear diagnosis after rheumatologic assessment 
(Machado et al., 2011). 
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 Prognosis in patients with RA (Tables 6 and 7) 
The majority of studies were conducted in patients fulfilling 1987 ACR RA criteria, 
either at or during follow-up. However, a small number of studies are available 
investigating prognostic factors in patients with RA defined according to a physician 
impression of RA (Contreras-Yanez et al., 2012; da Mota, L. et al., 2012; Ma et al., 
2012) or likely RA (Wevers-de Boer, K. V. C. et al., 2012). 
 
Variable definitions of UA and RA across these studies suggest the need for further 
investigation of the prognostic factors in patients with early IA in well-defined patient 
groups, relevant to contemporary clinical practice, i.e. in patients with UA or RA 
defined according to the 2010 ACR/EULAR RA criteria. 
 
2.2.2 Outcomes 
 Predicting persistence of disease or progression to RA, providing guidance 
for commencement of DMARD therapy  
Persistence of IA (defined by ongoing synovitis and/or concurrent treatment) and 
progression to RA have been shown to be associated with factors now included in 
the 2010 ACR/EULAR RA criteria (seropositivity for rheumatoid factor [RF] and/or 
ACPA, longer symptom duration, greater small joint involvement and higher levels 
of inflammatory markers such as CRP) (Tables 3 to 5). Additional poor prognostic 
factors include older age (Boire et al., 2005), female gender (Harrison et al., 1996; 
Quinn et al., 2003), initial symptoms in the upper limbs (de Rooy et al., 2011), 
presence of the shared epitope (de Rooy et al., 2011), poor physical function 
(greater Health Assessment Questionnaire [HAQ] score) (Quinn et al., 2003) and 
existing radiographic erosive damage (Boire et al., 2005). 
 
The need for DMARD therapy, or methotrexate therapy in particular (recommended 
as the optimal first-line therapy for patients with RA or those at risk of persistent 
disease (Combe et al., 2017; Smolen et al., 2017)), has been used as a proxy for 
disease which is likely to be persistent, such as in the development of the 2010 
ACR/EULAR RA criteria. Progression to RA has been largely defined using 1987 
ACR criteria. In clinical practice, knowledge of the predictors of persistence of 
disease may arguably be of greater value for the management of individual 
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patients, especially considering poor sensitivity of these criteria in early IA and the 
possibility that commencement of therapy may have prevented progression in a 
subset of patients in these cohorts.  
 
 Predicting severity or propensity of disease to cause radiographic damage 
and long-term disability, providing guidance as to whom may benefit from 
aggressive early treatment such as initial combination DMARD therapy or 
biologic therapy 
A selection of studies of patients with early IA have evaluated severity outcomes, 
identifying prognostic value of ACPA-positivity (Visser et al., 2002), RF-positivity 
(Bukhari et al., 2002; Funck-Brentano et al., 2013), age (Bukhari et al., 2002; 
Jansen et al., 2002), involvement of the hands (Jansen et al., 2002), symptom 
duration (Boire et al., 2005) and radiographic damage at baseline (Bukhari et al., 
2002). Outcomes employed varied from presence of radiographic erosions at 
follow-up (Bukhari et al., 2002), development of new radiographic erosions (Funck-
Brentano et al., 2013) or progression in radiographic scores (Visser et al., 2002), to 
combined outcomes of radiographic progression and/or significant disability 
(Jansen et al., 2002; Boire et al., 2005).  
 
Follow-up times varied from one to five years. It is conceivable that in studies with 
shorter follow-up, a number of potentially erosive patients may not yet have 
developed erosions visible on x-ray. Furthermore, it is plausible that the frequency 
of radiographic progression in early IA may be reduced in later studies due to the 
increased awareness of the need for early, aggressive treatment, and therefore 
large numbers of patients may be needed to provide significant power in later 
cohorts.  
 
Other severity outcomes studied in early RA include loss of bone mineral density 
(Deodhar et al., 2003; Boyesen et al., 2009; Hoff et al., 2009), specific aspects of 
functional ability (such as mobility, grip strength and self-care) (Evers et al., 1998), 
psychosocial outcomes (Smedstad et al., 1997), quality of life (Cohen et al., 2006; 
da Mota, L.M. et al., 2012) and work disability, including the continued ability to 
work (Albers et al., 1999; Verschueren et al., 2009) and work productivity (Puolakka 
et al., 2005). 
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 Predicting response to therapy, providing guidance for the choice of 
treatment  
Investigations of factors predictive of treatment response have largely been 
conducted in studies with protocolised treatment, in a selection of open-label 
(Verschueren et al., 2009; Bosello et al., 2011; Saevarsdottir et al., 2011; Wevers-
de Boer, K. V. C. et al., 2012; Gremese et al., 2013), single-blind (Wessels et al., 
2007; Heimans et al., 2013) and double-blind studies (Takeuchi et al., 2014). 
Baseline factors consistently identified as predictive of poor response are older age 
(Verschueren et al., 2009; Saevarsdottir et al., 2011; Heimans et al., 2013), female 
gender (Wessels et al., 2007; Bosello et al., 2011; Saevarsdottir et al., 2011; 
Wevers-de Boer, K. V. C. et al., 2012; Takeuchi et al., 2014), smoking (Wessels et 
al., 2007; Saevarsdottir et al., 2011), higher body mass index (BMI) (Wevers-de 
Boer, K. V. C. et al., 2012; Heimans et al., 2013), greater disease activity (Wessels 
et al., 2007; Saevarsdottir et al., 2011; Wevers-de Boer, K. V. C. et al., 2012), 
greater disability (Saevarsdottir et al., 2011; Wevers-de Boer, K. V. C. et al., 2012; 
Takeuchi et al., 2014) and longer symptom duration (Bosello et al., 2011; 
Saevarsdottir et al., 2011; Wevers-de Boer, K. V. C. et al., 2012; Gremese et al., 
2013). An early response to therapy is also associated with superior long-term 
response outcomes (Verschueren et al., 2009). 
 
The majority of studies were conducted in patients with RA (fulfilling 1987 ACR 
criteria). Evidence of the predictors of treatment response in early UA or RA fulfilling 
2010 criteria is more limited, with a small number of intervention studies available 
suggesting response to methotrexate may be more rapid in patients with 
seropositive disease (see section 2.4.2.4, below) (Wevers-de Boer, K. V. C. et al., 
2012).  
 
Various measures of response have been validated for use in clinical trials. The 
studies summarised here have largely assessed predictors of remission, or at least 
low disease activity. These outcomes are particularly pertinent to the management 
of patients with IA in modern-day clinical practice. Remission (or at least low 
disease activity) is now widely accepted as a realistic treatment goal and currently 
recommended as the ideal target for treatment in patients with RA or those at risk of 
persistent disease (Smolen et al., 2010; Smolen et al., 2016; Combe et al., 2017; 
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Smolen et al., 2017). However, remission may be defined by several composite 
measures, varying from definitions such as the 1981 ACR definition (Pinals et al., 
1981) which includes criteria not uniformly assessed in contemporary studies or 
clinical practice, such as tendon sheath swelling, to the more recently developed 
2011 ACR/EULAR Boolean remission criteria (Felson et al., 2011). Most of these 
composite measures include joint tenderness and/or patient-reported assessments 
which may be affected by chronic pain. Consequently, a higher level of pain may 
explain some of the poor response observed in females and patients with higher 
BMI (Verschueren et al., 2009; Saevarsdottir et al., 2011; Heimans et al., 2013). 
Implications of the choice of definition for remission as an outcome measure and as 
a target for treatment are discussed further in section 2.4.1.5.  
 
2.2.3 Statistical Methods 
Sample sizes and the number of candidate predictive factors considered varied 
across studies. Limited sample sizes and high numbers of relevant prognostic 
variables imply analyses may be underpowered to detect some independently 
predictive factors. Very few of the studies planned sample sizes on the basis of the 
number of variables to be included in statistical modelling for the prediction of 
outcome and the desired predictive power of such models (Reneses et al., 2009).  
 
Automated step-wise selection procedures have been commonly used, however 
this approach introduces error through multiple testing. It is also plausible that 
confounding factors, whilst modifying the predictive strength of any particular 
variable may not be significant independent predictors of outcome themselves, 
therefore being excluded from final models. Some studies made allowance for this, 
for example using goodness-of-fit testing after re-entry of excluded variables. 
Others have entered pre-determined variables considered to be significant 
confounders or potential predictors of outcome. 
 
The candidate variables included in statistical modelling also varied across studies. 
Knowledge of ACPA status or x-ray data, for example, was not available in all 
cohorts. Inclusion of factors with strong co-linearity (such as ACPA and shared 
epitope status) may also have led to missing potentially relevant factors. A large 
number considered only baseline variables, whilst others accounted for choice of 
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initial treatment, early response and disease activity or radiographic progression 
over follow-up. The foremost method is particularly pertinent to enable prediction of 
prognosis in patients at the onset of IA, in order to tailor therapy on an individual 
basis. It may be an appropriate means of assessing predictors of disease 
persistence or other outcomes in studies with uniform treatment protocols. 
However, for outcomes relating to disease activity, functional impairment and 
radiographic progression, adjustment for treatment in observational studies with 
inconsistent intervention strategies is essential in the interpretation of results, as 
efficacy of different regimens may vary substantially. Treatment is a likely 
confounder, being associated with baseline parameters such as disease activity as 
well as these disease outcomes.  
 
As pathogenic mechanisms in UA and RA are recognised to be heterogeneous, it is 
likely that some factors may influence disease course more strongly in certain 
patient groups. For example, differences between seropositive and seronegative 
disease mechanisms suggest factors, such as smoking, may have a different effect 
in these patient groups (previously discussed in section 2.1.1.2). However, only a 
selection of studies made allowance for this, fitting interaction terms within models 
or testing in serologically defined sub-groups (Wessels et al., 2007). 
 
The methods of fitting variables within models may be particularly relevant to some 
disease characteristics. For example, several studies enter symptom duration as a 
continuous variable, according to a linear trend, however its relationship  with 
outcomes such as DMARD-free remission may be non-linear (van Nies et al., 
2015). Sensitivity analyses, assessing the effect of categorisation of continuous 
variables, were conducted in a small number of studies.  
 
Studies also differed in their handling of missing data. The most common means of 
dealing with this has been exclusion of cases with missing baseline and/or follow-up 
data which may introduce bias if not missing at random. Some studies imputed 
missing data (for example using the last observation), with sensitivity analyses 
employed to test the effect of including or excluding such patients on results.
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 Longitudinal, prospective, inception cohort studies assessing prognostic factors in patients with UA, RA and non-RA.  Table 3.
Study 
Population 
Years 
patients 
recruited 
n 
Total 
number of 
patients 
seen by 
clinic/study 
group 
Inclusion 
Criterion 
Proportion 
of patients 
with RA 
(1987 
criteria) at 
baseline 
Treatment 
Protocol, if 
applicable 
Outcome 
Statistical Methods of Analysis and 
Predictive Factors with Statistical 
Significance 
(baseline variables unless otherwise 
stated, results of multivariable analyses 
are presented preferentially over 
univariable analyses where available) 
R
e
fe
re
n
c
e
 
Leiden 
(Netherlands) 
1993-1996 524  566  Symptoms <2 yrs 
 ‘Arthritis’ ≥1 joint 
 
30%  
(UA in 11%) 
- Persistent disease at 2 yrs 
(arthritis ≥1 joint and/or 
DMARDs/steroids within 
preceding 3 mths) in 40% 
 
Logistic continuation ratio model by 2-step 
process: backwards step-wise selection entering 
all clinical variables (retained if p≤0.10), followed 
by entry of laboratory and radiographic variables 
with retention if independently predictive. 
 Model included: symptom duration, 
EMS ≥1 hr, ‘arthritis’  ≥3 joint areas, 
bilateral MTP squeeze positive, RF-
positivity, ACPA-positivity, erosions. 
AUC 0.84 (SEM 0.02) 
(V
is
s
e
r e
t a
l., 2
0
0
2
) 
       In patients with persistent 
disease: persistent erosive 
disease at 2 yrs (modified 
Sharp erosion score ≥1 in 
hands/feet) in 60% 
Given persistence, logistic continuation 
regression model developed as above: 
 Model included variables as above. 
AUC 0.91 (SEM 0.02) 
Brittany 
(France, 
multicentre) 
1995-1997 270  Not reported  Symptoms <1 yr 
 Synovitis ≥1 joint 
(swelling and 
tenderness or 
decreased ROM) 
 
36%  
(SpA, ESSG 
criteria, in 
19%) 
- RA over follow-up (physician 
impression) in 52% 
 
(median follow-up 30 mths) 
Rate of RA in patients grouped according to joint 
involvement at baseline (Chi-square test): 
 45% in oligo/polyarthritis  
 61% in monoarthritis at presentation with 
patient-reported history of more extensive 
arthritis  
 0% in monoarthritis alone (p<0.001 for both 
comparisons to other groups) 
(B
in
a
rd
 e
t a
l., 
2
0
0
7
) 
Kuopio 
(Finland) 
2000 138  188  Any symptom 
duration 
 ≥1 swollen joint or 
imaging evidence 
of synovitis in the 
sacroiliac, 
shoulder or hip 
joints  
14% - Remission at 7-24 mths 
follow-up (5 of 1981 ACR 
remission criteria, excluding 
fatigue with/without 
treatment) in 25% of patients 
with RA at baseline and 58% 
of UA  
 
Multivariable logistic regression, entering 
pre-determined clinical and laboratory variables: 
 Older age (p=0.01) 
(S
a
v
o
la
in
e
n
 e
t 
a
l., 2
0
0
7
) 
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CHUS 
(Canada) 
Up to 2004 149  Not reported  Symptoms <1 yr 
 Synovitis ≥3 joints 
 
 
81% - Persistent disease at 30 
mths (synovitis ≥1 joint 
and/or current DMARD use, 
or ≥10 mg/day prednisone) 
in 84%  
Multivariable logistic regression, entering 
pre-determined clinical, laboratory and 
radiographic variables: 
 Symptom duration ≥4 mths (OR not given) 
 
(B
o
ire
 e
t a
l., 2
0
0
5
) 
       Severe disease at 30 mths 
(upper third of SHS or 
modified HAQ ≥1) in 38% 
Multivariable logistic regression, as above: 
 Age (OR 1.05, 95% CI 1.02-1.08) 
 SHS erosion score (OR 3.8, 95% CI 1.4-
10.1) 
NOR-VEAC 
(Norway, 
multicentre) 
2004-2006 287  384  Symptoms ≤16 
wks 
 ≥1 swollen joint 
 
Not reported - Persistent disease over 1 yr 
(≥1 swollen joint at ≥2/3 
follow-up assessments) in 
26% 
Multivariable logistic regression, entering 
variables with p<0.25 on univariable analysis: 
 ACPA-positivity (OR 4.5, 95% CI 2.2-9.3) 
 Small joint swelling (OR 2.1, 95% CI 
1.2-3.8) 
 HAQ score (OR 1.7, 95% CI 1.7-2.7) 
 CRP (OR 0.98, 95% CI 0.98-1.00) 
(M
ja
a
v
a
tte
n
 e
t a
l., 2
0
0
9
) 
       RA (physician diagnosis) at 
1 yr in 18% 
Multivariable logistic regression, as above: 
 ACPA-positivity (OR 19, 95% CI 6.8-54) 
 RF (OR 5.0, 95% CI 1.5-17) 
 Small joint swelling (OR 3.5, 95% CI 
1.2-9.9) 
 28TJC (OR 1.09, 95% CI 1.02-1.16) 
       DMARD-use over 1 yr in 
28% 
Multivariable logistic regression, as above: 
 ACPA-positivity (OR 8.1, 95% CI 3.6-19) 
 Small joint swelling (OR 3.9, 95% CI 
2.0-7.4) 
 HAQ score (OR 1.8, 95% CI 1.1-2.7) 
Leeds (UK) Not 
reported 
51 Not reported  Symptoms <1 yr 
 Oligoarthritis: 
synovitis (≥2 of:  
swelling, 
tenderness, 
decreased ROM) 
in 1-5 joints 
(excluding DIPs 
alone)  
Not reported Methylprednis-
olone IA in 
joints with 
synovitis +/- 
NSAIDs, 
sulfasalazine 
considered 
after 12 wks 
Persistent synovitis at 1 yr in 
49% 
Multivariable logistic regression, entering 
pre-determined clinical and laboratory variables: 
 Synovitis at 2 wks (OR 18, 95% CI 4-88) 
 RF-positivity (OR 12, 95% CI 2-115) 
 Symptom duration (wks) (OR 1.1, 95% CI 
1.03-1.21) 
(G
re
e
n
 e
t a
l., 2
0
0
1
) 
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Birmingham 
(UK) 
Not 
reported 
96 Not reported  Symptoms ≤12 
wks 
 Synovitis ≥1 joint 
Not reported - Persistent RA at 18 mths 
(1987 criteria and swelling 
≥1 joint and/or 
DMARDs/steroids within 
preceding 3 mths) in 20% 
Multivariable logistic regression, entering 
pre-determined clinical and laboratory variables: 
 Age (OR 1.08, 95% CI 1.01-1.2) 
 Symmetrical arthritis (OR 10, 95% CI 1-96) 
 ACPA and RF-positivity (OR 80, 95% CI 
8-850) 
(R
a
z
a
 e
t a
l., 
2
0
0
5
a
) 
58 Not reported As above, with US 
available 
21%  
(2010 
ACR/EULAR 
RA in 45%) 
- RA (1987 criteria) at 18 mths 
in 51% 
 
(Other outcomes persistent 
UA in 9%, other persistent 
IA in 14%, self-liming in 
28%)  
Multivariable logistic regression, entering clinical, 
laboratory and US (number of joints with GS/PD 
≥grade 1  and total GS/PD scores [sum of 
grades 0-3 at each joint] in all 38 jts [bilateral 
shoulders, elbows, wrists, MCP1-5, PIP1-5, 
knees, ankles, MTP2-5] and by jt region) 
variables with significance on univariable 
analysis and the Leiden prediction score (van 
der Helm-vanMil et al., 2007) (separate models 
constructed for each US variable): 
Global assessments: 
 Total GS score (AUC 0.96), total PD score 
(AUC 0.96), number of joints PD ≥grade 1 
(AUC 0.96) 
Reduced joint assessments/jt regions: 
 Total PD score in 12 jts (wrists, MCP2-3, 
knees and MTP2-3) (AUC 0.95), in 10 jts 
(wrists, MCP2-3., MTP2-3) (AUC 0.96) 
 Number jts GS ≥grade 1 hands (AUC 0.94), 
MCPs (AUC 0.94) 
 Number jts PD ≥grade 1 hands (AUC 0.94), 
MCPs (AUC 0.94). 
 Presence of GS ≥grade 2 wrists (AUC 0.94) 
 Presence of PD ≥grade 1 MTPs (AUC 0.93) 
 (all p<0.05, OR not given) 
(N.B AUC for model with no US variable 0.91) 
(F
ile
r e
t a
l., 2
0
1
1
) 
EMS: early morning stiffness, AUC: area under the receiver operating characteristic curve, SEM: standard error of the mean, SpA: spondyloarthropathy, ESSG: European 
Spondylarthropathy Study Group, CHUS: Centre hospitalier universitaire de Sherbrooke, OR: odds ratio, SHS: Sharp/van der Heijde score (total score unless otherwise 
specified), NOR-VEAC: Norwegian Very Early Arthritis Cohort, TJC: tender joint count, IA: intra-articular, GS: grey scale, PD: power Doppler activity, US: ultrasound. 
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 Longitudinal, prospective, inception cohort studies assessing prognostic factors in patients with UA and RA.  Table 4.
Study 
Population 
Years 
patients 
recruited 
n 
Total 
number of 
patients 
seen by 
clinic/study 
group 
Inclusion Criterion 
(excluding 
patients with non-
RA diagnoses) 
 
Proportion of 
patients with 
RA (1987 
criteria) at 
baseline 
Treatment 
Protocol, 
if 
applicable 
Outcome 
Statistical Methods of Analysis and Predictive 
Factors with Statistical Significance 
(baseline variables unless otherwise stated, 
results of multivariable analyses are presented 
preferentially over univariable analyses where 
available) 
R
e
fe
re
n
c
e
 
NOAR (UK) 1990-1994 312  992  Symptoms>4 wks 
and <1 yr 
 ≥2 swollen joints 
 RF available 
52% - DMARD/steroid-free 
remission (no 
swollen joints) at 
2 yrs in 25% 
Multivariable logistic regression model, developed with 
data from 60% randomly selected patients (n=199) using 
backwards step-wise selection (retention if p<0.20) 
entering baseline variables with a likelihood  ratio of ≥1.3 
on univariable analysis and DMARD/steroid use over 2 
yrs: 
 No DMARDs/steroids over 2 yrs (OR 8.7, 95%CI 3.6-
21), male gender (OR 3.9, 95%CI 1.7-8.7), TJC <6 
(OR 3.8, 95%CI 1.2-12) 
(H
a
rris
o
n
 e
t a
l., 
1
9
9
6
) 
 1990-not 
reported 
439 Not reported  Symptoms>4 wks 
and <1 yr 
 ≥2 swollen joints 
 X-rays available 
within 2 yrs of 
baseline (patients 
fulfilling  ≥2 of 1987 
ACR RA criteria) 
and at 5 yrs 
52% - Radiographic 
damage  at 5 yrs 
(Larsen score)  
 
(49% of patients 
with evidence of 
radiographic erosion 
at 5 yrs) 
Multivariable negative binomial regression, entering 
pre-determined clinical and laboratory variables (data 
complete for RF n=390, CRP n=340, shared epitope 
n=269: n with all variables complete not given): 
 RF titre (coefficient 2.7, 95% CI 1.8-4.7), CRP 
(coefficient 2.0, 95% CI 1.4-3.0), shared epitope both 
alleles positive (coefficient 2.5, 95% CI 1.3-4.7) 
With adjustment for Larsen score at first x-ray (within 2 yrs 
of baseline) only RF titre remained a significant predictor 
(coefficient not given). 
(B
u
k
h
a
ri e
t a
l., 2
0
0
2
) 
Leeds (UK) 1995-1997 63 Not reported  Symptoms<1 yr 
 Synovitis (≥2 of: 
swelling, 
tenderness, 
decreased ROM)≥2 
joints 
 ≥1 of: symptoms<3 
mths, asymmetric, 
symmetric MCPs 
involvement and 
prognostic score 
low* 
51% Single dose 
of steroid 
(methylpred-
nisolone 
≤140mg 
total IA or 
120 mg IM if 
SJC >5) 
DMARD/NSAID-free 
remission at 6 mths 
(absence of 
symptoms) in 22% 
Multivariable logistic regression, entering pre-determined 
clinical and laboratory variables: 
 Symptoms ≤12 wks (OR 4.9, 95%CI 1.3-17) 
 
(G
re
e
n
 e
t a
l., 1
9
9
9
) 
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Amsterdam 
(Netherlands) 
1995 
onwards 
545 1854  Symptoms <3 yrs 
 ‘Arthritis’ ≥2 joints 
Not reported at 
baseline (63% at 
1 yr) 
- Disease activity 
(DAS28), disability 
(HAQ) and 
radiographic 
damage (SHS) at 2 
yrs 
Analysis of ACPA and RF titres at baseline, and change in 
titres over 1 yr, using Spearman’s rank correlation: 
 Significant correlation with baseline RF and SHS only 
(after adjustment for baseline SHS); correlation 
coefficient 0.14 (p=0.002) 
(U
rs
u
m
 e
t 
a
l., 2
0
1
0
) 
STIVEA (UK, 
multicentre) 
2002-2006 253 572  Symptoms 4-11 
wks 
 ≥2 swollen joints 
(with ≥1 swollen 
wrist, MCP or PIP) 
Not reported Randomised 
to placebo 
or 80mg 
methylpred-
nisolone IM 
injections at 
week 0, 1 
and 2. 
DMARD/oral steroid 
use and/or 
SJC28≥3, TJC28≥6, 
EMS≥45min and 
ESR≥28mm/hr at 6 
months in 68% 
Univariable logistic regression of individual clinical and 
laboratory variables with adjustment for age, gender and 
treatment group: 
 DAS28-ESR3variables (OR 1.6, 95%CI 1.2-2.0) 
 Pain (VAS) (OR 1.02, 95%CI 1.01-1.03) 
 Fatigue (VAS) (OR 1.02, 95%CI 1.00-1.03) 
 Physician disease activity VAS (OR 1.02, 95%CI 
1.00-1.03) 
 RF-positivity (OR 4.3, 95%CI 2.1-8.7) 
 HAQ (OR 2.3, 95%CI 1.5-3.6) 
 SF-36 physical component (OR 0.93, 95%CI 0/89-
0.98) 
 EQ-5D (OR 0.1, 95%CI 0.1-0.4) 
(V
e
rs
ta
p
p
e
n
 e
t a
l., 2
0
1
1
) 
  222     RA (physician 
impression) at 1 yr in 
55% 
Logistic regression, as above: 
 DAS28-ESR3variables (OR 1.4, 95%CI 1.1-1.8) 
 Pain (VAS) (OR 1.01, 95%CI 1.00-1.03) 
 Fatigue (VAS) (OR 1.01, 95%CI 1.00-1.02) 
 Physician disease activity VAS (OR 1.02, 95%CI 
1.01-1.04) 
 RF-positivity (OR 10, 95%CI 4.8-22) 
 HAQ (OR 1.8, 95%CI 1.2-2.8) 
 EQ-5D (OR 0.3, 95%CI 0.1-0.8) 
 Current vs never smoker (n=148) (OR 3.4, 95% CI 
1.2-10) 
ESPOIR 
(France, 
multicentre) 
 
 
 
 
 
 
2002-2005 
 
 
 
 
 
 
 
 
731 813  Symptoms >6 wks 
and <6 mths 
 ≥2 swollen joints 
Not reported - RA over 1 yr (1987 
criteria and 
investigator’s VAS 
≥75/100 supporting 
diagnosis) in 51% 
Multivariable logistic regression, entering variables with 
p<0.20 on univariable analysis using a backwards step-
wise selection (retention if p<0.05). Separate models 
planned to include clinical variables only, clinical and 
radiographic variables only, or all clinical, laboratory and 
radiographic variables.  
 Greatest AUC (0.84) for model based on clinical, 
laboratory and radiographic variables. Included SJC, 
EMS, erosions, RF and ACPA 
(G
o
s
s
e
c
 e
t a
l., 
2
0
1
0
) 
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ESPOIR 
(contd.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2002-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
673 813 As above, with x-rays 
available  
72% - Radiographic 
progression 
(increase in SHS 
from baseline >1) at 
1 yr 
Multivariable logistic regression, entering variables with 
significance on univariable analysis using forwards step-
wise selection (inclusion if p<0.15): 
 ACPA-positivity (OR 4.1, 95% CI 2.6-6.5), SHS 
>median score (OR 2.4, 95% CI 1.6-3.7), 
HLA-DRB1-01 or 04 both alleles positive (OR 2.7, 
95% CI 1.3-5.6) or one allele positive (OR 1.7, 95% 
CI 1.0-2.7), ESR >median (OR 2.1, 95% CI 1.4-3.3) 
(M
o
u
te
rd
e
 e
t a
l., 
2
0
1
1
) 
573 
 
 
 
 
 
813 As above, with 5 yr 
data available 
75% 
(82% fulfilling 
2010 RA criteria 
at baseline, 93% 
fulfilling 2010 RA 
criteria over 
follow-up) 
- DMARD use within 5 
yrs in 90% 
Multivariable logistic regression, entering variables with 
p<0.15 on univariable analysis using forwards step-wise 
selection (inclusion if p<0.05) (continuous variables 
dichotomised by median): 
 Pain (VAS)>median (OR 2.2, 95% CI 1.4-3.5), 
fulfilling 2010 RA criteria (OR 2.5, 95% CI 1.6-4.0), 
ACPA-positivity (OR 4.9, 95% CI 2.5-9.6). 
(C
o
m
b
e
 e
t a
l., 2
0
1
3
) 
 Biologic use within 5 
yrs in 22% 
Multivariable logistic regression, as above: 
 Pain VAS>median (OR 2.2, 95% CI 1.4-3.3), 
TJC28>median (OR 2.3, 95% CI 1.5-3.6), ACPA-
positivity (OR 3.1, 95% CI 1.8-5.4), RF-positivity (OR 
1.9, 95% CI 1.1-3.4). 
 
 
Poor function 
(HAQ >median) at 5 
yrs 
Multivariable logistic regression, as above: 
 Age>median (OR 1.9, 95% CI 1.3-1.8), female (OR 
1.6, 95% CI 1.0-2.5), rest pain (VAS)>median (OR 
1.7, 95% CI 1.2-2.4), HAQ (OR 2.9, 95% CI 2.0-4.2). 
Radiographic 
progression 
(increase in SHS 
from baseline >1) at 
3 yrs 
Multivariable logistic regression, as above: 
 ACPA-positivity (OR 2.2, 95% CI 1.4-3.4), SHS 
erosion score (OR 2.3, 95% CI 1.4-3.8). 
661 813 As above, with x-rays 
available 
73% 
(79% fulfilling 
2010 RA criteria 
at baseline) 
- DMARD use within 6 
mths of onset of 
swelling in 47% 
Multiple logistic regression, entering pre-determined 
variables (age, gender, erosion, comorbidity, symmetric 
arthritis, involvement of hands and others below) to 
develop propensity score. Final score included: 
 DAS28, CRP, involvement of >3 jt groups, RF-
positivity, ACPA-positivity, research centre, symptom 
duration at first rheumatology visit. 
(L
u
k
a
s
 e
t a
l., 
2
0
1
1
) 
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ESPOIR 
(contd.) 
2002-2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
661 813 As above, with x-rays 
available 
73% 
(79% fulfilling 
2010 RA criteria 
at baseline) 
- Radiographic 
progression (change 
in SHS from 
baseline) at 1 yr 
Generalised linear model, assessing early DMARD 
(excluding HCQ, within 3 mths of onset of swelling, n=140) 
vs. no early DMARD (includes n=387 starting DMARD 
3mths-1yr after onset of swelling) with covariate propensity 
score, as above: 
 Early DMARD (estimated marginal mean 0.8 units vs 
1.7 units no early DMARD p=0.03). 
(L
u
k
a
s
 e
t a
l., 
2
0
1
1
) 
500 813 As above, with x-rays 
available (and 
excluding n=35 
patients receiving 
TNF-inhibitor, none of 
whom had rapid 
radiographic 
progression) 
71% - Rapid radiographic 
progression (change 
in SHS from 
baseline >5 per 
year, [5 units 
equivalent to sever 
destruction in 1 
joint]) in yrs 2 and 3 
in 18% 
Multiple logistic regression, entering clinical, laboratory 
and radiographic variables and cytokine levels with p<0.1 
on univariable analysis, using backwards step-wise 
selection: 
 Score for serology within 2010 RA criteria (0-3) (OR 
6), IL-6 (OR 1.5), baseline SHS erosion score (OR 3), 
rapid radiographic progression in SHS erosion score 
(change from baseline >2.5) at 1 yr (OR 5) (95% Cis 
not given). 
(T
o
b
ó
n
 e
t a
l., 2
0
1
3
) 
127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
813 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As above, for patients 
with US available 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radiographic 
erosion at 2 yrs in 
39%   
Multivariable logistic regression, entering age, DAS28, 
CRP, ESR, RF-positivity, ACPA-positivity, steroid use and 
presence of US erosion: 
 RF-positivity (OR 5.0, 95%CI 1.8-14), presence of US 
erosion (OR 1.44, 95%CI 1.04-1.98). 
(F
u
n
c
k
-B
re
n
ta
n
o
 e
t a
l., 2
0
1
3
) 
  (F
u
n
c
k
-B
re
n
ta
n
o
 e
t a
l., 2
0
1
3
) 
Rapid radiographic 
progression 
(increase in SHS 
erosion score ≥5) at 
1 yr in 9%  
Multivariable logistic regression, entering clinical, 
laboratory, treatment (steroid/DMARD/biologic use)  and 
US (number of jts with GS and number of jts with PD [and 
total PD score by sum of grades 0-3 each jt] of bilateral 
MCP2-5 and MTP5 and presence of erosion [and erosion 
score by sum of grades 0-4] at bilateral MCP2, MCP5 and 
MTP5]) but NOT radiographic variables, with p<0.3 on 
univariable analysis, using backwards step-wise selection: 
 RF-positivity (OR 7.4, 95%CI 1.4-40), total PD score 
(OR 1.2, 95%CI 1.04-1.42), number of joints with PD 
≥grade 1 (OR 1.33, 95%CI 1.04-1.69). 
Radiographic 
progression (change 
in SHS erosion 
score from baseline) 
at 1 yr  
Multiple linear regression, entering variables as above: 
 CRP (parameter estimate 0.02, p=0.002), presence 
of any PD (parameter estimate -0.9, p=0.003), total 
PD score (parameter estimate 0.8, p<0.001), 
presence of any US erosion (parameter estimate 0.8, 
p<0.001). 
  93 As above, in patients 
with no erosions at 
baseline  
Not reported - Radiographic 
erosion at 2 yrs  
Multivariable logistic regression, as above. 
 RF-positivity (OR not given). 
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NOR-VEAC 
(Norway, 
multicentre) 
2004-2007 376  572  Symptoms ≤16 wks 
 ≥1 swollen joint 
19% - Persistent disease 
at 1 yr (≥1 swollen 
joint and/or DMARD-
use) in 46% 
Multivariable logistic regression, entering pre-determined 
clinical and laboratory variables: 
 ACPA-positivity (OR 3.6, 95%CI 1.6-8.1), RF-
positivity (OR 2.7, 95%CI 1.2-6.2) 
(M
ja
a
v
a
tte
n
 
e
t a
l., 2
0
1
0
) 
IMPROVED 
trial 
(Netherlands, 
multicentre) 
2007-2010 610 730 screened  DAS >1.6  
Either: 
 RA (1987 ACR 
criteria) and 
symptoms <2 yrs  
Or: 
 Physician 
impression likely 
early RA, ≥1 
arthritic joint, ≥1 
other painful joint, 
any symptom 
duration 
60% fulfilled 
1987 RA criteria 
(2010 RA criteria 
in 79%) 
MTX 25 
mg/week 
and high 
dose of 
prednisone 
(60 mg/day, 
reducing 
over 7 
weeks to 7.5 
mg/day).  
Remission (DAS44 
<1.6) at 4 mths in 
61% 
Multivariable logistic regression, entering clinical and 
laboratory variables with p<0.1 on univariable analysis 
(separate models including DAS44 or number of swollen 
and/or tender small and large joints): 
 With DAS44: male (OR 2.0, 95%CI 1.3-3.1), BMI (OR 
0.94, 95%CI 0.90-0.98), symptom duration (OR 0.99, 
95%CI 0.98-0.997), DAS44 (OR 0.6, 95%CI 0.5-0.8), 
HAQ (OR 0.7, 95%CI 0.5-0.9), ACPA-positivity (1.6, 
95%CI 1.1-2.3).  
 With small and large joint involvement: male (OR 2.0, 
95%CI 1.3-3.1), BMI (OR 0.94, 95%CI 0.90-0.98), 
symptom duration (OR 0.99, 95%CI 0.98-0.997), no. 
small joints (OR 0.96, 95%CI 0.93-0.99), no. large 
joints (OR 0.8, 95%CI 0.7-0.9), HAQ (OR 0.6, 95%CI 
0.5-0.9). 
(W
e
v
e
rs
-d
e
 B
o
e
r, K
. V
. C
. e
t a
l., 
2
0
1
2
) 
488 80% fulfilled 
2010 RA criteria 
As above, 
then (if 
DAS44≥1.6) 
randomised 
to 
combination 
DMARD 
plus 
prednisolone 
or MTX plus 
adalimumab 
Radiographic 
progression (change 
from baseline in 
SHS≥0.5) at 2 yrs in 
10%. 
Multivariable logistic regression, entering clinical and 
laboratory variables with p<0.2 on univariable analysis 
(Anti-CarP and ACPA status entered as combined variable 
due to co-linearity):  
 Age (OR 1.03, 95%CI 1.00-1.06), AntiCarP and 
ACPA both positive (vs. both negative) (OR 2.5, 95% 
CI 1.2-5.6), symptom duration<12 wks, 
ESR≥28mm/hr and SHS all included (p=NS) 
(A
k
d
e
m
ir e
t a
l., 2
0
1
6
) 
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CATCH 
(Canada, 
multicentre) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2007-
2011 
1244/
1205 
Not reported  Symptoms 6-52 
wks  
Either: 
 ≥ 2 swollen joints  
Or: 
 1 swollen 
MCP/PIP and ≥1 
of: positive RF, 
positive ACPA, 
EMS >45 min, 
response to 
NSAIDs, or a 
positive MTP 
squeeze 
Not reported - Sustained remission 
over follow-up (for ≥ 
6 mths or 2 
consecutive visits for 
remission definitions 
below) (length of 
follow-up available 
not known): 
 ACR Boolean 
(using 28-joint 
counts and 
omitting CRP) 
in 25% of 
n=1244 
 SDAI in 23% of 
n=1205 
 
Multivariable logistic regression, method unclear (including 
whether patients with missing data were excluded). 
Entered pre-determined confounders (including initial 
treatment [MTX monotherapy or combination DMARD 
within 3 months and biologic within 6 months with those in 
models below], stating other clinical, laboratory and 
radiographic variables were not predictive. 
 Boolean definition: age (OR 0.98, 95%CI 0.96-0.99), 
female (OR 0.6, 95%CI 0.4-1.0), pain (VAS) (OR 
0.99, 95% CI 0.98-0.99), time to remission (OR 
0.997, 95%CI 0.996-0.998). 
 SDAI definition: age (OR 0.98, 95%CI 0.96-0.99), 
pain (VAS) (OR 0.98, 95% CI 0.98-0.99), time to 
remission (OR 0.997, 95%CI 0.996-0.998). 
(K
u
riy
a
 e
t a
l., 2
0
1
2
) 
2007-
2012 
523 
 
1431 As above With baseline 
serology 
available 
(n=841), 89% 
RA (2010 or 
1987 criteria) 
- Remission 
(DAS28<2.6) at 1 yr. 
Rate not given.  
 
Multiple logistic regression, entering pre-determined 
clinical, laboratory, radiographic and treatment variables, 
using forwards step-wise selection (inclusion if p<0.1) and 
serological status (ACPA-/RF-, ACPA+/RF-, ACPA-/RF+ 
or ACPA+/RF+): 
 Age, SJC28, CRP, DAS28, HAQ (OR not given). 
(B
a
rra
 e
t a
l., 2
0
1
4
) 
392 
 
Remission 
(DAS28<2.6) at 2 
yrs. Rate not given. 
Multiple logistic regression, as above: 
 Age, HAQ (OR not given). 
233 
 
New radiographic 
erosion(s) at 1 yr. 
Rate not given.  
Multiple logistic regression, as above: 
 ACPA+/RF- (vs -/-) (OR 5.5, 95% CI 1.4-21), 
ACPA+/RF+ (vs -/-) (OR 3.7, 95% CI 1.1-12). 
192 New radiographic 
erosion(s) at 2 yrs. 
Rate not given. 
Multiple logistic regression, as above: 
 DAS28 (OR not given). 
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CATCH 
(cont.) 
2007-
2012 
342/ 
520 
 
1431 As above 67% 1987 
RA and 75% 
2010 RA (of 
n=342 with 
ACPA 
available) 
and 65% 
1987 RA 
and 72% 
2010 RA (of 
n=520 with 
RF status 
available) 
- Remission 
(DAS28<2.6) at 1 yr 
in 53% of 342 (with 
known ACPA status) 
and 52% of 520 
(with known RF 
status) 
. 
Multiple logistic regression, entering pre-determined 
clinical, radiographic and baseline treatment if p<0.1 on 
univariable analysis and ACPA or RF status (low positive 
or moderate/high positive vs negative): 
 With ACPA (n=342): Age, gender, smoking status, 
SJC28, DAS28 and HAQ (OR not given). 
 With RF (n=520): as ACPA above. 
(B
a
rra
 e
t a
l., 2
0
1
3
) 
277/ 
376 
 
Remission (DAS28) 
at 2 yrs in 57% of 
277 (ACPA model) 
and 59% of 376 (RF 
model). 
Multiple logistic regression, as above: 
 With ACPA (n=277): Age, DAS28 and HAQ (OR not 
given). 
 With RF (n=376): as ACPA above. 
 249/ 
322 
 
Any radiographic 
erosion(s) at 1 yr in 
27% of 249 (ACPA 
model) and 27% of 
322 (RF model). 
Multiple logistic regression, as above: 
 With ACPA (n=249): CRP (OR not given), presence 
of erosions at baseline (OR not given), ACPA 
moderate/high positive (≥3xULN) (OR 3.4, 95% CI 
1.6-7.2). 
 With RF (n=322): CRP, presence of erosions at 
baseline (OR not given). 
 198/ 
247 
Any radiographic 
erosion(s) at 2 yrs in 
28% of 198 (ACPA 
model) and 27% of 
247 (RF model). 
Multiple logistic regression, as above: 
 With ACPA (n=198): DAS28, presence of erosions at 
baseline (OR not given). 
 With RF (n=247): DAS28 (OR not given), presence of 
erosions at baseline (OR not given), RF high positive 
(≥3xULN) (OR 2.4, 95% CI 1.1-5.2). 
NOAR: Norfolk Arthritis Register, SJC: swollen joint count, NSAID: non-steroidal anti-inflammatory drug, STIVEA: Steroids in Very Early Arthritis, ESR: 
erythrocyte sedimentation rate, DAS: disease activity score, VAS: visual analogue scale, SF-36: Short Form-36, EQ-5D: Euro-Qol-5 Dimensions (quality of life 
measure), ESPOIR: Étude et Suivi des Polyarthrites Indifférenciées Récentes (study and follow-up of early undifferentiated polyarthritis), HCQ: 
Hydroxychloroquine, IL: interleukin, IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease, 
Anti-CarP: anti-carbamylated protein antibodies, CATCH: Canadian Early Arthritis Cohort, SDAI: simplified disease activity index, ULN: upper limit of normal. 
 
*Composite score including RF, shared epitope, high HAQ, CRP, gender (Fries et al., 1980).  
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 Longitudinal, prospective, inception cohort studies assessing prognostic factors in patients with UA. Table 5.
Undifferentiated arthritis is defined as IA not fulfilling 1987 RA criteria, unless otherwise stated.  
Study 
Population 
Years 
patients 
recruited 
n 
Total 
number of 
patients 
seen by 
clinic/study 
group 
Inclusion Criterion  
(excluding 1987 ACR RA 
and non-RA diagnoses, 
unless otherwise stated) 
Treatment 
Protocol, 
if 
applicable 
Outcome 
Statistical Methods of Analysis and 
Predictive Factors with Statistical 
Significance 
(baseline variables unless otherwise stated, 
results of multivariable analyses are 
presented preferentially over univariable 
analyses where available) 
R
e
fe
re
n
c
e
 
Leiden 
(Netherlands) 
1993-2005 570 ~1900  Symptoms <2 yrs 
 Physician impression of IA 
- RA (1987 criteria) at 1 yr 
in 31% 
Multivariable logistic regression model, entering 
clinical and laboratory variables with p<0.05 on 
univariable analysis using backwards step-wise 
selection (retention if p≤0.10): 
 Age, female gender, localisation of symptoms 
(small joints, symmetrical and in upper +/- lower 
extremities), EMS severity (VAS), TJC, SJC (of 
66), CRP, RF-positivity, ACPA-positivity (OR 
not given). 
Discriminative ability (ROC curve analysis) of Leiden 
prediction rule, with categorisation (except age, as 
more predictive as continuous variable) and 
weighting (using regression coefficients) of variables 
in the above model: AUC 0.89 (SD 0.02).  
(v
a
n
 d
e
r H
e
lm
-v
a
n
M
il e
t a
l., 
2
0
0
7
) 
  538 ~1900 As above - Persistent disease at 5 yrs 
(absence of sustained 
DMARD-free remission 
defined as no swollen 
joints for ≥1 yr after 
cessation of DMARD) in 
39% 
Univariable logistic regression: 
 Female (OR 1.5, 95%CI 1.0-2.1), symptom 
duration (wks) (OR 1.01, 95%CI 1.00-1.02), 
EMS severity (OR 1.07, 95%CI 1.01-1.13), SJC 
(OR 1.07, 95%CI 1.02-1.13), CRP (OR 1.01, 
95%CI 1.00-1.01), RF-positivity (OR 4, 95%CI 
2-6), ACPA-positivity (OR 6, 95%CI 3-11) 
(d
e
 R
o
o
y
, v
a
n
 
d
e
r L
in
d
e
n
 e
t 
a
l. 2
0
1
1
) 
  518 ~1900 As above - RA (1987 criteria) at 1 yr 
in 31% 
Number of erosive joints added to the multivariable 
logistic regression model above. Not an independent 
predictor. 
(T
h
a
b
e
t 
e
t 
a
l., 
2
0
0
9
) 
Amsterdam 
(Netherlands) 
1995-1998 77 320  Symptoms <3 yrs 
 ‘Arthritis’ ≥2 joints 
 Excluded physician impression 
RA 1-3 wks after baseline 
- Progressive disease at 1 
yr (≥1 of: increase in SHS 
≥4, SHS ≥10, HAQ ≥1) in 
42% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.05 on 
univariable analysis with forwards step-wise 
selection: 
 Age (OR 1.05, 95% CI 1.01-1.09), ‘arthritis’ of 
hands (OR 4.2, 95% CI 1.04-17) 
(J
a
n
s
e
n
 e
t 
a
l., 2
0
0
2
) 
41 
 
Leeds (UK) 1996-1999 97 1877  Symptoms <1 yr 
 History, examination or 
laboratory data suggestive of 
IA 
 Hand symptoms 
 
Synovitis (≥2 of: swelling, 
tenderness, decreased ROM) in 
53% at baseline. 
Step-up 
treatment 
protocol:  
1) NSAIDs 
2) Single 
dose of 
corticosteroid  
3) DMARDs 
RA (1987 criteria) at 1 yr 
in 14% 
Multivariable logistic regression, stepwise procedure, 
other details unclear: 
 RF-positivity (OR 31, 95% CI 6-160), painful 
joint count (OR 1.06, 95% CI 1.00-1.12)  
(Q
u
in
n
 e
t a
l., 2
0
0
3
) 
 
    DMARD-use over 1 yr in 
30% 
Multivariable logistic regression, as above: 
 Greatest strength of association with synovitis 
at 12 wks (OR 49, 95% CI 13-180), other 
results not reported. 
    Persistent synovitis over 1 
yr in 36% 
Univariable analysis (Student’s t-test and Wilcoxon’s 
rank sum test): 
 RF-positivity, ≥1 swollen joint, synovitis (see 
definition across) (all p<0.05). 
    DMARD/NSAID-free 
remission at 1 yr (absence 
of symptoms without 
treatment) in 13% 
Univariable analysis (Student’s t-test and Wilcoxon’s 
rank sum test): 
 Lower HAQ, shorter symptom duration, less 
synovitis at 12 weeks, male gender (all p<0.05). 
Seville ROP 
(Spain) 
2002 
onwards 
56 322  Symptoms ≥4 wks and ≤1 yr 
 ‘Inflammation’ ≥2 joints 
 Excluded patients developing 
RA (1987 criteria) and non-RA 
diagnoses after 1 yr follow-up 
- RA (1987 criteria) after 3 
further yrs follow-up in 
20% 
Rate of RF and/or ACPA-positivity in patients 
grouped according to outcome (no statistical 
testing): 
 8/11 who developed RA versus 0/44 who 
remained as UA. 
(C
a
ro
-
O
le
a
s
 e
t 
a
l., 2
0
0
8
) 
TEACH 
(Canada) 
2003 
onwards 
105 Not reported  Symptoms ≥6 wks and ≤1 yr  
 ≥2 swollen joints or ≥1 swollen 
MCP/PIP with ≥1 of: positive 
RF or ACPA, EMS ≥45 min, 
NSAID response or pain on 
MTP squeeze 
- RA (1987 criteria) over ≥6 
mths follow-up (mean [SD] 
19 [9] mths) in 76% 
Univariable analysis (Student’s t-test and Chi-square 
test): 
 TJC (of 44) (p<0.001), SJC44 (p<0.001), 
DAS28-ESR (p<0.001), HAQ (0.006), RADAI 
(p=0.003), RF-positivity (p=0.001) and ACPA-
positivity (p<0.001). 
(K
u
riy
a
 e
t 
a
l., 2
0
0
9
) 
Berlin 
(Germany) 
2004 
onwards 
155 Not reported  Symptoms ≥4 wks and ≤1 yr 
 ‘Synovitis’ ≥2 joints 
- RA (1987 criteria) at 1 yr 
in 37% 
Leiden prediction rule re-derived (using data from 
Leiden cohort) substituting EMS duration for EMS 
severity. Discriminative ability (ROC curve analysis) 
of re-derived Leiden prediction rule:  
 AUC 0.82 (SEM 0.04). 
(v
a
n
 D
e
r H
e
lm
-v
a
n
 
M
il e
t a
l., 2
0
0
8
) 
 
Birmingham 
(UK) 
Not 
reported 
99 Not reported  Symptoms ≤3 mths 
 ≥1 swollen joint 
- RA (1987 criteria) over 18 
mths in 31% 
Discriminative ability (ROC curve analysis) of 
re-derived Leiden prediction rule (using EMS 
duration, see above):  
 AUC 0.83 (SEM 0.04). 
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Pavia (Italy) 2005-2012 215 Not reported  UA (not fulfilling 2010 
ACR/EULAR RA criteria) 
Symptom/disease duration not 
reported. 
MTX if 
fulfilled 1987 
ACR RA 
criteria, 
otherwise 
HCQ as 
first-line 
(given to 169 
[79%]). Then 
treatment to 
target 
(DAS28<3.2). 
Remission (DAS28<2.6) 
within 1 yr in 124 (58%). 
Median (IQR) follow-up 12 
(6-12) months. 
Cox regression for clinical variables, single items of 
the 2010 classification score and US (bilateral wrists 
and MCPs) variables, adjusted for age, gender, 
glucocorticoids and DMARDs (excluding HCQ) over 
time: 
 Age (HR 0.98, 95% CI 0.97-0.99), female (HR 
0.6, 95% CI 0.5-0.9),  
 ACPA and/or RF titre (as per 2010 
classification score) (HR 3.3, 95% CI 1.3-8.6),  
 Number of joints PD>0 (HR 1.2, 95% CI 1.0-
1.3) or PD>1 (HR 1.3, 95% CI 1.1-1.6) or total 
PD score (HR1.1, 95% CI 1.0-1.2). 
(S
a
k
e
lla
rio
u
 e
t a
l., 2
0
1
4
) 
Cairo (Egypt) Not 
reported 
173 Not reported  Symptoms <6 mths 
 Synovitis ≥ 2 joints (≥2 of: 
swelling, tenderness, 
decreased ROM) 
 EMS >30 min 
 Pain on MCP/MTP squeeze 
Step-up 
protocol:  
1) NSAIDs 
2) Single 
dose of 
corticosteroid  
3) DMARDs  
Persistent disease at 6 
mths (MRI findings of 
active inflammatory 
arthritis) in 46% 
Multivariable logistic regression, entering clinical and 
laboratory variables with p<0.25 on univariable 
analysis, Hosmer and Lemeshow goodness of fit 
testing to identify most predictive final model 
including independent predictors (p<0.05): 
 EMS duration (OR 1.16, 95% CI 1.09-1.22), 
ACPA-positivity (OR 11.2, 95% CI 1.7-75), 
change in HAQ at 3 mths (1.0, 95% CI 1.0-1.1) 
(E
l M
ie
d
a
n
y
 e
t 
a
l., 2
0
0
8
) 
Ancona 
(Italy) 
Not 
reported 
149 Not reported  Symptoms <16 wks 
 ≥1 swollen joint in hands  
 ≥1 of: positive RF, positive 
ACPA, EMS >30 min, pain on 
MTP squeeze 
Italian Society 
for 
Rheumatolog
y guidelines 
RA (1987 criteria) at 1 yr 
in 42% 
 
 
(Other outcomes: 
persistent UA in 32%, non-
persistent UA in 15% and 
alternative non-RA/non-
UA diagnosis in 12%) 
Multivariable logistic regression, clinical (not 
including swollen and tender joint counts), laboratory 
and US (number of joints with any GS and 
PD>grade 1 of bilateral wrists, MCP2-5 and PIP2-5) 
variables with p<0.05 on univariable analysis. 
Backwards step-wise selection (retention if p≤0.10) 
(continuous variables categorised as per 2010 RA 
criteria): 
•    ACPA and/or RF: high positive (OR 11, 95% CI 
2.6-47), low positive (OR 5.8, 95% CI 1.6-21), 
abnormal CRP/ESR (OR 5.3, 95% CI 1.6-18), 
symptoms ≥6 wks (OR 5.0, 95% CI 1.4-18), 
EMS >30 min (OR 3.2, 95% CI 1.1-9.5), PD≥
grade 2 (with GS≥grade 1): 1 joint (OR 9.9, 
95% CI 2.3-43), 2-3 joints (OR 18, 95% CI 4.7-
65), ≥4 joints (OR 49, 95% CI 8.7-272). 
(S
a
la
ffi e
t a
l., 2
0
1
0
) 
 
ROC: Receiver Operating Characteristic curve, SD: standard deviation, ROP: Recent Onset Polyarthritis unit, TEACH: Toronto Early Arthritis Cohort, RADAI: Rheumatoid 
Arthritis Disease Activity Index (5 item questionnaire for patient-reported disease activity).  
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 Observational and non-randomised open-label prospective studies assessing prognostic factors using multivariable analysis, in Table 6.
patients with early DMARD-naïve RA. 
Rheumatoid arthritis is defined according to fulfilment of 1987 RA criteria, unless otherwise stated.  
Study 
Population 
Years 
patients 
recruited 
n 
Total 
number 
of 
patients 
fulfilling 
inclusion 
criteria 
Inclusion 
Criterion 
(patients 
fulfilling 1987 
ACR RA criteria, 
unless otherwise 
stated) 
Treatment Protocol   
(if applicable) 
Outcome 
Statistical Methods of Analysis and Predictive 
Factors with Statistical Significance 
(baseline variables unless otherwise stated) 
R
e
fe
re
n
c
e
 
NOAR (UK) 
 
 
1990-
1993 
105 239  Symptoms <6 
mths 
- Radiographic erosions 
(Larsen score ≥2 in any joint 
of the hands or feet) ≥1 yr 
after symptom-onset in 35%. 
Multivariable logistic regression, entering clinical and 
laboratory variables, backwards selection (retention if 
p≤0.05):  
 RF-positivity, symptoms ≥3 mths, involvement ≥2 
large joints independent predictors (OR not given). 
(B
re
n
n
a
n
 
e
t a
l., 
1
9
9
6
) 
EURIDISS 
(France, 
Norway, 
Netherlands) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1991 
onwards 
318 706  Time from 
diagnosis <4 yrs 
- Radiographic damage (SHS) 
at follow-up (average 30 
mths) 
Multiple linear regression, entering age, gender, country, 
follow-up duration and other clinical, laboratory and 
radiographic variables with p≤0.10 on univariable 
analysis, using forwards and backwards step-wise 
selection: 
 Time from diagnosis (coefficient -0.1, p=0.03), ESR 
(coefficient 0.02, p<0.001), RF-positivity (coefficient 
5, p=0.05), VAS general health (coefficient 0.01, 
p=0.002), baseline SHS (coefficient 1.0, p<0.001). 
(G
u
ille
m
in
 e
t a
l., 
2
0
0
3
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 
 
 
 
 
 
 
706 
 
 
 
 
 
 
 
As above 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Radiographic progression 
(change in SHS from 
baseline ≥10 units) at 10 yrs 
in 59% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.15 on 
univariable analysis (+/- radiographic progression at 
baseline=SHS/disease duration): 
 Without adjustment for baseline radiographic 
progression: female (OR 3.3, 95% CI 1.3-7.6), ESR 
>20mm/hr (OR 3.2, 95% CI 1.2-7.6), ACPA-
positivity (OR 4.0, 95% CI 1.6-10), RF-positivity (OR 
3.1, 95% CI 1.2-7.9). 
 With adjustment for baseline radiographic 
progression: female (OR 3.2, 95% CI 1.1-9.4), ESR 
>20mm/hr (OR 3.1, 95% CI 1.3-7.8), ACPA-
positivity (OR 3.1, 95% CI 1.2-8.4), RF-positivity 
(OR 2.7, 95% CI 1.0-7.3). 
(S
y
v
e
rs
e
n
 e
t a
l., 2
0
0
8
) 
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EURIDISS 
(contd.) 
1991 
onwards 
125 
 
706 
 
 
 
 
 
 
As above - Radiographic progression 
(change in SHS from 
baseline ≥10 units) at 10 yrs 
in 59% 
Multivariable logistic regression, entering pre-determined 
variables (age, gender, CRP, ESR, RF-positivity and 
ACPA categorised as negative, low-moderate positive 
and high positive): 
 High ACPA (>200 U.ml) (OR 9.9, 95% CI 2.7-37) 
(low-moderate positive not significant vs ACPA 
negative, significance of other variables not given) 
(S
y
v
e
rs
e
n
 e
t 
a
l., 2
0
0
8
) 
Leipzig 
(Germany) 
1992 
onwards 
2 yr 
data in 
n=87, 
4 yr 
data in 
n=48 
93  Symptoms <2 yrs 
 Non-RA  
diagnoses within 
1 yr of follow-up 
excluded 
SSZ 2g/day or MTX 
15mg/wk, + low 
dose prednisolone 
Radiographic progression 
(mean yearly change in 
Larsen score) over 4 yrs 
Multiple linear regression, entering pre-determined 
clinical, laboratory and radiographic variables using 
backwards step-wise selection: 
 IgA RF titre (IU/mL) (coefficient 0.01, 95% CI 0.00-
0.02), shared epitope (coefficient 3.2, 95% CI 0.9-
5.6), time of x-ray assessment (≤2yrs vs >2 yrs 
since baseline) (coefficient -3.1, 95% CI -5.6 to -
0.5). 
(K
a
lte
n
h
ä
u
s
e
r e
t 
a
l., 2
0
0
1
) 
Mo-Co-To 
(France, 
multicentre) 
 
 
 
 
 
 
 
 
 
 
1993-
1994 
 
 
 
 
 
 
172 191  Disease duration 
<1 yr 
- Radiographic progression 
(increase in SHS from 
baseline ≥upper boundary of 
95% CI of the differences 
[3.2]) at 3 yrs in 41% 
Multiple logistic regression, entering clinical, laboratory 
and radiographic variables with p≤0.15 on univariable 
analysis, using step-wise selection (retention if p<0.05) 
(continuous variables dichotomised using median): 
 ESR ≥median mm/hr (OR 3.4, 95% CI 1.4–8.5), RF-
positivity (OR 3.9, 95% CI 1.4–11), shared epitope 
(OR 2.9, 95% CI 1.2–7.0), SHS erosion score 
≥median (OR 5.1, 95% CI 2.2–12.1). 
(C
o
m
b
e
 e
t a
l., 2
0
0
1
)      High radiographic 
progression (increase in 
SHS from baseline >median 
[4]) at 3 yrs 
Multivariable logistic regression, as above: 
 Pain VAS ≥59mm (OR 2.4, 95% CI 0.8–6.6), 
RF-positivity (OR 2.9, 95% CI 0.9–9.2), shared 
epitope (OR 2.9, 95% CI 1.0–8.0), SHS (OR 31, 
95% CI 10-95). 
 
 
 
 
 
 
 
 
 
 
 
134 191 As above - Remission (DAS44<1.6) at 3 
yrs in 36% of patients 
included in analysis 
Multivariable logistic regression, as above (separate 
models with and without DAS44 due to overlap with 
other candidate variable identified on univariable 
analysis, RAI): 
 With DAS44: DAS44<4 (OR 5.7, 95% CI 2.3-14), 
EMS>60min (OR 2.5, 95% CI 1.3-7.0), SHS (OR 
2.5, 95% CI 0.9-6.6). 
 Without DAS44: RAI<17 (OR 2.7, 95% CI 1.1-6.7), 
EMS>60min (OR 2.3, 95% CI 0.9-6.0), HAQ>1.25 
(OR 2.3, 95% CI 0.9-5.7), SHS (OR 2.9, 95% CI 
1.2-7.0). 
(G
o
s
s
e
c
 e
t a
l., 2
0
0
4
) 
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Mo-Co-To 
(contd.) 
 
1993-
1994 
134 191 As above - Sustained remission 
(DAS44<1.6 at 3 and 5 yrs) 
in 22% of patients included 
in analysis 
Multivariable logistic regression, as above: 
 With DAS44: DAS44<4 (OR 5.5, 95% CI 1.7-18), 
CRP <14.5mg/l (OR 2.5, 95% CI 0.8-7.4), SHS (OR 
2.7, 95% CI 0.9-8.1). 
 Without DAS44: RAI<17 (OR 4.2, 95% CI 1.4-12.1), 
CRP <14.5mg/l (OR 3.1, 95% CI 1.0-9.0), SHS (OR 
2.7, 95% CI 0.9-8.0). 
(G
o
s
s
e
c
 e
t a
l., 
2
0
0
4
 
  112 191 As above - High radiographic 
progression (increase in 
SHS from baseline >median) 
at 10 yrs 
Multivariable logistic regression, as above (except 
p≤0.10 on univariable analysis used as cut-off for entry 
into model): 
 SHS erosion score (OR 5.6, 95% CI 1.8–17.9). 
After excluding the baseline radiographic variables: 
 ESR (OR 3.2, 95% CI 1.2–8.8), ACPA-positivity 
(OR 3.9, 95% CI 1.2–12.8),  
(C
o
u
rv
o
is
ie
r e
t 
a
l., 2
0
0
8
) 
  156 191 As above - HAQ score at 5 yrs  Multiple linear regression, other details not specified: 
 RAI (coefficient 0.02, p=0.05), ESR (coefficient 
0.01, p=0.006), CRP (coefficient 0.01, p=0.001), 
HAQ score (coefficient 0.4, p<0.001), presence of 
erosion (p=0.05). 
(C
o
m
b
e
 
e
t a
l., 
2
0
0
3
) 
BARFOT 
(Sweden, 
multicentre) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1993-
1999 
355 839  Disease duration 
<1 yr 
No protocol for DMARD 
therapy. Randomisation 
to +/- low dose 
prednisolone in n=166 
Radiographic progression 
(SHS >smallest detectable 
change [5.8]) at 2 yrs 
Multivariable logistic regression, entering variables at 
baseline and 1 yr (including change in hand BMD) with 
p<0.1 on univariable analysis: 
 With change in SHS from baseline at 1 yr: change 
in SHS (OR 2.7, 95% CI 2.0-3.5), ACPA-positivity 
(OR 3.1, 95% CI 1.7-5.8). 
 Without change in SHS at 1 yr: SJC at 1 yr (OR 1.1, 
95% CI 1.0-1.2), ACPA-positivity (OR 3.1, 95% CI 
1.7-5.8), presence of erosion at baseline (OR 2.6, 
95% CI 1.5-4.5), change in hand BMD at 1 yr (OR 
0.97, 95% CI 0.96-0.99).  
(F
o
rs
lin
d
 e
t a
l., 2
0
1
2
) 
1993-
1997 
379 453 As above As above Radiological progression 
(change from baseline in 
Larsen score >median [8]) at 
2 yrs 
Multiple logistic regression, entering clinical, laboratory 
and radiographic variables with p<0.05 on univariable 
analysis, using forwards step-wise selection (continuous 
variables dichotomised using median): 
 ESR (OR 1.8, 95% CI 1.0-3.1), ACPA-positivity (OR 
3, 95% CI 2-5), baseline Larsen score (OR  9, 95% 
CI 5-16), 
(F
o
rs
lin
d
 e
t a
l., 2
0
0
4
) 
     High radiographic damage 
(Larsen score >median [10]) 
at 2 yrs 
 
Multivariable logistic regression, as above: 
 Baseline Larsen score (OR 15, 95% CI 8-28), 
ACPA-positivity (OR 5, 95% CI 3-9), ESR (OR 2.0, 
95% CI 1.1-3.5). 
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BARFOT 
(contd.) 
1993-
1999 
608 698 As above As above Sustained remission 
(DAS28<2.6 at ≥2 
consecutive visits, 
with/without treatment) at 
18mths, 2 yrs and 5 yrs in 
20% 
Multiple logistic regression, entering clinical and 
laboratory variables with p<0.1 on univariable analysis, 
using backwards step-wise selection (retention if 
p<0.05): 
 Male (OR 2.6, 95% CI 1.6-4.3), disease duration 
(mths) (OR 0.9, 95% CI 0.8-1.0), DAS28 (OR 0.8, 
95% CI 0.6-0.9), HAQ (OR 0.6, 95% CI 0.4-0.9), 
RF-positivity (OR 0.5, 95% CI 0.3-0.8). 
(F
o
rs
lin
d
 e
t a
l., 
2
0
0
7
) 
 1993-
2004 
127
1 
1587 As above As above EULAR response (good 
and/or moderate) at 1 yr 
Multiple logistic regression, entering pre-determined 
variables (age, RF, HAQ, steroid use and those below): 
 Female (OR 0.5, 95% CI 0.4-0.7), disease duration 
(mths) (OR 0.94, 95% CI 0.90-0.98), current smoker 
(OR 0.7, 95% CI 0.5-1.0), DAS28 (OR 0.8, 95% CI 
0.7-0.9), DMARD start at baseline (OR 1.5, 95% CI 
1.1-2.0). 
(S
ö
d
e
rlin
 a
n
d
 
B
e
rg
m
a
n
, 
2
0
1
1
) 
Leiden 
(Netherlands) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1993-
1999 
95 Not reported 
(152 
patients with 
RA, x-rays 
and 1yr data 
available) 
 Symptoms <2 yrs 
 RA (1987 criteria 
but without the 
criterion of 
symptoms >6 
wks) at/within 3 
mths of first 
presentation to 
the clinic 
1993-1996: initial therapy 
analgesics then 
chloroquine; 
1996-1998: initial therapy 
chloroquine or SSZ; 
After 1998: initial therapy 
SSZ or MTX. 
Radiographic progression 
(increase in SHS from 
baseline >0) at 1 yr 
Multivariable logistic regression, entering all pre-
determined clinical, laboratory and radiographic variables 
(sensitivity analysis including choice of initial DMARD did 
not change results): 
 SJC (of 22: PIPs, DIPs, MCPs and MTPs each 
scored as 1 joint for right and 1 for left) (coefficient 
1.7, p=0.01), RF-positivity (coefficient 10, p=0.003) 
 
(d
e
 V
rie
s
-B
o
u
w
s
tra
 
e
t a
l., 2
0
0
6
) 
285 285  
(total 1009 
patients with 
IA including 
UA, RA and 
non-RA) 
 Symptoms <2 yrs 
 Fulfilled 1987 RA 
criteria within 1 yr 
of enrolment 
As above Radiographic damage (SHS) 
at 1 yr 
Multivariable logistic regression, entering clinical and 
laboratory variables (including swelling at individual joint 
sites), using backwards step-wise selection (retention 
p<0.10): 
 Symptom duration (coefficient 0.2, p<0.001), SJC 
(of 22, as above) (coefficient 0.9, p=0.03), CRP 
(coefficient 0.02, p<0.01), ACPA-positivity 
(coefficient 8, p<0.001).  
(L
in
n
-R
a
s
k
e
r e
t 
a
l., 2
0
0
7
) 
1993-
2002 
454 590  Symptoms <2 yrs 
 Fulfilled 1987 RA 
criteria 
As above Drug-free remission 
(physician judgement with 
no swollen joints and no 
DMARD/steroid over 1 yr) 
during follow-up (maximum 
10 yrs) in 15% 
Multivariable Cox regression, entering baseline clinical 
and laboratory variables with p<0.10 on univariable 
analysis (SHS not included due to co-linearity with 
symptom duration), using backwards step-wise selection 
(retention if p≤0.10): 
 Symptom duration (HR 0.95, 95% CI 0.90-1.00), 
CRP (HR 0.99, 0.98–1.00), ACPA-positivity (HR 
0.09, 95% CI 0.04-0.20) 
(v
a
n
 d
e
r W
o
u
d
e
 
e
t a
l., 2
0
0
9
) 
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Leiden 
(contd.) 
1993-
2002 
424 Not reported  Symptoms <2 
yrs 
 Fulfilled 1987 
RA criteria 
 Excluding 
patients 
enrolled in 
BeSt 
As above Sustained drug-free 
remission at 5 yrs 
(DAS44<1.6 for ≥1 yr after 
cessation of 
DMARD/steroid) in 11% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.10 on 
univariable analysis, using backwards step-wise 
selection (retention if p≤0.10) 
 
(period of enrolment as 
surrogate for initial therapy not significant predictor on 
univariable analysis, therefore not included in model) 
(multiple imputation in n=50 with missing baseline data): 
 Symptom duration (wks) (OR 0.99, 95% CI 0.97-
1.00), ACPA-positivity (OR 0.09, 95% CI 0.04-0.24). 
(v
a
n
 d
e
r W
o
u
d
e
 e
t 
a
l., 2
0
1
2
) 
 1993-
2006 
598 Not reported 
(total 1881 
patients with 
IA including 
UA, RA and 
non-RA) 
 Symptoms <2 
yrs 
 Fulfilled 1987 
RA criteria 
As above Radiographic progression 
(change in SHS from 
baseline) over follow-up 
(maximum follow-up 6 yrs, 
median 4 yrs). 
Repeated-measures analysis assessing symptom 
duration at first rheumatology assessment (<12 weeks, 
n=186, vs ≥12 weeks, n=412) with adjustment for age, 
gender and period of enrolment: 
 Symptom duration ≥12 wks (coefficient 1.3, 
p=0.001). 
No adjustment for disease activity. 
(v
a
n
 d
e
r L
in
d
e
n
 e
t a
l., 2
0
1
0
) 
  557 As above Drug-free remission 
(physician judgement with 
no swollen joints and no 
DMARD/steroid over 1 yr) 
during follow-up (median 3 
yrs) in 13% 
Multivariable Cox regression, with adjustment for 
variables above: 
 Symptom duration ≥12 wks (HR 1.9, 95% CI 1.2-
3.0). 
No adjustment for disease activity. 
Amsterdam 
(Netherlands) 
1995-
1996 
111 145  Symptoms <3 yrs 
 Fulfilled 1987 RA 
criteria within 1 yr 
of presentation 
- Disability (HAQ >median 
[0.53]) at 1 yr 
Multivariable logistic regression, entering clinical, 
laboratory and socioeconomic variables with p<0.1, 
using forwards step-wise selection: 
 Pain (VAS) (OR 1.02, 95% CI 1.00-1.04), baseline 
HAQ (OR 3.0, 95% CI 1.5-5.9). 
(J
a
n
s
e
n
 
e
t a
l., 
2
0
0
0
) 
114 142 As above - Radiographic Progression 
(change in SHS from 
baseline >median[3]) at 1 yr 
Multivariable logistic regression, entering pre-determined 
clinical, laboratory and radiographic variables, using 
forwards step-wise selection: 
 CRP≥20mg/dL (OR 3.6, 95% CI 1.5-8.4), baseline 
SHS (OR 1.1, 95% CI 1.0-1.1), RF-positivity (OR 
2.6, 95% CI 1.1-6.0). 
(J
a
n
s
e
n
 e
t 
a
l., 2
0
0
1
) 
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Barcelona & 
Sabadell 
(Spain) 
1998-
2000 
60 65+  Symptoms <2 yrs 1
st
 yr: gold IM 
(50mg/week) + 
methylprednisolone 
4mg/day +/- addition of 
MTX at 6 mths  
Radiographic progression 
(change in modified Larsen 
score ≥ minimal clinically 
important difference [2] from 
baseline) at 1 yr in 37% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.15 on 
univariable analysis, using backwards selection: 
 Pain (VAS) (OR 1.02, 95% CI 1.02–1.09), baseline 
Larsen score (OR 1.1, 95% CI 1.1–1.6). 
(S
a
n
m
a
rti e
t a
l., 
2
0
0
3
) 
     Radiographic progression 
(increase in number of 
erosive joints from baseline) 
at 1 yr in 27%. 
Multivariable logistic regression, as above: 
 Pain (VAS) (OR 1.02, 95% CI 1.00–1.07), shared 
epitope (OR 5.7, 95% CI 1.1–26). 
1998-
2003 
105 115 As above As above  Remission (DAS28<2.6) at 2 
yrs in 32%. 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.25 on 
univariable analysis, using step-wise selection: 
 DAS28<5.1 (OR 4.1, 95% CI 1.6-11). 
(V
a
z
q
u
e
z
 e
t a
l., 
2
0
0
7
) 
Disability (modified HAQ >0) 
at 2 yrs in 73% 
Multivariable logistic regression: clinical, laboratory, 
radiographic and socioeconomic variables with p<0.1 on 
univariable analysis, forwards step-wise selection; 
 Age (OR 1.1, 95% CI 1.0-1.1), RF-positivity (OR 3.8, 
95% CI 1.2-12), baseline modified HAQ> 0.5 (OR 4.0, 
95% CI 1.4-12). 
(G
ra
e
ll e
t 
a
l., 2
0
0
9
) 
      Radiographic progression 
(change in modified Larsen 
score ≥minimal clinically 
important difference [4] from 
baseline) at 2 yrs in 32% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.25 on 
univariable analysis, using step-wise selection: 
 Female (OR 5.5, 95% CI 1.1-28), shared epitope (OR 
3.2, 95% CI 1.1-9.0). 
(S
a
n
m
a
rtí 
e
t a
l., 
2
0
0
7
) 
Leuven 
(Belgium) 
2001-
2005 
89 Not 
reported 
 Disease duration 
<1 yr 
Step-down therapy (SSZ 
+ MTX + prednisolone, 
randomised to SSZ or 
MTX at wk 40) or step-up 
(initial DMARD 
monotherapy) according 
to physician judgement 
 
35% received step-down 
therapy 
Remission (DAS28 <2.6) at 
time of analysis (median 
disease duration 18mths) in 
69%. 
Multivariable logistic regression, entering clinical, 
laboratory and treatment (initial step-up or step-down 
treatment) with significance on univariable analysis (in 
addition to pre-determined confounders: age,  gender and 
symptom duration): 
 Remission (DAS28-CRP<2.6) at 4 mths (OR 19, 95% 
CI 3.6-96) 
(V
e
rs
c
h
u
e
re
n
 e
t a
l., 2
0
0
9
) 
Normal function (HAQ=0) at 
time of analysis (median 
disease duration 18mths) in 
38%. 
Multivariable logistic regression, as above (additional pre-
determined confounders age, symptom duration and 
baseline DAS28-CRP): 
 Excluding HAQ=0 at 4 mths: female (OR 0.09, 95% 
CI 0.02-0.5), baseline HAQ (OR 0.1, 95% CI 0.03-
0.6), good EULAR response at 4 mths (OR 6.6, 95% 
CI 1.3-33). 
 Including 4 mth HAQ: female (OR 0.04, 95% CI 
0.003-0.5), HAQ=0 4 mths (OR 47, 95% CI 0.4-561) 
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ERAN (UK, 
multicentre) 
2002-
2005 
194 808 (Kiely 
et al., 2009) 
 Physician 
diagnosis new-
onset RA 
62% of all enrolled 
(n=808) fulfilled 
1987 RA criteria 
(Kiely et al., 2009) 
- Remission (DAS28<2.6) at 2 
yrs in 30% 
ROC curve analysis assessing predictive ability of model 
developed using multiple logistic regression for same 
outcome (entering clinical, laboratory and radiographic 
variables with p≤0.05 on univariable analysis) in  n=379 
CARDERA patients (UK multicentre double-blind RCT 
[MTX/ MTX+ciclosporin/ MTX+prednisolone/ 
MTX+ciclosporin+prednisolone] patients with 1987 ACR 
RA, disease duration <2 yrs, 3 of: SJC≥3, TJC≥6, 
EMS≥45min, ESR≥28mm/hr: 14% of all n=467 randomised 
had received prior DMARD). 
 Model including age, gender and TJC28: AUC 0.70 
(95% CI 0.62-0.78). 
(M
a
 e
t a
l., 2
0
1
2
) 
SWEFOT 
(Sweden, 
multicentre) 
2002-
2005 
322 487  Symptoms <1 yr 
 DAS28 >3.2 
1st phase open-label 
MTX: 10mg increasing to 
20mg over 4 weeks 
EULAR response (good 
and/or moderate) at 3-4 
mths in 73% 
Multivariable logistic regression, entering pre-determined 
clinical, laboratory and treatment (concurrent prednisolone 
and NSAID use) variables (excluding patients 
discontinuing MTX, treated as non-responders in sensitivity 
analysis n=355 with similar result) (separate models 
including DAS28 and HAQ due co-linearity): 
 Age (by decade) (OR 1.3, 95% CI 1.1-1.5), female 
(OR 0.5, 95% CI 0.3-0.8), symptom duration (mths) 
(OR 1.3, 95% CI 1.1-1.5), current smoker (OR 0.4, 
95% CI 0.2-0.6), DAS28 (OR 0.6, 95% CI 0.5-0.8), 
HAQ (OR 0.6, 95% CI 0.4-0.8), concurrent 
prednisolone (OR 2.8, 95% CI 1.4-5.6). 
(S
a
e
v
a
rs
d
o
ttir e
t a
l., 2
0
1
1
) 
      Remission (DAS28, SDAI 
and CDAI definitions) at 3-4 
mths in 18%, 11% and 12%, 
respectively 
Multivariable logistic regression, as above entering 
baseline DAS28, SDAI or CDAI for models testing 
respective remission outcomes: 
 HAQ (OR not given) for all remission outcomes. 
Seville 
(Spain) 
2002-
2006 
134 897  Symptoms  
>4wks and <1 yr 
 SJC ≥2 
 Fulfilled 1987 RA 
criteria at 
presentation 
and/or during 
follow-up 
- Radiographic damage (SHS 
erosion score) at 1yr 
Multiple linear regression, entering serological (RF and 
ACPA), treatment (steroid and no. DMARDs over 12 mths), 
genetic (genotype TNFα promoter, shared epitope) and 
baseline SHS erosion score, using backwards step-wise 
selection (retention if p<0.15) 
 Shared epitope (double positive vs double negative) 
(coefficient 1.8, 95% CI 1.5-3.0), baseline SHS 
erosion score (coefficient 1.6, 95% CI 1.4-1.7). 
(R
e
n
e
s
e
s
 e
t a
l., 
2
0
0
9
) 
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Umea 
(Sweden) 
Not 
reported 
43 Not 
reported 
 Symptoms <1 yr - Radiographic progression 
(change in Larsen score 
from baseline) at 2 yrs 
Multivariable logistic regression, entering variables (some 
pre-determined and some informed by univariable 
analysis: including age, gender, HAQ, CRP and those 
below): 
 SJC28 (coefficient 0.7, 95% CI 0.02-1.3), shared 
epitope (coefficient 9.3, 95% CI 1.9-17), baseline 
Larsen score (coefficient -0.4, 95% CI -0.7 to -0.1), 
EULAR response at 6 mths (good vs none coefficient 
-15, 95% CI -24 to -5) (moderate vs none coefficient -
11, 95% CI -20to -3). 
(B
e
rg
lin
 e
t a
l., 2
0
0
3
) 
Leeds (UK) Not 
reported 
182 182  Symptoms 
<2yrs 
 Fulfilling 1987 
ACR RA 
criteria at 
baseline or 
follow-up 
- Disability (HAQ and change 
in HAQ from baseline 
ordered by quartiles) at 1 
and 2yrs 
Multivariable ordinal regression, entering clinical, 
laboratory and radiographic variables, using forwards step-
wise selection: 
 HAQ at 1 and 2 yrs: baseline HAQ (p<0.001). 
 Change in HAQ at 1 and 2 yrs: baseline HAQ 
(p<0.05) RF-positivity (p<0.05) (OR not given). 
(Q
u
in
n
 e
t a
l., 2
0
0
6
) 
Radiographic erosions at 1yr 
in 51% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables, using forwards step-
wise selection: 
 CRP 13.5-43.5mg/L (p<0.05), RF-positivity (p<0.05), 
shared epitope (p<0.05) (OR not given). 
118 Radiographic progression 
(change in Larsen score 
from baseline ordered by 
quartiles) at 1yr and 2 yrs 
Multivariable ordinal regression, entering clinical, 
laboratory and radiographic variables, using forwards step-
wise selection: 
 At 1 yr: no variables with p<0.05. 
 At 2 yrs: shared epitope (p<0.05). 
In RF-negative subgroup (n=67): 
 At 2 yrs  high positive ACPA (p<0.05). 
Multicentre 
(Austria, 
Hungary, 
Slovenia) 
Not 
reported 
172 180  Symptoms <3 yrs - Poor outcome over 3 yrs (≥1 
of: increase in HAQ from 
6mths to 3yrs ≥1, increase in 
HAQ from 6mths to 3yrs 
≥0.3 and 6 mth HAQ≥2, new 
extra-articular RA feature 
[excluded sicca, Reynaud’s, 
nodules], drop-out due to: 
biologic/ cyclophosphamide/ 
azathioprine/pulse steroid, 
joint/tendon surgery, 
disability due to RA, death) 
in 24%. 
Multivariable determinant analysis, entering clinical,, 
laboratory (including experimental biomarkers such as 
cartilage oligomeric matrix protein [COMP]) and 
radiographic variables, using backwards and forwards 
step-wise selection: 
 DAS44, SJC (of 68), HAQ score, RF-positivity (IgM or 
IgG), COMP and Larsen score in feet in final model 
(effect sizes not given). 
(W
a
g
n
e
r e
t a
l., 2
0
0
7
) 
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3 centres, 
Italy 
2007-
2009 
481 481  SJC ≥2 for >2 
wks and <1 yr 
 DAS28>3.2 
(All fulfilled 1987 
and 2010 RA 
criteria) 
As per physician with 
loose protocol advised: 
initial MTX, step-up 
at/after 3 mths to 
combination DMARD if 
DAS28≥2.6 or TNF- 
inhibitor if DAS28≥3.2  
Remission (DAS28<2.6) at 1 
yr in 34% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p≤0.1 on 
univariable analysis, using backwards step-wise selection: 
 Symptom duration <3 mths (OR 2.0, 95% CI 1.3 to 
3.3) and starting DMARD within initial 3 mths (OR 1.7, 
95% CI 1.1 to 2.7). 
(G
re
m
e
s
e
 e
t 
a
l., 2
0
1
3
) 
CATCH 
(Canada, 
multicentre) 
2007-
2013 
1840 1897  Symptoms 6-52 
wks  
 Fulfilling 1987 or 
2010 RA criteria 
 Either: 
 ≥ 2 swollen joints  
Or: 
 1 swollen 
MCP/PIP and ≥1 
of: positive RF, 
positive ACPA, 
EMS >45 min, 
NSAID-response, 
or a positive MTP 
squeeze 
- Sustained remission (for ≥ 6 
mths or 2 consecutive visits 
for remission definitions 
below) over follow-up 
(maximum 5 yrs): 
 ACR Boolean (using 
28-joint counts) in 19%. 
 SDAI in 23%. 
 
Multivariable logistic regression, entering clinical, 
laboratory, radiographic, initial treatment (steroid and 
DMARD use within first 3 months) and time to remission 
variables if p<0.1 on univariable analysis, using backwards 
step-wise selection (retention if p<0.05 or pre-determined 
variable: age, gender, symptom duration, DAS28) (missing 
data for serology and x-rays imputed): 
 ACR Boolean definition: initial steroids (OR 0.5, 95% 
CI 0.3-0.7), initial combination DMARD (OR 1.6, 95% 
CI 1.1-2.3), time to remission (mths) (OR 0.94, 95% 
CI 0.92-0.96). 
 SDAI definition: initial steroids (OR 0.5, 95% CI 0.4-
0.8), initial combination DMARD (OR 1.5, 95% CI 1.1-
2.1), time to remission (mths) (OR 0.94, 95% CI 0.92-
0.95). 
(K
u
riy
a
 e
t a
l., 2
0
1
4
) 
Rome (Italy) 
 
 
Not 
reported 
121 Not 
reported 
 Symptoms <1 yr 
 Fulfilling 1987 
and 2010 RA 
criteria 
Initial MTX +/- low dose 
steroid. Addition of 
Adalimumab or 
Etanercept if 
DAS44 >2.4 
 
Remission (5 of 1981 ACR 
remission criteria at 2 visits 
for ≥3 months without f lare 
[DAS44>0.6] or change in 
DMARD/steroid within prior 
6 mths) at 1 yr in 25% 
Multivariable logistic regression, entering clinical, 
laboratory and radiographic variables with p<0.25 on 
univariable analysis, using backwards step-wise selection: 
 Symptoms<3 mths (OR 5.3, 95% CI 2.1–13). 
(B
o
s
e
llo
 e
t a
l., 2
0
1
1
) 
Remission (DAS44<1.6 at 2 
visits for ≥3 mths without 
flare [DAS44>0.6] or change 
DMARD/steroid for previous 
6 mths) at 1yr in 46%. 
Multivariable logistic regression, as above: 
 Male (OR 2.5, 95% CI 1.1–5.9), ESR<35 mm/hr (OR 
2.4, 95% C 2.2–5.1). 
Radiographic erosion(s) at 1 
yr in 40% 
Multivariable logistic regression, as above: 
 Symptoms ≥3 mths (OR 3.9, 95% CI 1.5–11). 
EURIDISS: European Research on Incapacitating Diseases and Social Support, SSZ: sulfasalazine, Mo-Co-To: Montpellier-Cochin-Tours/Toulouse cohort, 
BARFOT: Better Anti-Rheumatic Pharmacotherapy, BMD: bone mineral density, ERAN: Early RA Network, CARDERA: Combination Anti-rheumatic Drugs in 
Early Rheumatoid Arthritis, RCT: randomised controlled trial, SWEFOT: Swedish Pharmacotherapy Trial, CDAI: clinical disease activity index, CATCH: Canadian 
Early Arthritis Cohort.
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 Randomised trials assessing prognostic factors using multivariable analysis, in patients with early DMARD-naïve RA. Table 7.
Rheumatoid arthritis is defined according to fulfilment of 1987 RA criteria, unless otherwise stated.  
Study 
Population 
Years 
patients 
recruited 
n 
Total number 
of patients 
randomised 
Inclusion 
Criterion 
(patients 
fulfilling 1987 
ACR RA criteria, 
unless otherwise 
stated) 
Treatment Protocol    Outcome 
Statistical Methods of Analysis and Predictive 
Factors with Statistical Significance 
(independent variables are variables at baseline 
unless otherwise stated) 
R
e
fe
re
n
c
e
 
Utrecht 
(Netherlands) 
1990 
onwards 
128 Not reported  Disease duration 
<1 yr 
Initial NSAID vs. initial 
HCQ vs. initial IM gold 
vs. initial MTX (open-
label) 
Radiographic progression 
(change in SHS from 
baseline >0) at 1 yr in 75% 
Multivariable logistic regression, entering clinical,  
laboratory, radiographic and treatment variables using 
forwards step-wise selection: 
 joint score (joint swelling and tenderness, with 
weighting by size of joint)(Thompson et al., 1987) (OR 
1.9, 95% CI 1.0-3.5), RF-positivity (OR 12.3, 95% CI 
3.4-4.6), baseline SHS (OR 5.0, 95% CI 1.3-20). 
(v
a
n
 d
e
r H
e
id
e
 
e
t a
l., 1
9
9
5
) 
 1990-
1998 
397 562 As above 1
st
 yr: as above. 
2
nd
 yr: switch if no 
response (>50% 
improvement in ≥3 of: 
pain VAS, Thompson 
joint score, EMS, ESR) 
NSAIDs→DMARD, 
HCQ→auranofin,  
IM gold→penicillamine, 
MTX→SSZ. 
Yrs 3-4: no protocol. 
Remission (EMS≤15 min, 
VAS pain≤10mm, Thompson 
joint score≤10, ESR≤30 
mm/hr for ≥6 months) over 4 
yrs in 36% 
Multivariable Cox regression analysis, entering clinical, 
laboratory, radiographic variables and response at 6 mths 
using step-wise selection (not further specified): 
 Thompson joint score (coefficient 1.00, 95% CI 0.996-
1.00), pain (VAS) (coefficient 0.98, 95% CI 0.97-0.99), 
RF-negativity (coefficient 1.6, 95% CI 1.2-2.3), good 6 
mth response (as defined in treatment protocol) 
(coefficient 4.8, 95% CI 3.2-7.0). 
(V
e
rs
ta
p
p
e
n
 e
t a
l., 2
0
0
5
) 
Sample from 
2 RCTs 
(Netherlands, 
multicentre) 
1990-
1998 
78 394+  Disease duration 
<1 yr 
Protocol for DMARD 
therapy for first 2 years 
(van Jaarsveld et al., 
2000; van Everdingen et 
al., 2002) (open-label) 
Disease activity (composite 
score based on SJC and 
TJC of 38 joints and ESR) at 
3 and 5 years 
Multiple linear regression, entering baseline disease activity 
and clinical, laboratory and psychosocial variables with 
p<0.05 on univariable analysis, using sequential selection: 
 3yrs: baseline disease activity (correlation coefficient 
0.4, p<0.01), passive avoidance coping (correlation 
coefficient 0.3, p<0.01) social support (correlation 
coefficient -0.2, p<0.05). 
 5yrs: baseline disease activity (correlation coefficient 
0.3, p<0.05), passive avoidance coping (correlation 
coefficient 0.3, p<0.05). 
(E
v
e
rs
 e
t a
l., 2
0
0
3
) 
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FIN-RACo 
(Finland) 
1993-
1995 
157 199  Symptoms <2 yrs 
 SJC ≥3 
 ≥3 of: ESR ≥28 
mm/hr or CRP 
>19 mg/l, EMS 
≥29 min, SJC>5, 
TJC>10 
MTX + SSZ + HCQ + 
prednisolone vs. initial 
SSZ +/- low dose 
prednisolone (open-
label) 
Remission (1981 ACR 
remission criteria excluding 
fatigue and EMS) at 6 mths 
in 23% combination group 
vs. 9% initial SSZ group 
Multivariable logistic regression per treatment group, 
entering pre-determined variables (age, gender, symptom 
duration, SJC, TJC, ESR, RF-positivity and those below): 
 Combination group (vs initial SSZ) (OR 4.4, 95% CI 
1.6-12), soluble IL2 receptor (OR 4.7, 95% CI 1.4-15). 
(K
u
u
lia
la
 e
t a
l., 
2
0
0
5
) 
  165 199 As above As above Remission (5 of 1981 ACR 
remission criteria: EMS ≤15 
min, no joint pain, TJC=0, 
SJC=0, ESR <30 mm/hr in 
women or <20 mm/hr in 
men) at 2 yrs in 42% 
combination group vs. 17% 
in initial SSZ group 
Multivariable logistic regression per treatment group, 
entering pre-determined variables (age, gender, number of 
ACR criteria fulfilled, shared epitope and symptom 
duration): 
 Combination group: no variables independently 
predictive. 
 Initial SSZ: symptom duration <4mths (p=0.01). 
(M
ö
ttö
n
e
n
 e
t a
l., 
2
0
0
2
) 
COBRA 
(Netherlands, 
Belgium) 
 
1993-
1995 
135 156  Time from 
diagnosis <2 yrs 
Initial combination 
therapy (MTX, SSZ + 
high dose prednisolone) 
vs. SSZ + placebo 
(single-blind) 
Radiographic progression 
(increase in SHS ≥1) at 1 yr 
at the joint level (n=2,700 
joints) 
Conditional logistic regression, entering baseline swelling 
score (0-2), tenderness score (0-3) and SHS for individual 
joints: 
 Swelling score (OR 2.8, 95% CI 1.9-4.1), tenderness 
score (OR 1.8, 95% CI 1.3-2.4), SHS (OR 2.0, 95% CI 
1.6-2.6). 
(B
o
e
rs
 e
t 
a
l., 2
0
0
1
) 
  148 156 As above As above Mean change in SHS score 
per yr 
Multivariable generalised estimating equations, entering 
pre-determined variables (as below, plus age, gender, 
symptom duration, shared epitope, ESR and treatment use 
over follow-up): 
 Treatment group SSZ vs. combination (coefficient -
3.2, 95% CI -5.6 to -0.8), baseline DAS28-ESR 
(coefficient 1.2, 95% CI 0.2 to 2.2), RF-positivity 
(coefficient 3.6, 95% CI 1.2 to 5.0), baseline SHS 
(coefficient 0.2, 95% CI 0.1 to 0.3). 
(L
a
n
d
e
w
é
 e
t a
l., 
2
0
0
2
) 
CAMERA 
(Netherlands, 
multicentre) 
1999-
2003 
205 299  Symptoms <1 yr 1-2 yrs: initial MTX with 
dose escalation and 
addition of ciclosporin 
depending on response 
(determined by physician 
assessment every 3 
months or computer 
program every 4 weeks) 
(open-label) 
Radiographic progression 
(mean yearly change in SHS 
from baseline) over 5 yrs (4 
or 6 yr data used in n=76) 
Multiple linear regressions, entering all pre-determined 
variables (age, gender, DAS28, RF-positivity, treatment 
arm, baseline SHS, and 6 mth response): 
 EULAR good response at 6 mths (coefficient -0.4, 
95% CI -0.7 to -0.1), RF-positivity (coefficient 0.3, 95% 
CI0.1-0.6), SHS (coefficient 0.07, 95% CI 0.04-0.10). 
(B
a
k
k
e
r e
t a
l., 2
0
1
1
) 
DAS28-ESR at 5 yrs (4 or 6 
year data used in n=34) 
Multiple linear regressions, as above: 
 EULAR good response at 6 mths (coefficient -0.8, 
95% CI -1.2 to -0.3) 
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CIMESTRA 
(Denmark) 
1999-
2002 
130 
in 
MRI 
sub-
stud
y 
160  Disease duration 
<6 mths 
 SJC ≥2 
Yrs 1-2: MTX + 
ciclosporin vs. MTX + 
placebo, with IA steroid 
+/- addition HCQ ≥wk 68 
(double-blind to initial 
therapy)  
Radiographic progression 
(change in SHS from 
baseline >0) at 2 yrs in 30% 
Multivariable logistic regression, entering radiographic and 
MRI wrist variables with p<0.05 on univariable analysis and 
clinical and laboratory variables (age, gender, DAS28, 
shared epitope, ACPA, smoking) using backwards step-
wise selection: 
 MRI bone marrow oedema score (OR not given). 
(H
e
tla
n
d
 e
t 
a
l., 2
0
0
9
) 
     Yrs 1-2 as above. 
Yrs 3-5: step-up if 
required to MTX + SSZ + 
HCQ, then TNF-inhibitor  
Radiographic progression 
(change in SHS from 
baseline >0) at 5 yrs in 53% 
(intention-to-treat analysis) 
Multivariable logistic regression, entering pre-determined 
clinical, laboratory, radiographic and MRI wrist baseline 
variables (including age, gender, DAS28, MRI bone 
marrow oedema score, MRI erosion score, MRI synovitis 
score and those below): 
 ACPA-positivity (OR 4.0, 95% CI 1.7-9.8), baseline 
SHS (OR 1.12, 95% CI 1.03-1.21). 
 (H
e
tla
n
d
, S
te
n
g
a
a
rd
-
P
e
d
e
rs
e
n
 e
t a
l. 2
0
1
0
 
BeSt 
(Netherlands, 
multicentre) 
2000-
2002 
Not 
give
n 
508  
 
 Disease duration 
<2yrs 
 SJC (of 66) ≥6 
and TJC (of 68) 
≥6,  
 Either ESR ≥28 
mm/hr or a VAS 
global health ≥20 
mm 
Sequential DMARD 
monotherapy; step-up to 
combination DMARD 
therapy; initial DMARD 
combination therapy 
including 
high dose prednisone; or 
initial 
MTX + Infliximab 
(single-blind) 
Radiographic progression 
(increase in SHS from 
baseline >smallest 
detectable change 
[4.6]) at 2 yrs in 40%, 34%, 
19% and 18% across 
treatment groups, 
respectively 
Multivariable logistic regression, entering RF or ACPA-
positivity (separate models) with confounders (variables 
associated with RF or ACPA on univariable analysis with 
p<0.05: gender, smoking, DAS44-ESR, SHS erosion score 
≥0.5) in patients grouped by treatment arm: 
 RF-positivity (OR 4.7, 95% CI 1.5-14.5), ACPA-
positivity (OR 13, 95% CI 3-52) with sequential 
monotherapy. 
 No significance in other treatment groups. 
(d
e
 V
rie
s
-B
o
u
w
s
tra
 e
t 
a
l., 2
0
0
8
) 
465 508 As above As above Rapid radiographic 
progression (increase in 
SHS from baseline ≥5) at 1 
yr in 33% initial 
monotherapy, 13% initial 
DMARD combination and 
9% initial infliximab groups 
Multivariable logistic regression, entering variables with 
significance on univariable analysis (plus age, gender, BMI, 
smoking, symptom duration, SJC, DAS44, HAQ and 
treatment group) using backwards step-wise selection 
(retention if p≤0.10) (continuous variables categorised 
using tertiles): 
 SHS erosion score ≥4 (OR 4, 95% CI 2-9), RF or 
ACPA-positivity (OR 2, 95% CI 1-6), both positive (OR 
4, 95% CI 2-9), CRP ≥35mg/dL (OR 5, 95% CI 2-10), 
initial combination DMARD vs monotherapy (OR 0.1, 
95% CI 0.1-0.4), initial infliximab vs monotherapy (OR 
0.1, 95% CI 0.1-0.3). 
(V
is
s
e
r e
t a
l., 2
0
1
0
) 
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BeSt (contd.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2000-
2002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
497 508  
 
 Disease duration 
<2yrs 
 SJC (of 66) ≥6 
and TJC (of 68) 
≥6,  
Either ESR ≥28 
mm/hr or a VAS 
global health ≥20 
mm 
Sequential DMARD 
monotherapy; step-up to 
combination DMARD 
therapy; initial DMARD 
combination therapy 
including 
high dose prednisone; or 
initial 
MTX + Infliximab 
(single-blind) 
HAQ ≥1 at 3 mths, rates not 
given 
Multivariable logistic regression, entering variables with 
p<0.1 on univariable analysis (plus confounders, not 
specified) using backwards step-wise selection (retention if 
p≤0.10) (separate models constructed for variables with co-
linearity or overlapping, with selection of final model with 
maximum Nagelkerke’s’ R
2
) 
 
(continuous variables 
categorised using tertiles): 
 Treatment group; initial combination DMARD vs. 
monotherapy (OR 0.3, 95% CI 0.2–0.5) initial 
infliximab vs monotherapy (OR 0.4, 95% CI 0.2–0.6), 
HAQ; 2nd tertile (OR 2.6, 95% CI 1.6–4.2) 3rd tertile 
(OR 5.3, 95% CI 2.9–9.5) (vs lowest tertile HAQ<1.4), 
VAS pain; 2nd tertile (OR 2.2, 95% CI 1.3–3.8), 3rd 
tertile (OR 2.7, 95% CI 1.4–5.1) (vs lowest tertile 
VAS<40), RAI; 2nd tertile (OR 1.7, 95% CI 1.0–3.0), 
3rd tertile (OR 2.7, 95% CI 1.5–4.7) (vs lowest tertile 
RAI<10). 
(D
irv
e
n
 e
t a
l., 2
0
1
2
) 
508 508 As above  As above Sustained drug-free 
remission at 5 yrs 
(DAS44<1.6 for ≥1 yr after 
cessation of 
DMARD/steroid) in 10% 
Multivariable logistic regression, entering clinical, laboratory 
and radiographic variables with p<0.10 on univariable 
analysis, using backwards step-wise selection (retention if 
p≤0.10) 
 
(treatment group not significant predictor on 
univariable analysis, therefore not included in model): 
 Male gender (OR 2.4, 95% CI 1.3-4.5), symptom 
duration (wks) (OR 0.99, 95% CI 0.98-1.00), DAS44 
(OR 0.6, 95% CI 0.4-0.9), ACPA-positivity (OR 0.2, 
95% CI 0.1-0.4). 
(v
a
n
 d
e
r W
o
u
d
e
 e
t 
a
l., 2
0
1
2
) 
508 508 As above As above Failure of initial treatment 
(DAS44-ESR>2.4) 
Risk regression model with adjustment for sex, age, 
smoking, RF and baseline DAS44: 
 High BMI (≥25 vs. <25kg/m
2 
) (RR: 1.1, 95% CI 1.2-
1.4). 
 BMI (continuous variable) (RR: 1.02, 95% CI 1.01-
1.04). 
N.B. with stratification for treatment group, BMI (continuous 
variable) remained independently predictive of response to 
initial MTX monotherapy (groups 1 and 2). Linear mixed 
model demonstrated higher TJC and patient VAS in 
patients with high BMI over 1 yr 
(H
e
im
a
n
s
 e
t a
l., 2
0
1
3
) 
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BeSt (contd.) 2000-
2002 
186 508 As above, receiving 
initial MTX 
monotherapy, with 
blood samples for 
DNA analysis  
Sequential DMARD 
monotherapy and step-
up to combination 
DMARD groups received 
MTX 15mg x 3mths then 
escalated to 25-30mg 
weekly x 3 mths (if 
DAS44<2.4 at 3 mths) 
DAS44-ESR ≥2.4 at 6 mths 
in 53% 
Multivariable logistic regression, entering clinical and 
laboratory +/- genetic variables with p≤0.1 on univariable 
analysis, using backwards step-wise selection (retention if 
p≤0.10) 
 
(continuous variables categorised using quartiles) 
(RF-positivity fitted as interaction term with smoking) 
(separate models including and excluding genetic factors) 
 Female gender, RF-positivity in combination with 
smoking and DAS44 independent predictors (OR not 
given for non-genetic model).  
(W
e
s
s
e
ls
, v
a
n
 d
e
r 
K
o
o
ij e
t a
l. 2
0
0
7
 
ASPIRE RCT 2000-
2002 
100
4 
1049   Symptoms 
>3mths and 
<3yrs 
 SJ ≥10, TJC≥12 
 1 of: CRP 
>2mg/dL, 
RF- positivity, 
radiographic 
erosions 
MTX + placebo;  MTX + 
Infliximab 3mg/kg; or 
MTX + Infliximab 6mg/kg 
(double-blind) 
Radiographic progression 
(change in SHS from 
baseline >0) at 1 yr in 61% 
(MTX alone) vs. 39% (MTX 
+ Infliximab) 
Multivariable logistic regression, entering pre-determined 
variables (age, gender, SJC44, TJC44, RF-positivity, CRP, 
ESR, baseline SHS), separate models for MTX alone and 
MTX + infliximab groups: 
 MTX alone: SJC44 (OR 1.04, 95% CI 1.01-1.07), ESR 
(OR 1.02, 95% CI 1.01-1.03). 
 MTX + Infliximab: age (OR 1.02, 95% CI 1.01-1.04), 
SHS (OR 0.99, 95% CI 0.97-1.00). 
(S
m
o
le
n
 e
t a
l., 
2
0
0
6
) 
  Not 
give
n 
1049 As above As above Rapid radiographic 
progression (change in SHS 
from baseline ≥5) at 1 yr in 
23% (MTX alone) vs. 8% 
(MTX + Infliximab) 
Multivariable logistic regression, entering all variables 
identified using univariable analysis (SJC28, RF titre, ESR, 
CRP) and treatment group (separate models constructed 
for ESR and CRP due to co-linearity) (continuous variables 
categorised using tertiles). Matrix risk model developed 
with the following variables: 
 CRP (<0.6, 0.6–3 or >3 mg/dl) or ESR (<21, 21–50 
or >50 mm/h), SJC28 (<10, 10–17 or >17) and RF 
(<80, 80–200 or >200 U/ml), treatment (MTX vs MTX+ 
infliximab) 
(V
a
s
te
s
a
e
g
e
r e
t a
l., 
2
0
0
9
) 
RCT (Japan, 
multicentre) 
Not 
reported 
55 Not reported  Symptoms <2 yrs 
 TJC (of 48) ≥6, 
SJC (of 46) ≥3, 
CRP ≥1.0mg/dl 
or ESR ≥
30mm/hr 
MTX 8 mg/week, 
bucillamine 
200 mg/day, 
or MTX + bucillamine 
(double-blind) alternative 
DMARDs in non-
responders after 24 wks 
or after adverse events  
Radiographic progression 
(change in SHS from 
baseline) at 2 yrs 
Univariable linear regression, baseline variables: 
 SJC (coefficient 0.3, p<0.05), CRP (coefficient 0.3, 
p<0.05), DAS28-CRP (coefficient 0.4, p<0.01) (95% 
CIs not given) 
Multiple linear regression using step-wise procedure, 
(variables considered were ACR core measures at baseline 
and over follow-up, RF and ACPA-positivity and baseline 
SHS), method not further specified. 2 final models reported 
include the following independent predictors: 
 Baseline SHS and 12 wk SJC, CRP and patient pain 
VAS. 
 Baseline SHS and mean SJC and CRP over follow-up 
(assessed every 3 mths). 
(Ic
h
ik
a
w
a
 e
t a
l., 2
0
1
0
) 
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HOPEFUL 
(Japan, 
multicentre) 
 
 
 
 
 
 
 
2009-
2010 
 
 
 
 
 
 
 
 
Not 
clear 
 
 
 
 
 
 
 
 
 
 
334 
 
 
 
 
 
 
 
 
 Disease duration 
≤2 yrs 
 SJC≥8, TJC≥10, 
ESR≥28mm/hr or 
CRP≥10mg/l 
 RF positive or 
≥radiographic 
erosion 
MTX (6-8mg/wk) + 
placebo or Adalimumab 
+ MTX 
 
 
 
 
 
 
 
Clinical remission 
(DAS28<2.6) at 6 mths 
(proportions of patients 
achieving not reported).  
Multivariable logistic regression, entering all variables 
identified using univariable analysis(p<0.1): 
 MTX alone: Female (OR 0.3, 95% CI 0.1-0.8), HAQ-DI 
(OR 0.4, 95% CI 0.2-1.0), physician VAS disease 
activity (OR 1.0, 95% CI 0.9-1.0). 
 Adalimumab +MTX: ACPA positive (OR 0.3, 95% CI 
0.1-0.9), DAS28 (OR 0.5, 95% CI 0.3-0.9), HAQ-DI 
(OR 0.3, 95% CI 0.1-0.7), radiographic erosion (OR 
0.1, 95% CI 0.01-1.0). 
(T
a
k
e
u
c
h
i e
t a
l., 2
0
1
4
) 
 
No radiographic progression 
(change in SHS from 
baseline ≤0.5) at 6 mths in 
57/161 (35%) (MTX alone) 
vs. 106/171 (62%) 
(adalimumab + MTX). 
Multivariable logistic regression, as above: 
 MTX alone: CRP>3mg/l (OR 3.1, 95% CI 1.1-8.7), 
physician VAS disease activity (OR 0.98, 95% CI 
0.96-0.99). 
 Adalimumab +MTX: CRP per mg/dl (OR 0.8, 95% CI 
0.7-0.9), SJC (OR 0.9, 95% CI 0.8-1.0), physician 
VAS disease activity (OR 0.98, 95% CI 0.96-1.00), 
SHS (OR 0.99, 95% CI 0.97-1.00). 
FIN-RACo: Finnish Rheumatoid Arthritis Combination Therapy Trial, COBRA: Combinatietherapie Bij Reumatoide Artritis, CAMERA: Computer Assisted Management in 
Early Rheumatoid Arthritis, CIMESTRA: Ciclosporin, Methotrexate and Steroids in Rheumatoid Arthritis, BeSt: Behandelstrategieën voor Reumatoide Artritis [treatment strategies 
for rheumatoid arthritis], DNA: deoxyribonucleic acid, ASPIRE: Active controlled Study of Patients receiving Infliximab for treatment of Rheumatoid arthritis of 
Early onset.
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2.3 Ultrasound Imaging in the Assessment of Patients with 
Inflammatory Arthritis 
Musculoskeletal ultrasound offers a means of imaging which is safe (not involving 
exposure to ionising radiation or contrast), relatively inexpensive and quick in 
comparison to other imaging modalities such as MRI or computed tomography 
(CT). It may be performed in real time in clinic. Two-dimensional, grey scale (GS) 
images enable the assessment of synovitis (through the detection of joint effusion 
and synovial hypertrophy), tenosynovitis, tendon damage and bone erosion. 
 
Synovitis and tenosynovitis may also be measured via the detection of abnormal 
blood flow within microvessels in the synovium and tenosynovium, using methods 
based on the Doppler effect. Colour Doppler provides an image in which colour 
represents the difference in the frequency between transmitted ultrasound waves 
and those reflected back from moving blood cells. This is determined by the speed 
and direction of cells (Terslev et al., 2008). Whereas for images obtained using 
power Doppler, colour represents the amplitude of waves reflected back with a shift 
in frequency which is not dependent on the velocity of blood flow. Power Doppler 
activity (PD) is therefore more widely used in the assessment of the low-flow 
present in synovial microvessels (Wakefield et al., 2003). 
 
The use of ultrasound in clinical practice is increasing. Studies illustrating its 
potential value in real-life include a cross-sectional study of 46 patients with 
established RA; treatment decisions were altered after ultrasound (hands and 
wrists) in seven (15%) patients (Ceponis et al., 2014). Of note, patients with 
suspected fibromyalgia were excluded. In a retrospective study of patients with RA 
undergoing ultrasound for disease activity assessment within routine practice, the 
treatment decision was influenced by ultrasound results in 31/60 (52%) patients 
(Agrawal et al., 2009). Of course, by nature of the design of this latter study, 
ultrasound was conducted in these patients as it was deemed to be of clinical use. 
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2.3.1 Methods of Reporting 
The Outcome Measures in Rheumatology (OMERACT) group have provided 
standardised definitions of pathology visible on ultrasound, based on expert 
consensus (Wakefield et al., 2005): 
 Synovial effusion: abnormal intra-articular material which is compressible 
and usually anechoic/hypoechoic compared to subdermal fat (PD is absent). 
 Synovial hypertrophy: abnormal intra-articular material which is not 
compressible, is usually hypoechoic in comparison to subdermal fat and 
may be observed with/without PD.  
 Tenosynovitis: anechoic/hypoechoic thickened tissue, seen with/without fluid 
within the tendon sheath and in two perpendicular planes (with/without PD).  
 Tendon damage: an internal and/or peripheral focal tendon defect (i.e. 
absence of fibres) in the region enclosed by tendon sheath, seen in two 
perpendicular planes (Bruyn et al., 2014). 
 Cortical erosion: an intra-articular discontinuity of the bone surface visible in 
two perpendicular planes.  
 
 At the Joint Level 
Synovitis, tenosynovitis, tendon damage and erosive damage at the joint level may 
be reported using dichotomous outcomes (present or absent), semi-quantitative 
scales or quantitative methods. Reporting methods vary across studies, particularly 
for tenosynovitis (Alcalde et al., 2012). Most studies have defined or adopted 
semi-quantitative scales (Table 8), with GS synovitis commonly defined by 
combined assessment of synovial effusion and hypertrophy (as these processes 
usually occur together in pathological synovitis). Recently, the EULAR-OMERACT 
semi-quantitative global score for synovitis, combining both the GS appearance of 
synovial hypertrophy and PD assessments, has been developed using an expert 
consensus-based approach (D’Agostino et al., 2017). 
 
Quantitative measures include the depth of synovium for GS synovitis (Schmidt et 
al., 2004; Scheel, A. K. et al., 2005), the number or proportion of pixels affected by 
colour Doppler or PD on digital image analysis (Walther et al., 2001; Terslev et al., 
2008) and diameter of erosions (Zayat et al., 2015). Good correlations have been 
observed between semi-quantitative and quantitative methods of assessments of 
both GS (Scheel, A. K. et al., 2005) and PD synovitis (Walther et al., 2001).  
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 Semi-quantitative methods of scoring pathology on ultrasound. Table 8.
Research 
group 
Ultrasound 
parameter 
Grading 
Szkudlarek  
et al 
 
GS 
hypertrophy 
0: none, 
1: minimal synovial thickening (filling the angle between 
the periarticular bones, without bulging over the line 
linking tops of the bones),  
2: synovial thickening bulging over the line linking tops 
of the periarticular bones but without extension along 
the bone diaphysis,  
3: synovial thickening bulging over the line linking tops 
of the periarticular bones, with extension to at least one 
of the bone diaphyses (Szkudlarek, M. et al., 2003).  
Later publications include grade 4: extension to both 
diaphyses (Szkudlarek et al., 2004; Szkudlarek et al., 
2006). 
GS effusion 0: none,  
1: minimal amount of joint effusion,  
2: moderate amount of joint effusion (without distension 
of the joint capsule),  
3: extensive amount of joint effusion (with distension of 
the joint capsule) (Szkudlarek, M. et al., 2003). 
Leeds score GS 
hypertrophy 
0: none, 
1: mild, flat thickening,  
2: moderate thickening,   
3: marked thickening (Karim et al., 2004; Brown et al., 
2006). 
Newman et al PD synovitis 0: no or minimal hyperaemia,  
1: mild hyperaemia,  
2: moderate hyperaemia,  
3: marked hyperaemia (Newman et al., 1996). 
EULAR/ 
OMERACT 
GS 
hypertrophy  
0: no hypertrophy independently of presence of effusion, 
1: minimal; hypertrophy with or without effusion up to 
level of horizontal line connecting bone surfaces, 
2: moderate; hypertrophy with or without effusion 
extending beyond joint line but with upper surface 
concave (curved downwards) or hypertrophy extending 
beyond joint line but with upper surface flat, 
3: severe; hypertrophy with or without effusion 
extending beyond joint line but with upper surface 
convex (curved upwards) (D’Agostino et al., 2017). 
 PD synovitis 0: none,  
1: minimal; three single PD spots or up to one confluent 
spot and two single spots or up to two confluent spots, 
2: moderate; greater than grade 1 but <50% PD signals 
in the total GS, 
3: severe; PD affecting >50% of the background GS 
(D’Agostino et al., 2017). 
 GS 
hypertrophy 
and PD 
synovitis 
combined 
0: normal; no hypertrophy or PD, 
1: minimal; GS=grade 1 and PD≤grade 1 
2: moderate; GS=grade 2 and PD≤grade 2 or 
GS=grade 1 and PD=grade 2, 
3: severe; GS=grade 3 and PD≤grade 3 or GS=grade 1 
or 2 and PD=grade 3 (D’Agostino et al., 2017). 
 
 
 
 
GS 
tenosynovitis 
In longitudinal and transverse planes… 
0: normal, 
1: minimal, 
2: moderate, 
3: severe (Naredo et al., 2013a). 
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EULAR/ 
OMERACT 
(contd.) 
 
PD 
tenosynovitis 
Visible in 2 perpendicular planes and excluding normal 
feeding vessels… 
0: no signal, 
1: peritendinous focal signal within the widened synovial 
sheath (i.e. signals in only one area of the widened 
sheath),  
2: peritendinous multifocal signal within the widened 
synovial sheath (i.e. signals in more than one area of 
the widened sheath),  
3: peritendinous diffuse signal within the widened 
synovial sheath (i.e. signals filling most of 
the widened sheath). 
In the presence of abnormal intratendinous signal 
(visible in 2 perpendicular planes and excluding normal 
feeding vessels) in addition to grade 1 or 2 
peritendinous PD signal, increase grade by one point 
(Naredo et al., 2013a). 
OMERACT Tendon 
damage 
In longitudinal and transverse planes… 
0: normal, 
1: minimal, 
2: moderate, 
3: severe (Bruyn et al., 2014). 
Szkudlarek  
et al 
Erosion 0: regular bone surface,  
1: irregularity of the bone surface without formation of a 
defect seen in 2 planes,  
2: formation of a defect in the surface of the 
bone seen in 2 planes,  
3: bone defect creating extensive bone destruction 
(Szkudlarek, M. et al., 2003). 
Wakefield et al Erosion 
(cortical 
break seen in 
2 planes) 
Small: diameter <2mm, 
Moderate: diameter 2–4 mm,  
Large: diameter >4 mm (Wakefield et al., 2000). 
Zayat et al Erosion 
(cortical 
break seen in 
2 planes) 
0: none, 
1: erosions covering less than one third, 
2: erosions covering between one- and two-thirds, 
3: erosions covering more than two-thirds of the bone 
surface (Zayat et al., 2015). 
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 At the Patient Level 
The appropriate selection of joints and tendons to assess for an accurate depiction 
of disease activity and damage in an individual patient depends on a number of 
factors. These include the frequency of joint involvement (Iagnocco et al., 2008) as 
well as the sensitivity and specificity of ultrasound findings at various joint sites in IA 
(Backhaus et al., 2009). Integral within this is the accessibility of specific joints for 
imaging with ultrasound (Szkudlarek, M. et al., 2003; Iagnocco et al., 2008). 
Ultimately, the choice of joints to examine is dependent on the intended use of 
ultrasound. High sensitivity of an extensive joint assessment may be appropriate for 
use within a trial setting or for classification/prognostic assessment at the outset of 
treatment. In contrast, for monitoring of patients on treatment in clinical practice, 
examination of a reduced number of joints seems more feasible. 
 
Previous studies have largely reported joint counts of the number of joints affected 
by GS and/or PD synovitis, in addition to total scores for GS and/or PD calculated 
by summation of the respective semi-quantitative scores at individual joints (Mandl 
et al., 2011). Work is currently underway to establish the optimal selection of joints 
to score using the EULAR-OMERACT combined score to facilitate the monitoring of 
RA activity and improve comparability across studies in the future (Terslev et al., 
2017b). The performance of global ultrasound scores (calculated from examinations 
of multiple joints), in addition to ultrasound assessments at the level of individual 
joints, are discussed below. 
 
2.3.2 Effectiveness of Ultrasound According to the OMERACT Filter 
 
Ultrasound enables evaluation of joints and peri-articular structures based on GS 
appearance and PD in multiple planes, in real time. It is already widely used in 
clinical practice in the assessment of patients with IA, being relatively affordable 
and less time-consuming than other imaging methods (D’Agostino et al., 2009). 
Hence, it has face validity, content validity and feasibility. Other aspects of 
effectiveness of ultrasound as a tool in the assessment of early IA are discussed 
below, according to the criteria outlined within the OMERACT filter (Table 9) (Boers 
et al., 2014). 
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 The requirements of an effective measurement tool: definitions of terms Table 9.
within the OMERACT filter. 
Truth Face 
Validity 
The theoretic plausibility of a measurement tool for its 
intended use. 
 Content 
Validity 
The completeness of a tool to reflect the entirety of the 
concept it is intending to measure and the necessity 
for inclusion of all the components within the 
measurement tool (i.e. do all its aspects contribute 
uniquely to the overall measure). 
 Construct 
Validity 
Agreement with other measures which are 
theoretically related and lack of agreement with those 
which are not. 
 Criterion 
Validity 
Agreement with an ideal or ‘gold’ standard. This 
includes: 
 Concurrent validity: agreement with a ‘gold’ 
standard assessment conducted simultaneously 
with the proposed new measurement tool. 
 Predictive validity: agreement with a ‘gold’ standard 
assessment carried out in the future, i.e. ability of a 
tool to predict a future state. 
Discrimination Includes the ability of a tool to differentiate between health and 
disease, as well as between disease severity states (including 
reliability and responsiveness). 
 Reliability The ability of a tool to detect severity states with 
consistency. For example, between equipment 
or between observers (inter-observer) and by 
the same observer over time (intra-observer). 
 Responsiveness The ability to detect differences in severity over 
time, e.g. for the purposes of monitoring 
response to treatment. 
Feasibility Practicality of using the measurement tool, including involved time 
and financial costs. 
 
 
 
2.3.2.1 Synovitis 
 Synovitis: Construct Validity 
The most objective measure of active synovitis available real-time in clinic is 
presumed to be joint swelling on clinical examination, relative to other methods 
such as joint tenderness. However, clinically it may be difficult to distinguish active 
synovitis from other physical signs of swelling such as tenosynovitis, soft tissue 
oedema and osteophytes (Wakefield et al., 2004; Salaffi et al., 2008). Furthermore, 
subclinical synovitis may be detectable by ultrasound in the absence of overt 
clinical swelling. This has been confirmed in patients with early IA prior to treatment 
(Wakefield et al., 2004; Funck-Brentano et al., 2009), early RA (Szkudlarek et al., 
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2004; Salaffi et al., 2008) and established RA (Szkudlarek, M. et al., 2003; 
Szkudlarek et al., 2004; Ceponis et al., 2014; Kawashiri et al., 2014a). 
 
In comparison to synovitis detected by MRI as the reference standard, GS synovitis 
has been shown to offer higher sensitivity and slightly lower specificity in 
comparison to clinical examination. Amongst 40 patients with RA (20 of whom had 
been diagnosed within the preceding two years) and 20 controls, the sensitivity and 
specificity of low-grade GS synovitis at the MCPs (≥grade 1) was 70% and 78%, 
respectively (versus 40% and 85% for clinical swelling and/or tenderness) 
(Szkudlarek et al., 2006). For the MTPs, the sensitivity and specificity of GS 
synovitis was 87% and 74%, respectively (versus 43% and 89%, respectively, for 
clinical examination) (Szkudlarek et al., 2004).  
 
Higher levels of GS and PD synovitis (both defined as ≥grade 2) have been shown 
to be highly sensitive and specific for MRI osteitis in DMARD-naïve patients with 
suspected early RA (Damjanov et al., 2012; Kawashiri et al., 2014b). Sensitivity and 
specificity for GS synovitis was 100% and 84% at the MCPs and 93% and 94% at 
the wrists, respectively. Sensitivity and specificity for PD synovitis were 96% and 
91% at the MCPs and 83% and 90% at the wrists, respectively. Good correlations 
were observed between the respective semi-quantitative ultrasound scores and 
MRI osteitis scores (p<0.001). 
 
Concerning summative GS and PD synovitis scores calculated from assessments 
of multiple joints, construct validity has been evaluated by assessing their 
concordance with clinical and laboratory measures of disease activity in patients 
with RA (Mandl et al., 2011). Significant correlations have been observed with 
composite clinical measures (mainly DAS28) (Hameed et al., 2008; Naredo et al., 
2008b; Balsa et al., 2010; Perricone et al., 2012)  and inflammatory markers 
(Hameed et al., 2008; Scirè et al., 2009; Dougados et al., 2010; Perricone et al., 
2012). The selection of joints in such studies ranged from extensive assessments of 
44 joints (Scirè et al., 2009) to examinations of the hands and wrists alone 
(Hameed et al., 2008). Scores of PD synovitis and those including large joints 
appear to show greater concordance with inflammatory markers than either GS 
synovitis scores (Hameed et al., 2008) or assessments restricted to small joints 
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(Ozgocmen et al., 2004; Mandl et al., 2011), although these conclusions are largely 
based on studies conducted in patients with established RA. 
 
A systematic review concluded simplified assessments of either twelve (wrists, 
MCPs2-3, knees, ankles and elbows) (Naredo et al., 2008b) or seven joints 
(unilateral wrist, MCPs2-3, PIPs2-3 and MTP2 and 5) (Backhaus et al., 2009) 
provided good validity (Mandl et al., 2011). Significant correlations have been 
demonstrated between DAS28 and GS and PD scores for both the 12-joint and 
7-joint sets in patients with established RA commencing TNF inhibitor therapy 
(Naredo et al., 2008b) and a mixed cohort of patients with IA commencing or 
receiving a change in DMARD or TNF inhibitor therapy (Backhaus et al., 2009). 
These standardised 12- and 7-joint assessments also demonstrate good correlation 
with more extensive ultrasound assessments in other cohorts of patients with active 
RA (Naredo, E et al., 2005; Hammer, H.B. and Kvien, T.K., 2011). 
 
 Synovitis: Concurrent Validity 
Grey scale synovitis (≥grade 1) has been compared to the macroscopic 
appearance of synovitis at arthroscopy in 60 patients undergoing the procedure for 
the investigation and/or treatment of knee pain (including 16 patients with RA) 
(Karim et al., 2004). Grey scale synovitis was identified in 107/119 compartments 
with visible synovitis and 14/56 compartments with a normal appearance (sensitivity 
90% and specificity 75%). 
 
Comparisons have also been made to the microscopic appearance of synovium in 
patients undergoing surgery. Strong and statistically significant correlation has been 
observed between the semi-quantitative assessment of PD and the histological 
appearance of vascularity in knee (Walther et al., 2001) and hip (Walther et al., 
2002) synovium. Amongst 14 patients with RA in clinical remission (1981 ACR 
remission), undergoing procedures at various sites (including the knees, hips, 
wrists, shoulders, elbows and tendon sheaths), weak positive (but not statistically 
significant correlation) was observed between GS hypertrophy (graded 0-3) and 
synovial hyperplasia, and between PD (graded 0-3) and vascularity on histology 
(Anandarajah et al., 2014). Of note, these studies included patients with primary 
and secondary osteoarthritis. In addition, ex-vivo histological vascularity is arguably 
not an ideal gold standard, as PD represents more than simply the number and size 
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of vessels, but also the degree of perfusion in a living system. This is supported by 
the rapid resolution of PD which may be observed with steroid treatment within one 
(Strunk, Strube et al. 2006) or two weeks (Larché et al., 2010), or even a few days 
(Newman et al., 1996). 
 
Some studies have employed more comprehensive histological scores for synovitis. 
Amongst patients undergoing knee replacement (15 patients with RA and 5 patients 
with osteoarthritis), significant correlation (p<0.05) was demonstrated between both 
GS and PD semi-quantitative scores and a combined histological score 
(encompassing inflammatory cell infiltrate, synovial thickness and vascularity) 
(Takase et al., 2012). Data from 20 knee joint replacements (including 10 patients 
with RA) demonstrated PD in 9/9 knees with pannus (defined as synovial 
proliferation with evidence of invasive destruction of bone and/or cartilage on 
histological examination), but also 5/11 knees without pannus. Of the latter, four 
demonstrated some evidence of synovitis (effusion and/or synovial proliferation 
during surgery and above average number of vessels per synovial area on 
histological inspection). Furthermore, PD in four of these patients was scored as 
grade 1 only, such that sensitivity and specificity of PD≥grade 2 (moderate or 
intense perfusion) for the detection of pannus was 89% and 91%, respectively 
(Schmidt et al., 2000). 
 
Arguably, more pertinent to use of ultrasound in patients with early IA who may lack 
large joint involvement, data have also been obtained from percutaneous synovial 
biopsy of joints including the wrists and smaller joints. In 44 patients with 
inflammatory conditions, data obtained from synovial biopsy of various sites (mainly 
the knees or wrists but also small joints, bursae and tendon sheaths) demonstrated 
a weak positive (but not statistically significant) correlation between GS effusion, 
GS hypertrophy and PD (semi-quantitative scales) and a comprehensive 
histological score for synovitis (Koski et al., 2006a). In 29 patients with RA, 
ultrasound and biopsy of 58 wrists, 15 MCPs and 8 PIPs revealed a significant 
correlation between colour Doppler activity and comprehensive synovitis scores 
and densities of immunohistochemical staining using T cell, macrophage and 
vessel markers (Andersen et al., 2014). These studies included patients with a 
variety of disease durations. This is pertinent given that in very early RA PD may be 
absent from joints demonstrating histological evidence of inflammation (Koski, 
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2012) and GS change may be observed with chronic synovial thickening/fibrosis in 
patients with established RA.  
 
Limited data are available from DMARD-naïve patients with early RA (Vreju et al., 
2011). Synovial biopsies of the knee were obtained from 35 patients with symptoms 
for less than one year). Significant correlation was observed between PD 
assessments (graded 0-3) and immunohistochemical staining for expression of 
vascular endothelial growth factor. 
 
 Synovitis: Predictive Validity 
- Predicting Joint Damage in Patients with Early IA 
Support for the validity of ultrasound synovitis as representative of true, active 
synovitis is provided by data from longitudinal studies demonstrating its association 
with radiographic damage over time. Such studies have been conducted in 
DMARD-naïve patients with early IA (the ESPOIR cohort) (Funck-Brentano et al., 
2013) and patients with early RA who are exclusively DMARD-naïve (Naredo et al., 
2007; Macchioni et al., 2013) or may have recently commenced DMARDs (Pascual-
Ramos et al., 2009; Fukae et al., 2010; Bøyesen et al., 2011). 
 
In the ESPOIR study, the presence of any PD and total PD score (MCPs2-5 and 
MTP5, bilaterally) appeared to predict radiographic progression over one year on 
multivariable analysis (see Table 4) (Funck-Brentano et al., 2013). A major 
limitation was that no adjustment was made for existing radiographic damage at 
baseline. In a subgroup analysis of joints without radiographic erosions at baseline, 
ultrasound synovitis did not appear to be an independent predictor on multivariable 
analysis, whilst the predictive value of existing ultrasound erosions at baseline was 
suggested (p=0.052 for the association with new radiographic erosion). The low 
number of joints developing erosion (n=26 of 1091 joints) and the overlapping 
nature of some of the predictor variables in these models limit the conclusions that 
may be drawn.  
 
In DMARD-naïve RA patients (fulfilling 1987 ACR criteria) ultrasound synovitis has 
been associated with progression in SHS over one year at both the level of single 
MCP joints (Macchioni et al., 2013) and the patient level (Naredo et al., 2007). At 
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MCPs, the following variables demonstrated significance in a conditional logistic 
regression model for the prediction of progression: presence of x-ray erosion at 
baseline (odds ratio [OR] 4.4, 95% CI 1.7-11), GS synovitis (≥grade 2) at baseline 
(OR 3.6, 95% CI 1.3-10) and PD synovitis (≥grade 2) on at least two occasions over 
one year (at 0, 6 and/or 12 months, OR 8.3, 95% CI 1.8-39) (Macchioni et al., 
2013). No significant relationship was identified between clinical signs (swelling or 
tenderness) and radiographic progression in this small study in which progression 
of erosive disease was observed in only 17/240 joints. This is despite the relatively 
severe phenotype of these patients; inclusion criteria included DAS28>4 and raised 
inflammatory markers, 12 (50%) patients had radiographic erosions at baseline and 
disease duration ranged up to almost ten years. At the patient level, total GS and 
PD scores (28-joint assessments), the number of swollen joints and DAS28 scores 
over time (area under the curve calculations over one year) have been significantly 
associated with change in total SHS over one year (p<0.05) (Naredo et al., 2007). 
The correlation appeared strongest with ultrasound synovitis; regression 
coefficients 0.61 for GS score and 0.59 for PD score, in comparison to 0.46 for 
swollen joint count (SJC28) and 0.40 for DAS28. Again, this was a small study 
(n=42). Methods were restricted to univariable analyses and confidence intervals 
were not reported. 
 
Validity of GS synovitis in predicting progression of erosive damage observed on 
MRI (increase in OMERACT RA MRI score) has been evaluated in the wrists of 
patients with early RA (symptoms up to one year, the majority were receiving 
DMARDs at baseline) (Bøyesen et al., 2011). Age, gender and 
clinical/laboratory/US/MRI variables with significance (p<0.25) on univariable 
analysis were entered into a multivariable model using a backwards step-wise 
approach. The number of areas in the wrist at which GS synovitis was present 
(radio-carpal joint, radial extensor tendons, dorsal midline extensor tendons, ulnar 
extensor tendons and flexor tendons) was an independent predictor of progression 
(OR 2.0, 95% CI 1.1-3.5), alongside MRI-measured bone marrow oedema (OR 1.3, 
95% CI 1.0-1.6) and male gender (OR 4.4, 95% CI 1.1-18). 
 
Two further studies have reported predictive validity of quantitative assessments of 
ultrasound synovitis. In Mexico, GS score was the sum of the measurements for the 
maximum depth of synovitis across all joints in the dominant hand and severity of 
PD was the sum of the measurements for the maximum depth of synovitis in 
69 
 
PD-positive joints (Pascual-Ramos et al., 2009). It was not clear that standardised 
views/probe positions were used and measurements of maximum depth may not be 
representative of the whole joint due to their variable shape. Other deficiencies 
included the outcome measure, presence of radiographic erosion, which was 
determined by consensus of between a radiologist and rheumatologist not blinded 
to patient data or chronology and variation in the duration of follow-up. In the final 
model, risk of erosion (at final follow-up, one to two years) was significantly 
associated with baseline PD score (HR 1.3, 95% CI 1.1-1.5) and the number of 
1987 ACR criteria fulfilled (HR 2.3, 95% CI 1.1-5.0). In Japan, significant correlation 
between the number of colour pixels present, at the level of individual MCP and PIP 
joints, and  Genant-modified Sharp score over 20 weeks has been demonstrated 
amongst 19 patients; however, analyses were restricted to univariable linear 
regression (Fukae et al., 2010). Trends were observed between semi-quantitative 
PD assessments (grading 0-3) and progression at the level of individual joints but 
these were not statistically significant. In MCP joints with PD at baseline, 
improvement in the number of colour pixels over eight weeks (as a proportion of the 
baseline number) showed a significant inverse correlation with progression at the 
individual joints.  
 
- Predicting Joint Damage in Patients with Established, Active RA 
Studies have been conducted in patients with various levels of disease activity and 
treatment regimens (Reynolds et al., 2009; Ogishima et al., 2014) as well as in a 
slightly more homogeneous groups of patients such as those with active disease 
requiring step-up or switch to an alternative biologic therapy (Taylor et al., 2004; 
Naredo et al., 2008a; Fukae et al., 2011; Dougados et al., 2013). The majority have 
examined radiographic progression by use of validated scoring methods including 
the SHS (Taylor et al., 2004; Naredo et al., 2008a) and Genant-modified Sharp 
score (Fukae et al., 2011) or alternative assessments of erosion and joint space 
narrowing (Dougados et al., 2013; Ogishima et al., 2014). Reynolds et al. have 
examined the predictors of progression of ultrasound erosive damage (Reynolds et 
al., 2009). 
 
In an observational study of 59 patients requiring a TNF-inhibitor for RA, with at 
least six swollen joints, generalised estimated equation modelling was used to 
investigate any association between ultrasound synovitis and radiographic 
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progression at two years at the level of individual joints (Dougados et al., 2013). 
Worsening of radiographic erosion and/or joint space narrowing, as judged by a 
blinded assessor who was aware of the chronology of films, occurred in 9% of 1888 
joints (wrists, MCPs, PIPs and MTPs). With adjustment for age, gender, disease 
duration, tender joint count (TJC), SJC, erythrocyte sedimentation rate (ESR), joint 
site and baseline x-ray damage score, either physician-judged definite clinical 
synovitis (OR 1.6, 95% CI 1.1-2.4), GS≥grade 1 (OR 1.6, 95% CI 1.1-2.4), 
GS≥grade 2 (OR 1.6, 95% CI 1.1-2.5) or PD≥grade 1 (OR 1.8, 95% CI 1.2-2.7) 
were significantly associated with the combined outcome of worsening of erosion 
and/or joint space narrowing. Sub-analyses of this study demonstrated the 
relevance of both subclinical GS≥grade 1 and PD≥grade 1. Amongst joints with 
normal clinical findings, worsening of erosion and/or joint space narrowing was 
observed in 11% of 420 joints with any GS present versus 4% of 675 joints without 
GS (OR 2.2, 95% CI 1.2-4.0) and 16% of 132 joints with PD present versus 5% of 
963 joints lacking any PD (OR 3.5, 95% CI 1.8-7.0).  
 
Further observational data suggests the relevance of subclinical PD to the risk of 
future joint damage (Ogishima et al., 2014). Amongst a heterogeneous group of 30 
patients (approximately half of patients were receiving biologics and approximately 
one third were in clinical remission), wrists, MCPs1-5 and PIPs2-5 were scanned by 
ultrasound; 450 joints had normal clinical and ultrasound findings, 120 joints had 
clinical swelling and/or tenderness and 30 joints had subclinical PD (≥grade 1). 
Across these joint groups, progression of erosion was observed in 1/450 (0.2%), 
2/120 (2%) and 1/30 (3%) joints, respectively. Progression of joint space narrowing 
was observed in 3/450 (0.7%), 6/120 (5%) and 1/30 (3%) joints, respectively. No 
statistical testing was performed for these infrequently occurring outcomes. 
 
In one of the largest studies to date, ultrasound assessments of 28 joints were 
available for 278 patients receiving TNF-inhibitor therapies in clinic (Naredo et al., 
2008a). Measures of GS and PD (number of joints affected and the sum scores of 
grading 0-3 at individual joints) were not independently predictive of change in SHS 
at one year on multiple linear regression analyses. In a second model considering 
time-integrated variables (area under the curve calculations for measures over one 
year), the number of joints with PD (coefficient 0.002, p<0.05), RF titre (0.0005, 
p<0.05) and ESR (0.0004, p<0.05) were significantly associated with progression. 
The lack of significance of baseline scores in this study may be related to the 
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efficacy of TNF-inhibitors in preventing joint damage. Indeed, on analysis of a small 
randomised-controlled trial of infliximab versus placebo (24 patients with 
inadequate response to methotrexate), total GS and PD scores for MCPs at 
baseline were significantly associated with change in SHS at one year, on 
univariable analysis, only amongst the placebo group (Taylor et al., 2004). 
Predictive validity of change in PD over time, in patients receiving biologics, is 
supported by a small observational study (Fukae et al., 2011). A 70% improvement 
in the number of colour pixels at MCPs and PIPs by week 8 was significantly 
associated with lack of progression at week 20 in 10 patients commencing 
adalimumab and 15 patients commencing tocilizumab. 
 
Finally, a study examining predictors of progression in ultrasound erosion score did 
not detect any significant association between clinical variables or GS or PD scores 
on univariable analyses (Reynolds et al., 2009). Only baseline ultrasound erosion 
score was associated with progression (discussed further in section 2.3.2.3, below).  
 
- Predicting Radiographic Progression and Disease Flare in 
Early IA and RA Patients Achieving Clinical Remission 
The association between PD and radiographic progression is also apparent 
amongst DMARD-treated RA patients achieving clinical remission or low disease 
activity (Brown et al., 2008; Foltz et al., 2012; Raffeiner et al., 2017). Furthermore, 
the prevalence of PD is independently predictive of future clinical relapse in patients 
continuing therapy (Scirè et al., 2009; Foltz et al., 2012; Saleem et al., 2012) and 
those tapering or discontinuing biologic therapies (Iwamoto et al., 2014; Naredo et 
al., 2015).  
 
In patients achieving remission according to physician judgement, radiographic 
progression over the subsequent one year of follow-up (determined by change in 
total Genant score) occurred in 17/90 patients (Brown et al., 2008). Total PD score 
(sum of PD scores, grades 0-3, at the wrist and MCPs2-5 of the dominant hand) 
was significantly associated with progression (OR 1.36, 95% CI 1.02-1.81), 
whereas associations with clinical measures of disease activity did not reach clinical 
significance. In the subset of joints lacking any swelling, tenderness or pain, 
presence of PD predicted progression at the individual joint level (OR 8.8, 95% CI 
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1.5-50), despite the low rate of progression which was observed (approximately 2% 
of 378 joints).  
 
Amongst patients achieving DAS28 remission for at least six months with treatment 
with TNF-inhibitor, several PD variables were identified as predictors of progression 
in total SHS after one year (occurring in 17/121 [14%] patients) on univariable 
analysis (Raffeiner et al., 2017). Novel findings in this study included the potential 
importance of the location of PD: the presence of PD observed in contact with bone 
was associated with radiographic progression, with a risk ratio of 3.5 (95% CI 
2.5-4.9), in comparison to PD without bone contact which showed no association 
with this outcome. Multivariable modelling which was conducted only considered 
PD variables and did not include adjustment for relevant factors such as baseline 
SHS or clinical joint swelling. Interestingly, radiographic progression was observed 
at different locations to the joints at which PD was observed. The authors suggest 
the lack of sensitivity of x-ray and the ability of TNF-inhibitor therapy to prevent joint 
damage as potential explanations.  
 
Amongst patients achieving stable low disease activity (DAS44<2.4 at consecutive 
assessments two months apart), only PD parameters were significantly associated 
with radiographic progression (change in SHS) and relapse over one year on 
multivariable logistic regression analysis (Foltz et al., 2012). Demographic, clinical, 
radiographic, ultrasound and MRI parameters, with significance on univariable 
analyses at the p<0.20 level, were entered using a forwards, step-wise procedure. 
Total PD score (sum of grades 0-3, at the wrists, MCPs2-3, MCP5, MTPs2-3 and 
MTP5) was associated with progression (occurring in 9/80 patients); OR 1.4 (95% 
CI 1.1-1.9). The number of joints with PD was associated with relapse (defined by 
DAS44>2.4 and/or increase in DMARD/steroid therapy, occurring in 26/81 
patients); OR 6.3 (95% CI 2.0-20). Results for other variables were not significant 
and not reported. 
 
Predictors of flare have also been investigated for patients achieving clinical 
remission, according to the impression of their treating physician (Saleem et al., 
2012), or defined by DAS44 (Peluso et al., 2011). Multivariable analyses confirmed 
presence of PD (within the wrist and MCPs of the dominant hand) and physical 
function (HAQ) predicted the need for treatment escalation, independently of 
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whether patients fulfilled any of the standardised criteria for clinical remission 
(Saleem et al., 2012). In patients achieving sustained DAS44 remission, presence 
of PD (within the wrists, MCPs2-3 and PIPs2-3) was associated with flare 
(DAS44≥1.6): flare occurred in 7/34 (20%) and 28/60 (47%) of patients with 
absence or presence of PD, respectively (p=0.01). However, only early disease, 
and not ultrasound characteristics, appeared to be associated with absence of flare 
on multivariable analysis. Statistical methods were not fully described and the 
cohort was mixed, including patients with early (n=48, two-thirds receiving 
methotrexate monotherapy and one third receiving a TNF-inhibitor) and established 
RA (n=46, all receiving a TNF-inhibitor). 
 
In the only study exclusive to patients with early IA, 106 patients with early morning 
stiffness and at least three swollen joints or positive MCP/MTP squeeze test were 
followed for two years (Scirè et al., 2009). Protocol dictated initial methotrexate or 
hydroxychloroquine, with switch to methotrexate, increase in methotrexate dose 
and ultimately addition of TNF-inhibitor therapy according to a target of DAS44<2.4. 
Sustained DAS44 remission was achieved in 43 patients at or after one year, of 
whom 14 relapsed (DAS44≥1.6) within six months. The presence of any PD 
(≥grade 1 within 44 joints) was independently predictive of relapse (OR 13, 95%CI 
1.6-104) in a model including the following variables: SJC>1, DAS44>1.1, abnormal 
GS in more than one joint (Schmidt et al., 2004) and steroid treatment (p≥0.05 for 
these variables).  
 
Concerning the prediction of relapse in patients achieving DAS28 remission on 
biologic therapy, presence of PD has been associated with flare on univariable 
(Iwamoto et al., 2014) and multivariable analyses (Naredo et al., 2015) with biologic 
tapering (Naredo et al., 2015) or cessation (Iwamoto et al., 2014). Amongst 40 
patients stopping biologic therapy, 16 (40%) patients relapsed (DAS28>3.2 with 
treatment escalation) within six months (Iwamoto et al., 2014). Total GS score≥14 
or total PD score≥3 (sum of 0-3 grading at 40 joints) optimally differentiated those 
relapsing and were significantly associated with this outcome, whereas clinical 
disease activity greater than the cut-point identified for DAS28 was not significantly 
associated with flare. No independent predictors of relapse were identified on 
multivariable analysis in this small sample. The larger study revealed a rate of 
failure of biologic dose reduction (DAS28 and/or SDAI non-remission with increase 
in treatment) of 36/77 (47%) over one year (Naredo et al., 2015). This was 
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significantly more likely in patients with detectable PD (within 36 joints or reduced 
joint sets of 20 or 12 joints), with adjustment for the presence of a higher DAS28 
(DAS28≥2.2). 
 
- Predicting Disease Persistence and/or Progression in 
DMARD-naïve Patients with Early IA 
In patients with new-onset clinical synovitis, studies investigating the ability of 
ultrasound to predict subsequent diagnosis of RA (defined according to 1987 ACR 
criteria) are summarised in Tables 3 and 5 (Salaffi et al., 2010; Filer et al., 2011). In 
Birmingham, of 58 patients with very early IA (at least one swollen joint with 
symptoms for up to three months), 29 (50%) fulfilled 1987 ACR RA criteria by 18 
months (Filer et al., 2011). Of note 21% of patients fulfilled 1987 ACR RA criteria at 
baseline. Assessments of GS at the wrists and MCPs, and PD assessments at the 
MCPs and MTPs, were predictive of 1987 ACR RA, independently of the Leiden 
prediction score (van der Helm-vanMil et al., 2007). The total PD score (sum of PD 
scores, graded 0-3, at individual joints) calculated for 10 joints (wrists, MCPs2-3 
and MTPs2-3) combined with the Leiden score was superior in the prediction of 
1987 ACR RA in comparison to the Leiden score alone (area under the curve 0.96 
versus 0.90, p<0.05).  
 
A similar rate of progression to fulfil 1987 ACR RA criteria was observed amongst 
patients with very early UA (not fulfilling 1987 ACR criteria, with at least one swollen 
joint with symptoms for up to 16 weeks): 62/149 (42%) progressed after a mean 
duration of follow-up of 12 months (range 11-14 months) (Salaffi et al., 2010). The 
number of joints with GS≥grade 1 and PD≥grade 2 predicted progression, 
independently of other clinical parameters such as inflammatory markers and early 
morning stiffness. However other clinical assessments (for example swollen or 
tender joint counts) were not considered in the model. 
 
- Predicting Disease Persistence and/or Progression in 
DMARD-naïve Patients with Inflammatory Symptoms +/- Joint 
Swelling 
Studies have also been conducted in more heterogeneous patient groups, not 
restricted to patients with clinical joint swelling (Ozgul et al., 2009; Freeston et al., 
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2010; Kawashiri et al., 2013; Nakagomi et al., 2013; Pratt et al., 2013; Minowa et 
al., 2016). In the earliest study, 33/51 (65%) patients with early morning stiffness of 
at least 30 minutes for up to one year (excluding patients fulfilling 1987 ACR RA 
criteria or with x-ray erosions) progressed to fulfil 1987 ACR RA criteria over two 
years (Ozgul et al., 2009). Superior agreement was demonstrated between 
progression and the symmetrical appearance of GS changes on extensive 
ultrasound examination in comparison to the agreement with symmetrical 
appearance of synovitis on Technetium99 bone scanning (kappa values 0.6 and 0.2, 
respectively). The prognostic value of clinical or other ultrasound parameters was 
not assessed. 
 
In a cohort of 50 patients presenting with early morning stiffness in the hands for at 
least one hour and symptoms for up to 12 weeks, all patients with positivity for RF 
and/or ACPA demonstrated persistence of IA (physician diagnosis) at one year 
(Freeston et al., 2010). In patients who were seronegative, predictive utility of 
ultrasound was demonstrated in the proportion of patients with at least one of the 
following features: joint swelling, abnormal CRP or x-ray erosion. In this group, the 
presence of GS=grade 3, PD≥grade 1 and ultrasound erosion in the wrists or MCPs 
raised the post-test probability of persistent IA from 2-30% to 50-94%, whilst if none 
of these features were present it reduced to 0-5% (diagnostic uncertainty remained 
in patients with one or two of these ultrasound features). 
 
The value of including ultrasound findings in the context of the 2010 ACR/EULAR 
RA criteria has been assessed in patients with suspected RA in predicting the need 
for DMARDs (Kawashiri et al., 2013) or methotrexate in particular (Nakagomi et al., 
2013; Minowa et al., 2016). In a study restricted to univariable analyses, the 
presence of PD≥grade 2 in any of the wrists, MCPs and PIPs appeared to 
demonstrate the greatest accuracy (amongst various clinical, laboratory and 
imaging variables) to predict the need for DMARDs within three months; sensitivity 
and specificity were 81% and 94%, respectively, versus 60% and 88% for the 
clinical fulfilment of 2010 criteria (Kawashiri et al., 2013). Multivariable analysis of 
real-life data, from a retrospective study of ultrasounds conducted in the course of 
managing patients with no firm diagnosis and arthralgia (Minowa et al., 2016), 
demonstrated the presence of at least one wrist, MCP or PIP joint with GS=grade 3 
(OR 3.6, 95% CI 1.1-14) or with PD≥grade 2 (OR 2.8, 95% CI 1.6-15) were 
significantly associated with commencement of methotrexate for a physician 
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impression of RA after at least six months, independently of fulfilment of 2010 
ACR/EULAR RA criteria (OR 4.7, 95% CI 0.9-20). However, treatment was 
commenced in the knowledge of ultrasound findings.  
 
In the most comprehensive study, ultrasound of 38 joints was used to determine 
fulfilment of 2010 criteria at baseline at two-steps (Nakagomi et al., 2013). Firstly, 
by substituting the requirement for clinical swelling in at least one joint, with 
ultrasound synovitis in at least one joint, then by determining joint involvement 
(score 0-5 points) by ultrasound synovitis. Two definitions for ultrasound synovitis 
were considered: GS≥grade 1, and a more stringent definition of GS≥grade 2 
and/or PD≥grade 1. Fulfilment of 2010 criteria using ultrasound better differentiated 
patients requiring methotrexate from those who did not. The area under the receiver 
operating characteristic curve (AUC) was greatest for the latter definition of 
ultrasound synovitis, although confidence intervals overlapped: AUC was 0.84 (95% 
CI 0.74-0.90), 0.87 (95% CI 0.80-0.94) and 0.89 (95% CI 0.83-0.95) for fulfilment of 
2010 criteria with joint involvement determined clinically, by GS≥grade 1 and 
GS≥grade2/PD≥grade1, respectively. Multivariable logistic regression was used to 
determine the value of ultrasound findings at individual joint sites in predicting 
methotrexate use. Presence of various grades of GS and PD at individual joints, 
with p<0.05 on univariable analysis, were entered along with the 2010 criteria score 
(score 0-10, determined clinically), using a forwards step-wise approach. Presence 
of GS≥grade 1 and PD≥grade 2 at the wrist predicted methotrexate use 
independently of fulfilment of 2010 criteria. Inclusion of both GS and PD at any one 
joint site within a single model indicates a degree of uncertainty in these results, 
due to the overlapping nature of these variables.  
 
In the largest study available, 389 unselected patients presenting with arthralgia in 
Newcastle were followed for at least one year (Pratt et al., 2013). Ten patients with 
persistent UA at the end of follow-up (not fulfilling 1987 ACR criteria) were 
excluded. At baseline, 18% of patients had a working diagnosis of RA, 36% had a 
working diagnosis of osteoarthritis or non-inflammatory arthralgia and 54% of 
patients had no swollen joints. Persistent IA (physician diagnosis) was observed in 
162/379 (43%) patients, at a median duration of follow-up of 27 months. Predictors 
of persistent IA were determined by multivariable logistic regression (backwards 
step-wise method, retaining demographic/clinical/laboratory/ultrasound variables 
with significance at p<0.1). The presence of GS≥grade 1 in at least three joints (of 
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MCPs2-4, PIPs2-4 and MTPs1-2) was independently predictive of persistence (OR 
4.9, 95% CI 2.3-10) in addition to the following clinical characteristics: age, 
symptom duration, presence of joint swelling, CRP, ESR and ACPA-positivity. 
However, the AUC was comparable for a model constructed by the same method 
but excluding ultrasound variables. In a subgroup analysis of 91 patients with UA 
(not fulfilling 1987 RA criteria) at baseline, AUCs for models constructed with and 
without the consideration of ultrasound variables were also comparable. 
 
- Predicting Development of Arthritis in Patients With Joint 
Symptoms in the Absence of Swelling 
Ultrasound measures of synovitis have been associated with the development of IA 
in cohorts of seropositive (van de Stadt et al., 2010; Rakieh et al., 2015) and 
seronegative (Zufferey et al., 2017) patients with joint symptoms alone. Amongst 
seropositive (for RF and/or ACPA) patients with arthralgia, 45/192 (23%) developed 
at least one swollen joint over a median follow-up of 26 months (range 6-54 
months) (van de Stadt et al., 2010). At the joint level, the presence of GS≥grade 2 
and PD≥grade 1 (tender/painful joints and adjacent joints within MCPs, PIPs and 
MTPs) were significantly associated with development of swelling in that joint 
(78/1823 joints developed swelling). However, the predictive value of clinical 
variables, such as tenderness, was not evaluated, and the trend for an association 
between ultrasound variables and the development of arthritis at the patient level 
was not statistically significant. Amongst ACPA-positive patients with new-onset 
musculoskeletal symptoms, the presence of PD (≥grade 1 in at least one joint of the 
wrists, MCPs and PIPs) was significantly associated with the development of at 
least one swollen and tender joint on multivariable analysis (independently of the 
presence of small joint tenderness, early morning stiffness, high ACPA and/or RF 
titre, and presence of the shared epitope) (Rakieh et al., 2015). Rate of progression 
was higher in this cohort (50/100 progressed over a median follow-up of 20 
months), although only 50% had small joint tenderness at baseline. Analysis was 
conducted by entering variables with significance (HR≥1.5) on univariable analysis. 
Grey scale synovitis was not reported. 
 
As expected, a lower rate of progression has been observed amongst seronegative 
patients with polyarthralgia: IA developed in 9/80 (11%) patients, seven of whom 
fulfilled 2010 ACR/EULAR RA criteria, over a mean follow-up of 18 months 
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(Zufferey et al., 2017). Only five patients displayed PD on the baseline ultrasound 
assessment of elbows, wrists, MCPs2-5, PIPs2-5 and knees; however, GS 
synovitis (the total score considered as a continuous variable or presence of 
significant GS defined by either total score greater than eight, or presence of 
GS≥grade 2 in at least two joints) was independently associated with progression to 
RA or IA (in a multivariate logistic regression model with age, gender, abnormal 
CRP, duration of follow-up and anti-nuclear antibody [ANA] positivity). 
 
- Predicting Response to Treatment 
Limited data is available in DMARD-naïve patients with UA (not fulfilling 2010 
ACR/EULAR RA criteria) at baseline, suggesting baseline PD is predictive of 
response to a treatment to target strategy (Table 5) (Sakellariou et al., 2014). 
Measures of PD were significantly associated with DAS28 remission within one 
year, but whilst adjustment was made for some relevant confounders (age, gender 
and treatment), others, such as clinical disease activity and serology, did not 
appear to be included in the same model. 
 
The ability of PD to predict continuation of the same TNF-inhibitor therapy after one 
year (as a proxy for clinical response to treatment) has been evaluated (Ellegaard 
et al., 2011). Of 162 patients with established RA commencing TNF-inhibitors, 
complete data was available for 109 patients, of whom 78 were continuing on the 
same therapy at one year. Doppler activity of a target joint (selected as a joint with 
greatest Doppler activity at baseline, with preference for a wrist joint) was assessed 
by colour fraction (percentage of colour pixels). This was the only variable of 
several clinical, laboratory and treatment parameters assessed, to be significantly 
associated with treatment persistence (standardised mean difference 0.5, p=0.01). 
Although this outcome is not wholly representative of response (8 patients stopped 
therapy due to side-effects), it is a pragmatic measure of response in patients with 
established RA in clinical practice, in whom DAS and other clinical response 
measures may not be truly reflective of inflammatory disease activity. For example, 
joint damage may be expected to contribute to joint pain. 
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 Synovitis: Discrimination  
- Differentiation from Normal 
The discriminative validity of ultrasound synovitis has been evaluated using GS 
imaging and with Doppler in a number of studies (Table 10). Small, early studies 
reported a low rate of GS change in healthy individuals (Hau et al., 1999; Hameed 
et al., 2008) and did not identify Doppler activity in healthy volunteers (Hau et al., 
1999). However, with increased sensitivity of machines used in more recent 
studies, low-grade GS changes are now accepted as a relatively common finding in 
small joints of healthy individuals (Ellegaard et al., 2007; Keen et al., 2008; Millot et 
al., 2011; Kitchen and Kane, 2015). In addition, Doppler activity may be observed 
within the synovium of asymptomatic controls (Terslev et al., 2004; Hameed et al., 
2008; Keen et al., 2008; Rosenberg et al., 2009; Millot et al., 2011; Carotti et al., 
2012; Witt et al., 2013; Zufferey et al., 2014; Kitchen and Kane, 2015; Padovano et 
al., 2016).  
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 Prevalence of GS effusion/hypertrophy and Doppler activity observed on ultrasound examination in healthy subjects. Table 10.
  
Reference n 
Method of 
recruitment 
Age (yrs) Joints examined Prevalence of GS and/or Doppler activity 
GS synovitis in wrists, hands and feet 
(Wiell et al., 
2007) 
5 Not fully reported 
(exclusions: 
history/signs of joint 
disease) 
Median 
63, range 
35-71 
MCP2-5, PIP2-5, DIP2-5, 
MTP1-5 (Bilateral) 
GS (effusion and/or hypertrophy)≥grade 2 in 3% of 
MCPs and PIPs, and 34% of MTPs.  
(Szkudlarek et 
al., 2006) 
20 Not reported Median 
52, range 
27-79 
MCPs 2-5, PIPs 2-5 
(Unilateral) 
GS (effusion and/or hypertrophy)≥grade 2 in 5 (3%) 
MCP/PIP joints. 
(Szkudlarek et 
al., 2004) 
20 Not reported Median 
52, range 
25-78 
MTPs 1-5 (Unilateral) GS (effusion and/or hypertrophy)≥grade 2 in at least 
1 MTP in 50% subjects. 
Most frequent at MTP1 (7/20 [35%] first MTPs and 
15/80 [19%] MTP2-5 joints). 
(Witt et al., 
2013) 
30 Age- and gender-
matched to patients 
with early RA 
(exclusions: 
arthralgia, joint 
disease) 
Mean 52 
(SD 17) 
Wrists, MCPs, PIPs, MTPs 
(Bilateral) 
GS (effusion and/or hypertrophy)=grade 1 in 15% of 
joints. 
Prevalence of higher GS grades not reported. 
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Colour Doppler in wrists and hands  
(Terslev et al., 
2004) 
27 Medical staff 
members and staff 
relatives (exclusions: 
arthritis, trauma, use 
of hands in 
sports/labour, 
arthralgia) 
Mean 45, 
range  
18-93 
Wrist, MCP1-5, PIP1-5 
(Unilateral) 
Colour Doppler in 26 (9%) joints. 
Most frequent at wrist (15 [56%] wrists). 
(Carotti et al., 
2012) 
43 Volunteers (age- and 
gender-matched to 
patients with 
symptomatic 
osteoarthritis) 
Mean 55, 
SD 11 
Wrist,  MCP2-3, PIP2-3 
(Bilateral) 
Colour Doppler in 45 (10%) joints. 
Most frequent at wrist (39 [86%] wrist joints).  
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GS and PD synovitis in wrists and hands 
(Rosenberg et 
al., 2009). 
46 Medical students 
(exclusions: arthralgia, 
hand use in sports, 
trauma, IA) 
Mean 26 
(age>40 
excluded) 
PIP2-5, DIP2-5 
(Bilateral) 
GS effusion in 100/368 PIPs. 
No PD observed. 
 
(Keen et al., 
2008) 
19 Musculoskeletal clinic 
patients without hand 
pain. Included patients 
with tender joints and/or 
recent low-grade trauma. 
Median 
58, IQR 
51-71 
CMC1, MCP1-5, PIP1-5, 
DIP2-5 (Bilateral) 
GS (effusion and/or hypertrophy)≥grade 1 in 64 
[34%] MCPs (grade 1 in 53 [28%]) and 62 [33%] of 
PIPs. 
PD≥grade 1 in 4% of MCPs and 2% of PIPs. 
N.B. Osteophytes in 11% of MCPs and 33% of PIPs. 
(Hameed et 
al., 2008) 
25 Not fully reported 
(exclusions: history/signs 
of joint disease)  
Mean 45, 
range 
24-62 
MCPs (Bilateral) GS (hypertrophy)=grade 1 in 2 (8%) subjects (in 3 
MCPs). No higher GS grades observed. 
PD≥grade 1 in 8 (32%) subjects (in 13 [5%] of all 
MCPs). Grade 1 in each. 
N.B. Both subjects with GS and 4/8 subjects with PD 
engaging in manual labour. 
GS and PD synovitis in wrists, hands and feet 
(Millot et al., 
2011) 
127 Hospital staff and 
patients with sciatica, 
age- and gender-
matched to early IA 
patients in ESPOIR 
Mean 50  MCP2,5 and MTP5 
(Bilateral) 
GS (hypertrophy)≥grade 2 in 12 (9%) subjects (in 
14/1016 [1%] MCPs, in none of MTP5 joints). 
PD in 5 (4%) of subjects (1 MCP in each, PD was 
universally absent at MTP5). 
(Padovano et 
al., 2016) 
207 Staff, students, relatives 
of patients and other 
volunteers (exclusions: 
osteoarthritis, trauma, 
arthralgia) 
Mean 36, 
range 18-
74 
Wrists, MCPs, PIPs, 
MTPs (Bilateral) 
GS effusion≥grade 1 alone in 95 (46%) subjects. 
GS hypertrophy≥grade 1 (with/without either 
effusion or PD) in 87 (42%) subjects. 
GS effusion and/or hypertrophy≥grade 2 only 
observed at MTPs. 
PD≥grade 1 in 44/6621 (<1%) joints. 
Most frequent in wrists (6 [1%] of wrists) and MTP1 
joints (31 [7%] MTP1 joints). 
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GS and PD in wrists, hands, feet and large joints 
(Zufferey et 
al., 2014) 
38 Gender-matched to 
patients with 
established RA (age-
matching was 
unsuccessful) 
Median 47 Elbow, wrist, MCP2-5, 
PIP2-5, knee (Bilateral) 
GS (effusion and/or hypertrophy)≥grade 2 in 26% 
subjects (in at least 2 joints in 8% subjects). Total 
GS score>8/66 in 10% subjects. 
PD in 2 (5%) subjects (grade 1 in 1 joint in each).  
 
(Kitchen and 
Kane, 2015) 
30 Volunteers 
(exclusions: history of 
arthritis, heavy 
manual labour, 
trauma) 
Mean 39, 
range 
22-63 
Shoulder, elbow, wrist, 
MCPs, PIPs, knees, ankles, 
MTPs (Bilateral) 
GS (effusion and/or hypertrophy)≥grade 2 in 3% of 
MCPs and PIPs, 2% of wrists, 32% of MTP1 joints 
and 6% of MTP2-5 joints . 
GS infrequent in larger joints (excepting grade 1 in 
the knee). 
PD≥grade 1 in 121 (10%) joints. Most frequent in 
wrists (25 [42%] of wrists) and MTP1 joints (17 
[28%] MTP1 joints). PD≥grade 2 in 13 joints (wrists 
and MTP1 joints only).  
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These studies varied in their methods of recruitment. Factors such as occupation 
(Hameed et al., 2008), as well as age and gender of controls are of relevance. 
Studies demonstrate a significant association between age and presence and/or 
severity of GS changes (Ellegaard et al., 2007; Kitchen and Kane, 2015; Padovano 
et al., 2016) and statistically significantly higher total GS scores in men versus 
women (Kitchen and Kane, 2015). Asymptomatic osteoarthritis may not fully explain 
this observation, as osteophytes have been observed infrequently on ultrasound 
when reported in these studies (5/332 joints) (Ellegaard et al., 2007). 
 
In the small joints of the hands, small effusions are relatively prevalent and 
particularly visible on the volar/palmer aspect of joints (Boutry et al., 2004; Scheel, 
A. K. et al., 2005; Rosenberg et al., 2009). The size of effusions appears to differ 
significantly between controls and patients with RA (Scheel, A. K. et al., 2005). In a 
study of 102 staff, students and authors’ friends, Schmidt et al. reported 
measurements for the GS appearance of effusion/hypertrophy which may be 
considered within the limits of normality (lying within 2 standard deviations of the 
mean) (Schmidt et al., 2004). The normal depth of GS change was greater at the 
MTPs in comparison to the small joints of the hands: normal limits were ≤3.5mm at 
MTP1 and ≤3.1mm at MTP2 in comparison to ≤1.9mm at MCP2 and ≤1.6mm at 
PIP2. Increased prevalence and volume of GS change at the MTPs, particularly 
MTP1, in comparison to other small joints has been confirmed by other groups. 
(Szkudlarek et al., 2004; Szkudlarek et al., 2006; Wiell et al., 2007; Padovano et al., 
2016).  
 
A cut-off level, at which ultrasound findings of GS and PD may be considered of 
pathological significance, is desirable (Terslev et al., 2017a). Grade 1 GS changes, 
as defined by Szkudlarek et al. (Szkudlarek, M. et al., 2003), have been considered 
to be physiological by several investigators (Szkudlarek et al., 2004; Szkudlarek et 
al., 2006; Ellegaard et al., 2007; Wiell et al., 2007; Witt et al., 2013; Zufferey et al., 
2014). The EULAR-OMERACT combined score for synovitis has been restricted to 
synovial hypertrophy, given the frequent occurance of visible effusion in healthy 
joints (Terslev et al., 2017b). The clinical relevance of grade 1 GS synovitis is also 
questionable, given the significantly lower rate of swelling, tenderness and PD 
which has been observed in association with grade 1 GS synovitis in comparison to 
GS≥grade 2 (Witt et al., 2013). However, no comparison was made to joints lacking 
any GS synovitis (grade 0) in this study. Power Doppler appears to be a less 
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frequent finding, and if present has generally been observed at a low level, except 
in the wrists and first MTPs (Kitchen and Kane, 2015; Padovano et al., 2016). 
 
- Differentiation from Osteoarthritis 
Although not considered to be an inflammatory arthritis in the same way as RA and 
other aggressive arthropathies, sensitive imaging techniques including ultrasound 
and MRI have confirmed that synovial inflammation is involved in the pathology of 
osteoarthritis. This is an important consideration in view of the high prevalence of 
osteoarthritis and its frequent coexistence with inflammatory arthritis. In Leeds, 
ultrasound of the hands was conducted in 36 patients with symptomatic hand 
osteoarthritis (patients with suspected IA were excluded) (Keen et al., 2008). 
Considering the joints frequently affected by RA, GS synovitis was observed at 
PIPs2-5 in 126/287 (44%) joints and at MCPs2-5 in 72/288 (25%) joints. Power 
Doppler was observed in 23 (8%) and 12 (4%) joints at these sites, respectively. 
Notably, this included low-grade changes of grade 1 GS. Prevalence of GS 
restricted to grades which may be considered pathological was not presented. A 
higher rate of GS change (p<0.001) and PD synovitis (p=0.002) was observed in 
the most painful joints (one joint selected per subject, from all MCP, PIP, DIP and 
first CMC joints) in comparison to the other joints examined. 
 
In a further study of 78 patients with hand osteoarthritis, GS≥grade 1 was observed 
in at least one joint in 73 (94%) patients and PD≥grade 1 was observed in 33 (42%) 
patients on ultrasound examination of 30 joints including several not included in 
assessments of RA (CMC1, MCPs1-5, PIPs1-5 and DIPs2-5 bilaterally) 
(Mathiessen et al., 2016). The distribution of joints affected was not reported. Of 
1078 joints with definite evidence of radiographic osteoarthritis (Kellgren-Lawrence 
grade≥2), GS=grade 1 was demonstrated in 16%, GS≥grade 2 was demonstrated 
in 12% and PD≥grade 1 was demonstrated in only 5%. Interestingly, presence of 
GS (even grade 1 changes) and PD synovitis were significantly associated with 
radiographic progression over 4-5 years with adjustment for age, gender, BMI, 
follow-up time and presence of radiographic erosive osteoarthritis (although not for 
baseline radiographic change or clinical joint swelling).  
 
The prevalence of positive US findings in the hands of patients with hand OA has 
also been evaluated in comparison to patients with RA, in a real-life cohort study 
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(Hussain et al., 2017). Scans of 73 patients with hand OA and 224 patients with 
established RA, conducted in the course of their clinical management (for example, 
to aid in diagnosis or to exclude ongoing disease activity in patients with known 
RA), were analysed retrospectively. The proportion of patients with synovitis, 
determined by GS or PD, was greater for patients with RA vs OA: 57% vs 40% of 
patients displayed GS=grade 1 in at least one joint (rates were 43% vs 31% for 
grade 3 GS) and 46% vs 8% of patients displayed PD≥grade 1 in at least one joint. 
Of note, the patients with OA were significantly older and had fewer swollen joints 
than patients with RA.  
 
 Synovitis: Reliability 
A notorious limitation of ultrasound is that it is operator dependant. Findings are 
dependent on the scanning technique, but also rely on operator experience in the 
interpretation of images, particularly in differentiating physiological from pathological 
findings. A systemic literature review of the inter-observer and intra-observer 
reliability of ultrasound to detect synovitis illustrates great variation across study 
methods (Cheung et al., 2010).  
 
The majority of studies assessing inter-observer reliability for the acquisition and 
interpretation of ultrasound images have done so between two observers within 
single-centres. Reliability exercises, undertaken by the OMERACT ultrasound task 
force, have addressed this, including a number of experienced operators from 
several European countries (D'Agostino et al., 2005; Scheel, A K et al., 2005; 
Naredo et al., 2006; Bruyn et al., 2009; D’Agostino et al., 2017; Terslev et al., 
2017b). As may be expected, agreement in the interpretation of still images was 
generally superior to agreement in the acquisition and interpretation of real-time 
examination of patients (D'Agostino et al., 2005). Rating of PD appears reliable, 
with at least good levels of agreement determined by kappa (kappa >0.6) generally 
reported (D'Agostino et al., 2005; Bruyn et al., 2009). However, inter-observer 
agreement for GS synovitis suggests less reliability in this measure (D'Agostino et 
al., 2005; Scheel, A K et al., 2005; Bruyn et al., 2009). Unfamiliarity of the experts 
with the machines used in these studies may have contributed to poor agreement, 
but the difficulty in differentiating active synovitis from inactive fibrous synovial 
thickening (Mandl et al., 2011) or from the appearance of GS in healthy joints 
(Schmidt et al., 2004; Scheel, A. K. et al., 2005) is appreciated. Initial studies to test 
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the reliability of the EULAR-OMERACT scoring systems for GS hypertrophy, PD 
synovitis and synovitis combining the two measures, have generally demonstrated 
moderate to good intra- and inter-reliability across a variety of joints (Terslev et al., 
2017b; Ventura-Ríos et al., 2017). Reliability was improved with use of the EULAR-
OMERACT standardised scanning technique; grading synovitis from images 
obtained in the midline of the dorsal aspect of the joint, with joint positioning as 
instructed according to joint site (Terslev et al., 2017b). 
 
Interpretation of PD may be less dependent on the experience of the observer 
(Koski et al., 2006b). Reliability of PD measurements are, however, still dependant 
on several aspects of scanning technique (Koski et al., 2006b), including: pressure 
applied to the joint with the transducer (Wakefield et al., 2003; Joshua et al., 2005), 
movement of the patient or transducer which produces artefacts (Wakefield et al., 
2003; Torp-Pedersen and Terslev, 2008), temperature (Strunk et al., 2006; 
Ellegaard et al., 2009) and joint position (Lee et al., 2009; Zayat et al., 2012).  
 
Reliability may also be affected by differences in machine characteristics such as 
image resolution. However, a study conducted by the same OMERACT ultrasound 
task force using six different machines concluded these differences were not a 
major contributory factor to the variance observed in the reporting of GS and PD at 
MCP joints amongst 11 experts. This accounted for an estimated 1-6% of the 
variance, in comparison to 21-55% of variance attributable to differences in 
operator-dependant techniques and interpretation (D'Agostino et al., 2008). 
 
Reliability of ultrasound should be considered in the context of other measures of 
active synovitis available real-time in clinic, i.e. clinical joint swelling. This is also 
dependent on the examiner and their level of experience. Intra- and inter-observer 
agreement of 28-joint swollen joint counts have been shown to vary between 
poor/fair and good (Marhadour et al., 2010), i.e. not even the most experienced 
physicians in this study (experience of at least 5 years) demonstrated excellent 
kappa values for reproducibility. Furthermore, outwith these 28 joints, MTP joint 
examination may be particularly unreliable (Naredo, E et al., 2005; Salaffi et al., 
2008; Damjanov et al., 2012). 
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 Synovitis: Responsiveness 
Power Doppler synovitis appears to be sensitive to change, with reductions in PD 
being observable within two weeks of steroid administration (Newman et al., 1996; 
Strunk et al., 2006; Larché et al., 2010). In patients with established RA, synovial 
thickening detected on GS imaging may be chronic and represent fibrous change 
rather than active synovial inflammation. As such, it may be difficult to distinguish 
between GS hypertrophy representative of synovitis (as defined by OMERACT as 
usually hypoechoic thickening) and inactive thickening (echoic or hyperechoic), 
hence GS may be less responsive to change. Despite this, good responsiveness 
has been observed in both total GS and PD synovitis scores, including the 7-joint 
(Backhaus et al., 2009) and 12-joint assessments (Naredo et al., 2008b) mentioned 
above (Hammer et al., 2010; Mandl et al., 2011).  
 
Recently, the EULAR-OMERACT combined synovitis score has been tested in 
patients receiving abatacept (D'Agostino, M.-A. et al., 2016). Improvement in the 
sum score for MCP2-5 joints bilaterally was observed as early as week one. 
Responsiveness for the sum score for 44 joints was similar to sum scores for 
various reduced joint sets including the aforementioned 12-joint assessment and 
bilateral examination of the 7-joint assessment. 
 
2.3.2.2 Tendon Abnormalities 
A systematic review identified 24 studies assessing the construct validity of 
ultrasound assessment of tendon abnormalities (Alcalde et al., 2012). The majority 
investigated the agreement between tenosynovitis and clinical and/or MRI 
assessment. Results generally suggested superior sensitivity of ultrasound in 
comparison to clinical examination. In a relatively large study of patients with early, 
DMARD-naïve RA (n=50), sensitivity and specificity of ultrasound for the detection 
of tenosynovitis (reported as present/absent) were 44% and 99% in the flexor 
tendons and 15% and 98% in the extensor tendons of the fingers at the level of the 
MCP joints, with reference to MRI as the gold standard (Wakefield et al., 2007). 
Only two studies were identified which addressed criterion validity. One addressed 
concurrent validity, assessing finger extensor tendon damage (partial tendon tears) 
in patients with RA, rather than inflammatory changes, against surgical inspection 
as the gold standard (Swen et al., 2000). The other, concerning predictive validity, 
assessed global inflammatory disease activity on ultrasound, of which assessment 
89 
 
of tendons was a small component (findings of this study are discussed above in 
section 2.3.2.1) (Naredo et al., 2008a).  
 
Since the time of this review, few other studies have emerged. Data from patients 
with early RA (fulfilling 1987 ACR RA criteria) enrolled in an observational study 
between 2002 and 2004 (Haavardsholm et al., 2008) were analysed by Lillegraven 
et al. (Lillegraven et al., 2011). Progression in erosive disease at one year, 
determined by MRI at the dominant wrist (change from baseline in MRI RAMRIS 
erosion score of ≥1 unit), was demonstrated in 39/60 patients with complete data. 
Multivariable logistic regression (entering variables with p<0.20 on univariable 
analysis, using a backwards step-wise procedure) revealed the presence of 
extensor carpi ulnaris GS tenosynovitis independently predicted progression (OR 
7.2, 95% CI 1.6-33) in a final model which also included MRI RAMRIS bone 
oedema score at the wrist, age and gender. 
 
In the multicentre, observational STARTER study, cross-sectional analysis of 
baseline data suggested US-detectable tenosynovitis is independently associated 
with recent symptoms of flare in patients achieving clinical remission (Bellis et al., 
2016). Amongst 427 patients with established RA in remission (defined by any one 
of various definitions including DAS28 and expert rheumatologist opinion), 
multivariate logistic regression (adjusting for age, gender, disease duration, 
remission duration, treatment and ACPA status) demonstrated an association 
between the presence of PD tenosynovitis (PD≥grade 1 on bilateral ultrasound 
assessment of wrist and finger tendons) was associated with a flare score ≥3 
(patient questionnaire designed to identify symptoms of flare within the preceding 
three months). The presence of GS or PD synovitis (≥grade 1 in at least one MCP 
or PIP) or GS tenosynovitis was not significantly associated with this measure. The 
presence of PD tenosynovitis, particularly of the extensor carpi ulnaris tendon, also 
appears to be predictive of RA (fulfilment of 1987 ACR criteria) amongst patients 
with swelling of at least one joint, with symptoms for up to three months (Sahbudin 
et al., 2015). However, methods were limited to univariable analyses. 
 
Available studies assessing inter-observer agreement for ultrasound-detected 
tenosynovitis, between more than two sonographers, suggest fair to moderate 
levels of agreement (Scheel, A K et al., 2005; Bruyn et al., 2009; Ohrndorf et al., 
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2012; Naredo et al., 2013a). Reported kappa values vary between 0.2  for GS 
tenosynovitis (Bruyn et al., 2009) and 0.6 for PD tenosynovitis (Bruyn et al., 2009; 
Naredo et al., 2013a). Responsiveness of tenosynovitis detected by ultrasound has 
been confirmed in patients commencing biologic therapies (Backhaus et al., 2009; 
Hammer, H. and Kvien, T., 2011; Vlad et al., 2015) as well as in a small number of 
patients commencing or receiving a change in DMARD therapy (Backhaus et al., 
2009). 
 
2.3.2.3 Erosions 
 Erosions: Construct Validity 
Bone erosions are a defining feature of RA, with evidence of radiographic erosions 
being included in both the 1987 ACR and 2010 ACR/EULAR classification criteria 
for RA. Studies conducted in patients with early (Wakefield et al., 2000; Szkudlarek 
et al., 2004; Szkudlarek et al., 2006; Bajaj et al., 2007) and established RA 
(Wakefield et al., 2000; Klocke et al., 2001; Szkudlarek et al., 2004; Szkudlarek et 
al., 2006) demonstrate the majority of erosions detected by conventional 
radiography are indeed detectable by ultrasound. X-ray erosions undetected by 
ultrasound are perhaps more likely to be those occurring at sites which are more 
difficult to visualise by ultrasound, such as MCP4, the ulnar aspect of MCP2 
(Wakefield et al., 2000) and medial aspect of MTP5 (Klocke et al., 2001). Moreover, 
these studies and others demonstrate it is possible to detect more erosive 
abnormalities on ultrasound than are visible on x-ray in early (Wakefield et al., 
2000; Szkudlarek et al., 2004; Szkudlarek et al., 2006; Bajaj et al., 2007) and 
established RA (Wakefield et al., 2000; Klocke et al., 2001; Weidekamm et al., 
2003; Szkudlarek et al., 2004; Scheel et al., 2006; Szkudlarek et al., 2006). Reports 
of the prevalence of ultrasound erosions in early, treatment-naïve IA (including 
patients with UA) suggest a three-fold higher prevalence of erosions may be 
detected by ultrasound, in comparison to x-ray (Funck-Brentano et al., 2009; 
Sheane et al., 2009). However, ultrasound in these studies was limited to a small 
number of joints: examination of MTP5 only in 30 patients with a mean duration of 
symptoms of 15 months (a proportion of whom had previous DMARD exposure) 
(Sheane et al., 2009) and bilateral ultrasound examination of MCP2, MCP5 and 
MTP5 in the ESPOIR study (Funck-Brentano et al., 2009). 
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Interestingly, RA patients lacking any swollen or tender joints with subclinical PD 
(either PD≥grade 1 or ≥grade 2 in any wrist, MCP or PIP) were significantly more 
likely to demonstrate erosions on ultrasound, in comparison to patients without PD, 
in a cross-sectional, univariable analysis (radiographic erosions were not assessed) 
(Kawashiri et al., 2014a). Joints with PD may also be more likely to display 
ultrasound erosion in patients with sustained low disease activity (DAS28<3.2) on 
biologic therapy for RA; erosion was observed on ultrasound in 10/31 wrist/finger 
joints with PD, in comparison to 7/607 joints without PD in a further Japanese 
cross-sectional, univariable analysis (Kawashiri et al., 2017). 
 
 Erosions: Concurrent Validity 
Concurrent validity of ultrasound in the detection of erosions in RA has been 
demonstrated in a recent systematic literature review (Szkudlarek et al., 2016). 
Good correlations are observed between erosions detected with ultrasound and 
those detected by MRI (Wakefield et al., 2000; Szkudlarek, M. et al., 2003; Magnani 
et al., 2004; Szkudlarek et al., 2004; Szkudlarek et al., 2006; Rahmani et al., 2010; 
Szkudlarek et al., 2016) or CT (Dohn et al., 2006; Finzel et al., 2011; Szkudlarek et 
al., 2016) as gold standards. Vascular bone channels (particularly at the palmar 
aspect of MCPs) and pseudo-erosions created by osteophytes have been identified 
as potential reasons for false-positive results for erosion detected on ultrasound, in 
comparison to micro-CT (Finzel et al., 2011). Good correlation between the number 
of erosions detectable by ultrasound and the true number of erosions has also been 
demonstrated using an experimental bovine model (Koski et al., 2010).  
 
 Erosions: Predictive Validity 
Limited evidence for the predictive validity of ultrasound erosions is available. In an 
early prospective study of 12 patients with established RA with no evidence of 
radiographic erosions, ultrasound erosions were observed in nine out of a total of 
96 joints examined by ultrasound (unilateral MCPs2-5 and PIPs2-5) (Scheel et al., 
2006). After seven years, x-ray erosion had developed in 2/9 (22%) of joints with 
ultrasound erosions versus 23/87 (26%) of joints without ultrasound erosion. The 
low sensitivity of these baseline ultrasound assessments, performed in 1996, may 
not be relevant to modern-day ultrasound scanning. Analysis of the ESPOIR study 
demonstrated the presence of ultrasound erosion at baseline (although only 
assessed in MCP2, MCP5 and MTP5) was associated with presence of 
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radiographic erosion within the hands and/or feet at two years (Funck-Brentano, 
Gandjbakhch et al. 2013). However, baseline radiographic erosions were not 
considered within the multivariable model (27% of patients displayed radiographic 
changes typical of RA at baseline). When subgroup analysis was carried out in 
patients with no radiographic erosions at baseline (n=93), the association of 
ultrasound erosions at baseline and radiographic erosion at two years was no 
longer significant, although the low number of patients with this outcome (n=13, 
14%) should be borne in mind. Subgroup analysis was also conducted at the joint 
level: radiographic erosion at one year was observed in 26 of 1091 joints without 
radiographic erosion at baseline. With adjustment for age, DAS28, CRP, ESR, RF-
positivity, ACPA-positivity, steroid/DMARD/biologic use and ultrasound parameters 
including total GS and PD scores, CRP and RF-positivity were independent 
predictors of erosion at one year. There was a trend towards an association with 
the presence of ultrasound erosion at baseline (p=0.052) suggesting larger studies 
are desirable. 
 
A Japanese study suggested that in patients with RA, achieving low disease activity 
(DAS28<3.2), the presence of ultrasound erosions is a risk factor for failure of 
biologic drug cessation (treatment escalation within the following year) (Kawashiri et 
al., 2017). The presence of ultrasound erosion in any wrist, MCP or PIP was 
significantly associated with treatment escalation (occurring in 19/40 patients); 
OR 8.4 (95% CI 1.8-53), adjusted for gender and SDAI at biologic initiation. This 
model was constructed by entering variables with potential significance (p<0.2) on 
univariable analysis; other ultrasound variables, including GS and PD synovitis 
were considered, however univariable results for radiographic erosions were not 
reported. 
 
Other evaluations of the predictive validity of ultrasound erosion have been 
restricted to univariable analyses. In the Birmingham very early IA cohort, the 
presence of any ultrasound erosion at the wrists, MCPs, PIPs or MTPs 
demonstrated 38% sensitivity and 93% specificity for the fulfilment of 1987 ACR RA 
criteria over 18 months (Filer et al., 2011). In patients with early inflammatory 
symptoms presenting in Leeds, 53% sensitivity and 73% specificity was 
demonstrated for the presence of any ultrasound erosion at the wrists or MCPs in 
the determination of persistence of IA at one year (defined according to a physician 
diagnosis) (Freeston et al., 2010). In one of the aforementioned Japanese cohorts 
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of patients with suspected RA, any ultrasound erosion detected in the wrists, MCPs 
and PIPs, was only 20% sensitive but 100% specific for the use of DMARDs within 
the following three months (Kawashiri et al., 2013). In Newcastle, ultrasound 
erosions at MCPs2-4, PIPs2-4 and MTPs1-2 were considered as a potential 
variable for inclusion in a prediction model of persistent IA (physician diagnosis or 
diagnosis of RA according to fulfilment of 1987 ACR criteria), however this variable 
was not identified as discriminatory and was therefore not included in the final 
reported model (Pratt et al., 2013). 
 
One study has aimed to assess the predictive value of ultrasound (including 
severity of ultrasound erosion at baseline, as well as measures of ultrasound 
synovitis) at the individual joint level, in predicting progression in ultrasound erosive 
disease as an outcome measure (Reynolds et al., 2009). In each of 40 patients with 
established RA (fulfilling 1987 ACR RA criteria), a target joint was selected for 
ultrasound examination in order to provide 10 joints in each of the following 
categories: clinically swollen and tender joints, swollen but not tender joints, tender 
but not swollen joints and joints without clinical swelling or tenderness. However, a 
significant number of patients were excluded from the analysis: 2 died, 4 declined 
follow-up and 9 had a baseline ultrasound erosion score of 3 and therefore could 
not demonstrate progression. Ultrasound erosion was scored on a 0-3 grade (0=no 
erosion, 1=erosion<2mm, 2=erosion>2mm or >2 erosions<2mm, 
3=large/diffuse/regional joint destruction) at baseline and follow-up (mean 26, range 
24-32 months). Progression was defined by a worsening in grade from baseline. 
Progression was observed in 12/25 patients (2 receiving NSAIDs alone, 6 receiving 
DMARDs and 4 patients receiving TNF-inhibitors). Baseline ultrasound erosion 
score was the only ultrasound variable significantly associated with progression on 
univariable analysis (p=0.05). 
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 Erosions: Discrimination 
The appearance of erosion on ultrasound may be observed in healthy individuals, 
perhaps as a result of normal variation in bone profile or artefacts (Szkudlarek et 
al., 2012). Table 11 displays the prevalence of erosion-like change which has been 
observed in various control groups. Erosive change may also be reflective of aging 
or degenerative processes. Indeed, the study by Zayat et al. demonstrated an 
increase in the number of erosive joints with age, although this was amongst their 
entire cohort including patients with RA, psoriatic arthritis, gout and osteoarthritis as 
well as healthy controls (Zayat et al., 2015).  
 
This study by Zayat et al. included several comparator groups, including 60 patients 
with osteoarthritis (which excluded patients with knee or hip osteoarthritis alone). A 
high prevalence of ultrasound erosion was observed in patients with osteoarthritis: 
at least one erosive joint was found in 42 (70%) and large erosion 
(diameter≥2.5mm) was found in 11 (18%) patients. The most frequently affected 
joint sites were similar to controls; 18 (30%) of patients displayed erosion at the 
wrist (radius) and 13 (22%) displayed erosion at the proximal aspect of MTP1. This 
compares to a rate of any erosion of 64/70 (91%) observed in RA patients in this 
study, and a rate of any large erosion (≥2.5mm diameter) of 48/70 (69%). The most 
frequently involved joint site in RA was the proximal aspect of MTP5. In calculating 
the sensitivity and specificity for joint erosion detectable at individual joint sites for 
the discrimination of RA (versus all other comparator groups), the best combination 
was demonstrated at this site (sensitivity 69%, specificity 85%).  
 
Whilst the size of erosions also appeared to be relatively discriminatory for RA 
(sensitivity and specificity for the presence of at least one large erosion ≥2.5mm 
diameter were 69% and 68%, respectively), the majority of RA patients had 
established disease (n=42) and healthy controls were excluded from this analysis 
(Zayat et al., 2015). Subgroup analysis suggested that erosions were smaller 
amongst the early RA patients (n=28) in comparison to those with established RA. 
The study by Millot et al. also indicated that size of erosions is not sufficient to 
differentiate findings in normal individuals from those with early IA (Millot, Clavel et 
al. 2011). 
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 Prevalence of erosion-like change observed on ultrasound examination in healthy subjects. Table 11.
Reference n 
Method of 
recruitment 
Age (yrs) Joints examined Prevalence of US Erosion 
(Padovano et 
al., 2016) 
207 Staff, students, 
relatives of patients 
and other volunteers 
(exclusions: 
osteoarthritis, trauma, 
recent arthralgia) 
Mean 36, 
range 18-
74 
Wrists, MCPs, PIPs, MTPs 
(Bilateral) 
4/6621 joints (all MTP1). 
(Zayat et al., 
2015) 
60 Across 2 sites (Leeds 
and Copenhagen) 
Mean 40, 
range  
23-73 
Wrist, MCP2,3,5, PIP2-3, 
MTP1,5 (Bilateral) 
20 (33%) of subjects. 
Most frequent at wrist (radius) (12 [20%] subjects) 
and MTP1 (6 [10%] subjects). 
Only 1 subject with erosion ≥2.5mm diameter. 
(Millot, Clavel 
et al. 2011) 
127 Hospital staff and 
patients with sciatica, 
age- and gender-
matched to early IA 
patients in ESPOIR 
Mean 50  MCP2,5 and MTP5 
(Bilateral) 
14 (11%) of subjects (1 erosive joint in each; MTP5 
in 8, MCP2 in 5 and MCP5 in 1 subject). 
Only 3 subjects with erosion >2mm diameter. No 
erosion observed in association with GS or PD 
signal in the same joint. 
(Wiell et al., 
2007) 
5 Not reported Median 
63, range 
35-71 
MCP2-5, PIP2-5, DIP2-5, 
MTP1-5 (Bilateral) 
9 erosive joints in an unknown number of subjects; 
5 PIPs, 3 MTPs and 1 MCP. 
(Terslev et al., 
2004; Terslev 
et al., 2008) 
27 Staff and staff family 
members 
Mean 45, 
range 
18-93 
Wrist, CMC1, MCP1-5, 
PIP1-5 (Unilateral) 
Erosions in 3 CMCs only. 
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(Bajaj et al., 
2007) 
5 Not reported Mean 45 MCP2,5, most swollen PIP 
(one per hand), MTP5 
(Bilateral) 
No erosions (although defined as size >2mm 
diameter). 
(Szkudlarek et 
al., 2006) 
20 Not reported Median 
52, range 
27-79 
MCPs 2-5, PIPs 2-5 
(Unilateral) 
No erosions. 
(Szkudlarek et 
al., 2004) 
20 Not reported Median 
52, range 
25-78 
MTPs 1-5 (Unilateral) 2 (10%) subjects. 
Occurring in MTP1 (2 subjects) and MTP5 (1 
subject). 
97 
 
 Erosions: Reliability 
Several studies have addressed the reliability of US between two operators 
(Wakefield et al., 2000; Szkudlarek, M. et al., 2003; Scheel, A K et al., 2005; 
Naredo et al., 2006; Wiell et al., 2007; Millot et al., 2011). Levels of agreement for 
the presence of erosion on ultrasound, denoted by kappa, have ranged between 
0.5 (moderate) (Wiell et al., 2007) and 0.9 (excellent) (Millot et al., 2011). The 
former was observed at the PIP joints amongst six patients with psoriatic arthritis, 
one patient with RA and one control; in this same study, good to excellent 
agreement was observed at other sites (MCPs, DIPs and MTPs). In Mexico, 
ultrasound examination of MCP2 and the ulnar head, revealed poor inter-observer 
agreement for erosions amongst five operators (Chávez-López et al., 2013). 
Insufficient time to perform an adequately thorough examination (ten minutes to 
examine the wrist, MCPs2-3 and PIPs2-3 for synovitis, tenosynovitis and erosion) 
and poor familiarity with the equipment were cited as potential contributory factors 
to the poor agreement. When considering all of these studies, the prevalence of 
erosions (which has not always been reported) should be considered as kappa 
estimates are susceptible to prevalence bias. The kappa statistic represents the 
agreement which exceeds the expected level of agreement arising by chance; 
therefore, at the extremes of prevalence (very rare or ubiquitous findings) values 
may be misleadingly low.  
 
In reliability exercises undertaken by OMERACT, including a large number of 
sonographers from across Europe, respectable rates of inter-observer agreement 
for ultrasound-detected erosions and cortical abnormalities were reported (Scheel, 
A K et al., 2005; Naredo et al., 2006; Bruyn et al., 2015). In the earliest study, four 
patients with positive ultrasound findings (using agreement of at least 10/14 
operators as the reference standard) volunteered: ultrasound erosions were present 
at the humeral head in a patient with RA, MCP2 in a patient with remitting 
seronegative symmetrical synovitis with pitting oedema, the knee in a patient with 
gout and the talonavicular joint in a patient with reactive arthritis (Scheel, A K et al., 
2005). Agreement for the presence of erosion was observed in 14/14, 13/14, 11/14 
and 12/14 operators, respectively. In a later exercise, wrist and hand ultrasound 
was conducted in six patients with RA, and ankle and foot ultrasound was 
conducted in a further three patients with RA, two patients with SpA and one patient 
with osteoarthritis (Naredo et al., 2006). Erosions were detectable at CMC1, MCP2, 
PIP2, talonavicular, MTP1 and MTP5 joints; kappa values for agreement for cortical 
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abnormalities were 0.6 at each region amongst 23 operators. Limitations of these 
studies included the small number of joints examined (Scheel, A K et al., 2005) and 
the method of reporting cortical abnormalities which grouped erosive findings 
together with osteophytes (Naredo et al., 2006). 
 
 Erosions: Responsiveness 
A small number of studies have reported change in ultrasound erosive damage 
over time. In one of the earliest prospective studies, ultrasound of MCPs2-5 and 
PIPs2-5 (unilaterally) in 16 patients with established RA demonstrated erosions in 
12/128 (9%) joints in 1996 and 62/128 (49%) joints seven years later, in 2003 
(Scheel et al., 2006). However, advancement in the sensitivity of ultrasound 
technology may have accounted for at least some of this difference as a different 
machine was used at follow-up.  
 
Concerning patients with early disease, of 58 patients with early RA (1987 ACR 
criteria with disease duration less than one year) development of new ultrasound 
erosions at the distal ulna was observed in 11/58 (19%) patients over one year 
(Hammer et al., 2009). In a more extensive examination of 11 joints (unilateral 
MCPs1-5, PIPs1-5 and the wrist), 46 patients with early RA (fulfilling 1987 ACR RA 
criteria, within two years of diagnosis) were studied (Hoving et al., 2004). The 
number of patients with ultrasound erosions increased from 14/46 (30%) to 19/46 
(41%) over six months. No statistical testing was performed and this study was also 
conducted relatively early (1999-2003). 
 
A small number of studies have assessed responsiveness of various scoring 
systems for erosions, although without much consistency of scoring methods 
(Szkudlarek et al., 2016). At the level of a single MCP or PIP joint, Reynolds et al. 
observed progression in ultrasound erosion score (grade 0-3 according to erosion 
size) from baseline to follow-up (range 24-32 months) in 12/25 patients with RA (6 
were receiving DMARDs, 4 receiving TNF-inhibitors and 2 receiving NSAIDs only) 
(Reynolds et al., 2009). In 120 patients with RA initiating or receiving a change in 
DMARD therapy, no change in the number of ultrasound erosions across six joints 
(unilateral MCPs2-3, PIPs2-3 and MTP2,5) was observed between baseline and 6 
month follow-up examinations (mean 2.6 erosions at both time-points) (Backhaus et 
al., 2009). Of note, the majority of patients (59%) were treated with TNF-inhibitors. 
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A semi-quantitative score for ultrasound erosions (according to their size) has also 
been shown to improve amongst 38 patients with established RA starting or 
receiving a change in DMARD/biologic therapy (53% receiving biologics): the mean 
total score (for 13 joints of the clinically most affected hand and foot) improved from 
21.5 to 18.1 after one year (p=0.046) (Ohrndorf et al., 2014). 
 
2.3.3 Summary 
This evidence supports ultrasound as a valid tool to define the phenotype of 
patients with IA and assess disease activity in patients receiving treatment. It offers 
supplementary information to clinical and radiographic evaluations. Studies suggest 
the predictive value of ultrasound, however further research is needed to determine 
the prognostic value of ultrasound-detected synovitis and erosions, particularly in 
early IA in the context of the new 2010 ACR/EULAR RA criteria.  
 
Assessment of synovitis (and possibly joint damage) by ultrasound is now 
recommended by experts within European guidelines for the confirmation of early 
IA (Colebatch et al., 2013; Combe et al., 2017). Nevertheless, with the increasing 
use of ultrasound as an aid in diagnosing and directing treatment decisions it is 
critically important to be aware its limitations. These include its operator-dependant 
nature and the existence of ultrasound abnormalities in normal or osteoarthritic 
joints, such as low-grade synovitis or erosive-like change.  
 
The choice of joints to include in an ultrasound examination is contingent on its 
intended purpose. An assessment to determine future prognosis in a patient with 
early UA may include more joints than if assessing disease activity in a patient 
already receiving treatment or as an outcome in a clinical trial. A more extensive 
joint examination may be expected to be more sensitive, albeit with a potential 
trade-off in specificity and reliability. Ultrasound within research should be replicable 
and conducted in such a way that results are interpretable and generalisable to the 
target population. In this setting, therefore, standardised ultrasound of a core set of 
joints may be appropriate versus a clinical setting in which ultrasound may be 
directed according to clinical history and restricted to examination of just the hands, 
or hands and feet, for example. Feasibility, especially in this latter setting, is another 
key consideration.  
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The definition for abnormality at the joint level may also depend on the clinical 
situation. For example, GS synovitis may be a useful measure of disease activity in 
treatment-naïve early IA (bearing in mind that a small volume of low-grade GS 
synovitis may be observed in normal individuals), whilst in later disease it may be 
difficult to differentiate active synovitis from inactive fibrous synovial thickening 
using GS appearance alone, in which circumstance PD may be more informative. 
Indeed, GS synovitis has been shown to correlate with disease duration in patients 
with established RA (Saleem et al., 2009). 
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2.4 Strategies for Management 
2.4.1 Rheumatoid Arthritis 
2.4.1.1 The Therapeutic Window of Opportunity in Early RA 
The key principle in the management of patients with RA is that inflammatory 
disease activity over time leads to cumulative joint destruction. In addition, 
inadequately supressed inflammation contributes to an increased risk of 
comorbidities related to chronic inflammatory diseases such as cardiovascular 
disease and lymphoma. It has been shown that joint damage occurs early in the 
disease process. Indeed, prospective data from biannual hand and feet radiographs 
has demonstrated the rate of progression of joint damage to be significantly greater 
in the first year, in comparison to the second and third years, from diagnosis (van 
der Heijde et al., 1995). 
 
It follows that early effective treatment offers favourable long-term outcomes, 
through limiting the burden of inflammation over time. This has been a prevailing 
concept in management since the 1990s (Quinn et al., 2001) and is supported by 
comparisons of patients receiving early and delayed DMARD therapy in both a 
non-randomised (Lard et al., 2001; Nell et al., 2004) and randomised (van der 
Heide et al., 1996) manner. Further evidence is available from several 
observational cohorts and randomised-controlled studies in early IA in which 
symptom duration at baseline has been consistently identified as an independent 
predictor of poor outcome (see Tables 3-5) (Bosello et al., 2011; Lukas et al., 2011; 
Söderlin and Bergman, 2011; Gremese et al., 2013).  
 
Over and above the quantitative reduction in inflammation that may be afforded by 
DMARD therapy, a window of opportunity may exist in very early disease in which 
pathogenic mechanisms are not yet fully evolved and may be more readily 
modifiable with therapy. The early initiation of DMARD therapy positively impacts on 
the aggressive and persistent nature of the disease in the future, with 
meta-analyses demonstrating lower rates of future radiographic progression (Finckh 
et al., 2006) and higher rates of DMARD-free remission (van Nies et al., 2014). 
More recently, in patients receiving TNF-inhibitors as first-line therapy in 
randomised controlled trials, the importance of early initiation of such therapy in 
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order to achieve optimal remission rates (Emery, P. et al., 2010) and sustained 
remission after TNF-inhibitor cessation (Saleem et al., 2010) has also been 
demonstrated.  
 
Recently, pivotal results from an analysis of RA patients receiving DMARDs in 
observational cohorts (Leiden EAC and ESPOIR) have demonstrated a non-linear 
relationship between a patient’s symptom duration at their first visit to a 
rheumatologist and achievement of DMARD-free remission (van Nies et al., 2015). 
This is fundamental to the concept of a therapeutic window of opportunity in early 
disease. In this combined cohort, symptoms for up to 19 weeks prior to the first visit 
provided the optimal combination of sensitivity and specificity for discriminating the 
ability to achieve DMARD-free remission in the future. The timing of the window of 
opportunity is likely to vary according to disease characteristics, with studies 
suggesting it may be narrower in patients with ACPA-positive disease (van Nies et 
al., 2015) and even narrower or non-existent in patients who continue to smoke 
(Söderlin and Bergman, 2011). 
 
An underlying hypothesis is that, within this critical phase in early disease, 
immunosuppressive therapy may enable full reversal of immunopathogenic 
abnormalities and hence reduce the propensity for disease mechanisms to become 
chronic (Raza, 2010). It has been postulated that this window, in which disease 
mechanisms may be distinct from those in established disease, may exist very early 
in the disease process. A distinct cytokine profile has been observed in the synovial 
fluid of patients with early IA (symptoms <12 weeks) who later fulfilled 1987 ACR 
RA criteria, in comparison to patients with established RA (Raza et al., 2005b). 
Synovial tissue immunohistochemical analysis has also demonstrated features 
apparently unique to patients with very early IA (symptoms <6 weeks) destined to 
later fulfil the 1987 ACR RA criteria (Singh et al., 2004). Whereas the histological 
appearance of synovium from patients with RA already fulfilling 1987 ACR RA 
criteria, within one year of onset of joint swelling, has been found to be similar to 
that observed in later disease (Tak et al., 1997). 
 
These studies highlight the importance of early identification of IA and prompt 
commencement of therapy. Connotations for the various definitions of symptom or 
disease duration within studies of patients with early IA (i.e. time from onset of 
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symptoms, joint swelling or fulfilment of classification criteria) are also an area of 
on-going discussion (Raza et al., 2012). 
 
2.4.1.2 Treatment Strategies: Synthetic DMARDs 
 Initial Combination Synthetic DMARD Therapy versus DMARD 
Monotherapy 
The COBRA study was the first to demonstrate the benefit of initial combination 
DMARD therapy (sulfasalazine, methotrexate and high dose prednisolone) over 
DMARD monotherapy (sulfasalazine) (Boers et al., 1997). The high steroid doses 
administered in the combination treatment arm may have contributed significantly to 
the results. The FIN-RACo study also demonstrated superior clinical outcomes in 
patients randomised to combination therapy (sulfasalazine, methotrexate, 
hydroxychloroquine and low-dose prednisolone) versus initial sulfasalazine 
(Möttönen et al., 1999). This study was more realistic in allowing patients with 
persistent disease activity in the sulfasalazine monotherapy arm to receive 
additional steroid therapy and switch treatment to methotrexate, and subsequently 
to alternative DMARDs. In the CIMESTRA study, methotrexate plus ciclosporin was 
compared to methotrexate and placebo (Hetland et al., 2006). Patients in both arms 
also received frequent assessment and intra-articular steroid treatment for swollen 
joints (at 0, 2, 4, 6 and 8 weeks, then 4-weekly intervals). Patients receiving initial 
combination therapy achieved higher ACR20 response rates at one year (the 
primary end-point) in comparison to those receiving methotrexate monotherapy; 
85% versus 68%, respectively (p=0.02). 
 
 Treatment-to-Target Strategies 
Several studies support initial DMARD therapy, either as monotherapy or in 
combination with other DMARDs, with adjustment in therapy according to a 
pre-defined target of clinical remission or at least a low disease activity state. These 
include treatment regimens restricted to synthetic DMARDs only (Grigor et al., 
2004; Proudman, Susanna M. et al., 2007; Verstappen et al., 2007; Saunders et al., 
2008; Knevel et al., 2010; den Uyl et al., 2014; Verschueren et al., 2017), as well as 
studies designed with protocolled escalation to biologic therapies (Soubrier et al., 
2009; van Vollenhoven et al.; Goekoop-Ruiterman et al., 2010; Knevel et al., 2010; 
Soubrier et al., 2011; Moreland et al., 2012; de Jong et al., 2014; Hørslev-Petersen 
et al., 2014; Nam et al., 2014a; Scott et al., 2014; Smolen, Josef S. et al., 2014; 
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Heimans et al., 2016). The latest evidence-based guidelines, first published in 2010 
by EULAR, recommend this approach (Smolen et al., 2010; Smolen, Josef S et al., 
2014; Singh et al., 2016; Smolen et al., 2016; Smolen et al., 2017).  
 
For example, in the TICORA study, tight control of disease proved advantageous 
over routine treatment (Grigor et al., 2004). Intensive management involved 
monthly assessment and step-up to combination DMARD therapy according to a 
target of low disease activity, in comparison to three-monthly monitoring without use 
of a formal measure of disease activity. At 18 months, clinical remission 
(DAS44-ESR<1.6) was achieved in 65% of the intensive therapy group, compared 
to only 16% of the routine treatment group (although the intensive group also 
received greater steroid doses). 
 
Initial intensive combination therapy, based on the COBRA regimen, has also been 
compared to initial DMARD monotherapy (either methotrexate, sulfasalazine, 
hydroxychloroquine or azathioprine) with change in therapy according to a target of 
DAS28 remission (Verschueren et al., 2008). However, this was a pragmatic study 
based on daily practice. Allocation to either initial combination or monotherapy was 
based on physician judgement, as was initial choice of DMARD monotherapy and 
subsequent treatment adjustments. In a further open-label study, randomisation to 
treatment groups and a protocol for escalation was employed (den Uyl et al., 2014). 
Patients were randomised to ‘COBRA’ (methotrexate, sulfasalazine and 
prednisolone tapering from 60mg daily) or ‘COBRA-light’ (methotrexate escalating 
to 25mg weekly, over approximately two months, in combination with prednisolone 
tapering from 30mg daily) regimens. At three months, methotrexate treatment was 
escalated according to a target of remission (DAS44<1.6): an increase in oral dose 
in ‘COBRA’-treated patients or switch to subcutaneous administration in 
‘COBRA-light’ patients. Non-inferiority for the primary outcome (change from 
baseline DAS44 at six months) between the regimens was suggested. However, 
the confidence interval for the estimated difference between the groups included 
0.5, the pre-defined clinically relevant difference suggesting non-inferiority, and the 
low starting dose of methotrexate in the original COBRA regimen may be of 
significance.  
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The CareRA trial concluded that initial methotrexate monotherapy with prednisolone 
(30mg daily, reducing to stop over nine months) with addition of leflunomide after 
16 weeks in the instance of DAS28≥3.2, was as effective as initial combination 
DMARD therapy; either the COBRA regimen (including prednisolone 60mg, 
tapering over 9 months) or methotrexate and leflunomide (in combination with 30mg 
prednisolone daily, tapering over 9 months) (Verschueren et al., 2015; Verschueren 
et al., 2017). However, a greater number of patients in the initial methotrexate 
monotherapy arm received intra-muscular and/or intra-articular steroids and both 
the high cumulative dose of prednisolone and the escalation to a combination of 
methotrexate and leflunomide may not be ideal for routine clinical use due to their 
side-effect profiles.  
 
2.4.1.3 Treatment Strategies: The Role of Biologic Therapy 
TICORA and other pragmatic studies demonstrate that clinical remission is a 
realistic goal but it is not always achievable with synthetic DMARD therapy alone; 
indeed rates of remission are often quite low (Proudman, S. M. et al., 2007; 
Verstappen et al., 2007; Saunders et al., 2008). In patients failing to achieve 
remission in this way, biologic therapy may be indicated. TNF-inhibitor therapies 
were initially introduced, followed by rituximab and subsequently abatacept and 
tocilizumab, all licensed for use in these patients. In the UK, the National Institute 
for Health and Care Excellence (NICE) currently recommends biologic therapies in 
the instance of failure of two synthetic DMARDs (including methotrexate) and in the 
presence of high disease activity (DAS28>5.1). 
 
The DREAM study offers some insight into efficacy of a treatment-to-target 
regimen, with escalation to biologic therapy in patients with persistent disease 
activity, within a clinical setting (Vermeer et al., 2011). It was a single arm, 
open-label, pragmatic study of patients with early RA (defined by physician 
impression, 82% of patients were fulfilling 1987 ACR criteria at baseline). Patients 
were treated with initial methotrexate, with subsequent steps of addition of 
sulfasalazine and switch of sulfasalazine to adalimumab in the instance of 
DAS28≥3.2 at or after six months. The rate of DAS28 remission at one year, 58%, 
was still less than ideal. Evidence of the efficacy of treatment-to-target management 
in a UK clinical setting, with potential barriers to adherence to treatment-to-target 
guidelines such as NICE restrictions for the use of biologics, is currently limited.  
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There is an argument for the earlier introduction of biologic therapy, particularly in 
patients with poor prognostic factors, owing to the therapeutic window of 
opportunity in early disease and the superior efficacy of biologics in comparison to 
methotrexate therapy (St Clair et al., 2004; Breedveld et al., 2006; Emery et al., 
2008; Emery et al., 2009) (Table 13). However, evidence for the early initiation of 
biologic therapy versus initial use of synthetic DMARDs with ongoing management 
within a treatment-to-target regimen, or initial combination synthetic DMARD 
therapy, is less conclusive. The evidence for these treatment strategies, in patients 
with either early or DMARD/methotrexate-naïve RA, is reviewed here. Randomised 
studies are grouped according to the categories described in Table 12. 
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 Summary of randomised studies assessing treatment strategies Table 12.
including biologic therapies in DMARD/MTX-naïve patients. 
Treatment Regimen and  
Simplified Schematic of Study Design 
Study Examples 
Fixed Treatment Regimens 
1.  Biologic (+/- MTX) versus MTX monotherapy See Table 13 
2.  Biologic + combination DMARDs versus combination DMARDs NEO-RACo 
 
 
 
 
 
 
 
 
 
Step-up regimens: first-line DMARD regimens with step-up in therapy 
(including delayed biologic therapy) according to a disease activity target 
3.  MTX monotherapy with escalation to delayed biologic versus MTX 
monotherapy with escalation to combination DMARDs 
 
 
 
SWEFOT 
4.  MTX monotherapy with ongoing treatment-to-target (including 
escalation to delayed biologic) versus combination DMARDs with 
ongoing treatment-to-target (including escalation to delayed 
biologic) 
 
tREACH 
 
Extension of 
COBRA vs. 
COBRA-light study 
  
 
 
 
 
 
MTX 
DMARD/ 
MTX-naïve 
Randomise 
Biologic + MTX 
Placebo + MTX 
Randomise 
DMARD/ 
MTX-naïve 
Placebo + combination DMARDs 
Biologic + combination DMARDs 
Persistent 
disease activity: 
Randomise 
Biologic + MTX 
Combination DMARDs 
Randomise 
MTX 
Combination 
DMARDs 
DMARD/ 
MTX-naïve 
Ongoing  
treatment-to-target  
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5.  MTX monotherapy with escalation to delayed biologic versus MTX 
monotherapy with escalation to combination DMARDs, followed 
by later escalation to biologic 
 
IMPROVED 
Step-up regimens: first-line biologic therapy versus first-line DMARD 
regimens with step-up in therapy according to a disease activity target 
6.  Biologic (+ MTX) versus MTX monotherapy with escalation to 
delayed biologic 
 
OPTIMA 
HOPEFUL 
 
 
 
 
 
 
 
7.  Biologic (+ MTX) with ongoing treatment-to-target including switch 
to alternative biologic versus MTX monotherapy with ongoing 
treatment-to-target including delayed biologic 
 
 
U-Act-Early 
IDEA 
Similar examples: 
 GUEPARD 
(open-label, i.e. 
no placebo) 
 OPERA 
(escalation to 
combination 
DMARDs, i.e. no 
delayed biologic 
in patients 
randomised to 
initial MTX 
monotherapy) 
8.  Studies with multiple treatment arms (see text for descriptions of 
studies) 
BeSt 
TEAR 
 
  
  
 
 
 
 
 
  
 
 
 
 
 
Randomise 
Biologic + MTX 
Placebo + MTX 
DMARD/ 
MTX-naïve 
Ongoing  
treatment-to-target  
DMARD/ 
MTX-naïve 
Randomise 
Biologic + MTX 
Placebo + MTX 
Persistent disease 
activity:  
Biologic + MTX 
MTX 
Persistent 
disease activity: 
Randomise 
Biologic + MTX 
Combination 
DMARDs 
Ongoing  
treatment-to-target  
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Fixed treatment regimens 
1. First-line biologic (+/- methotrexate) versus first-line methotrexate 
monotherapy 
Double-blind randomised controlled trials of biologic therapies in patients with early 
RA are summarised in Table 13. Early trials were largely conducted in patients with 
indicators of severe, progressive disease, such as high disease activity, 
RF-positivity and radiographic erosions. With accumulating evidence of the safety 
and efficacy of these therapies, and the importance of the achievement of remission 
to optimise long-term outcomes in patients with early RA, later studies have been 
conducted in patients with lower disease activity at baseline (Emery et al., 2008; 
Emery et al., 2009). Increasingly ambitious primary outcomes have been set 
including clinical remission, first assessed in the COMET study (Emery et al., 2008). 
The majority of trials excluded patients with significant prior exposure to 
methotrexate, whilst several more recent studies excluded patients receiving any 
prior DMARDs. 
 
The HIT-HARD study was recently conducted with the intention of assessing the 
efficacy of a short duration of biologic therapy, with a primary outcome several 
months after biologic withdrawal (Detert et al., 2013). Although the difference in the 
primary outcome was not statistically significant (see Table 13), significant 
differences were observed between the groups in secondary outcomes. These 
included clinical responses whilst receiving the study treatments at six months, and 
radiographic outcomes after treatment withdrawal at one year. Results of follow-up 
studies of a number of the randomised trials described in Table 13 are also 
available. These include a follow-up of patients receiving initial infliximab and 
methotrexate versus methotrexate and placebo (Quinn, M. A. et al., 2005): eight 
years on, 40% of patients initially treated with infliximab were still in remission, in 
comparison to none of the controls (Bejarano et al., 2010). The impact of tapering 
and stopping biologic and/or synthetic DMARDs has also been reviewed in 
open-label and single-blind studies including treatment-to-target/step-up treatment 
arms and initial combination synthetic DMARD therapy arms (discussed below). 
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 Efficacy of biologic therapy in early RA patients (fulfilling 1987 ACR RA criteria, unless otherwise stated as fulfilling 2010 ACR/EULAR Table 13.
criteria) in double-blind randomised controlled trials. Controls were treated with methotrexate. Only groups treated with the dose 
currently approved for clinical practice are presented. 
Drug and Study 
Inclusion Criteria 
Primary/Co-primary endpoints 
Results: 
Primary outcome(s) in active treatment 
group (dose used in clinical practice) 
vs. controls*** 
Disease 
Activity  
Disease 
Duration*/ 
Previous 
DMARD 
Exposure** 
Other 
Prognostic 
Factors 
Etanercept 
monotherapy, 
Enbrel ERA (Bathon  
et al., 2000) 
SJC ≥10, 
TJC ≥12,  
EMS≥45min, 
ESR≥28mm/hr 
CRP≥20mg/l. 
≤3 yrs/ 
MTX-naïve 
RF+ or ≥3 
x-ray 
erosions. 
Clinical response over 6 mths (area 
under the curve for ACR-N up to 6 
mths). 
Mean change in SHS from baseline 
at 12 mths. 
Significantly greater area under the curve 
for ACR-N (p<0.05). 
Mean change in SHS 1.0 vs. 1.6 (p=0.11). 
 
Etanercept with 
MTX, COMET 
(Emery et al., 2008) 
DAS28≥3.2, 
ESR 
≥28mm/hr or 
CRP≥20mg/l. 
≤2 yrs/ 
MTX-naïve 
- Clinical remission at 52 wks 
(DAS28-CRP<2.6). 
Change in SHS from baseline to 
wk 52. 
DAS28 remission in 50% vs. 28% 
(p<0.0001) (mITT based on 528 of 542 
patients randomised). 
Change in SHS 0.3 (95% CI -0.1 to 0.7) 
vs. 2.4 (95% CI 1.5-3.4) (mITT based on 
476 of 542 patients randomised). 
Infliximab with MTX, 
ASPIRE (St Clair et 
al., 2004) 
SJC ≥10, 
TJC ≥12.  
 
≤3 yrs 
(persistent 
synovitis)/ 
MTX-naïve 
≥1 of: RF+, 
≥1 x-ray 
erosion, 
CRP 
≥20mg/l. 
Clinical response over 54 wks 
(area under the curve for ACR-N 
up to wk 54). 
Change in SHS (baseline to wk 
54). 
Median ACR-N 39% vs. 26% (p<0.001). 
Mean (SD) change in SHS 0.4 (5.8) vs. 
3.7 (9.6) (p<0.001). 
Both outcomes mITT based on 1004 of 
1049 patients randomised. 
Infliximab with MTX  
(Quinn, M. A. et al., 
2005) 
MCP joint 
involvement. 
 
<1 yr 
(symptoms)/ 
DMARD-
naïve 
PISA≥3. MRI synovitis (measured at MCP2-
5 of the dominant hand) at wk 14. 
Reduction in median total synovitis score 
from 5.5 to 3.4 vs. 6.2 to 5.9 (p<0.05). 
111 
 
 
Infliximab with MTX 
(Durez et al., 2007) 
SJC ≥6,     
TJC ≥8. 
<1 yr/ MTX-
naïve (and 
excluded 
patients who 
had 
received >2 
previous 
DMARDs) 
- Change from baseline in MRI 
sores for synovitis, bone 
marrow oedema and erosion 
(assessed using semi-
quantitative methods at wrists, 
MCP2-5 and MTP1-5, 
bilaterally) at wk 18 and wk 52. 
Median (IQR) change in score from baseline 
(mITT based on 26 of 29 patients randomised): 
Wk 18: synovitis: -7(8) vs. -1(2) (p<0.001) 
           oedema: -5.5(15) vs. -2(7) (p=0.03) 
           erosion: 1 (2) vs. 1 (2) (p=NS). 
Wk 52: synovitis: -10.5(11) vs. -4.5(9)(p=0.02) 
            oedema: -9(20) vs. -2(6) (p=NS) 
            erosion: 1 (3) vs. 1 (6) (p=NS). 
Adalimumab with 
MTX and 
Adalimumab 
monotherapy, 
PREMIER 
(Breedveld et al., 
2006) 
SJC ≥8,        
TJC ≥10, 
ESR 
≥28mm/hr or 
CRP≥15mg/l. 
 
<3 yrs/ MTX-
naïve (and 
excluded 
patients who 
had 
received >2 
other 
DMARDs) 
RF+ or ≥1 
x-ray 
erosion. 
ACR50 at 1 yr. 
Mean change in SHS from 
baseline at 1 yr. 
 
Adalimumab in combination with MTX superior 
to adalimumab monotherapy or MTX alone:  
ACR50 in 62% vs. 41% (adalimumab 
monotherapy) and 46% (MTX monotherapy) 
(p<0.001 combination therapy vs. either 
monotherapy group). Mean change in SHS 1.3 
vs. 3.0 (adalimumab monotherapy) and 5.7 
(MTX monotherapy) (p≤0.002 combination 
therapy vs. either monotherapy group). 
Adalimumab with 
MTX (Bejarano et 
al., 2008) 
None specified 
(mean DAS28 
6). 
<2 yrs 
(symptoms)/
MTX-naïve  
Self-
reported 
RA-related 
work 
impairment. 
Job loss/imminent job loss 
at/after wk 16 (defined as 
failure to achieve ACR20 and 
either WIS score deterioration 
or persistent high WIS score). 
12/75 vs 20/73 (p=0.092) (data for all 
withdrawals imputed as no job loss in this ITT 
analysis, greater withdrawals observed in 
controls due to high disease activity). 
Adalimumab with 
MTX (MTX 
4-8mg/wk consistent 
with local practice in 
Japan), HOPEFUL 
(Takeuchi et al., 
2014) 
SJC≥8, 
TJC≥10, 
ESR 
≥28mm/hr or 
CRP≥15mg/l. 
<2 yrs/ MTX-
naïve/LEF-
naïve 
(excluded 
patients who 
had 
received >2 
DMARDs) 
RF+ or ≥1 
x-ray 
erosion 
Mean change in SHS at wk 26. Mean change 2.3 vs. 4.3 (p<0.001) (mITT 
based on 232 of 234 patients randomised). 
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Adalimumab with 
MTX, HIT-HARD 
(adalimumab 
stopped at 24 wks) 
(Detert et al., 2013) 
SJC≥6, 
TJC≥6, 
EMS≥30min, 
ESR 
≥28mm/hr or 
CRP≥10mg/l. 
<1 yr/ 
DMARD- 
naïve 
- DAS28 at wk 48. Mean DAS28 (SD): 3.2 (1.4) vs. 3.4 (1.6). 
Difference between the groups 0.21 (95% 
CI -0.3 to 0.7, p=0.41). 
Golimumab with 
MTX, GO-BEFORE 
(Emery et al., 2009) 
SJC ≥4, 
TJC ≥4.  
 
≥3 mths (no 
upper limit, 
mean 3.5 yrs 
vs. 2.9 yrs in 
controls)/ 
MTX-naïve 
≥2 of: 1) ESR 
≥28mm/hr or 
CRP≥15mg/l, 
2) EMS≥30 
min, 3) ≥1 
erosion on 
x-ray or MRI, 
4) RF+ or 
ACPA+. 
ACR50 at 24 wks. 40% vs. 29% (p=0.038).  
 
Certolizumab with 
MTX, C-EARLY 
(Emery et al., 2017) 
SJC≥4 (of 28), 
TJC≥4 (of 28), 
DAS28>3.2, 
ESR 
≥28mm/hr or 
CRP≥10mg/l. 
≤1 yr/ 
DMARD- 
naïve 
RF+ or 
ACPA+. 
Fulfilling 
2010 
ACR/EULAR 
RA criteria. 
Sustained remission at 1 yr 
(DAS28<2.6 at wks 40 and 52). 
29% vs. 15% (p<0.001) (mITT based on 
868 of 879 patients randomised). 
Certolizumab with 
MTX, C-OPERA 
(Atsumi et al., 2016) 
DAS28≥3.2. ≤1 yr 
(persistent 
symptoms)/ 
MTX-naïve/ 
LEF-naïve 
ACPA+ 
(≥3xULN) 
and either 
RF+ or 
radiographic 
erosions. 
Fulfilling 
2010 RA 
criteria. 
Mean change from baseline in 
SHS at 1 yr. 
Mean (SD) change in SHS 0.4 (2.7) vs. 
1.6 (4.9) (p<0.001) (mITT based on 315 of 
319 patients randomised). 
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Rituximab every 24 wks with 
MTX, IMAGE (Tak et al., 
2011) 
SJC ≥8, 
TJC ≥8, 
CRP≥10mg/l. 
≤4 yrs/ 
MTX- 
naïve 
RF+ or ≥1 
x-ray erosion. 
Mean change in Genant-
modified total Sharp Score at 
52 wks. 
Mean change in radiographic score 0.4 vs. 
1.1 (p<0.001) (mITT based on 473 of 503 
patients randomised). 
Abatacept with MTX 
(Westhovens et al., 2009) 
SJC ≥10, 
TJC≥12, 
CRP≥4.5mg/l
. 
≤2 yrs/ 
MTX- 
naïve 
RF+ or 
ACPA+, 
and ≥1 x-ray 
erosion. 
DAS28 remission at 1 year  
Mean change in Genant-
modified total Sharp score 
from baseline at 1 yr. 
Remission in 41% vs. 23% (p<0.001). 
Mean change in radiographic score 0.6 vs. 
1.1 (p=0.04). 
Tocilizumab with MTX and 
Tocilizumab monotherapy, 
FUNCTION (Burmester et 
al., 2016) 
SJC≥4, 
TJC≥6, 
DAS28>3.2, 
ESR 
≥28mm/hr or 
CRP≥10mg/l. 
<1 yr/ 
MTX- 
naïve 
RF+ or 
ACPA+ or ≥1 
x-ray erosion. 
Fulfilling 
1987 ACR or 
2010 RA 
criteria. 
Clinical remission 
(DAS28<2.6) at wk 24. 
Remission in 45% (tocilizumab with MTX) 
vs. 39% (tocilizumab monotherapy) and 
15% (MTX controls) (p<0.0001 for 
comparisons of either tocilizumab group 
vs. controls). 
Tocilizumab with MTX and 
Tocilizumab monotherapy 
(addition of HCQ if 
DAS28≥2.6 or SJC[of 28]>4 
with maximum MTX), U-Act-
Early (Bijlsma et al., 2016) 
DAS28≥2.6. ≤1yr/ 
DMARD- 
naïve 
Fulfilling 
1987 ACR or 
2010 
ACR/EULAR 
RA criteria. 
Sustained clinical remission 
(DAS28<2·6 and SJC[of 28]≤4 
for ≥24) on initial treatment 
regimen (duration varied 
according to treatment arm 
and response). 
Sustained remission in 86% (tocilizumab 
with MTX) vs. 84% (tocilizumab 
monotherapy) and 44% (MTX controls) 
(p<0.0001 for comparisons of either 
tocilizumab group vs. controls). 
*Time since diagnosis, unless otherwise stated, **Studies excluded patients receiving previous biologics, ***Statistical analyses based on all 
randomised patients receiving ≥1 dose of study medication, unless otherwise stated as modified-intention-to-treat (mITT) analysis. 
MTX: methotrexate, ACR-N: mean American College of Rheumatology response, EMS: early morning stiffness duration, ERA: Early Rheumatoid 
Arthritis, COMET: combination of methotrexate and etanercept in early rheumatoid arthritis, ASPIRE: Active-controlled Study of Patients receiving 
Infliximab for the treatment of Rheumatoid arthritis of Early onset, PISA: Persistent Inflammatory Symmetrical Arthritis score (scoring 1 point for 
each of the following: RF-positivity, possession of the shared epitope (HLA–DR1/DR4/DR10), CRP>20 mg/L, female sex, Health Assessment 
Questionnaire raw score>4, or 2 points for HAQ raw score >11), NS: not significant, ACR20/50: American College of Rheumatology response 
criteria improvements of 20% or 50%, respectively, WIS: Work Instability Scale, LEF: leflunomide, HIT-HARD: High Induction Therapy with Anti-
Rheumatic Drugs, GO-BEFORE: Golimumab Before Employing methotrexate as the First-line Option in the treatment of Rheumatoid arthritis of 
Early onset, C-OPERA: Certolizumab-Optimal Prevention of joint damage for Early RA, ULN: upper limit of normal, HCQ: hydroxychloroquine. 
114 
 
 
2. First-line biologic + combination DMARDs versus first-line combination 
DMARDs 
The NEORACo study offered early aggressive treatment in the form of initial 
combination therapy of methotrexate, sulfasalazine, hydroxychloroquine, 
prednisolone and randomisation to either infliximab or placebo (Leirisalo-Repo et 
al., 2013). Intra-articular steroid was also administered to swollen joints. In the 
instance of inefficacy or intolerance to synthetic DMARDs, these were switched to 
alternatives. If ACR50 response was not achieved after six months (at two 
consecutive visits) patients were considered non-responders (in statistical 
analyses) and treatment was unrestricted to enable alternative biologic therapy 
(occurring in 3 of the 99 patients randomised). The primary end-point was remission 
at two years (SJC66=0, TJC68=0 and at least 3 of: early morning stiffness<15min, 
no fatigue, no joint pain and normal ESR). This was achieved in 66% of patients 
randomised to infliximab and 53% of patients randomised to placebo (p=0.2). 
However, the groups differed significantly in analyses of secondary outcomes, with 
infliximab offering superior rates of sustained remission and radiographic outcomes 
in comparison to placebo. Rates of sustained remission (at every visit between 6 
and 24 months) were 26% and 10% (p=0.04), mean changes in total SHS from 
baseline to two years were 0.2 and 1.4 (p=0.006), and rates of absence of 
radiographic progression were 80% and 53% (p=0.006), respectively. With these 
intensive regimens nine serious adverse events occurred in seven (7%) patients. 
The rate of adverse events or serious adverse events was similar between the two 
treatment groups. 
 
Step-up regimens: first-line DMARD regimens with step-up in therapy 
(including delayed biologic therapy) according to a disease activity target 
3. First-line methotrexate monotherapy with escalation to delayed biologic 
versus first-line methotrexate monotherapy with escalation to combination 
DMARDs 
The SWEFOT study demonstrated that, subsequent to failure of three months’ 
initial treatment with methotrexate monotherapy (DAS28>3.2), single-step 
escalation to addition of infliximab (3mg/kg 8-weekly, increasing to 6-weekly in the 
instance of insufficient response) is superior to addition of sulfasalazine and 
hydroxychloroquine (van Vollenhoven et al., 2009b). The primary end-point was 
EULAR good response at one year in randomised patients (with reference to 
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disease activity at the point of randomisation). Of 487 patients enrolled, 145 (30%) 
achieved DAS28≤3.2 after three months of methotrexate, and 258 patients were 
randomised and included in the intention to treat analysis. A EULAR good response 
at one year was achieved in 50/128 (39%) patients receiving infliximab and 32/130 
(25%) of patients receiving synthetic DMARDs (p=0.02). The open-label study 
design and lack of permissible treatment escalations (other than a moderate dose 
increase in sulfasalazine from 2g to 3g daily) in patients with a poor response to 
combination therapy, who in clinical practice may be eligible for biologic therapy 
according to NICE criteria, are significant limitations of this study. It demonstrates 
that a clinically significant proportion of patients may achieve good responses to 
methotrexate monotherapy and combination synthetic DMARD therapy. However, 
rates of remission (the treatment goal of today) have only been reported in the 
group of patients who continued on initial methotrexate monotherapy, and ongoing 
radiographic damage has been observed in these patients (Rezaei et al., 2012).    
 
4. First-line methotrexate monotherapy with ongoing treatment-to-target 
(including escalation to delayed biologic) versus first-line combination 
DMARDs with ongoing treatment-to-target (including escalation to delayed 
biologic) 
Results of a single-blind study, tREACH, are available (de Jong et al., 2014; Kuijper 
et al., 2016). Patients with either RA or UA (arthritis affecting at least one joint), with 
symptoms lasting for less than one year, were grouped according to their risk of 
persistent arthritis as defined by Visser et al. (Visser et al., 2002). Those at high risk 
of developing a persistent arthritis were randomised to either triple synthetic 
DMARD therapy (methotrexate, sulfasalazine and hydroxychloroquine) or 
methotrexate monotherapy, with both groups receiving initial corticosteroid bridging 
therapy; 95% and 98% of patients in these groups fulfilled 2010 RA criteria at 
baseline. Disease activity was assessed every three months, with escalation of 
treatment according to achievement of a target of DAS44 low disease activity, as 
follows: step-up to methotrexate plus etanercept, followed by switch of etanercept 
to adalimumab and subsequently abatacept, as required. In the instance of a 
patient achieving sustained DAS44 remission (at two consecutive visits), therapy 
was tapered. Over the course of the first year, superior disease control was 
observed in patients randomised to initial triple therapy; the primary outcome AUC 
for DAS44 was generally lower in these patients by an estimated difference of 2.4 
(95% CI 0.0-4.8, p=0.0497). A trend was also observed in favour of initial triple 
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DMARD therapy in physical function over one year, as measured by the AUC for 
HAQ, with secondary analysis adjusting for baseline characteristics (RF, ACPA and 
baseline HAQ) demonstrating a significant difference between the groups. 
However, the superior suppression of disease activity observed with triple therapy 
did not appear to translate into superior radiographic outcomes. No statistically 
significant difference was detected between the groups in the proportion of patients 
with radiographic progression at one year: rates were 24% and 23% in patients 
randomised to triple DMARD and methotrexate monotherapy, respectively. As may 
be expected, a greater proportion of patients in the methotrexate monotherapy arm 
required biologic therapy over this year (43% in comparison to 26% in the 
comparator triple therapy DMARD arm, p=0.01) which may account for the similar 
radiographic outcomes. Aspects of this study to consider include the proportion of 
patients who were either demonstrating a degree of response to methotrexate 
monotherapy, and/or had favourable prognostic factors, prior to step-up to 
etanercept at three months (16 of the 36 patients with DAS44≥2.4), in whom 
escalation to triple DMARD therapy may have been considered a more appropriate 
treatment escalation. Likewise, the DAS44 low disease activity target after three 
months of biologic therapy may have necessitated switch in biologic in patients who 
were demonstrating a clinical response, which is not entirely reflective of clinical 
practice. Interestingly, a greater proportion of patients failed their first biologic in the 
methotrexate monotherapy arm (16%) in comparison to the triple DMARD therapy 
arm (6%, p=0.03). 
 
Subsequent to the initial six month phase of open-label ‘COBRA’ versus 
‘COBRA-light’ therapy (see above, section 2.4.1.2), in which methotrexate therapy 
was altered at three months according to a target of remission (DAS44<1.6), 
etanercept was added at six months (or nine months in patients responding at six 
months with subsequent disease flare) according to the same target (ter Wee et al., 
2015). At one year, rates of remission (DAS44<1.6) were similar between the 
groups (38% versus 31%, respectively, p=0.2). Fewer patients receiving the 
‘COBRA’ regimen than receiving the ‘COBRA-light’ regimen required the addition of 
etanercept per protocol (59% versus 75%, p=0.03). However, a significant number 
of the patients requiring etanercept per protocol (n=108) did not receive it (41 [38%] 
of these patients), and the proportion starting etanercept of those requiring it was 
less in the ‘COBRA’ group (p=0.04), implying a degree of uncertainty in the results. 
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5. First-line methotrexate monotherapy with escalation to delayed biologic 
versus first-line methotrexate monotherapy with escalation to combination 
DMARDs, followed by later escalation to biologic 
The IMPROVED study investigated the efficacy of initial methotrexate in 
combination with prednisolone, followed by a treatment-to-target regimen in 
patients with early IA (Heimans et al., 2016). Inclusion criteria included either 
fulfilment of 2010 ACR/EULAR RA criteria with symptoms lasting for up to two 
years, or the presence at least one swollen joint and one other painful joint clinically 
suspected as due to early RA (the majority, approximately 80%, fulfilled 2010 RA 
criteria at baseline). Patients with DAS441.6 after four months of methotrexate and 
tapering prednisolone were randomised (with single-blinding) to triple synthetic 
DMARD therapy or methotrexate plus adalimumab (40mg fortnightly). Treatment 
was escalated according to a target of DAS44 remission to methotrexate plus 
adalimumab 40mg fortnightly or methotrexate plus adalimumab 40mg weekly, 
respectively. A tapering regimen was employed for patients achieving remission.  
 
Of 610 patients enrolled, 387 (63%) achieved DAS44 remission at four months and 
161 patients were randomised according to protocol. Fewer patients randomised to 
combination synthetic DMARD therapy achieved the primary outcome, DAS44 
remission at one year, in comparison to those randomised to adalimumab: rates 
were 21/83 (25%) versus 32/78 (41%), respectively (p<0.05). Limitations include 
the potentially, relatively short duration of adalimumab therapy; four months in 
patients randomised to triple synthetic DMARD therapy requiring treatment 
escalation at eight months, and patients randomised to adalimumab and tapering 
therapy at eight months due to the achievement of remission. In addition, the 
maximum dose of adalimumab is not currently approved for use in clinical practice, 
being associated with higher cost and dose-dependent side-effects such as 
infection. At two years (with treatment allocated according to the physician in 
non-responders to maximum-dose adalimumab), rates of DAS44 remission and 
drug-free DAS44 remission were similar between the groups: 27% versus 31% 
(p=0.76) and 7% and 9% (p=0.73), respectively (Heimans et al., 2016). No 
differences in radiographic outcomes were detected. However, the groups did 
appear to differ in the rate of achievement of more stringent remission criteria, with 
2% versus 18% of patients, respectively, achieving 2011 ACR/EULAR Boolean 
remission at two years. 
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In all of these studies, it may be argued that the early window of opportunity, to gain 
the maximum benefits from biologic therapy in the patients with the most resistant 
disease, has been missed. Insight into whether this may be to the long-term 
detriment of such patients is provided by strategy trials comparing first-line use of 
biologic therapies with relevant comparator regimens, including treatment-to-target 
regimens and initial combination synthetic DMARD regimens (discussed below). 
 
Step-up regimens: first-line biologic therapy versus first-line DMARD 
regimens with step-up in therapy according to a disease activity target 
6. First-line biologic (+ methotrexate) versus first-line methotrexate 
monotherapy with escalation to delayed biologic 
In OPTIMA, patients were randomised to initial adalimumab plus methotrexate or 
placebo plus methotrexate, with addition of adalimumab after six months in patients 
with DAS28CRP≥3.2 (Smolen, Josef S. et al., 2014). The study was designed with 
a combined primary end-point of DAS28CRP<3.2 and radiographic 
non-progression at 18 months in the group of patients who had achieved sustained 
DAS28CRP<3.2 at six months, and were, therefore, continuing their initial regimen 
of adalimumab and methotrexate or methotrexate monotherapy. Post-hoc analyses 
provided data demonstrating that similar clinical outcomes (rates of ACR response 
and remission) were observed six months after commencement of adalimumab in 
both patients receiving adalimumab from the outset and patients requiring addition 
of adalimumab due to persistent disease activity at six months.  
 
In patients requiring escalation to adalimumab, the six month delay to treatment 
escalation may not be considered comparable to a tight-control treatment-to-target 
regimen by today’s standards, in which additional corticosteroids and DMARDs may 
be considered. In addition, radiographic outcomes in this group may be expected to 
be inferior, as illustrated in analyses of the open-label extension study to the initial 
randomised, double-blind, controlled trial, HOPEFUL (see Table 13) (Takeuchi et 
al., 2014). After completing the initial six month phase of this trial, all patients were 
eligible to receive open-label adalimumab and methotrexate (Yamanaka et al., 
2014). Although clinical disease activity (DAS28) amongst patients initially 
randomised to adalimumab and placebo groups appeared to converge after 
approximately eight weeks of open-label adalimumab, and remission outcomes at 
one year were similar between the groups, radiographic progression was greatest 
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amongst patients receiving initial methotrexate and placebo (mean change in SHS 
from baseline was 3.3 versus 2.6, p<0.001). 
 
7. First-line biologic (+ methotrexate) with ongoing treatment-to-target 
including switch to alternative biologic versus first-line methotrexate 
monotherapy with ongoing treatment-to-target including delayed biologic 
In an open-label study, GUEPARD, patients were randomised to initial adalimumab 
plus methotrexate or methotrexate monotherapy with the following treatment 
adjustments every three months: if DAS28≥3.2 adalimumab added (or dose 
increased in patients already receiving adalimumab); if DAS28≥3.2 despite 
increased dose of adalimumab switched to etanercept and subsequently to 
leflunomide. Cessation of adalimumab was indicated in the instance of DAS28<3.2 
after at least three months of adalimumab treatment. Despite a superior rate of 
early remission (DAS28<2.6 at 12 weeks) in patients receiving initial adalimumab 
versus initial methotrexate monotherapy (36% vs 13%, p=0.02), there was a trend 
towards an inferior rate of remission at one year (39% vs 59%, p=0.2). In part, this 
may be explained by administration of an insufficient duration of adalimumab 
therapy in patients demonstrating a good response early. 
 
The U-Act-Early study offers further insight, with randomisation of patients to initial 
regimens of tocilizumab plus methotrexate, tocilizumab monotherapy and 
methotrexate monotherapy, all with or without later addition of hydroxychloroquine 
in patients not achieving remission (DAS28<2.6 and SJC[of 28]≤4) (Bijlsma et al., 
2016). Three months after the addition of hydroxychloroquine, patients who were 
not achieving remission switched to tocilizumab plus methotrexate, or tocilizumab 
was switched to a TNF-inhibitor in patients already receiving combination therapy. 
Primary outcomes were rates of sustained remission (DAS28<2.6 and SJC[of 28]≤4 
for 24 weeks) achieved with the initial treatment regimens (see Table 13) and over 
the entire two year study. Over two years, initial tocilizumab appeared superior to 
initial methotrexate monotherapy, with 86%, 88% and 77% of patients achieving 
sustained remission in the respective treatment groups (p=0.06 for initial 
combination therapy versus methotrexate alone, and p=0.04 for initial tocilizumab 
monotherapy versus methotrexate alone). Therapy was tapered and stopped in 
patients achieving sustained remission. Sustained drug-free remission was 
observed in 35%, 27% and 11% of patients, respectively (p<0.001 for initial 
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combination therapy versus methotrexate alone, and p=0.003 for initial tocilizumab 
monotherapy versus methotrexate alone). No significant differences were detected 
in the secondary outcomes of clinical response and physical function at two years; 
however, radiographic progression was significantly lowest in patients receiving 
initial tocilizumab. A major strength of this study was the double-blinding of 
tocilizumab and methotrexate. Drawbacks include the relatively slow escalation of 
methotrexate (commenced at 10mg weekly and slowly increased to 30mg over 20 
weeks if remission was not achieved), followed by addition of a relatively mild 
DMARD, hydroxychloroquine, and a lag-time of three months to assess its effect 
prior to further escalation. The methotrexate monotherapy arm may therefore be 
considered sub-standard relative to current daily practice.  
 
The OPERA and IDEA studies are two further double-blind randomised trials which 
included what may be considered as more intensive treatment regimens, with 
protocolled administration of steroid as well as escalation of DMARD therapy 
according to disease activity targets. The OPERA study compared initial 
adalimumab plus methotrexate to placebo plus methotrexate, with concomitant 
intra-articular triamcinolone (in up to four swollen joints, up to a maximum total dose 
of 160mg; up to fortnightly for the first three months, then monthly) (Hørslev-
Petersen et al., 2014). Sulfasalazine and hydroxychloroquine were added in both 
groups in patients with DAS28CRP≥3.2 and at least one swollen joint at three 
months, or in patients requiring at least 160mg intra-articular triamcinolone monthly 
for three consecutive months up to six months. At or after six months, patients with 
DAS28CRP≥3.2 were treated as non-responders and could receive open-label 
biologic therapy. There was no significant difference in the primary end-point, 
DAS28CRP<3.2 at 12 months, although patients receiving initial adalimumab were 
significantly more likely to achieve DAS28 remission (achieved in 74% versus 49% 
of patients receiving initial methotrexate monotherapy, p<0.001) and demonstrated 
greater improvements in physical function and quality of life measures.  
 
In IDEA patients were randomised to receive either methotrexate plus infliximab or 
methotrexate plus one dose of 250mg intravenous methylprednisolone followed by 
placebo infusions (Nam et al., 2014a). Patients in both arms were treated with a 
total of 120mg methylprednisolone (intramuscularly and/or intra-articular) according 
to a target of DAS44<2.4, initially every six-eight weeks for the first six months, then 
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three-monthly. After six months, treatment was unblinded and therapy was 
escalated according to the same treatment target and a protocolled regimen 
including increased infliximab dose in patients already receiving this or addition of 
sulfasalazine and hydroxychloroquine followed by switch to methotrexate and 
leflunomide in patients receiving initial methotrexate with intravenous 
methylprednisolone. During the unblinded phase, biologic therapies were permitted 
according to NICE criteria. Although the rate of early remission (at week six) was 
superior with initial infliximab therapy, no significant differences were apparent 
between the treatment groups at one year in either the mean change in SHS (the 
primary end-point) or rate of DAS44 remission. In a sub-group of patients 
undergoing ultrasound examination of 22 joints (bilateral wrists, MCPs2-3, PIPs2-3 
and MTPs1-5) at week 50, evidence of ongoing synovitis (GSgrade 2 and 
PDgrade 1 in at least one joint) was apparent in a lower proportion of patients 
receiving infliximab plus methotrexate first-line versus methylprednisolone plus 
methotrexate (41% versus 79%, p=0.001). 
 
8. Studies with multiple treatment arms 
The randomised, double-blind trial, TEAR, compared four treatment regimens in 
methotrexate-naïve patients (Moreland et al., 2012). Two groups received initial 
methotrexate monotherapy with a planned step-up in treatment at six months if 
DAS28ESR≥3.2; to triple synthetic DMARD therapy in one group (‘ST’), and 
methotrexate and etanercept in the other (‘SE’). The remaining two groups received 
first-line combination therapy; either initial triple synthetic DMARD therapy (‘IT’) or 
initial etanercept and methotrexate therapy (‘IE’) without any step-up in their 
treatment. No significant differences were observed across all four groups for the 
various outcomes; mean DAS28 score between years one and two, levels of ACR 
response at year two and radiographic progression between baseline and year two. 
However, there was an indication that initial etanercept and methotrexate, followed 
by initial methotrexate with step-up to etanercept if required, may be slightly 
favourable to other treatment regimens. No radiographic progression (change in 
SHS score≤0.5) was observed in 79%, 71%, 68% and 65% patients across the 
groups IE, SE, ST and IT, respectively (p=0.33 across all groups, p=0.02 for IE and 
SE groups combined versus ST and IT groups combined). A similar trend was 
observed in ACR70 response rate at two years; 18% of patients in IE and SE 
groups combined, versus 11% of patients in the ST and IT groups combined, 
achieved this superior level of clinical response (p=0.01). Limitations include the 
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six-month interval between commencing therapy and escalation of therapy in the 
relevant step-up treatment groups, as well as the analysis which did not assess 
differences between individual treatment groups of interest; i.e. between the 
step-up groups, or between initial etanercept and initial combination synthetic 
DMARD therapy. 
 
The BeSt study, a randomised, single-blind trial, compared four treatment strategies 
in early RA: sequential DMARD monotherapy; initial methotrexate with step-up to 
combination DMARD therapy; initial combination synthetic DMARD therapy 
(methotrexate and sulfasalazine) with high dose corticosteroid; and initial infliximab 
and methotrexate (Goekoop-Ruiterman et al., 2007). In all groups, treatment was 
switched every three months in the instance of DAS44≥2.4 according to a protocol 
which varied across the groups. More rapid clinical improvement was achieved in 
patients randomised to initial combination of synthetic DMARDs or infliximab with 
methotrexate, with less progression of joint damage seen on radiographs. Of note, 
the protocol for patients randomised to initial methotrexate with step-up to 
combination DMARD therapy, was relatively unaggressive in comparison to more 
recent trials: escalation steps, occurring as frequently as every three months if 
required according to disease activity, were addition of sulfasalazine, addition of 
hydroxychloroquine, then addition of prednisolone and only later switching to 
methotrexate and infliximab if the combination of these four medications failed. 
Switch to biologic therapy, if required, therefore occurred significantly later in these 
patients in comparison to patients randomised to the initial combination DMARD 
therapy arm (switching to methotrexate and ciclosporin with prednisolone, followed 
by switching to methotrexate and infliximab). Of note, after failure of infliximab 
(3mg/kg every eight weeks) and methotrexate to achieve DAS44<2.4 after three 
months, infliximab dose was increased (in steps up to a maximum of 10mg/kg every 
eight weeks) followed by switching to alternative synthetic DMARDs (i.e. no 
alternative biologic therapies were permitted within the protocol) which is not 
entirely reflective of current clinical practice. In cases where disease remained 
effectively suppressed, drug therapies (preferentially corticosteroids and infliximab 
in the first instance) were tapered and withdrawn. This was most successful in the 
group initially treated with infliximab: 53% of patients were on just one drug for 
disease control at the end of the two-year study (compared to 31-36% in other 
groups).  
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2.4.1.4 Treatment Strategies: Summary 
Presently, European and American guidelines recommend the use of DMARD 
monotherapy (with a preference for methotrexate) as first-line therapy, with 
consideration for concomitant glucocorticoids in the short-term (Singh et al., 2016; 
Smolen et al., 2017). Biologic therapies are recommended (preferably in 
combination with methotrexate) if a pre-defined target for treatment is not achieved 
with either the first-line DMARD regimen (in patients with poor prognostic factors) or 
after failure of additional synthetic DMARDs (preferably used in combination with 
methotrexate) (Singh et al., 2016; Smolen et al., 2017). The American (ACR) 
recommendations are a recent update from their previous guidance suggesting a 
TNF-inhibitor combined with methotrexate could be used first-line as an alternative 
to synthetic DMARD therapy in patients with poor prognostic factors (Singh et al., 
2012). 
 
Indeed, there is an argument for the early introduction of biologic therapy, 
particularly in patients with poor prognostic factors, owing to the therapeutic window 
of opportunity in early disease and the superior efficacy of biologics in comparison 
to methotrexate therapy (St Clair et al., 2004; Breedveld et al., 2006; Emery et al., 
2008; Emery et al., 2009) (Table 13). However, evidence for early initiation of 
biologic therapy versus combination synthetic DMARD therapy, or an aggressive 
step-up treatment-to-target regimen, is less conclusive. Several studies report 
similar clinical outcomes at one or two years between these treatment groups 
(Goekoop-Ruiterman et al., 2007; Moreland et al., 2012; Leirisalo-Repo et al., 
2013), although results for their secondary outcomes and the long-term follow-up of 
these patients have often indicated certain advantages to using biologic therapies 
either first-line or very early within a treatment-to-target regimen. Superior disease 
control in the early stages of the disease may afford greater protection against joint 
damage (Moreland et al., 2012; Leirisalo-Repo et al., 2013; Bijlsma et al., 2016) 
and physical disability (Hørslev-Petersen et al., 2014), a greater reduction in 
subclinical synovitis (Nam et al., 2014a) and improved rates of sustained remission 
(Leirisalo-Repo et al., 2013) and biologic- or DMARD-free remission (Quinn, M. A. 
et al., 2005; Goekoop-Ruiterman et al., 2007; Bejarano et al., 2010; Saleem et al., 
2010; Bijlsma et al., 2016).  
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Hence, it is perceivable that early, short-term use of biologics may be cost-effective, 
potentially offsetting the need for long-term treatment with several, sequential 
biologic therapies in the most resistant patients (de Jong et al., 2014). This remains 
controversial and further studies are ongoing (Dumitru et al., 2016).  
 
2.4.1.5 Defining the Target for Treatment 
The EULAR guidelines recommend remission as the target for treatment (Smolen 
et al., 2010; Smolen et al., 2016). Clinical remission (by various definitions) is 
associated with improved cardiovascular disease risk markers (Provan et al., 2011) 
and long-term outcomes, in comparison to even low disease activity, across several 
studies (Radner et al., 2010; van Tuyl et al., 2010). Guidelines define remission as 
the ‘absence of signs and symptoms of significant inflammatory disease activity’. 
They advise the use of composite measures, incorporating clinical assessments of 
swelling and tenderness, to monitor disease activity (Smolen et al., 2010; Smolen et 
al., 2016; Smolen et al., 2017).  
 
Many validated measures are available for this purpose. Since the publication of the 
original disease activity score, DAS44 (van der Heijde et al., 1990), alternative 
measures have been developed which are easier to incorporate into clinical 
practice. The modified disease activity score, DAS28, has been validated in the 
assessment of disease activity in RA for use in clinical trials (Prevoo et al., 1993; 
Smolen et al., 1995), and can be used reliably by assessors with varying levels of 
experience in clinical practice (Walsh et al., 2008). The simplified disease activity 
index (SDAI) is even easier to calculate by adding variables (SJC28, TJC28, CRP, 
physician global and patient global visual analogue scale [VAS] assessments) 
rather than using the more complicated DAS formulae (Smolen et al., 2003). The 
SDAI correlates with DAS28 as well as patients’ physical function (HAQ score) 
(Smolen et al., 2003; Aletaha et al., 2005). 
 
There are pitfalls in the use of composite scores of which clinicians should be 
aware of. Clinical assessments included in simplified scores, such as DAS28 and 
SDAI, do not include the feet, although disease activity at this site is represented to 
an extent within the included global assessments (for example, patient general 
health VAS) (Landewé et al., 2006). The DAS28, in particular, has been criticised 
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as high TJC and small changes in ESR at low levels (<20mm/hr) may 
disproportionately affect the score (Gardiner et al., 2005). Such a composite index 
has limitations in accurately reflecting synovitis; in particular, the complex 
interrelationship between an individual’s pain perception on subjective components 
including TJC and patient VAS is well-recognised (Ton et al., 2012; Cordingley et 
al., 2014). The presence of comorbidities may also exaggerate disease activity by 
affecting the patient general health assessment, although the patient global disease 
activity assessment may be used an alternative, within the DAS score (www.das-
score.nl, 2011). In early disease especially, disease activity may also be 
underestimated due to the insensitivity of the clinical assessment or the lack of 
elevation in inflammatory markers in peripheral blood, despite true joint synovitis. 
Furthermore, the cut-off for DAS28 remission (DAS28<2.6) allows for the presence 
of clinically significant joint swelling (Mäkinen et al., 2005).  
 
With multiple measures of disease activity available, to facilitate the comparison of 
results across clinical studies, a provisional ACR/EULAR definition of remission for 
use in clinical trials was recently published (Felson et al., 2011) and has since been 
validated using observational study data in patients with early RA (Zhang et al., 
2012). In development of the criteria (Felson et al., 2011), and their validation using 
data from the ESPOIR cohort (Zhang et al., 2012), it was apparent that that SDAI 
and CDAI remission performed better than DAS28 remission in predicting a good 
outcome (stable state in radiographic joint damage and HAQ score). The use of 
either of two stringent definitions for remission in clinical trials was proposed, SDAI 
remission or a definition developed using a Boolean-approach: a score of one or 
less in TJC, SJC (out of 28 joints assessed by DAS28 plus feet and ankles), patient 
global VAS (0-10 cm) and CRP (mg/dL).  
 
However, in unselected patients in clinical practice, these measures may be too 
stringent for their universal application. In an observational study, patients with 
established RA achieving SDAI and Boolean remission actually demonstrated 
significantly superior physical functioning in comparison to controls who were age- 
and gender-matched (Thiele et al., 2013). Additionally, these patients were less 
likely to have comorbidities, including degenerative joint disease, than those 
achieving DAS28 remission but missing SDAI or Boolean remission. In 
cross-sectional analyses of two large observational RA cohorts, 2011 ACR/EULAR 
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remission was observed in up to 10% of patients, however, long-term remission 
was rare (Shahouri et al., 2011). The patient global VAS was found to be the best 
predictor of fulfilment of both SDAI and Boolean remission, and variability in this 
assessment was identified as a major reason for non-remission in patients 
previously fulfilling the criteria, possibly related to the poor reliability of this measure 
(Lassere et al., 2001). Furthermore, heterogeneity was observed amongst 
physician assessments, particularly the SJC and physician global VAS. 
 
Limitations in the universal application of remission criteria are acknowledged within 
the clinical guidelines, accepting the importance of physician judgement of 
remission in reaching decisions on future treatment, and acceptability of a target of 
low disease activity in specific patients, such as those with established disease. In 
essence, all of these measures rely on clinical assessments that may not be 
entirely accurate in delineating the true absence of inflammatory disease activity.  
 
The inability of clinical criteria to accurately reflect a true absence of inflammatory 
disease activity is illustrated by studies demonstrating progression of radiographic 
damage in patients achieving persistent remission by these standards (Molenaar et 
al., 2004). Ultrasound imaging is also able to identify subclinical synovitis in patients 
achieving clinical remission, which has been shown to have prognostic implications 
(section 2.3.2.1). Several groups have reported the frequency of ongoing PD in 
patients with established RA across various definitions of remission including 
DAS28 (Brown et al., 2006; Saleem et al., 2009; Balsa et al., 2010; Saleem et al., 
2011; Montecucco et al., 2012; Naredo et al., 2013b; Geng et al., 2014; Harman et 
al., 2014; Iwamoto et al., 2014; Zufferey et al., 2014; Naredo et al., 2015; Vlad et 
al., 2015; Bellis et al., 2016; Vreju et al., 2016; Raffeiner et al., 2017), DAS44 
(Peluso et al., 2011; Foltz et al., 2012) and 2011 ACR/EULAR Boolean-defined 
remission (Saleem et al., 2011; Geng et al., 2014; Harman et al., 2014; Zufferey et 
al., 2014; Vlad et al., 2015; Bellis et al., 2016). These studies have included 
ultrasound assessments limited to the hands (Brown et al., 2006; Ozgocmen et al., 
2008; Saleem et al., 2009; Peluso et al., 2011; Saleem et al., 2011; Montecucco et 
al., 2012; Gärtner et al., 2013; Geng et al., 2014; Harman et al., 2014; Vlad et al., 
2015; Bellis et al., 2016; Vreju et al., 2016) or have involved more extensive joint 
assessments (Balsa et al., 2010; Foltz et al., 2012; Naredo et al., 2013b; Iwamoto 
et al., 2014; Zufferey et al., 2014; Naredo et al., 2015; Raffeiner et al., 2017).  
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Cross-sectional analysis of patients with RA achieving a stringent definition of 
remission (SDAI≤3.3 and absence of swollen and tender joints of 66- and 68-joint 
examinations respectively) has confirmed the existence of subclinical PD in the 
absence of any physical evidence of synovitis (Kawashiri et al., 2014a). The 
presence of PD≥grade 1 or ≥grade 2 in any wrist, MCP or PIP joint was detected in 
17/29 (59%) and 9/29 (31%) patients, respectively. 
 
Evidence for the persistence of ultrasound synovitis in patients achieving clinical 
remission in early disease is more limited. In patients with early RA (fulfilling 1987 
ACR RA criteria at one year after starting treatment), responding to methotrexate, 
the rates of achievement of absence of PD were 50/72 (69%), 43/56 (77%), 25/28 
(89%) and 21/22 (95%), for patients achieving DAS44, DAS28, SDAI and Boolean 
remission, respectively (Sakellariou, Garifallia et al., 2013). The exclusion of 
patients with more severe or resistant disease, who had required addition of a TNF-
inhibitor in the first year of treatment, and the restricted ultrasound assessment 
(MCPs and wrists) were limitations of this study. A further analysis, using a 44-joint 
ultrasound assessment in this cohort, demonstrated absence of PD in only 41% of 
43 patients achieving sustained DAS44 remission (DAS44<1.6 at two visits three 
months apart) (Scirè et al., 2009). A similar level of disparity between sustained 
DAS44 remission (DAS44<1.6 for 6 months) and absence of PD on ultrasound was 
observed in another cohort (Peluso et al., 2011). Power Doppler activity in any of 10 
joints (wrists, MCPs2-3 and PIPs2-3, bilaterally) was observed in 42% of 48 early 
RA patients. In addition, PD was observed in 14% of 27 patients achieving the 
stringent 1981 ACR remission criteria (Pinals et al., 1981).  
 
Data are now beginning to emerge with respect to targeting ultrasound evidence of 
synovitis in the treatment of RA. Data from a randomised trial are available in 
patients with early IA (either RA or UA with ACPA-positivity and at least three 
swollen joints, i.e. the majority of patients were likely to have fulfilled 2010 RA 
criteria) (Dale et al., 2016). Patients were randomised to two groups, differing in the 
treatment target used to guide their treatment escalations (occurring at a maximum 
frequency of every three months); either DAS28 low disease activity (n=58) or a 
total PD joint count≤1 (PD of any grade affecting ≤1of 14 joints [wrists, MCPs2-3, 
PIPs2-3, MTP2 and MTP5 joints]) with ultrasound conducted in the presence of 
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DAS28<3.2 or SJC≤1 swollen joints (treatment escalated on clinical grounds if 
DAS28>5.1 or DAS28≥3.2 with SJC≥2) (n=53). Treatment was methotrexate 
monotherapy, escalating to triple synthetic DMARD therapy, followed by triple 
DMARD therapy with etanercept (occurring at nine months or later). No significant 
differences were observed in the co-primary endpoints in patients completing the 
18-month study (101 of 111 patients randomised), including mean change from 
baseline in DAS44 and progression in MRI erosive damage in the dominant hand. 
However, a significantly higher rate of DAS44 remission was observed in patients 
managed with ultrasound (66%, versus 43% in patients managed clinically, 
p=0.03). In the ultrasound arm, of 271 visits at which patients were achieving 
DAS28 remission, PD was demonstrated in more than one joint at 66 (24%) visits. 
 
The ARCTIC study had a similar design, randomising patients with early RA 
(fulfilling 2010 RA criteria, with symptoms of joint swelling for up to two years) to 
clinically-directed and ultrasound-targeted treatment groups (Haavardsholm et al., 
2016). The ultrasound assessments were more extensive, comprising assessments 
of GS and PD (graded 0-3) at 32 joints. Treatment was escalated up to every two 
months, unless response since the last treatment change was observed or the 
treatment target was reached. In the ultrasound-targeted group response was 
defined by improvement in DAS44≥1.2, reduction in total ultrasound score (sum of 
GS and PD scores)≥20% and current DAS44>2.4, or improvement in DAS44≥0.6, 
reduction in total ultrasound score (sum of GS and PD scores)≥10% and current 
DAS44≤2.4. The target was DAS44 remission (DAS44<1.6) with no swollen joints 
and no PD detectable in any joint. In the clinically-directed treatment group, the 
same definitions were used, except with exclusion of the ultrasound components. 
Swollen joints, and joints with PD in the ultrasound-targeted arm, were also injected 
with corticosteroid. Other differences from the TASER study included potentially 
earlier addition of a TNF-inhibitor (protocolled as early as four months in patients 
with high disease activity and poor prognostic factors), the protocolled increase in 
dose/frequency of TNF-inhibitor and later switch to alternative biologics in 
non-responders. No significant difference was observed between the groups in the 
primary outcome, sustained remission (DAS44<1.6, no swollen joints and no 
radiographic progression between 16 and 24 months). However, there was a trend 
towards less radiographic progression over two years in patients receiving 
ultrasound-targeted treatment (median [IQR] change in SHS from baseline 
1.0 [0-2.5], versus 1.5 [0.5-3.0] in patients receiving clinically-directed care alone, 
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p=0.05). As may be expected, significantly less PD was also observed in these 
patients, with potential implications for longer-term outcomes: 75% of patients in the 
ultrasound-targeted arm demonstrated ultrasound remission (total PD score=0), 
versus 62% of patients in the clinically-directed treatment arm (p=0.02).  
 
Other limitations of these studies include the incomplete blinding of ultrasound 
assessments, inclusion of DAS44 in combined primary endpoints (which was also 
used either directly or related to measures used [DAS28 in TASER study] in 
directing treatment decisions), and the potential rate of protocol deviations (reported 
as 19% in ARCTIC and not reported in TASER) (D'Agostino et al., 2017). The 
limitations of current therapies to achieve a complete and universal absence of 
inflammatory activity must also be borne in mind. The indications for when 
treatment should be escalated in view of combined clinical and ultrasound targets 
were also arguably quite complicated, in comparison to clinical practice in which an 
ultrasound may be conducted when the clinician perceives a difference between 
their impression and DAS.  
 
The TURA (Targeted Ultrasound in RA) and REVECHO studies are currently 
recruiting patients with RA in stable low disease activity or remission states. They 
aim to evaluate the effect of treating subclinical ultrasound-detected synovitis (in 
addition to clinical signs of active disease), in comparison to targeting clinical 
evidence of disease activity alone on patient outcomes such as loss of remission 
and radiographic progression (Bruyn et al., 2015). 
 
Issues of face validity of the clinical composite measures as indicators of remission, 
which have previously been raised in established RA, therefore appear to be 
pertinent to early RA and the currently recommended treatment strategy of 
targeting clinical remission. Due to the limitations of studies in early RA identified 
here, further data are needed to evaluate the potential use of the 2011 ACR/EULAR 
remission criteria and ultrasound assessments within the treatment-to-target 
management of patients with RA in clinical practice.  
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2.4.2 Undifferentiated Arthritis 
Patients with UA may also require treatment to alleviate the symptoms and 
functional impairment associated with active synovitis. The impact of UA on patient 
function (Jansen et al., 2002; Krabben et al., 2012), work impairment (Marzo-
Ortega et al., 2007) and unemployment due to the illness (Marcos et al., 2011) has 
previously been shown to be comparable to that of RA in longitudinal (Jansen et al., 
2002; Krabben et al., 2012) and cross-sectional studies (Marzo-Ortega et al., 2007; 
Marcos et al., 2011). Furthermore, loss of bone mineral density (Haugeberg et al., 
2006) and radiographic progression (van Aken et al., 2006) have been 
demonstrated in patients with early UA. Albeit acknowledging these studies largely 
defined UA as non-fulfilment of the 1987 ACR criteria. 
 
Extending the RA treatment paradigm, highlighting the systemic as well as local 
joint-related consequences of the inadequate control of inflammation (including 
cardiovascular morbidity), adds further justification to intervening in UA. Based 
largely on expert opinion and RA studies, EULAR guidelines for the treatment of 
early IA recommend that if a definitive diagnosis cannot be reached, DMARD 
therapy (ideally methotrexate) should be initiated as early as possible in patients at 
risk of persistent arthritis (Combe et al., 2007; Combe et al., 2017).  
  
2.4.2.1 Longitudinal Observational Studies 
Over the last 20 years, treatment of patients with UA has varied within and between 
observational early IA cohorts, with practices evolving considerably over this time. 
Bias introduced through the non-random assignment of treatment (confounding by 
indication) is inherent within these studies, although statistical modelling can help to 
minimise this. Propensity modelling takes account of a single treatment 
decision/pathway per patient (Bukhari et al., 2003; Lukas et al., 2011; Escalas et 
al., 2012), whilst marginal structural modelling may be used to weight results 
according to the probability of receiving various treatments over time (Farragher et 
al., 2010).  
 
Efficacy of early methotrexate was recently assessed in the ESPOIR cohort which 
included a proportion of patients with UA (77% of patients fulfilled 2010 RA criteria 
at baseline) (Gaujoux-Viala et al., 2012). Patients receiving at least three months of 
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methotrexate within the first six months (n=313) were compared to those receiving 
any other treatments within the same time frame (including less than three months 
of methotrexate, but excluding patients receiving sulfasalazine, leflunomide or TNF 
inhibitors due to their known efficacy in preventing structural damage) (n=384). 
After adjustment for propensity score, there was no significant difference between 
the groups in DAS28 or HAQ at six months, but significantly less radiological 
progression at one year was observed amongst patients receiving methotrexate. 
However, 29% of patients had stopped methotrexate prior to one year, 10% of 
patients initially commenced methotrexate in combination with other DMARDs and 
the proportion of patients escalating treatment to combination therapy over 
follow-up was not reported. 
 
Efficacy of immediate versus delayed treatment has been addressed in analyses of 
patients followed in the ESPOIR and NOAR cohorts. In ESPOIR, after adjustment 
for propensity score (based on the probability of receiving treatment over the initial 
six months), statistically less radiographic progression over 12 months was 
observed in patients who received DMARDs (excluding hydroxychloroquine alone) 
within three months of diagnosis compared to those who did not (Lukas et al., 
2011). Sub-analysing patients grouped according to propensity score quintile 
revealed a significant superiority of early treatment only amongst patients in the 4th 
and 5th quintiles. Therefore, this study does not fully answer the question as to 
whether it may be acceptable to delay DMARD therapy in a subset of patients with 
UA, likely lying in the lower quintiles. In NOAR, delay to DMARD and/or steroid 
treatment from symptom onset appeared to adversely affect long-term radiographic 
outcomes (Bukhari et al., 2003). In comparison to patients never treated, 
progression in Larsen score over five years was 1.1 times (95% CI 0.8-1.7) greater 
in patients commencing DMARDs and/or steroids within six months, compared to 
1.6 times (95% CI 1.0-2.6) and 1.5 times (95% CI 1.0-2.2) for patients first treated 
between six and 12 months and after 12 months, respectively. In these studies, the 
influence of treatment changes over time was not accounted for which could have 
been considerable considering the time-points of the outcome assessments.  
 
Using marginal structural modelling, NOAR data suggests that ACPA-negative 
patients may benefit more than ACPA-positive patients from early treatment 
(Farragher et al., 2010). The mean difference in change in HAQ at five years 
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between patients treated with DMARDs and/or steroids within six months of 
symptom onset and those never treated was calculated for each group: -0.31 
(95% CI -0.53 to -0.09) for ACPA-negative patients versus -0.14 (95% CI -0.52 to 
0.24) for ACPA-positive patients. However, numbers in some groups were small 
(only 22 ACPA-positive patients were never treated) and confidence intervals were 
overlapping. Treatment profiles in this cohort (initial sulfasalazine in 57% and 
methotrexate in only 5%) and the higher incidence of self-limiting disease amongst 
seronegative patients must also be borne in mind.  
 
A multivariable model, with adjustment for propensity score and confounders for 
prognosis, was employed in ESPOIR to determine efficacy of initial methotrexate 
and a treatment-to-target strategy (Combe et al., 2007; Escalas et al., 2012). 
Patients in whom treatment deviated from this strategy (77% of patients) were at 
increased risk of developing at least one new radiographic erosion at one year (OR 
2.0, 95% CI 1.1-3.6), and functional impairment (HAQ≥1.0) at two years (OR 2.4, 
95% CI 1.2-4.7). Of note, propensity score by quintile was associated with disability 
(p<0.0001) but not with radiographic progression (p=0.75). 
 
2.4.2.2 Pragmatic, Open-label and Single-blind Studies 
A selection of prospective cohort studies have utilised protocols to maintain 
treatment homogeneity (see Tables 3-5). In cohorts excluding patients with RA 
(fulfilling 1987 ACR criteria), or restricting patients to those less likely to fulfil RA 
criteria (such as oligoarthritis), NSAIDs and/or steroids have been assessed prior to 
addition of DMARDs (Green et al., 1999; Green et al., 2001; Quinn et al., 2003; El 
Miedany et al., 2008). In others, initial methotrexate (Kudo-Tanaka et al., 2015) and 
treatment-to-target strategies (Heimans et al., 2016) have been employed.  
 
Methotrexate versus no DMARD therapy has been evaluated (NSAIDs and 
corticosteroids ≤10mg prednisolone daily were permitted in both groups) (Kudo-
Tanaka et al., 2015). Patients with ACPA-positive UA (not fulfilling 1987 ACR RA 
criteria) were assigned to treatment group according to the treating physician’s 
judgement. The proportion of patients fulfilling 2010 RA criteria was not reported. 
The rate of progression to fulfilment of 1987 ACR RA criteria over one year was 
significantly lower in the methotrexate group (17% of 29 patients) than in patients 
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never receiving DMARDs (79% of 19 patients); the HR, adjusted for potential 
confounders, including fulfilment of the 2010 RA criteria, was 0.03 (95% CI 0.003-
0.25, p=0.001).  
 
In the IMPROVED study, patients with early RA (fulfilling 2010 RA criteria, results 
discussed previously in section 2.4.1.3) and UA (at least one swollen joint and one 
other painful joint, clinically suspected as due to early RA) were treated with four 
months of methotrexate and tapering prednisolone followed by a treatment-to-target 
strategy including the addition to adalimumab if required (Heimans et al., 2016). In 
patients with UA at baseline, the primary outcomes of DAS44 remission and drug-
free remission at two years were achieved in 64/122 (52%) and 41/122 (34%) 
patients, respectively. Patients with RA achieved a similar rate of DAS44 remission 
(p=0.25), but lower rate of drug-free remission (19%, p<0.001). In addition, post-hoc 
analysis did not demonstrate any statistical difference in the rate of early remission 
(DAS44<1.6) after four months of treatment with methotrexate and prednisolone 
(Wevers-de Boer, K. V. C. et al., 2012). 
 
The single-blinded STREAM study, compared conventional care to initial 
methotrexate with addition of adalimumab according to a target of DAS44<1.6 (van 
Eijk et al., 2012). Patients were required to have between two and five swollen 
joints and a SHS score less than five (one-third and two-thirds of patients fulfilled 
1987 and 2010 RA criteria respectively at baseline). Less progression of 
radiographic damage was demonstrated in patients in the treat-to-target arm 
although this was not statistically significant. Of relevance was the significantly 
greater steroid exposure in patients receiving conventional treatment. 
 
An open-label study of abatacept has been conducted in twenty patients with early 
IA (symptomatic synovitis of at least two joints and PD in at least one 
wrist/MCP2-5/PIP2-5/knee, with a maximum symptom duration of 18 months) (Buch 
et al., 2017). All but one patient was ACPA-negative, and less than half of patients 
(n=9) fulfilled 2010 RA criteria, at baseline. Only 2/20 patients achieved the primary 
outcome: DAS44 remission at six months, a maximum of one swollen joint for at 
least three consecutive months and no radiographic progression over one  year. 
However, reductions in disease activity were reported: mean (SD) DAS44 reduced 
from 2.66 (0.77) at baseline to 1.78 (0.95) at one year, and median (IQR) PD score 
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(sum of PD graded 0-3 at 20 joints) reduced from 10 (4-23) at baseline to 3 (0-5) at 
one year. Of note, two patients required additional DMARD therapy (permitted at 
the discretion of the physician in patients with persistent arthritis). 
 
2.4.2.3 Randomised Double-blind Placebo-Controlled Trials 
Trials in early IA patients with limited joint involvement, have demonstrated steroid 
may have a short-term effect on disease activity (Machold et al., 2010) and delay 
the need for DMARD therapy (Verstappen et al., 2010), but not greatly alter the 
long-term course of the disease. The double-blind PROMPT study demonstrated 
short-term methotrexate may also delay but not prevent the development of RA 
(defined by 1987 ACR criteria) in patients fulfilling the ACR 1958 criteria for 
probable RA at baseline (van Dongen et al., 2007). Escalation of methotrexate was 
relatively slow (15mg weekly, increasing in 5mg intervals to 25mg every three 
months if DAS44>2.4). 
 
Trials of biologics have been conducted in patients with early IA with poor 
prognostic factors. Eligibility criteria and baseline characteristics in these studies 
indicate a proportion of subjects would fulfil 2010 ACR/EULAR RA criteria, but a 
diagnosis of RA was not required for inclusion. For example, in ADJUST, 50% of 
patients had erosions at baseline. A trial of infliximab was terminated early due to 
poor outcome in all patients (only 2/10 infliximab- and 1/7 placebo-treated patients 
achieved remission at week 26) (Saleem et al., 2008). In the ADJUST trial, 
ACPA-positive patients meeting between one and three of the 1987 ACR RA 
criteria, with synovitis of at least two joints, were randomised to receive abatacept 
or placebo for six months (Emery, P et al., 2010). The primary end-point, fulfilment 
of 1987 ACR criteria after one year (six months after abatacept discontinuation) 
occurred in fewer patients receiving abatacept (46% versus 67% of controls), but 
this difference was not statistically significant. The AVERT study randomised 
patients with at least two synovitic joints, DAS28≥3.2 and ACPA-positivity to 
abatacept plus methotrexate or methotrexate alone (Emery et al., 2015). The 
primary end-point, DAS28 remission at one year, was achieved in 61% of 115 
patients receiving abatacept and methotrexate versus 45% of 115 patients 
receiving methotrexate alone (p=0.01). Amongst patients achieving DAS28<3.2 at 
one year, in whom all treatment was withdrawn, 18/73 (25%) versus 9/53 (17%) of 
patients, respectively, remained in drug-free remission after a further six months. In 
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EMPIRE, inclusion criteria were presence of at least one swollen and one tender 
joint and either RF, ACPA or shared epitope positivity (Nam et al., 2014b). No 
significant difference was observed in the primary endpoint, the absence of swollen 
and tender joints at one year, in patients randomised to etanercept plus 
methotrexate or methotrexate alone, although DAS28 remission was achieved 
earlier in patients receiving etanercept. With the exception of AVERT and EMPIRE, 
biologics were used without methotrexate.  
 
2.4.2.4 Response to Methotrexate in Patients with Seropositive versus 
Seronegative IA 
Subgroup analyses of a number of these studies suggest a possible differential 
response to methotrexate according to serological status. In IMPROVED, after four 
months of treatment with methotrexate, remission was achieved less often in 
ACPA-negative patients with RA (51%) compared to patients with UA (62%) and 
ACPA-positive patients with RA (66%), p=0.006 (Wevers-de Boer, K. V. C. et al., 
2012). One may have expected patients with UA to achieve a higher rate of 
remission; their baseline characteristics were generally more favourable, although 
they had comparable symptom duration and radiographic damage at baseline 
(erosions were present in 9%). It is possible that the remission rate was falsely high 
in the RA group accepting that some patients are overclassified by the 2010 RA 
criteria; however, the rate of remission in patients fulfilling 1987 ACR RA criteria 
was also similar to the rate observed in patients with UA. Multivariable analysis 
identified ACPA-positivity amongst independent predictors for remission after four 
months (OR 1.6, 95% CI 1.1-2.3), although the result was not significant in a 
second model including the baseline numbers of affected small and large joints (OR 
1.4, 95% CI 1.0-2.1). At one year, after four months of initial methotrexate 
monotherapy followed by a treatment-to-target regimen, similar proportions of 
patients achieved remission regardless of their UA/RA classification or ACPA 
status. This implies response to methotrexate may be slower in patients who are 
ACPA-negative, or that methotrexate may be less effective. 
 
Subgroup analysis of the PROMPT study demonstrated that methotrexate 
significantly delayed progression to RA, in comparison to placebo, only amongst 
ACPA-positive patients (van Dongen et al., 2007). A post hoc analysis of the 
EMPIRE study detected a more rapid response to treatment (methotrexate +/- 
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etanercept) in ACPA-positive patients; significantly greater improvements in DAS28 
were noted at two weeks and six months (with adjustment for treatment group and 
baseline DAS28), whilst no statistically significant differences were observed at 
three months or one year (Nam et al., 2014b). However, this analysis was restricted 
to the subset of patients in whom ACPA status was known at baseline and the 
authors acknowledged that the number of patients with ACPA-negative IA was 
small (15 patients receiving methotrexate and etanercept and 10 patients receiving 
methotrexate plus placebo). 
 
These data have implications for the management of patients with IA in clinical 
practice. Not only is serology useful in the stratification of future disease severity, 
but it may also be relevant to directing therapies according to the likelihood of 
response to therapies, potentially including methotrexate. 
 
2.4.3 Realising the Need for Early Intervention in Clinical Practice 
The realisation of early treatment is dependent on several factors: a patient 
promptly seeking medical attention after symptom onset (stage i), rapid referral 
from primary care to a rheumatologist (stage ii), punctual assessment by a 
rheumatologist (stage iii), and timely initiation of DMARDs after their first 
assessment (stage iv). 
 
2.4.3.1 Time to First Assessment by a Rheumatologist: Stages (i) to (iii) 
Studies conducted in Europe have demonstrated average times between symptom 
onset and first assessment by a rheumatologist (stages i to iii) of between four and 
nine months, with only 10-40% of patients being assessed within 12 weeks (Kumar 
et al., 2007; Kiely et al., 2009; www.nao.org.uk, 2009; van der Linden et al., 2010; 
Raza et al., 2011). These studies have suggested delays at stages (i) and (ii), in 
particular, are a major hindrance to the early assessment of patients with new-onset 
IA. 
 
In the UK, half of patients diagnosed with RA appear to delay seeking help from 
their general practitioner (GP) (stage i) for at least three months after the onset of 
symptoms, a finding which seems to have been constant over time 
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(www.nao.org.uk, 2009; van der Linden et al., 2010). Delays arising at the level of 
the GP (stage ii) may also be relevant (Sandhu et al., 2008), with up to half of 
patients in the UK attending their GP several times before being referred to a 
specialist and subsequently being diagnosed with RA (www.nao.org.uk, 2009). 
Delays at this level of primary care also appear to be the principal factor precluding 
early rheumatologist assessment in other healthcare systems (van der Linden et al., 
2010; Jamal et al., 2011; Raza et al., 2011).  
 
Numerous studies have investigated the causes for delays at stages (i) (Stack et 
al., 2012; van Nies et al., 2013a) and (ii) (Suter et al., 2006; Spies-Dorgelo et al., 
2009). Recurring themes include a lack of awareness of IA, its seriousness and the 
importance of early treatment. Strategies to increase public and GP awareness of 
the importance of early treatment in IA are therefore warranted (Villeneuve et al., 
2013). Recent measures include the introduction of national guidelines 
recommending urgent referral in individuals with suspected IA with specific 
indicators of disease (www.nice.org.uk, 2009). 
 
In secondary care, triage systems and EACs aim to minimise the time between 
referral and assessment by a rheumatologist (stage iii) (Govoni et al., 2013; 
Villeneuve et al., 2013). The majority of studies evaluating triage systems and 
EACs have demonstrated their efficacy in reducing the time lag between referral 
and first assessment by a rheumatologist, in comparison to patients referred via 
conventional routes (Govoni et al., 2013; van Nies et al., 2013b). Further strategies 
to minimise delay include the recent introduction of payments to secondary care by 
the Department of Health in the UK, for meeting a three-week target for assessment 
of patients with suspected early IA by a rheumatologist after their referral 
(www.gov.uk, 2013).  
 
2.4.3.2 Time from First Assessment to Treatment: Stage (iv) 
Previous studies demonstrate that delays at this stage may be inversely associated 
with the number of swollen joints (Jamal et al., 2011; De Cock et al., 2013). This is 
reasonable considering there may be less diagnostic uncertainty in patients with 
greater disease activity. Other relevant factors include concomitant musculoskeletal 
conditions (Tavares et al., 2012) and socio-economic factors (Hernandez-Garcia et 
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al., 2000). In an American study, socio-economic status was associated with delays 
at the level of the rheumatologist, although the time of diagnosis and treatment was 
determined by patient interview after the events which may have been affected by 
recall bias (Molina et al., 2015).  
 
In the UK, the Department of Health have introduced payments to secondary care 
for the initiation of DMARD treatment within six weeks of referral (www.gov.uk, 
2013). Furthermore, the recent development of the 2010 ACR/EULAR RA 
classification criteria now provide a guide to rheumatologists for the identification of 
patients who are likely to benefit from methotrexate, which may help in reducing 
time between first rheumatologic assessment and DMARD initiation (Aletaha, D. et 
al., 2010).  
 
2.5 Summary 
This literature review has identified several concepts relevant to the management of 
patients with IA. These include the ability to stratify patients for risk of persistent 
and aggressive disease on the basis of their clinical phenotype. The most 
compelling characteristics associated with poor prognosis are now incorporated in 
the 2010 ACR/EULAR RA classification criteria, providing a tool for the early 
identification of patients with unexplained clinical synovitis who are likely to benefit 
from methotrexate (i.e. patients who are at risk of persistent or erosive disease). It 
must be borne in mind that they were developed for use in disease classification in 
clinical trials, rather than as diagnostic criteria for use in clinical practice. Although 
their sensitivity in predicting severe and/or persistent IA has proved superior to the 
pre-existing 1987 ACR RA criteria, they are not fully sensitive or specific when 
applied in early IA cohorts (see Table 2). Therefore, a means of identifying patients 
with UA (not fulfilling 2010 RA criteria) who may also benefit from early treatment is 
needed, as well as a method for stratifying patients who fulfil the criteria in order to 
avoid over treating a subset of these patients (Combe et al., 2017).  
 
The body of evidence supporting the ultrasound assessment of synovitis as a valid 
and effective tool in the assessment of IA has been presented. Its prognostic value 
in DMARD-naïve patients with early IA has previously been evaluated. Limitations 
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in these studies have been noted. In the ESPOIR cohort, PD appeared to predict 
radiographic progression, although baseline radiographic damage was not 
accounted for in the analysis (Funck-Brentano et al., 2013). In addition, low rates of 
radiographic progression may be expected with modern-day treatment strategies. 
Therefore radiographic progression is arguably not the only measure of outcome 
which should be considered. Studies investigating the ability of ultrasound synovitis 
to predict future disease progression in early IA have employed the 1987 ACR RA 
criteria as their measure of outcome (Salaffi et al., 2010; Filer et al., 2011). Studies 
addressing the potential added prognostic value of ultrasound to predict disease 
persistence and/or progression, over and above the new 2010 ACR/EULAR criteria, 
are lacking. Even less is understood regarding the prevalence and predictive 
validity of ultrasound erosions in early IA. The ongoing need to better define the 
diagnostic and prognostic value of ultrasound has recently been promoted by 
experts (Combe et al., 2017). 
 
Determining the predictors of response to treatment is another significant area of 
interest. A window of opportunity is recognised in early disease in which effective 
treatment permits the attainment of optimal outcomes in the future. Hence, avoiding 
delays through the use of personalised medicine, directing therapy according to the 
likelihood of response, is an objective for future research (Smolen et al., 2017). In 
particular, efficacy of methotrexate according to serological status, and in patients 
with UA is one matter which needs to be clarified further. 
 
In terms of treatment for patients with RA, advantages of early, tight control of 
inflammation are now widely accepted. Clinical disease activity measures, including 
various composite scores, can be used to direct treatment with the aim of achieving 
clinical remission. Superior outcomes, in both the short- and long-term, can be 
achieved with this approach versus non-target driven treatment. However, studies 
demonstrate subclinical ultrasound synovitis may persist in patients achieving even 
the most stringently defined clinical remission states. In established RA, these 
findings appear to be associated with future disease flare and radiographic 
progression. This research raises the question as to whether superior outcomes 
may be achievable with the use of ultrasound to direct therapy, in addition to clinical 
assessments (Combe et al., 2017).  
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 : Hypothesis, Aims and Objectives Chapter 3
 
3.1 Hypothesis 
The clinical and imaging phenotype of a patient’s disease at diagnosis is predictive 
of their future disease course. Ultrasound may provide additional prognostic 
information over the 2010 ACR/EULAR RA criteria and other clinical and laboratory 
characteristics of disease.  
 
3.2 Aims 
The overarching aims are to determine the clinical and imaging phenotype, 
management and outcomes of patients with early IA in a clinical practice setting 
and identify strategies for improvement in their care. This includes risk stratifying 
patients according to disease progression and future severity in the context of the 
new 2010 ACR/EULAR criteria, determining their response to treatment and 
evaluating the utility of ultrasound within the treatment-to-target management of RA.  
 
3.3 Objectives 
In subsequent chapters, the following objectives are addressed: 
Chapter 5: To audit the performance of the Leeds EAC. This includes determining 
the phenotype of all-comers to the clinic, the efficacy of triage of referrals to the 
clinic and any delays in the assessment and treatment of patients presenting with 
IA, against national standards. 
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Chapter 6: To describe the clinical and imaging phenotypes of patients presenting 
to the Leeds EAC with new-onset, DMARD-naïve IA (specifically patients with UA 
and RA, classified according to the 2010 ACR/EULAR RA criteria). Specific 
objectives were to determine: 
 The proportion of patients with UA or RA whose disease may be 
reclassified with consideration of ultrasound evidence of synovitis in the 
application of the 2010 criteria. 
 Whether reclassification with the use of ultrasound is more discriminating 
for the presence of erosions at diagnosis than application of the 
classification criteria using clinical findings alone.  
Chapter 7: To determine the one year outcomes, and predictors of outcome, for 
patients attending the Leeds EAC with new-onset, DMARD-naïve IA (specifically 
patients with UA and RA classified according to the 2010 ACR/EULAR RA criteria). 
 
In order to investigate the efficacy of, and predictors of response to, particular 
intervention strategies in patients with early IA, subsequent chapters focus on 
subgroups of patients receiving specific treatment in the clinic:  
Chapter 8: To determine clinical response to methotrexate in patients with 
new-onset, DMARD-naive IA in clinical practice. In particular, to establish whether 
there is any difference in response according to serological status or fulfilment of 
the 2010 ACR/EULAR RA classification criteria. 
Chapter 9: In patients with early RA managed according to the EULAR 
treat-to-target guidelines, to assess how the paradigm for targeting clinical 
remission translates into clinical practice, particularly in relation to ultrasound 
imaging. Specific objectives were to evaluate: 
 Adherence to the EULAR treat-to-target guidelines and identify potential 
barriers to adherence in clinical practice. 
 The rates of DAS28 remission, DAS44 remission, 2011 ACR/EULAR 
Boolean remission and imaging remission. 
 Agreement between these clinical remission states and imaging remission.  
 Predictors of achievement of these clinical and imaging remission 
outcomes. 
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 : Methods Chapter 4
4.1 Patients 
4.1.1 Early Arthritis Clinic Audit 
A clinical audit was conducted in all new-comers to the Leeds EAC. This clinic 
includes patients referred from primary and secondary care. Referrals are triaged 
by rheumatologists, with preference for rapid assessment in the EAC in the 
instance of possible new-onset IA. Clinical notes were obtained for 100 patients 
consecutively attending this EAC for the first time on or after January 9th 2012. They 
were reviewed retrospectively. Results of laboratory tests and imaging, performed 
as clinically indicated, were recorded from the clinical results server. All recorded 
data was anonymised. 
 
4.1.2 Prospective Observational Inflammatory Arthritis Cohort Study  
Between 2010 and 2014, patients attending the Leeds EAC with suspected 
new-onset IA were invited to participate in a pragmatic, prospective, observational 
study. Inclusion criteria were age at least 18 years, provision of informed consent 
and likely new-onset IA, defined by a consultant rheumatologist impression of new 
IA with current or recent history of any of the following: (i) symptoms of IA (including 
early morning stiffness of at least one hour), (ii) clinical signs of IA such as joint 
swelling, or (iii) imaging evidence of IA including synovitis, erosion or tenosynovitis. 
The study was approved by the Leeds West Regional Ethics Committee. Data was 
recorded at the time of assessment using electronic case report forms. 
 
In order to obtain informed consent, eligible patients were provided with written 
information about the study at their first EAC consultation. They returned to give 
written consent (and to collect baseline data) at the next opportunity after 24 hours. 
In patients receiving DMARDs or significant corticosteroids prior to consent (i.e. 
prior to or at the first EAC visit, when it was deemed unethical to delay treatment), 
baseline data was obtained retrospectively from clinical notes (as permitted within 
the study protocol). Significant corticosteroid was defined as at least 120mg 
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methylprednisolone intramuscularly or intra-articularly (or equivalent triamcinolone 
or oral prednisolone dose) within the preceding three months. 
 
The following patients were selected from this cohort for this research: patients with 
current or history of clinical swelling of at least one joint (as documented by a 
rheumatologist), UA or RA (defined by the 2010 ACR/EULAR RA criteria) at 
baseline, and patients enrolling in the study between June 2010 and September 
2012. The 2010 criteria were applied cumulatively from symptom onset as per their 
intended use (Aletaha, D. et al., 2010). Joint involvement within the criteria was 
primarily determined by clinical findings (swelling and/or tenderness). Radiographic 
change sufficient for a diagnosis of RA was defined using the published definition 
(van der Heijde et al., 2013). 
 
4.2 Clinical Assessments 
4.2.1 Baseline characteristics 
In the prospective observational study, general characteristics recorded at baseline 
were age, gender, BMI, smoking status (current or previous history of smoking), 
presence of comorbidity (including hypertension, hypercholesterolaemia, ischaemic 
heart disease, cerebrovascular disease, peripheral vascular disease, asthma, 
chronic obstructive airways disease, diabetes, peptic ulcer disease, chronic kidney 
disease, chronic liver disease, epilepsy, demyelination, depression, thyroid 
dysfunction, cancer) and current or previous history of osteoarthritis (defined by 
diagnosis by a rheumatologist, with symptoms and signs consistent with 
osteoarthritis). 
 
Baseline variables relevant to the clinical phenotype of IA were: 
 Symptom duration: rheumatologist judgement of duration of inflammatory 
symptoms relevant to the current presentation of IA, obtained through 
patient consultation. 
 Presence of features of SpA (defined within the Assessment of 
SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis: inflammatory back pain, enthesopathy, uveitis, dactylitis, 
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psoriasis [skin and/or nail], inflammatory bowel disease, family history, 
HLA-B27 positive, sacroiliitis on imaging) (Rudwaleit et al., 2009). 
 Joint involvement according to four categories: (i) palindromic arthritis (no 
swollen joints at baseline, with no steroid exposure within three months, but 
documented history of swollen joints determined by a rheumatologist), 
(ii) monoarthritis (1 swollen joint), (iii) oligoarthritis (2-4 swollen joints) and 
(iv) polyarthritis (>4 swollen joints). 
 Symmetrical joint swelling (as defined within the 1987 ACR RA criteria). 
 Duration of early morning stiffness. 
 RF status. 
 ACPA status. 
 Disease activity; recorded using examination of 28 and 44 joints for swelling 
(SJC28 and SJC44, respectively), and 28 and 53 joints for tenderness 
(TJC28, TJC53 and Ritchie Articular Index [RAI]) by rheumatologists and 
rheumatology nurse specialists, patient Visual Analogue Scale assessment 
of Disease Activity (VASDA) and CRP. Composite scores, calculated using 
these variables, were DAS28-CRP and DAS44-CRP.  
 Physical function; recorded using the HAQ score. 
 
4.2.2 Follow-up assessments 
Over the following 12 months, data were collected prospectively every three months 
(or as clinically indicated). This included assessments of disease activity as 
performed at baseline and the HAQ score. 
 
4.3 Imaging Assessments 
4.3.1 X-ray 
Posteroanterior radiographs of the hands and feet were performed at baseline. 
Musculoskeletal radiologists reported the presence and location of erosions. 
Erosive disease on x-ray was defined as the presence of any radiographic erosion 
within the hands and feet, as well as according to 1987 ACR and 2010 
ACR/EULAR definitions, i.e. radiographic changes typical of rheumatoid arthritis on 
hand and wrist radiographs (Arnett et al., 1988) and erosion in at least three 
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separate joints amongst the PIP, MCP, wrist and MTP joints (van der Heijde et al., 
2013), respectively. 
 
4.3.2 Ultrasound 
Ultrasound examinations of 26 joints (elbows, wrists, second and third 
metacarpophalangeal [MCP2-3] and proximal interphalangeal [PIP2-3] joints, 
knees, ankles and first to fifth metatarsophalangeal [MTP1-5] joints) were 
performed at baseline and 12 months. Scans were conducted in a clinical 
out-patient setting by either a rheumatologist (n=7) or ultrasonographer 
(n=2) who were blinded to clinical details. All sonographers had undergone 
independent calibration training with an experienced EULAR teacher and consultant 
rheumatologist. The same machine (GE E9) was used, employing either a 15-6 or 
18-8 MHz linear array transducer as appropriate for the size of joint.  
 
The joints were selected on the basis of the frequency of ultrasound involvement 
previously reported at these sites in RA (Naredo, E. et al., 2005). A reduced joint 
assessment, in comparison to the number of joints assessed clinically, was 
conducted in order to optimise feasibility; each ultrasound examination required up 
to 30 minutes of time. 
 
Due to the number of patients in the study, the availability of clinicians and the 
availability of only one ultrasound machine, it was not always possible to perform 
clinical assessments on the same day as ultrasound assessments. Assessments 
were generally undertaken within the same week. Any treatment changes were 
made after both clinical and ultrasound examinations.  
 
4.3.3 Synovitis 
Scoring of GS and PD synovitis was performed according to a standard operating 
procedure, showing probe positions and scoring scenarios utilising the 
semi-quantitative EULAR/OMERACT scoring system (Table 8, section 2.3.1). Each 
joint was graded 0-3 for severity of GS synovitis and 0-3 for PD. At the joint level, 
significant ultrasound synovitis was defined as the appearance GSgrade 2 and/or 
PDgrade 1, i.e. excluding GS=grade 1 changes which may be observed in healthy 
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controls (Kitchen and Kane, 2015). At the patient level, global ultrasound measures 
of synovitis were the number of joints displaying significant synovitis and the total 
GS and PD scores (the sum of the GS and PD semi-quantitative scores, 
respectively, in all 26 joints giving a maximum total score of 78 for each). 
 
Ultrasound evidence of synovitis was used to reclassify patients as UAUS or RAUS 
with consideration of ultrasound evidence of significant synovitis in the 
determination of joint involvement within the 2010 ACR/EULAR RA criteria 
(Aletaha, D. et al., 2010). It was also used to define ‘active’ erosion as the 
co-existence of significant ultrasound synovitis and erosion within the same joint.  
 
4.3.4 Erosions 
Eighteen of the small joints examined (wrists, MCPs2-3, PIPs2-3 and MTPs2-5) 
were assessed for the presence of erosion, defined as a cortical break observable 
in two planes. The first MTP was excluded due to the low specificity of ultrasound 
erosions previously observed at this site (Zayat et al., 2015). Erosive disease at the 
patient level was defined as the presence of at least one erosion within these 18 
joints.  
 
4.4 Intervention 
All patients were reviewed and managed by consultant rheumatologists in an 
out-patient clinical setting, following EULAR treatment-to-target guidelines for the 
management of RA when clinically appropriate (Smolen et al., 2010; Smolen, Josef 
S et al., 2014). Treatment escalation to biologic DMARD was in accordance with 
National Institute of Health and Care Excellence (NICE) technology appraisals, 
stipulating at least high disease activity (DAS28>5.1) after failure of at least two 
DMARDs (including methotrexate). Current therapies (DMARDs and/or 
corticosteroids) and change in therapy from the previous assessment were 
recorded at each visit.  
 
The target for treatment was defined as DAS28-CRP remission (DAS28-CRP<2.6). 
This was selected due to the familiarity of clinicians with its use in the management 
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of IA in an out-patient setting, prior to publication of the 2011 ACR/EULAR 
remission criteria. The use of CRP, rather than ESR, was selected due to the 
dependency of ESR on age and gender (Crowson et al., 2009). The DAS28-CRP 
has been validated as a measure of disease activity in RA for use in clinical trials 
(Prevoo et al., 1993; Smolen et al., 1995) and can be used by assessors with 
varying levels of experience in clinical practice (Walsh et al., 2008). As this 
definition of remission may allow persistence of clinical evidence of disease activity, 
including joint swelling (Mäkinen et al., 2005), the clinician impression of disease 
remission also factored in treatment decisions, as did other considerations such as 
comorbidity, in accordance with guidelines (Smolen et al., 2010).  
 
4.5 Outcomes 
4.5.1 Clinical 
In the prospective observational study, clinical outcomes were; (i) the requirement 
for methotrexate within 12 months, and (ii) persistence of IA at 12 months (defined 
as presence of clinically swollen joints at one year and/or use of DMARD or 
corticosteroid within the preceding three months, and the absence of an alternative 
diagnosis, other than UA or RA). In the subset of patients with UA at baseline, 
progression to fulfilment of 2010 ACR/EULAR RA criteria within 12 months was 
also reported. In patients fulfilling 2010 RA criteria at baseline, requirement for triple 
DMARD (methotrexate, sulfasalazine and hydroxychloroquine) or biologic therapy 
within 12 months was reported.  
 
These outcomes were selected on the basis of their use in previous research and 
their clinical relevance. Initiation of treatment, within the context of clinical 
guidelines, was likely to have been related to baseline characteristics perceived to 
be related to poor prognosis (including baseline disease activity and characteristics 
previously discussed, see section 2.2), as well as disease activity during follow-up. 
This includes ultrasound findings, as treating clinicians were not blinded to 
ultrasound results. However, the use of methotrexate was employed as an outcome 
measure given that this was considered by experts to be reflective of patients at risk 
of developing persistent and/or erosive arthritis that would currently be considered 
to be RA, in the development of the 2010 ACR/EULAR RA criteria.  
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Disease activity outcomes were not considered appropriate in the exploration of 
prediction of outcome in the main cohort (all patients with UA or RA) due to 
heterogeneity of patient and treatment-related factors. Instead, the outcomes 
persistence of IA, progression to RA in patients with UA, and need for triple 
DMARD or biologic therapy in patients with RA, were judged to be easier to 
interpret and less ambiguous. Disease activity outcomes were considered in 
analyses of subgroups of patients receiving a particular treatment or treatment 
strategy (first-line treatment with methotrexate in Chapter 8 and a 
treatment-to-target strategy in RA in Chapter 9, see sections 8.3 and 9.3).  
 
4.5.2 Imaging 
Imaging outcomes included the presence of new ultrasound erosion at 12 months 
at the patient and the joint level. New ultrasound erosion was defined as ultrasound 
erosion detectable in any joint (of the 18 examined for erosions) previously lacking 
ultrasound or x-ray erosion at baseline. New ultrasound erosion was selected over 
radiographic outcomes due to the expected low rate of radiographic progression. 
 
In patients managed according to treatment-to-target guidelines (Chapter 9) 
imaging remission was defined as absence of PD on ultrasound examination of 26 
joints at 12 months. 
 
4.6 Statistics 
Characteristics were described using frequencies for categorical variables and 
means and standard deviations for continuous variables following a normal 
distribution. For non-parametric data median values and interquartile ranges were 
calculated. 
 
4.6.1 Missing data 
In the analyses of the main clinical outcomes, data from last assessments were 
carried forward for patients with missing clinical data at 12 months. A patient’s 
status at their last assessment was felt to be relevant to the main 12 month clinical 
outcomes, including the requirement for methotrexate and disease persistence, 
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especially considering the intention that the cohort would include patients with mild, 
potentially self-limiting disease in whom ongoing follow-up may not be clinically 
indicated. Other methods of imputation were not considered appropriate due to the 
frequency of missing data which occurred with the pragmatic design of the study. In 
the instance of lack of any clinical follow-up data within 12 months, patients were 
excluded. In the analyses of imaging outcomes, patients with missing imaging data 
were excluded. 
 
To determine any difference between patients included in analyses and those 
excluded due to missing data, the following tests were performed: Chi-squared 
tests (or Fisher’s exact tests when appropriate according to expected numbers) for 
categorical variables, t-tests for continuous variables following a normal distribution 
(either before or after log transformation, using Shapiro-Wilks test to assess 
normality), and Mann-Whitney-U tests for non-parametric variables.  
 
Other statistical methods specific to individual chapters are discussed under the 
relevant chapter headings. 
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 : A Clinical Audit of all First-Time Attendees to the Chapter 5
Leeds Early Arthritis Clinic. 
5.1 Introduction 
The concept of a window of opportunity in which appropriate treatment initiation 
affords maximal benefits in the treatment of IA has steered early IA research and 
management since the 1990s (Quinn et al., 2001; Sokka et al., 2007; Kiely et al., 
2009; van der Linden et al., 2010) (see section 2.4.1.1). Current guidelines based 
on evidence and expert opinion recommend specialist assessment by a 
rheumatologist and commencement of DMARD therapy as early as possible (ideally 
within 3 months of symptom onset (www.nice.org.uk, 2009)) in patients with RA 
(Smolen et al., 2017) and patients with UA at risk of persistent or erosive disease 
(Combe et al., 2017).  
 
Over the last decade there has been improvement in the early assessment and 
diagnosis of patients with RA (Sørensen and Hetland, 2015), although recent data 
suggests the target to initiate DMARD therapy within three months of the onset of 
symptoms remains unmet for the majority of patients (Raza et al., 2011; De Cock et 
al., 2013; van Nies et al., 2013b; Sørensen and Hetland, 2015). Early treatment 
initiation is reliant on several factors (see section 2.4.3): a patient seeking medical 
attention after symptom onset (stage i), prompt referral from primary care to a 
rheumatologist (stage ii), punctual assessment by a rheumatologist (stage iii), and 
timely initiation of DMARDs after their assessment (stage iv).  
 
Strategies for reducing delays at the level of primary care (stage ii) include UK 
guidelines recommending urgent referral in individuals with suspected IA with 
specific with indicators (www.nice.org.uk, 2009). In secondary care, triage systems 
and EACs aim to minimise the time between referral and assessment by a 
rheumatologist (stage iii) (Govoni et al., 2013; Villeneuve et al., 2013). In 2013, the 
Department of Health introduced payments to secondary care for meeting the 
following standards of best practice: assessment of patients with suspected early IA 
by a rheumatologist within three weeks of referral and initiation of DMARD 
151 
 
 
treatment within six weeks of referral (www.gov.uk, 2013). Furthermore, the recent 
development of the 2010 ACR/EULAR RA classification criteria now provide a 
guide to rheumatologists in the identification of patients who are likely to benefit 
from methotrexate, which may help in reducing time between first rheumatologic 
assessment and DMARD initiation (stage iv) (Aletaha, D. et al., 2010).  
 
Studies evaluating triage systems and EACs have mostly demonstrated their 
efficacy in reducing the time between referral and first assessment by a 
rheumatologist, in comparison to patients referred via conventional routes (Govoni 
et al., 2013; van Nies et al., 2013b). Intuitively, this may reduce delays in time to 
treatment. Only a limited number of studies have investigated this directly and the 
majority were conducted prior to the availability of the 2010 ACR/EULAR RA 
classification criteria (Jamal et al., 2011; Govoni et al., 2013). Previous studies 
describing the characteristics of patients attending EACs have generally excluded 
patients lacking confirmed arthritis (van Nies et al., 2013b) or joint swelling  (Marcos 
et al., 2011). 
 
An audit of the Leeds EAC was conducted, prior to the introduction of the 2013 
Department of Health standards for best practice, to identify any areas requiring 
improvement in order to meet these targets. The characteristics of all patients 
attending the clinic were of interest, regardless of whether arthritis was confirmed, 
in order to inform triage procedures in the future.  
 
5.2 Aims and Objectives 
 To evaluate the phenotypes of patients attending a large EAC. 
 To determine the efficacy of triage of referrals to the clinic and assess whether 
national standards for best practice (early specialist assessment and DMARD 
initiation in patients with UA and RA) have been achieved. 
 To identify reasons for any delays in the assessment and treatment of patients 
with IA in order to inform future practice. 
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5.3 Methods 
A clinical audit was conducted in first-time attendees to the Leeds EAC (see section 
4.1.1). 
 
5.3.1 Triage 
Written letters from GPs or other referring clinicians (for example in the instance of 
patients first presenting to the accident and emergency department) formed the 
basis of referral to the EAC. Rheumatologists used the information provided within 
referral letters to allocate urgent and more routine EAC appointments according to 
the possibility of new-onset IA. Patients with other reasons for rheumatology referral 
could be triaged to alternative clinics. 
 
5.3.2 Assessments 
Referral information was retrospectively reviewed for the presence of the NICE 
indicators for urgent referral. These were documentation of suspected synovitis, 
joint swelling or arthritis with any of the following: involvement of the small joints of 
the hands or feet, involvement of more than one joint or duration of symptoms of 
three months or longer at the time of referral.  
 
Clinical, laboratory and imaging assessments conducted at the first EAC visit 
(performed on the basis of clinical need) were recorded. A clinical pro forma was 
used in the EAC to aid patient assessments, including prompts for clinical 
examination of 66 joints for swelling and 68 joints for tenderness. In the instance of 
suspected IA, the duration of symptoms was defined as duration of inflammatory 
symptoms. Capacity for simultaneous ultrasound examination was available during 
the clinic, conducted by a rheumatologist with experience in musculoskeletal 
ultrasound. Musculoskeletal radiologists read the X-rays. 
 
A patient’s primary diagnosis at the first EAC visit was determined by the 
impression of a consultant rheumatologist and the 2010 ACR/EULAR RA 
classification criteria when applicable (i.e. in the presence of at least one clinically 
swollen joint not explicable by a non-RA diagnosis). For patients in whom more 
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than one differential diagnosis was documented for the rheumatologist’s 
impression, the primary diagnosis was defined as that which was documented 
foremost in the correspondence to the GP. The rheumatologist’s impression of IA 
was categorised according to the primary diagnosis and rheumatologist’s 
examination as: non-IA (non-IA primary diagnosis), possible IA (rheumatologist’s 
impression of possible IA in the absence of current joint swelling, i.e. a history 
compatible with IA) and confirmed IA (primary diagnosis of IA in the presence of at 
least one clinically swollen joint). 
 
5.3.3 Outcomes 
Efficacy of triage was evaluated by calculating the time between referral and first 
EAC assessment and the proportion of patients who met the national standard for 
assessment by a rheumatologist within three weeks of referral. Other outcomes 
included change in diagnosis from the primary diagnosis over the following 12 
months.  
 
Outcomes in patients with UA and RA were DMARD initiation over 12 months and 
achievement of national targets for early DMARD commencement: within six weeks 
of referral (www.gov.uk, 2013) and three months of symptom onset 
(www.nice.org.uk, 2009). Areas for service improvement were explored by 
calculating the length of delays occurring at stages (i) to (iv), described above, and 
identifying reasons for delays arising after rheumatologic assessment (stage iv) 
through retrospective review of clinical notes.  
 
5.3.4 Statistics 
Descriptive statistics were used to illustrate the clinical phenotypes of patients, 
grouped according to the prevalent primary diagnoses. To evaluate the triage 
process, the times between referral and first EAC assessment were compared for 
patients with and without any of the NICE indicators for urgent assessment 
identifiable from their referral letters (www.nice.org.uk, 2009) and according to the 
impression of IA at first EAC assessment. To evaluate the reliability of referral 
information, presence of the NICE indicators for urgent assessment within referral 
letters was also compared according to the impression of IA. Mann-Whitney U and 
Chi-square tests (or Fisher’s exact test, as appropriate for numbers of expected 
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values) were used to compare patients with and without the presence or absence of 
NICE indicators for urgent referral. Kruskal-Wallis and Chi-square tests were used 
to compare patients across the three IA categories. 
 
5.4 Results 
Clinical notes were reviewed for 105 patients consecutively attending the EAC 
between 9th January and 6th February 2012. Five patients were excluded from the 
audit due to the presence of established IA, having been re-referred after loss to 
follow-up after a previous diagnosis of IA under the care of a rheumatologist. 
 
5.4.1 Clinical phenotypes 
Of 100 patients attending the EAC for the first time, 24 cases of IA were confirmed 
in 24 patients (Figure 1). The majority of patients (65%) had non-IA primary 
diagnoses including: osteoarthritis (n=27), other mechanical joint pain (n=26), 
hypermobility (n=3), fibromyalgia (n=2), polymyalgia rheumatica (n=2), post-viral 
arthralgia (n=2), connective tissue disease, ANA-associated arthralgia and sicca 
syndrome (each n=1). 
 
Diagnoses of confirmed IA were RA (n=9), UA (n=8), crystal arthropathy (n=4) and 
SpA (psoriatic arthritis in 2 patients and undifferentiated SpA in 1 patient). In a 
further 11 patients the rheumatologist’s opinion was of possible IA, although no 
current clinical joint swelling was found (i.e. patients with histories compatible with 
IA). The primary suspected diagnoses for these patients were: crystal arthropathy 
(n=4), non-specific arthralgia (n=4) and SpA (psoriatic arthritis, reactive arthritis and 
inflammatory bowel disease-associated SpA in 1 patient each).  
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Figure 1. Prevalence of non-inflammatory and inflammatory arthritis primary diagnoses amongst one hundred all-comers to the EAC and 
changes in diagnoses over 12 months of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PMR: polymyalgia rheumatic, CTD: connective tissue disease, ANA: anti-nuclear antibody.
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The characteristics of all patients at their first EAC assessment and patients with 
the main primary diagnoses (osteoarthritis, other mechanical joint pain, RA, UA, 
crystal arthropathy and SpA) are displayed in Table 14 and Figure 2. Although no 
statistical tests were carried out due to the small size of the diagnostic groups, the 
following trends were observed in the phenotypes of patients: 
 Age appeared highest in patients with osteoarthritis, RA and crystal 
arthropathy (mean age>50 years). 
 There was a predominance of females amongst patients diagnosed with 
osteoarthritis and other mechanical joint pain. There was a predominance of 
males amongst patients with crystal arthropathy and SpA. 
 Symptom duration was longest in patients with osteoarthritis and other 
mechanical joint pain (eight patients reporting symptoms for more than five 
years). Symptom duration was generally shortest amongst patients with 
crystal arthropathy; excluding patients with a prior GP diagnosis of gout 
(n=3), the maximum reported symptom duration was one month. 
 Most patients reported less than 30 minutes of early morning stiffness 
except for those with likely RA or SpA. 
 At least one feature of SpA was reported in approximately a quarter of 
patients. As expected, these were more prevalent in patients diagnosed with 
SpA. Three or more features of SpA were reported in three patients with 
SpA, whilst no more than two features of SpA were reported amongst other 
patients. Features of SpA that were exclusively reported in patients with 
SpA were dactylitis, abnormal sacroiliac joints on imaging and HLAB27 
positivity. 
 There was a predominance of symptoms affecting the upper limbs. 
Exceptions were patients with crystal arthropathy, in whom the lower limbs 
more commonly affected, and patients with UA or SpA, in whom symptoms 
in the upper and lower limbs were reported with approximately similar 
frequency. 
 Joint involvement was greatest in patients with RA; of whom, most had 
oligoarthritis and one third of had polyarthritis. The majority of patients with 
UA had monoarthritis, whilst half of patients with crystal arthropathy or SpA 
had no clinically detectable joint swelling. 
 Raised CRP (>10mg/dL) was more frequently observed in patients with RA, 
UA, crystal arthropathy and SpA, in comparison to patients with 
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osteoarthritis or other mechanical joint pain. Levels were generally highest 
amongst patients with SpA. 
 Testing for RF was performed in most patients (90% of the total audit 
sample). Rheumatoid factor was detected in two-thirds of patients with RA 
and approximately 20% of patients with osteoarthritis, other mechanical joint 
pain, crystal arthropathy and SpA. All patients with UA were RF-negative.  
 Positivity for ACPA was only detected in patients with RA and one patient 
with non-specific arthralgia who was diagnosed with RA within the following 
12 months. 
 Radiographs of the hands and feet were complete in one third of patients, in 
whom erosions were detected in four (2 patients with RA, 1 patient with UA 
and 1 patient with psoriatic arthritis). Only one patient fulfilled the 2010 
ACR/EULAR definition for erosive RA (van der Heijde et al., 2013). 
 
Other investigations included a symptom-directed ultrasound in 11 patients. Power 
Doppler synovitis was detected in patients with RA (n=3) and UA (n=2). Grey scale 
synovitis alone was demonstrated in a further patient with UA and a patient with 
other mechanical joint pain. Bursitis alone was found in three further patients with 
other mechanical joint pain. In the final patient undergoing ultrasound (diagnosed 
with UA) no abnormalities were recorded.
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 Characteristics of one hundred all-comers to the EAC. Table 14.
Characteristics are summarised for the total group and sub-groups classified according to the most prevalent primary diagnoses. 
Values are median (IQR) and number of patients (percentage of patients), unless otherwise stated. 
 
All patients 
n=100 
Osteoarthritis 
n=27 
Other 
mechanical 
n=26 
RA 
n=9 
UA 
n=8 
Crystal 
arthropathy 
n=8 
SpA
a 
n=6 
Age, mean (SD) 48 (16) 56 (12) 40 (10) 63 (15) 46 (23) 54 (15) 35 (8) 
Female 67 (67%) 23 (85%) 21 (81%) 4 (44%) 6 (75%) 0 1 (17%) 
Symptom duration, months 8 (3-36)
e 
11 (3-36)
g 
12 (6-36)
g 
8 (4-15)
 
6 (2-24)
 
2 (1-36) 6 (1-29)
 
Early morning stiffness, minutes 0 (13-56)
f 
0 (13-30)
g 
4 (0-30)
 
60 (34-60)
g 
10 (0-120)
g 
0 (0-18)
 
60 (0-75)
 
≥1 feature of SpA
b
 24 (24%) 5 (19%) 1 (4%) 2 (22%) 2 (25%) 0 5 (83%) 
Symptom distribution:       Predominantly upper limb 
Predominantly lower limb 
Upper & lower limb affected equally 
Predominantly axial 
No joint symptoms 
44 (44%) 
23 (23%) 
29 (29%) 
3 (3%) 
1 (1%) 
16 (59%) 
4 (15%) 
7 (26%) 
0 
0 
10 (38%) 
3 (12%) 
11 (42%) 
2 (8%) 
0 
5 (56%) 
1 (11%) 
3 (33%) 
0 
0 
4 (50%) 
3 (38%) 
1 (13%) 
0 
0 
1 (13%) 
6 (75%) 
1 (13%) 
0 
0 
1 (17%) 
2 (33%) 
2 (33%) 
1 (17%) 
0 
Joint involvement
c
:                                          1 M/L
d
 
2-10 M/L 
1-3 S 
4-10 S 
>10 joints (at least 1 S) 
6 (6%) 
2 (2%) 
6 (6%) 
8 (8%) 
5 (5%) 
0 
0 
0 
2 (7%) 
0 
1 (4%) 
0 
0 
0 
0 
0 
0 
2 (22%) 
3 (33%) 
4 (44%) 
3 (38%) 
1 (13%) 
2 (25%) 
2 (25%) 
0 
2 (25%) 
0 
1 (13%) 
0 
1 (13%) 
1 (17%) 
0 
1 (17%) 
1 (17%) 
0 
Pattern of joint swelling:                 No swollen joints 
Monoarthritis (SJC=1) 
Oligoarthritis (SJC=2-4)  
Polyarthritis (SJC>4)                            
74 (74%) 
10 (10%) 
10 (10%) 
6 (6%) 
25 (93%) 
0 
2 (7%) 
0 
26 (100%) 
0 
0 
0 
0 
1 (11%) 
5 (56%) 
3 (33%) 
0 
6 (75%) 
1 (13%) 
1 (13%) 
4 (50%) 
2 (25%) 
1 (13%) 
1 (13%) 
3 (50%) 
1 (17%) 
1 (17%) 
1 (17%) 
TJC68 1 (0-8) 0 (0-8) 1 (0-4) 7 (4-13) 2 (0-4) 1 (0-1) 1 (0-4) 
CRP, mg/dL 0 (0-11) 0 (0-1) 0 (0-8) 10 (0-18) 5 (0-100) 4 (0-22) 37 (9-101) 
RF-positivity, number positive/number tested 19/90 5/26 4/22 6/9 0/8 1/5 1/5 
ACPA-positivity, number positive/number tested 5/78 0/19 0/18 4/9 0/8 0/4 0/5 
Radiographic erosions, number of patients with 
erosion/number with complete hand and feet x-rays 
4/33 0/9 0/5 2/6 1/2 0/3 1/3 
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M/L: medium-sized or large joint, L: large joint, S: small joint (according to 
definitions employed in the 2010 ACR/EULAR RA criteria). 
aIncludes primary diagnoses of psoriatic arthritis in 3 patients and reactive arthritis, 
inflammatory bowel disease-associated SpA and undifferentiated SpA in 1 patient 
each. 
bAs defined within Assessment of Spondyloarthritis (ASAS) criteria: inflammatory 
back pain, enthesopathy, uveitis, dactylitis, psoriasis (skin and/or nail), inflammatory 
bowel disease, family history, HLA-B27 positive, sacroiliitis on imaging. 
cAs defined within 2010 ACR/EULAR RA criteria 
dOr involvement of joints not included in 2010 criteria 
e-gExcludes missing data in e3, f4 and g1 patients. 
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Figure 2. Characteristics at first EAC assessment in patients grouped according to the prevalent primary diagnoses. Boxplots of: A) age, 
B) symptom duration, C) duration of early morning stiffness, D) number of tender joints and E) CRP. 
A) Age at first EAC assessment according to primary diagnosis.  
 
 
 
 
 
B) Symptom duration at first EAC assessment according to primary 
diagnosis. 
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C) Duration of early morning stiffness at first EAC assessment 
according to primary diagnosis. 
 
 
 
D) Number of tender joints at first EAC assessment according to 
primary diagnosis. 
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E) Value of CRP at first EAC assessment according to primary diagnosis.  
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5.4.2 Efficacy of triage 
The majority of patients were referred by their GP (84/95 [88%] patients in whom 
the source of the referral was known). Date of referral was available in 93 patients; 
amongst these patients, the median (IQR) time between initial referral and first EAC 
assessment was 3 (2-5) weeks and the target for assessment within three weeks of 
referral was met in 55/93 (59%) patients. Three patients did not attend the first EAC 
appointment which was allocated to them. After exclusion of these patients, the 
maximum delay between initial referral and first EAC assessment was 10 weeks.  
 
Further referral details were available in 86 patients. Documentation of at least one 
NICE indicator for urgent assessment was identifiable from referral information in 
38 (44%) of these patients. Presence of at least one NICE indicator differed 
significantly across the IA categories: identified in 16/23 (70%), 2/9 (22%) and 
20/54 (37%) patients with confirmed IA, possible IA and non-IA, respectively 
(p=0.01). The difference was not significant between patients with possible IA and 
non-IA (p=0.5), but significant between patients with confirmed IA and non-IA 
(p=0.01). 
 
Presence of at least one NICE indicator within referral information was not 
associated with time to assessment. The median (IQR) time from referral to 
assessment was 3 (2-5) weeks in both patients with and without documentation of 
at least one indicator (p=0.7) (Table 15).  
 
In the subset of patients with a primary diagnosis of RA or UA, at least one NICE 
indicator was identifiable in 6/8 (75%) and 7/8 (89%) with referral information 
available, respectively. There was variation in the indication for urgent referral. As 
may be expected due to the weighting of small joint involvement within the RA 
criteria, involvement of the small joints of the hands or feet and involvement of more 
than one joint were more prevalent in patients with RA (both documented in all six 
patients) in comparison to patients with UA (both documented in three patients). 
Duration of symptoms of at least three months at the time of referral was 
documented in with 3 (38%) patients with RA and 6 (75%) patients with UA. 
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 Referral information for one hundred all-comers to the EAC. Table 15.
Patients grouped according to the presence of NICE indicators for urgent assessment and impression of IA. Values are number of 
patients (percentage of patients with complete data), unless otherwise stated. 
 Presence of NICE indicator for 
urgent assessment within 
referral information 
Impression of IA at first EAC assessment 
None 
 
n=48 
At least 
1  
n=38 
p 
Non-IA 
n=65 
Possible IA
a 
n=11 
Confirmed IA
b 
n=24 
p 
 
 
Missing 
Values 
 
Missing 
Values 
 
Missing 
Values 
Source of referral:        Primary care 
Secondary care 
41 (85%) 
7 (15%) 
35 (92%) 
3 (8%) 
0.5 
54(90%) 
6(10%) 
5 
7(64%) 
4(36%) 
- 
23(96%) 
1(4%) 
- NA 
Presence of NICE indicators for 
urgent assessment identifiable 
within referral letters: 
Suspected synovitis with… 
 Involvement of the small 
joints of hands/feet 
 Involvement of ≥1 joint  
 ≥3 months symptom 
duration at time of referral 
 At least 1 of the above 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
27 (71%) 
 
21 (55%) 
 
21 (55%) 
 
100% 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
15(28%) 
 
10(19%) 
 
10(19%) 
 
20(37%) 
 
 
 
 
11 
 
 
 
 
 
 
 
 
 
1(11%) 
 
1(11%) 
 
1(11%) 
 
2(22%) 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
11(48%) 
 
10(43%) 
 
10(43%) 
 
16(70%) 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
0.1 
 
0.04 
 
0.04 
 
0.01 
Time between initial referral and 
first EAC assessment:  
median (IQR), weeks 
achieving ≤3 week target 
 
 
3 (2-5) 
29 (60%) 
 
 
3 (2-5) 
21 (55%) 
 
 
0.7 
0.6 
 
 
3 (2-4) 
38(64%) 
 
6 
 
 
3 (3-5) 
6(55%) 
 
1 
 
 
4 (2-6) 
11(48%) 
 
1 
 
 
0.5 
0.4 
NA: not assessed (>20% of cells with expected number <5, therefore not appropriate to perform Chi-square test).  
aPossible IA defined as a primary impression of possible IA without current clinical joint swelling (i.e. history compatible with IA) at first EAC 
assessment. 
bConfirmed IA defined as a primary diagnosis of IA and presence of at least one clinically swollen joint at first EAC assessment.  
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5.4.3 Management 
5.4.3.1 Corticosteroids 
Corticosteroids were prescribed for a total of 32 patients at the first EAC 
assessment: 23 patients received 120mg methylprednisolone (intramuscular and/or 
intra-articular), 7 patients received ≤120mg methylprednisolone and 2 patients were 
prescribed oral prednisolone (including 1 patient with polymyalgia rheumatica). The 
frequency with which any corticosteroids were administered across the prevalent 
primary diagnoses were: 7/27 (26%) patients with osteoarthritis, 2/26 (8%) patients 
with other mechanical joint pain, 4/9 (44%) patients with RA, 5/8 (63%) patients with 
UA, 4/8 (50%) patients with crystal arthropathy, and 4/6 (66%) patients with SpA.  
 
Of note, 10 patients received treatment with corticosteroids prior to their first EAC 
assessment. They included patients with possible IA (crystal arthropathy [n=3], 
non-specific arthralgia [n=1]) and confirmed IA (RA and UA [each n=1]).  
 
5.4.3.2 DMARDs 
Fifteen patients were treated with DMARDs, either at their first EAC assessments or 
within the subsequent 12 months. The frequency of DMARD use in patients with a 
primary diagnosis of UA and RA is shown in Table 16. One patient with an initial 
primary diagnosis of UA, subsequently diagnosed with ANA-associated arthralgia 
and treated with hydroxychloroquine, was excluded. Other primary diagnoses in 
patients receiving DMARDs were psoriatic arthritis (n=2 receiving methotrexate), 
non-specific arthralgia (n=1, subsequently diagnosed as RA, receiving 
sulfasalazine), osteoarthritis and ANA-associated arthralgia (each n=1, receiving 
hydroxychloroquine). 
 
5.4.4 Change in diagnosis over 12 months 
Approximately one third of patients were discharged with a definitive diagnosis at 
their first EAC visit (n=29), one third were discharged within 12 months (n=37) and 
one third remained under follow-up at 12 months (n=34). The median (IQR) length 
of follow-up in patients discharged after their first EAC visit, but before 12 months, 
was 21 (11-29) weeks. In patients with at least one follow-up assessment, a change 
in diagnosis was observed in thirteen (Figure 1), including four patients with 
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non-specific arthralgia at their first EAC assessments who were subsequently 
diagnosed with mechanical joint pain (n=2), ANA-associated arthralgia (n=1) and 
RA (1 patient with ACPA-positivity who had received oral prednisolone from their 
GP prior to their first EAC assessment). No patients with a non-IA diagnosis at their 
first presentation were subsequently diagnosed with IA and only one patient with 
confirmed IA (unilateral knee swelling at their first EAC assessment, classifiable as 
monoarthritic UA) received a revised diagnosis of non-IA (ANA-associated 
arthralgia).  
 
5.4.5 DMARD initiation in patients with UA and RA 
One patient with a primary diagnosis of UA was excluded from the following 
analysis due revision of their diagnosis to ANA-associated arthralgia during 
follow-up. Of the remaining 16 patients with a consistent diagnosis of UA or RA 
from their first assessment, 9 (56%) commenced DMARDs within 12 months: 2/7 
(29%) patients with UA and 7/9 (78%) patients with RA (Table 16). Patients who did 
not commence DMARDs experienced resolution of synovitis, either with (n=4) or 
without corticosteroids (n=1), or did not attend any follow-up (n=2). These patients 
were all seronegative for RF and ACPA and the majority presented with 
monoarthritis at their first assessment. 
 
National standards for early DMARD commencement were achieved in two 
patients: one with UA commencing hydroxychloroquine within six weeks of referral 
and three months of symptom onset and one with RA commencing methotrexate 
within six weeks of referral. Time delays occurring at stages (i) to (iv) and factors 
contributing to delays at the level of the rheumatologist, identifiable from clinical 
notes, are shown in Table 16. Unfortunately it was not possible to establish when 
patients first sought medical attention from medical records, therefore the time 
between symptom onset and referral (stages i and ii combined) was reported. The 
commonest reason identified for delay at stage (iv) was consideration of therapy 
within a clinical trial, relevant in 4/7 (57%) patients with RA commencing DMARDs. 
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 Management and one year outcomes of patients diagnosed with UA or Table 16.
RA from their first EAC assessment. 
Values are number of patients (%) and median (IQR) or actual values 
where number in the sample was small (n=2). 
 UA  
(n=7) 
RA  
(n=9) 
Outcomes over 12 months: 
Commencement of DMARD therapy 
Self-limiting/resolution with corticosteroids 
Not attending any follow-up 
 
2 (29%) 
3 (42%)a 
2 (29%)c 
 
7 (78%) 
2 (22%)b 
0 
First-line DMARD:                                   Methotrexate 
Hydroxychloroquine  
Azathioprine 
None 
1 (14%) 
1 (14%)d 
0 
5 (71%) 
6 (66%) 
0 
1 (11%)e 
2 (22%) 
In patients commencing DMARD therapy: (n=2) (n=7) 
Length of delays in DMARD initiation: 
 Stages (i) and (ii), time between symptom onset 
and referral, weeks 
 Stage (iii), time between referral and first EAC 
assessment, weeks 
 Stage (iv), time between first EAC assessment and 
DMARD initiation, weeks 
 
11, 203 
 
1, 5 
 
0, 12 
 
29 (12-46) 
 
6 (2-6) 
 
8 (4-27) 
Total Rheumatologist Delay, stages (iii) and (iv): 
Time between referral and DMARD initiation:    
                     actual values or median (IQR), weeks 
achieving ≤6 week target 
 
 
2, 18 
1 (50%) 
 
 
14 (8-33) 
1 (14%) 
Total Delay, stages (i) to (iv): 
Time between symptom onset and DMARD initiation:          
                          actual values or median (IQR), weeks 
achieving ≤3 month target 
 
 
13, 221 
1 (50%) 
 
 
43 (28-80) 
0 
Factors contributing to delays at stage (iv): 
Diagnostic uncertainty  
Contraindications to DMARDs 
Considering biologic clinical trial 
 
1 
0 
0 
 
1 
2e,f 
4 
aSynovitis resolved with a single dose of methylprednisolone in 3 patients (2 
patients remaining under follow-up at 12 months and 1 patient discharged at 9 
months). Clinical presentations in these patients were monoarthritis of the knee, 
monoarthritis of the midtarsal joint and polyarthritis affecting the wrists and MTPs. 
bSynovitis resolved with a single dose of methylprednisolone in a patient, initially 
presenting with oligoarthritis of the hands/wrists, who remained under follow-up at 
12 months. Synovitis resolved in a further patient without corticosteroids, initially 
presenting with monoarthritis of the knee, who was discharged at 9 months.  
cClinical presentations in these patients were monoarthritis of the knee and 
monoarthritis of the ankle. 
d-eContraindications to methotrexate occurring in one patient case each, including 
dderanged liver function tests and eabnormal chest-x-ray (interstitial lung disease 
later confirmed on CT).  
fAbnormal chest-x-ray (pleural granuloma later confirmed on CT). 
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5.5 Discussion  
This audit provides insight into the function of an EAC within a large rheumatology 
centre. It reports clinical characteristics of all-comers, including patients diagnosed 
with non-IA who formed the majority of patients referred to the clinic. Previous 
studies have largely excluded patients lacking joint swelling as determined by a 
rheumatologist (Govoni et al., 2013). Limited data are available from an Austrian 
rapid access clinic, demonstrating a diagnosis of degenerative joint pain in a 
quarter of patients referred, with discharge after initial assessment being possible in 
43%, similar to the Leeds audit (Pflugbeil et al., 2009).  
 
New-onset RA was detected in 10% of patients in this audit. With the Leeds EAC 
serving a secondary-care population of 800,000, receiving approximately 1000 
referrals annually, this incidence of RA is consistent with rates reported across 
northern Europe (Guillemin et al., 1994; Söderlin et al., 2002; Savolainen et al., 
2003; Pedersen et al., 2009; Humphreys et al., 2013). 
 
At the time of this audit, room for improvement in order to meet the national 
standards for the timely commencement of DMARDs was identified. Symptom 
duration at first assessment in patients with IA was significant, consistent with 
previous studies (Kumar et al., 2007; Kiely et al., 2009; www.nao.org.uk, 2009; van 
der Linden et al., 2010; Raza et al., 2011) (see section 2.4.3). In line with these 
studies, the delay between symptom onset and referral to rheumatology contributed 
most to the total delay in DMARD initiation in patients with UA and RA, and, in the 
main, precluded achievement of the NICE recommendations for commencement of 
DMARDs within three months of symptom onset (www.nice.org.uk, 2009). 
Unfortunately, methods employed in this audit did not allow discrimination between 
delays arising at stages (i) or (ii), or the reasons for such.  
 
Significant delays were observed at the level of the rheumatologist; between 
referral and the first EAC assessment (stage iii) and between the first EAC 
assessment and DMARD initiation (stage iv). With respect to stage (iii), almost half 
of patients were assessed later than the three week national standard for timely 
assessment which was due to be introduced (www.gov.uk, 2013). This included 
patients who were identified as having possible and confirmed IA, and those with a 
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primary diagnosis of UA or RA. Whilst the NICE indicators appear to be of use in 
the triage of patients with suspected IA, being observed more frequently in referral 
information for patients with confirmed IA, this audit suggests that they may not be 
the only factors used to prompt allocation of urgent EAC appointments. There was 
no association between the identification of NICE indicators within referral 
information and the time to assessment. This is justifiable as they were not 
universally present in referral information in patients with IA. Other expected 
differences in the characteristics of patients with the main non-IA and IA diagnoses, 
confirmed in this audit (such as early morning stiffness lasting over 30 min and 
abnormal CRP in patients with IA), may also have value in a triage process and 
may inform future procedures for allocating urgent appointments. 
 
Although delay in DMARD initiation was noted at the level of the rheumatologist 
(stage iv), approximately half of patients with UA or RA were treated with 
intramuscular corticosteroid (120mg methylprednisolone) at their first assessment. 
The use of bridging corticosteroid therapy is standard practice in the management 
of early RA (Smolen et al., 2017) and there may be an argument for withholding 
DMARD therapy with a trial of corticosteroid in patients with IA with favourable 
prognostic factors. Audit data supports this, given that no ongoing synovitis or 
DMARD use was observed in a significant number of patients with UA or RA at their 
last visit within the subsequent 12 months. Delays in DMARD initiation may also be 
justifiable on clinical grounds, for example due to the need for further investigations 
in cases of diagnostic uncertainty or apparent contraindications to DMARDs. The 
necessity to provide patients with time to consider all options for treatment 
(including clinical trials) also appeared to be a factor in the delay. Since this audit, 
provision of appropriate study information to all patients potentially eligible for 
clinical trials is now recommended at their first assessment.  
 
Limitations of this audit include its generalisability to other centres, including smaller 
district general hospitals. The method of sampling may have introduced bias in the 
range and frequency of clinical characteristics and diagnoses observed, due to 
seasonal variations in disease aetiology and/or symptoms (Iikuni et al., 2007). The 
reduced availability of clinic appointments over the Christmas period (clinics were 
not operating over two bank holidays) may also have contributed to delays in 
assessment. As noted by other groups, symptom onset may be subject to recall 
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bias (De Cock et al., 2013). Bias may also be present in the reasons identified for 
delay to DMARD initiation after rheumatology assessment; some factors, such as 
lack of follow-up appointments, may not have been obvious from retrospective 
review of clinical notes. Conclusions are limited by grouping patients into broad 
diagnostic categories, particularly ‘other mechanical joint pains’ which included 
complaints ranging from mild, localised complaints (e.g. epicondylitis) to 
widespread pains (e.g. with muscle deconditioning). Furthermore, patients with 
suspected new-onset SpA or connective tissue disease with associated IA may 
have been triaged to specific SpA and connective tissue disease clinics, 
respectively.  
 
In order to optimise outcomes for patients with early IA, strategies to improve their 
earlier assessment, both prior to and after referral, are required. The use of a 
referral pro forma in primary care, to include the NICE clinical indicators for urgent 
referral as well as other relevant factors such as CRP and early morning stiffness, 
may assist in creating a more efficient triage system. Earlier recognition of eligibility 
for treatment within a clinical trial may also streamline the commencement of 
treatment. Although the 2010 ACR/EULAR RA criteria may be a useful guide in 
assessing the need for DMARDs in daily practice, they were developed for use as 
classification criteria in clinical trials (as opposed to diagnostic criteria) and are not 
entirely sensitive or specific (Sakellariou, G. et al., 2013; Radner et al., 2014), as 
suggested by this audit. It is problematic to draw conclusions in patients with UA 
and RA, defined according to these criteria, in this audit due to their small numbers. 
Further data are needed in order to describe the phenotype and assess outcomes 
in patients classified with prospective application of these criteria. 
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 : What are the Clinical and Imaging Phenotypes of Chapter 6
Patients with New-Onset UA and RA, Defined According 
to the 2010 ACR/EULAR Criteria?   
Does inclusion of ultrasound synovitis within the criteria 
improve the differentiation of patients with erosive disease? 
6.1 Introduction 
With awareness of the importance of early, aggressive treatment in the 
management of RA, the need for sensitive, accurate diagnostic tools has become 
paramount. Defining features of RA include small joint synovitis and bone erosions; 
however, existing methods for their detection (clinical examination and radiography, 
respectively) have limitations. Clinical examination is known to be poorly 
reproducible and may be inaccurate (Wakefield et al., 2004; Salaffi et al., 2008; 
Marhadour et al., 2010), and radiography is poorly sensitive for the detection of 
erosions, particularly in early disease (van der Heijde et al., 2013). Ultrasound is 
becoming increasingly used in clinical practice as a sensitive measure of synovitis 
and erosion, in determining the phenotype of patients with early IA (Colebatch et 
al., 2013; Combe et al., 2017). 
 
Review of the literature has identified a number of questions pertinent to 
understanding the clinical and imaging phenotype of early IA, which remain to be 
answered, particularly in the context of the new 2010 ACR/EULAR RA criteria. It 
has been proposed that the addition of ultrasound, in the assessment of joint 
involvement, may improve the accuracy of the criteria (Nakagomi et al., 2013). 
However this study used an extensive 38-joint count which may not be feasible in 
clinical practice and included patients lacking clinical evidence of synovitis (in whom 
the criteria are not intended for). The 2010 ACR/EULAR RA criteria include the 
optional use of ultrasound in the determination of joint involvement, although a 
definition for ultrasound synovitis is not given (Aletaha, D. et al., 2010).  
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Whilst ultrasound assessment of inflammation has been recommended by experts 
in the diagnosis of IA in clinical practice (Combe et al., 2017), the majority of 
ultrasound studies have been conducted prior to development of the 2010 RA 
criteria or in heterogeneous groups of early IA patients (including UA, RA and other 
diagnoses). Less is understood regarding the validity of ultrasound assessment of 
erosions (Colebatch et al., 2013). Reports of the prevalence of ultrasound erosions 
in early, treatment-naïve IA (including patients with UA) are limited to studies of a 
small number of joints (Funck-Brentano et al., 2009; Sheane et al., 2009). It has 
been suggested that erosion observed in association with ultrasound synovitis (GS 
and/or PD) may be specific to IA (Millot et al., 2011). 
 
A greater understanding is required of clinical and imaging phenotypes of patients 
with early UA and RA, classified using the 2010 RA criteria. Knowledge of the 
prevalence, distribution and agreement between clinical and ultrasound synovitis, 
as well as x-ray and ultrasound erosions and ‘active’ erosions (erosion observed in 
association with ultrasound synovitis), is needed in such patients. This will help to 
establish the optimal use of ultrasound in the classification of IA and guide future 
research in determining its prognostic value. In particular, it is important to 
determine whether inclusion of ultrasound synovitis within the 2010 RA criteria 
improves the accuracy of disease classification. 
 
6.2 Aims and Objectives 
 To describe the clinical and imaging phenotypes of patients with new-onset, 
DMARD-naïve IA (specifically UA and RA, classified according to the 2010 
ACR/EULAR RA criteria).  
 To evaluate the prevalence, distribution and concordance between clinical and 
ultrasound synovitis, and erosions and ‘active’ erosions (associated with 
ultrasound synovitis) detectable by radiography and ultrasound. 
 To assess the proportion of patients with UA or RA whose disease may be 
reclassified with consideration of ultrasound evidence of synovitis in the 
application of the 2010 RA criteria. 
 To determine whether reclassification with the use of ultrasound is more 
discriminating for the presence of erosions at diagnosis than application of the 
classification criteria using clinical findings alone. 
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6.3 Methods 
A prospective, observational study was conducted in patients with new-onset, 
DMARD-naïve UA and RA, presenting to the Leeds EAC between June 2010 and 
September 2012 (see Chapter 4). Baseline data from this study was analysed. 
Additional exclusion criteria for these analyses were: incomplete clinical, ultrasound 
and x-ray data at baseline and change of initial diagnosis to an alternative non-RA 
diagnosis within 12 months of follow-up. 
 
6.3.1 Assessments 
Baseline assessments were recorded as per sections 4.2 and 4.3. Patients were 
primarily classified as RA or UA according to whether they fulfilled the 2010 
ACR/EULAR RA criteria, or not, using clinical findings alone to determine their 
score for joint involvement.  
 
Subsequently, the criteria were applied in the following two ways; (i) considering 
both clinical and ultrasound findings of significant synovitis, and (ii) ultrasound 
findings of significant synovitis alone, in the determination of joint involvement. 
Therefore, a joint was considered involved in the presence of; (i) clinical swelling 
and/or tenderness and/or GS≥grade 2 and/or PD≥grade 1 (see section 4.3.3 for 
further details regarding the definition of ultrasound synovitis), or (ii) on the basis of 
GS≥grade 2 and/or PD≥grade 1 only. Therefore, ultrasound of 24 joints (first MTPs 
being excluded as per 2010 RA criteria) enabled the categorisation of patients on 
the basis of: 
(i) Clinical and ultrasound findings of synovitis; 
 Patients with UA reclassified as RA in the instance of sufficient 
clinical and subclinical synovitis (UA→RAclinical+US). Alternatively, 
their disease remained classified as UA (UA→UAclinical+US). 
(ii) Ultrasound findings of synovitis alone; 
 Patients with UA reclassified as RA in the instance of sufficient 
subclinical synovitis (UA→RAUS). Alternatively, their disease 
remained classifiable as UA (UA→UAUS). 
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 Patients with RA reclassified as UA in the instance insufficient 
ultrasound synovitis (RA→UAUS). Alternatively, their disease 
remained classified as RA (RA→RAUS). 
 
6.3.2 Statistics 
Characteristics were compared between patients with UA and RA. Differences were 
evaluated using Chi-Squared or Fisher’s exact tests for categorical variables (as 
appropriate for numbers of expected values), and t-tests for continuous variables 
following a normal distribution (Shapiro-Wilks test was utilised to assess for 
normality). For non-parametric data, Mann-Whitney-U testing was performed.  
 
Descriptive summary statistics were used to analyse the concordance between 
clinical and ultrasound-detected synovitis, and x-ray and ultrasound-detected 
erosions. Other tests for agreement, such as kappa statistics, were not performed 
due to the variation in the prevalence of ultrasound findings according to joint site. 
 
The ability of the 2010 ACR/EULAR RA criteria to discriminate patients with 
evidence of erosive disease at baseline (presence of any x-ray or ultrasound 
erosion) was determined by comparing the rates of erosive disease between: 
(i) patients with UA who were reclassified, using ultrasound findings in addition to 
clinical findings, as RA (UA→RAclinical+US) and patients with UA whose disease 
remained classified as UA (UA→UAclinical+US), and (ii) patients with RA who were 
reclassified, using ultrasound findings alone, as UA (RA→UAUS) and patients with 
RA whose disease remained classified as RA (RA→RAUS). 
 
6.4 Results 
6.4.1 Patients 
During the study period, 1946 patients were referred to the Leeds EAC; 441 
patients, with suspected new-onset IA, were screened for inclusion in the study. In 
total, 333 were DMARD-naïve with new-onset UA or RA (Figure 3). Fifteen patients 
received an alternative diagnosis (other than UA or RA) over 12 months of follow-up 
and were therefore excluded. Of the remaining patients, clinical and imaging joint 
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assessments were complete for 235 patients at baseline; 38 were diagnosed with 
UA and 197 fulfilled 2010 ACR/EULAR RA classification criteria (with joint 
involvement determined by clinical examination). Differences between included 
patients (n=235) and those excluded due to incomplete data (n=83) were 
statistically significant (p<0.05) for age, clinical joint involvement (as defined within 
2010 ACR/EULAR RA criteria) and swollen joint counts. These were all greater in 
included patients (Table 17). 
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Figure 3. Disposition of patients registered in the longitudinal prospective 
observational study and included in the analysis of clinical and imaging 
phenotype. 
 
 
 
 
 
 
 
 
 
 
 
  
Suspected new-onset IA  
n=441 
Included in analysis 
n=235 
 
- No clinical joint swelling n=52 
- Declined consent n=18 
- Not re-attending for baseline visit n=11 
- Alternative diagnosis (diagnoses other than 
RA or UA) at baseline n=24 
- Other reason n=3 
Alternative diagnosis (other than RA or UA) 
over 12 months of follow-up n=15 
 
New-onset UA or RA at 
baseline  
n=333 
Included in analyses 
n=235 
 
Incomplete joint assessment at baseline n=83 
- Missing ultrasound data n=75 
- Missing x-ray data n=7 
- Incomplete clinical joint examination n=55 
 
Eligibl  for inclusion  
318
 
All referrals to the EAC 
n=1946 
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 Baseline characteristics of all patients with new-onset UA and RA Table 17.
included in the analysis of clinical and imaging phenotype, and those 
excluded due to incomplete data.  
Values are median (IQR) or n (%) unless otherwise stated. 
 Included in analyses Excluded due to 
incomplete data 
p 
 
(n=235) 
Missing 
Values 
(n=83) 
Missing 
Values 
Age, mean (SD) 55 (14) - 51 (15) - 0.03 
Female 163 (69%) - 64 (77%) - 0.2 
BMI, mean (SD) 28 (5) 23 29 (6) 18 0.1 
Symptom duration, months 7 (4-13) - 8 (4-16) - 0.7 
Current/previous smoker                                134 (57%) - 52 (64%) 2 0.3 
Number of comorbidities:                1 
2 
3 
≥4 
71 (30%) 
50 (21%) 
26 (11%) 
11 (5%) 
- 
 
17 (20%) 
12 (14%) 
9 (11%) 
9 (11%) 
- 0.5 
History/current evidence of 
coexistent osteoarthritis 
81 (34%) - 27 (33%) - 0.7 
≥1 feature of SpA 26 (11%) - 7 (8%) - 0.5 
Clinical joint involvement:         1M/L
 
2-10 M/L 
1-3 S 
4-10 S 
>10 (at least 1 S) 
2 (1%) 
3 (1%) 
36 (15%) 
82 (35%) 
112 (48%) 
- 
1 (1%) 
1 (1%) 
20 (24%) 
33 (40%) 
28 (34%) 
- 0.02 
Pattern of joint swelling:  
Palindromic arthritis
 
Monoarthritis (SJC=1) 
Oligoarthritis (SJC=2-4)  
Polyarthritis (SJC>4) 
 
1 (<1%) 
28 (12%) 
83 (35%) 
123 (52%) 
- 
 
1 (1%) 
13 (16%) 
35 (43%) 
33 (40%) 
1 0.06 
Symmetrical joint swelling
 
150 (64%) - 50 (60%) - 0.6 
RF positive 
ACPA positive 
139 (59%) 
138 (59%) 
- 
- 
47 (57%) 
50 (60%) 
- 
- 
0.7 
0.8 
Fulfilment of RA classification 
criteria (clinically):      1987 ACR RA 
2010 ACR/EULAR RA
 
 
134 (57%) 
197 (84%) 
 
- 
 
44 (53%) 
64 (77%) 
 
- 
- 
 
0.5 
0.2 
Early Morning Stiffness ≥60 min 165 (70%) - 65 (78%) - 0.2 
TJC28                                                                 
SJC28                                                                 
7 (3-14) 
4 (2-8) 
- 
- 
6 (3-10) 
4 (1-6) 
2 
2 
0.2 
0.04 
RAI                                                                      
SJC44                                                                 
6 (4-10) 
5 (3-9) 
- 
- 
4 (2-9) 
3 (2-5) 
55 
55 
0.07 
0.006 
CRP, mg/L 13 (0-34) - 12 (0-27) - 0.5 
Patient VASDA, mm  50 (25-69) 48 50 (26-81) 53 0.7 
DAS28-CRP                                                    4.5(3.6-5.5) 48 4.5(3.4-5.2) 53 0.6 
DAS44-CRP                                                    2.9(2.3-3.5) 48 2.8(1.7-3.5) 63 0.4 
HAQ                                                                    1.0(0.4-1.6) 40 0.8(0.3-1.8) 54 0.8 
Ultrasound of 26 joints: 
Number of joints GS≥grade 1 
Number of joints GS≥grade 2 
             Total GS score
 
Number of joints PD≥grade 1 
Total PD score
 
 
10 (7-14) 
5 (2-9) 
16 (9-25) 
2 (0-4) 
3 (0-6) 
- NR 75 NR 
Ultrasound erosion (in PIP2-3, 
MCP2-3, wrists or MTP2-4) 
91 (39%) - NR 75 NR 
Radiographic erosion in the hands 
and feet:                                     Any 
1987 ACR definition  
2010 ACR/EULAR definition
 
 
34 (14%) 
21 (9%) 
15 (6%) 
 
- 
 
14 (18%) 
11 (14%) 
5 (7%) 
7 
 
0.4 
0.1 
1.0 
M/L: medium-sized or large joint, L: large joint, S: small joint (according to 
definitions employed in the 2010 ACR/EULAR RA criteria). 
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6.4.2 Baseline characteristics of patients with UA and RA 
Baseline characteristics are shown in Table 18. In line with the weighting of joint 
involvement and serology within the 2010 ACR/EULAR RA criteria, patients with RA 
had more extensive joint involvement (evidenced by greater clinical, laboratory and 
ultrasound measures of disease activity) and only a minority of patients with UA 
were seropositive for ACPA and/or RF. Patients with UA were also significantly 
younger and demonstrated lower rates of smoking, comorbidity and osteoarthritis. 
Features of SpA were more frequently recorded in patients with UA: at least one 
feature was documented in one quarter of patients with UA, in comparison to 9% of 
patients with RA (p=0.02). 
 
Four patients who did not fulfil 2010 ACR/EULAR RA criteria fulfilled the 1987 ACR 
RA criteria, at baseline. In comparing patients fulfilling either of the 2010 or 1987 
criteria (n=201) to patients fulfilling neither criteria (n=34), differences were 
observed between these groups for the same variables, with the exception of the 
number of comorbidities and evidence of osteoarthritis which were no longer 
significant.  
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 Comparison of baseline characteristics between patients with UA and Table 18.
RA (defined according to fulfilment of 2010 ACR/EULAR RA criteria, 
with joint involvement determined by clinical swelling and/or 
tenderness). 
Values are median (IQR) or n (%) unless otherwise stated. 
 UA RA 
p  
(n=38) 
Missing 
Values 
(n=197) 
Missing 
Values 
Age, mean (SD) 44 (15) - 57 (13) - <0.001 
Female 26 (68%) - 137 (70%) - 0.9 
BMI, mean (SD) 27 (6) 4 28 (5) 19 0.9 
Symptom duration, months 10 (3-19) - 7 (4-13) - 0.2 
Current/previous smoker                                15 (39%) - 119 (60%) - 0.02 
Number of comorbidities:          1 
2 
3 
≥4 
14 (37%) 
3 (8%) 
4 (11%) 
0 
 
- 
 
57 (29%) 
47 (24%) 
22 (11%) 
11 (6%) 
 
- 
0.02 
History/current evidence of 
coexistent osteoarthritis 
7 (18%) - 74 (38%) - 0.02 
≥1 feature of SpA 9 (24%) - 17 (9%) - 0.02 
Clinical joint involvement:   1M/L
 
2-10 M/L 
1-3 S 
4-10 S 
>10 (at least 1 S) 
2 (5%) 
2 (5%) 
15 (39%) 
19 (50%) 
0 
- 
0 
1 (1%) 
21 (11%) 
63 (32%) 
112 (57%) 
- <0.001 
Pattern of joint swelling:  
Palindromic arthritis
 
Monoarthritis (SJC=1) 
Oligoarthritis (SJC=2-4)  
Polyarthritis (SJC>4) 
 
0  
11 (29%) 
18 (47%) 
9 (24%) 
- 
 
1 (1%) 
17 (9%) 
65 (33%) 
114 (58%) 
- <0.001 
Symmetrical joint swelling
 
13 (34%) - 137 (70%) - <0.001 
RF positive 
ACPA positive 
2 (5%) 
3 (8%) 
- 
- 
137 (70%) 
135 (69%) 
- 
- 
<0.001 
<0.001 
Fulfilment of 1987 ACR RA 
classification criteria
 4 (11%) - 130 (66%) - <0.001 
Early Morning Stiffness ≥60 min 17 (45%) - 148 (75%) - <0.001 
TJC28                                                                 
SJC28                                                                 
4 (2-6) 
2 (1-4)
- 
- 
8 (4-14) 
5 (3-9) 
- 
- 
<0.001 
<0.001 
RAI                                                                      
SJC44                                                                 
4 (2-6)
2 (1-4)
- 
- 
8 (4-10) 
5 (3-10) 
- 
- 
<0.001 
<0.001 
CRP, mg/L 7 (0-22) - 14 (0-38) - 0.03 
Patient VASDA, mm  45 (25-68) 8 50 (26-71) 40 0.03 
DAS28-CRP                                                3.8(3.0-4.5) 8 4.8(3.7-5.7) 40 <0.001 
DAS44-CRP                                                   2.4(1.7-2.9) 8 3.1(2.4-3.7) 40 <0.001 
HAQ                                                                    0.3(0.1-0.9) 6 1.1(0.5-1.6) 34 <0.001 
Ultrasound of 26 joints: 
Number of joints GS≥grade 1 
Number of joints GS≥grade 2 
             Total GS score
 
Number of joints PD≥grade 1 
Total PD score
 
 
7 (4-10) 
2 (1-5) 
10 (5-17) 
1 (0-1) 
1 (0-2) 
- 
 
11 (7-14) 
6 (3-9) 
18 (11-26) 
2 (0-4) 
3 (0-8) 
- 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Ultrasound erosion (in PIP2-3, 
MCP2-3, wrists or MTP2-4) 
4 (11%) - 87 (44%) - <0.001 
Radiographic erosion in the 
hands and feet:                     Any 
1987 ACR definition 
2010 ACR/EULAR definition
 
 
3 (8%) 
1 (3%) 
- 
 
- 
 
31 (16%) 
20 (10%) 
15 (8%) 
 
- 
 
0.2 
0.2 
0.1 
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6.4.3 Inflammation 
6.4.3.1 Clinical synovitis 
Figure 4 illustrates the frequency of joint involvement determined by clinical 
examination (swelling and/or tenderness) in patients with UA and RA. There was 
predominance for clinical involvement of the small joints in the hands in both 
groups. Clinical swelling was detected in at least one MCP or PIP joint in 
26/38 (68%) patients with UA and 173/197 (88%) patients with RA (p=0.001). A 
further four (11%) patients with UA and 13 (7%) patients with RA had tenderness 
without swelling of at least one of these joints.  
 
In patients lacking any swelling of the small joints of the hands, swelling was most 
frequently detected at the following sites: wrists (4/12 patients with UA and 17/24 
patients with RA), knees (4/12 patients with UA and 5/24 patients with RA), MTPs 
(2/12 patients with UA and 4/24 patients with RA), ankles (2/12 patients with UA 
and 3/24 patients with RA), elbows (1 patient with UA) and shoulders (1 patient with 
RA). Joint swelling was less frequently symmetrical in patients with UA (34%) in 
comparison to patients with RA (70%, p<0.001), although this may be expected due 
to the greater number of swollen joints present in the latter group.
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Figure 4. Percentage of patients with clinical swelling and/or tenderness detected in at least one joint per joint site, in patients with A) UA and 
B) RA. 
A)  Clinical Findings in Patients with UA at baseline.
 
 
 
 
B) Clinical Findings in Patients with RA at baseline. 
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6.4.3.2 Synovitis detected by ultrasound 
The majority of patients demonstrated significant ultrasound synovitis (GS≥grade 2 
and/or PD≥grade 1) within the 26 joints examined. This was present in at least one 
of the 26 joints in 32/38 (84%) patients with UA and 184/197 (93%) patients with 
RA. A further three (8%) patients with UA and 12 (6%) patients with RA 
demonstrated GS=grade 1 only. 
 
The location of ultrasound synovitis was similar between patients with UA and RA 
(Figures 5 and 6). There was preponderance for the presence of ultrasound 
synovitis at the MTPs, wrists and MCPs in both groups. The proportion of patients 
in which ultrasound synovitis was detected in at least one of these joints, in patients 
with UA and RA, respectively, was as follows: MTP2 (50% and 66%), MTP1 (37% 
and 59%), MTP3 (39% and 56%), MTP4 (34% and 45%), wrists (29% and 55%), 
MCP2 (16% and 46%) and MCP3 (18% and 39%). Ultrasound synovitis at MTP5 
was observed exclusively in patients with RA. 
 
Ultrasound synovitis was symmetrical (significant synovitis observed bilaterally in at 
least one joint site, i.e. bilateral involvement of the elbows, wrists, MCPs, PIPs, 
knees, ankles or MTPs) in 18 (47%) of patients with UA and 153 (78%) of patients 
with RA. A number of patients had symmetry at the MTPs alone (10 [26%] patients 
with UA and 49 [25%] patients with RA), whilst eight (21%) of patients with UA and 
104 (53%) of patients with RA demonstrated symmetry in at least one other joint 
site.
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Figure 5. Percentage of patients with ultrasound (US) synovitis (GS≥grade 2 and/or PD≥grade 1) affecting at least one joint on bilateral 
ultrasound examination in patients with A) UA and B) RA.  
 
 
A) Ultrasound Synovitis in Patients with UA at baseline. 
 
 
 B) Ultrasound Synovitis in Patients with RA at baseline. 
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Power Doppler was most frequently observed in association with significant GS 
synovitis (Table 19). The distributions of GS and PD findings are depicted in 
Figure 6. The frequency of GS synovitis was the major contributing factor to the 
high prevalence of ultrasound synovitis observed at MTPs2-4. In contrast, the 
prevalence of PD was approximately similar to the prevalence of GS synovitis at the 
wrists and MCPs2-3, at the patient level. Power Doppler was most commonly 
observed at the wrists, MCPs2-3 and MTP1.  
 
 Relationship between GS and PD synovitis, at the joint level (n=6110 Table 19.
joints). 
  PD Activity 
  Absent (grade 0) Present (≥grade 1) 
GS Synovitis 
Absent (grade 0) 3708 6 
Grade 1 only 897 128 
Significant (≥grade 2) 897 474 
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Figure 6. Percentage of patients with GS and PD affecting at least one joint on bilateral ultrasound examination in patients with A) UA and 
B) RA. 
 
A) Ultrasound Findings in Patients with UA at baseline. 
 
 
 
B) Ultrasound Findings in Patients with RA at baseline. 
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6.4.3.3 Concordance between clinical and ultrasound examination for 
the detection of synovitis 
Of 6110 joints examined both clinically and by ultrasound, 913 were clinically 
swollen. Of these swollen joints, significant ultrasound synovitis was demonstrated 
in 439 (48%) joints. Grade 1 GS changes without PD were observed in a further 
113 (12%) joints. Amongst non-swollen joints (n=5197), significant ultrasound 
synovitis was detected in 1066 (21%) joints. Tenderness on clinical examination 
was detected in only 259/1066 (24%) of these joints.  
 
At the patient level, subclinical synovitis (GS≥grade2 and/or PD≥grade1 in the 
absence of clinical swelling) was observed in at least one joint in 28/38 (74%) 
patients with UA and 177/197 (90%) patients with RA (p=0.006). The median (IQR) 
number of joints with subclinical synovitis was 2 (0-4) and 5 (2-7) in patients with 
UA and RA, respectively (p=0.001). The distribution of subclinical synovitis in 
patients with UA and RA was similar (Figure 7); subclinical synovitis was most 
prevalent at the MTP joints, followed by the wrists. 
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Figure 7. Frequency of synovitis detectable by clinical examination (swelling) and ultrasound (GS≥grade 2 and/or PD≥grade 1), at the joint level, 
in patients with A) UA and B) RA. 
   A)  Clinical and Ultrasound Findings in Patients with UA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
    B)  Clinical and Ultrasound Findings in Patients with RA. 
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6.4.4 Erosions 
6.4.4.1 Radiography 
Erosions were detected on x-ray in three (8%) and 31 (16%) patients with UA and 
RA, respectively. Fifteen (8%) patients with RA had erosive disease to constitute 
classification as erosive RA according to the EULAR definition (van der Heijde et 
al., 2013); all fifteen also fulfilled the 2010 ACR/EULAR RA classification criteria 
regardless of x-ray findings, in line with the intended high specificity for this 
definition (van der Heijde et al., 2013). The commonest sites for erosions detectable 
by x-ray were: the wrists (n=16), MTP5 (n=13), MTP2 (n=8), MTP3 (n=7) and 
MCP2-3 (n=6). 
 
In joints of the hands and feet examined exclusively by radiography, erosions were 
observed at MTP1 (n=3), MCP4 (n=2), MCP5 (n=2), PIP4 (n=2), MCP1 and PIP5 
(each n=1). Of note, all patients with x-ray erosions in joints of the hands and feet 
examined exclusively by radiography also displayed x-ray erosions in joints 
evaluated by both methods, except for a single patient with UA with bilateral x-ray 
erosions at MTP1 only.  
 
6.4.4.2 Ultrasound 
Ultrasound of 18 joints (wrists, MCPs2-3 and MTPs2-5) detected at least one 
erosion in four (11%) and 87 (44%) patients with UA and RA, respectively. Only one 
patient with UA and 20 (10%) patients with RA demonstrated ultrasound erosions in 
at least three joints included in the EULAR definition of erosive RA. Erosions 
detectable by ultrasound were most frequently observed at MTP5 (n=48), MCP2 
(n=32), wrists (n=22) and MCP3 (n=12), see Figure 8. 
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6.4.4.3 Concordance between radiography and ultrasound for the 
detection of erosion 
Of 4230 joints evaluated for erosions by both radiography and ultrasound, erosions 
were detected exclusively by radiography in 54 (1.3%) joints, exclusively by 
ultrasound in 215 (5%) joints and by both modalities in 39 (0.9%) joints. Erosions 
were demonstrated in a greater number of joints with ultrasound than with x-ray at 
all sites examined with exception of MTPs2-4 (Figure 8). 
 
At the patient level, amongst patients with UA, erosive disease was demonstrated 
by radiography alone in one (3%) patient, ultrasound alone in two (5%) patients and 
both modalities in a further two (5%) patients. Amongst patients with RA, erosive 
disease was detected by radiography alone in five patients (3%), ultrasound alone 
in 61 (31%) patients and both imaging methods in 26 (13%) patients.
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Figure 8. Percentage of patients with erosion detected by x-ray and/or ultrasound in at least one joint on bilateral imaging (at sites examined by 
both modalities), in patients with A) UA and B) RA. 
 
 
A)  Distribution of Erosions in Patients with UA at baseline.
 
 
 
B) Distribution of Erosions in Patients with RA at baseline. 
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6.4.5 ‘Active’ Erosions 
At the patient level, amongst patients with erosive disease visible on x-ray, 
ultrasound synovitis (GSgrade 2 and/or PDgrade 1) was observed in association 
with at least one radiographically-defined erosive joint in 27/34 (79%) patients (2/3 
patients with UA and 25/31 patients with RA). In patients with ultrasound-detected 
erosive disease, concomitant ultrasound synovitis was observed in at least one 
ultrasound-defined erosive joint in 61/91 (67%) (4/4 patients with UA and 57/87 
patients with RA). 
 
At the joint level, ultrasound synovitis was evident in 30/52 (58%) joints with 
erosions detected by radiography alone, 78/142 (55%) joints with erosions detected 
by ultrasound alone, and 28/37 (76%) with erosions detectable by both methods. 
The distribution of erosions observed in association with concomitant ultrasound 
synovitis was similar to the distribution of joints affected by any erosion (Figure 9), 
with exception of PIP2-3s and MTP5, which were proportionately more frequently 
affected by erosion without associated ultrasound synovitis. 
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Figure 9. Number of joints with erosions detectable by x-ray and/or ultrasound, in all patients with UA and RA: A) any erosion and B) ‘active’ 
erosion, i.e. erosion detected by x-ray or ultrasound with ultrasound synovitis (GS≥grade 2 and/or PD≥grade 1) in the same joint.
A) Distribution of Erosion in All Patients with IA. 
 
 
 
 
B) Distribution of ‘Active’ Erosions in All Patients with IA.
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6.4.6 Reclassification of IA with use of ultrasound in the application of 
the 2010 ACR/EULAR RA criteria 
Of 38 patients with UA, defined according to the 2010 ACR/EULAR RA criteria with 
joint involvement determined by clinical examination alone, consideration of 
ultrasound synovitis changed disease classification to RA in four (11%) patients 
(joint involvement defined by clinical swelling and/or tenderness and/or ultrasound 
synovitis, UA→RAclinical +US). Only one patient also demonstrated sufficient 
ultrasound synovitis on ultrasound examination of 24 joints (excluding MTP1 as 
stipulated by the criteria) to fulfil criteria with joint involvement determined solely by 
ultrasound synovitis irrespective of clinical findings (UA→RAUS).  
 
Forty-seven (24%) patients with RA (fulfilling the 2010 criteria on the basis of 
clinical examination) did not demonstrate sufficient ultrasound synovitis within the 
relevant 24 joints examined by ultrasound, to fulfil the criteria with joint involvement 
determined by ultrasound alone (reclassified as RA→UAUS). 
 
6.4.7 Performance of the 2010 ACR/EULAR RA criteria to discriminate 
patients with erosive disease at baseline, with joint involvement 
determined clinically or by ultrasound 
Of the four patients with UA whose disease was reclassified as UA→RAclinical+US, 
x-ray erosions were observed in one patient (25%); erosions were observed at both 
wrists. Ultrasound erosions were also only observed in this one patient; it was in 
this patient that ultrasound erosions were detected in at least three joints included 
in the EULAR definition of erosive RA.  
 
Amongst patients for whom the diagnosis of UA did not change (UA→UAclinical+US, 
n=34), erosions were detected by x-ray in two (6%) patients and by ultrasound in 
three (9%) patients, all of whom had less than three erosive joints detectable by 
either method. No statistically significant difference was identified in the rate of 
x-ray or ultrasound erosion between patients with UA→RAclinical+US and 
UA→UAclinical+US (p=0.3 and p=0.4 for comparisons in the rate of x-ray and 
ultrasound erosions, respectively). 
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In the singular patient with UA (determined clinically) demonstrating sufficient 
ultrasound synovitis to fulfil criteria with joint involvement determined solely by 
ultrasound synovitis, irrespective of the findings of clinical examination (UA→RAUS), 
no erosions were observed by either x-ray or ultrasound. No statistical tests were 
conducted due to low numbers (n=1) in this group. 
 
Amongst the majority of patients with RA in whom classification of IA did not 
change (RA→RAUS), erosions were detected on x-ray in 27/150 (18%) and by 
ultrasound in 73/150 (49%) patients. Erosions were less frequent amongst the 
47 patients reclassified as UA (RA→UAUS); erosions were detected by x-ray in 
4/47 (9%) and ultrasound in 14/47 (30%) patients (p=0.1 and p=0.02 for 
comparisons in the rates of x-ray and ultrasound erosion between patients with 
RA→RAUS and RA→UAUS, respectively). 
 
6.5 Discussion 
This study is the first to depict several aspects of the imaging phenotypes of 
patients with early UA and RA, defined according to the 2010 ACR/EULAR RA 
criteria, in a large, true inception cohort. It confirms the presence of significant 
levels of subclinical ultrasound synovitis and ultrasound erosion, and is the first 
description of the concept of ‘active’ erosion. Further analyses in subsequent 
chapters aim to determine the prognostic significance of these parameters. 
 
Clinical characteristics of patients with UA in this study appear similar to those 
previously described in IA cohorts with retrospective application of the 2010 RA 
criteria, including the Leiden (Krabben et al., 2012; Krabben et al., 2013a), 
Birmingham (Cader et al., 2011; Krabben et al., 2013a) and Amsterdam 
(Britsemmer et al., 2011; Krabben et al., 2013a) EAC cohorts. Low rates of ACPA-
positivity and slight female predominance were also reported in these studies 
(Britsemmer et al., 2011; Cader et al., 2011; Krabben et al., 2012; Krabben et al., 
2013a). Whilst a similarly high frequency of small joint involvement in the hands has 
been observed in some cohorts (Cader et al., 2011; Krabben et al., 2012; Krabben 
et al., 2013a), others have demonstrated greater involvement of larger joints and 
the lower extremities (Britsemmer et al., 2011; Krabben et al., 2013a). Differences 
may be reflective of different inclusion criteria; for example, greater swollen joint 
195 
 
 
counts were observed the latter study which required the presence of at least two 
swollen joints. It should be noted that prior to the publication of the ACR/EULAR 
definition of erosive disease, which is sufficient to fulfil 2010 RA classification 
criteria (in the context of a compatible history) (van der Heijde et al., 2013), typical 
erosions have been defined inconsistently in the application of the criteria in these 
previous studies. 
 
As expected, the burden of synovitis was significantly lower in patients with UA, in 
comparison to patients fulfilling 2010 RA criteria at presentation. Of note, the sites 
affected by synovitis (clinically and on ultrasound) appeared similar to patients with 
RA, within the limitations of the clinical and ultrasound examinations performed. 
There was predominance for small joint involvement in both groups; in particular, 
MCP and PIP involvement was prominent clinically and MTP involvement was 
predominant on ultrasound examination. However, the higher prevalence of SpA 
features in patients with UA suggests a possible difference in disease pathogenesis 
between these groups, at least in a subset of patients. In comparison to other early 
IA cohorts, a relatively low number of patients (n=15) progressed to non-RA 
diagnoses within one year (excluded from these analyses). Divergence in disease 
phenotypes may have become apparent with longer follow-up. It is also likely that 
additional patients with features of non-RA arthritides, such as SpA or connective 
tissue disease, were triaged and followed-up in specific SpA and connective tissue 
disease clinics, as discussed previously (section 5.5). 
 
This study confirms the discordance between the clinical and ultrasound 
assessment of synovitis identified previously in patients with early IA (Wakefield et 
al., 2004; Salaffi et al., 2008; Funck-Brentano et al., 2009; Filer et al., 2011; 
Nakagomi et al., 2013). Of these studies, perhaps the most similar in terms of the 
included cohort was the ESPOIR study which reported a similar rate of 
ultrasound-detectable synovitis, occurring in 52% of clinically swollen joints and 
26% of clinically non-swollen joints (Funck-Brentano et al., 2009). A high 
prevalence of subclinical synovitis was identified in our data (observed in at least 
one joint in three-quarters of patients with UA and 90% of patients with RA), 
consistent with rates of subclinical GS observed in an earlier UA study (Wakefield 
et al., 2004). Although their ultrasound assessment was restricted to ten joints per 
patient (MCPs2-5 and MTP5 bilaterally) and joints with GS=grade 1 alone were 
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included in their definition of ultrasound synovitis. The distribution of subclinical 
synovitis (MTPs most frequently affected, followed by wrists) is in accordance with 
other early IA cohorts reporting distribution of findings, in which wrists (Nakagomi et 
al., 2013) and MTPs followed by wrists (Filer et al., 2011) were similarly identified 
as the most affected sites. This is with exception of the low prevalence of 
subclinical synovitis observable at the large joints in our study in comparison to 
these two studies. Possible explanations again include the incorporation of 
GS=grade 1 within the definition of ultrasound synovitis (Filer et al., 2011; 
Nakagomi et al., 2013), as well as inclusion of non-RA patients and restriction to 
patients with symptoms less than three months (including crystal arthropathy and 
early seronegative spondyloarthropathy, for example) in the latter study (Filer et al., 
2011). 
 
This Leeds data also verifies the greater sensitivity of ultrasound for the detection of 
erosion in comparison to x-ray, previously reported in RA (Wakefield et al., 2000; 
Klocke et al., 2001; Szkudlarek, M. et al., 2003; Weidekamm et al., 2003; 
Szkudlarek et al., 2004; Scheel et al., 2006; Szkudlarek et al., 2006; Bajaj et al., 
2007; Sheane et al., 2009). Ultrasound of 18 joints detected erosive disease in 
approximately three times the number of patients in whom erosive disease was 
detected by conventional radiography of the hands and feet, consistent with other 
studies in patients with early IA. Amongst patients with synovitis of at least one 
joint, ultrasound erosions at MTP5 were reported in 17/30 (57%) patients (versus 
presence of x-ray erosions in 23%), appreciating a proportion of patients had prior 
DMARD exposure and the mean duration of symptoms was 15 months (Sheane et 
al., 2009). In ESPOIR, on bilateral ultrasound examination of MCP2-5 and MTP5, 
ultrasound erosions were observed in 42/114 (37%) patients (versus x-ray erosions 
in 11% of patients, when read in the usual manner) (Funck-Brentano et al., 2009).  
 
Our data demonstrate MTP5 as the commonest site for erosions identifiable by 
sonography, consistent with studies in patients with RA (Hulsmans et al., 2000; 
Klocke et al., 2001; Lopez-Ben et al., 2004; Szkudlarek et al., 2004; Funck-
Brentano et al., 2009; Tămaş et al., 2014; Zayat et al., 2015). Indeed, a recent 
study including patients with polyarticular osteoarthritis and healthy controls, 
confirms erosions at MTP5 are relatively specific to patients with IA, in particular 
patients with RA (Zayat et al., 2015). A greater number of erosive joints were 
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observed with ultrasound in comparison to x-ray at all sites examined with 
exception of MTPs2-4, possibly explained by reduced ultrasound visualisation of 
these joints, consistent with previous studies (Szkudlarek et al., 2004). 
 
Previous cross-sectional studies have reported an association between subclinical 
ultrasound synovitis and ultrasound erosion in patients with established RA on 
treatment (Kawashiri et al., 2014a; Vreju et al., 2016; Kawashiri et al., 2017). Data 
from ESPOIR suggests the concomitant finding of both synovitis and erosion on 
ultrasound may be specific to patients with IA, with this combination of findings 
being absent from joints of healthy controls (Millot et al., 2011). However, the 
concept of ‘active’ erosion, and the prevalence of such, has not previously been 
reported in patients with early, DMARD-naïve IA. In our study, the majority of 
erosive joints identified by ultrasound were ‘active’, i.e. associated with concomitant 
ultrasound synovitis. The proportion of ultrasound erosions associated with 
ultrasound synovitis was similar to the proportion of erosive joints detected by x-ray 
which were affected by concomitant ultrasound synovitis. This suggests the 
potential relevance of ‘active’ ultrasound erosions to disease assessment in early 
IA.  
 
A small proportion of patients with UA (n=4, 11%) received a revised diagnosis with 
consideration of ultrasound synovitis, in addition to clinical findings, in determining 
the joint involvement score within the 2010 RA criteria. Amongst patients with RA, 
fulfilling the 2010 criteria clinically, fulfilment of the criteria using the standardised 
ultrasound of 24 joints alone to determine joint involvement score (irrespective of 
clinical findings) was associated with a higher rate of ultrasound erosion. A previous 
study addressing the use of ultrasound within the criteria (defining joint involvement 
as GSgrade 2 and/or PDgrade 1) reported reclassification of disease in 7/69 
(10%) of patients with UA and 17/40 (43%) of patients with RA (as determined 
clinically) (Nakagomi et al., 2013). Differences in study methods included use of a 
more extensive 38-joint ultrasound examination, which may not always be feasible 
in clinical practice, and inclusion of patients without clinical joint swelling within their 
definition of UA. 
 
This study highlights the challenges of data collection in a clinical practice setting, 
with a number of patients being excluded from the analysis due to incomplete data 
198 
 
 
(particularly ultrasound data). Patients excluded due to missing data were more 
likely to be younger, score less for clinical joint involvement within the 2010 criteria 
and have a lower burden of swollen joints. Results may therefore be skewed 
towards patients with more extensive disease. A potential explanation may be the 
non-attendance for ultrasound examination due to time pressures in younger 
patients (plausibly more likely to have work or childcare commitments) and the 
perceived importance of the examination (likely to be reduced in patients with less 
severe disease). Other limitations, inherent to the use of ultrasound, include the 
inability to differentiate low-grade changes of synovitis relevant to IA from changes 
associated with osteoarthritis, or even normal findings in healthy individuals. In 
particular, GS and PD findings at the first MTPs and PD at the wrists may be 
particularly unreliable, as evidenced by a recent study of 30 healthy controls: 
GS≥grade 2 was observed in 32% of the first MTPs (19/60 joints) and PD≥grade 1 
or greater was observed in 28% (17/60) of the first MTPs and 42%(25/60) wrists 
(Kitchen and Kane, 2015). Other strengths and limitations of this study are detailed 
in the main discussion (Chapter 10). 
 
Further research is needed to determine the predictive value of ultrasound findings 
in determining the future disease course. There is a need to assess the prognostic 
implications of several prevalent findings in patients with early IA which have been 
identified here, including: ultrasound-detectable synovitis, ultrasound erosions, 
‘active’ ultrasound erosions and reclassification of IA with inclusion of ultrasound 
synovitis in the application of the 2010 ACR/EULAR RA criteria. 
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 : One-Year Outcomes for Patients with New-Onset Chapter 7
UA and RA, Defined According to the 2010 ACR/EULAR 
Criteria.  
What are the prognostic implications of 
ultrasound-detectable synovitis and erosions? 
7.1 Introduction 
A window of opportunity is recognised in early IA in which effective treatment 
permits the attainment of optimal outcomes (section 2.4). There is an ongoing need 
to establish effective biomarkers to predict disease persistence and response to 
treatment to avoid potentially detrimental delays in the initiation of effective 
treatment (Combe et al., 2017; Smolen et al., 2017). 
 
The 2010 ACR/EULAR RA classification criteria were recently developed in order to 
provide a means of identifying patients with IA who are likely to benefit from 
methotrexate, early in their disease course (Aletaha, D. et al., 2010). Retrospective 
application of the 2010 RA criteria across several early IA cohorts has shown they 
offer greater sensitivity, in comparison to the 1987 ACR RA criteria, in 
discriminating patients for various RA outcomes (Table 2, section 2.1.3). 
Meta-analyses of such studies report pooled sensitivity and specificity of the order 
of 80% and 60% respectively for the identification of disease requiring DMARDs 
(Sakellariou, G. et al., 2013; Radner et al., 2014). This suggests a risk of 
misclassifying a proportion of patients with RA under the current criteria. In addition, 
there may be a proportion of patients with UA in whom early intervention may also 
be beneficial.  
 
Furthermore, there is limited data concerning the natural history/progression of 
disease in patients with UA or RA (determined by 2010 RA criteria) in contemporary 
real-life cohorts. Hence, there is a need to determine modern-day disease 
outcomes for these patients, as well as methods for predicting which of these 
patients are likely to have persistent or progressive disease. 
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Ultrasound has been identified as a potential additional tool for determining which 
patients may benefit from early treatment. The prognostic value of ultrasound 
synovitis to predict radiographic joint damage has been demonstrated in patients 
with established RA with active disease commencing TNF-inhibitors (Dougados et 
al., 2013) as well as in patients in clinical remission (Brown et al., 2008) (section 
2.3.2.1). 
 
Studies investigating the prognostic value of ultrasound in the prediction of 
outcomes amongst patients with early IA are now beginning to emerge, suggesting 
the significance of GS synovitis (Freeston et al., 2010; Filer et al., 2011; Nakagomi 
et al., 2013; Pratt et al., 2013) and PD (Freeston et al., 2010; Salaffi et al., 2010; 
Filer et al., 2011; Kawashiri et al., 2013; Nakagomi et al., 2013). The outcomes 
studied have included persistence of disease (Freeston et al., 2010; Pratt et al., 
2013), the requirement for DMARDs (Kawashiri et al., 2013) or methotrexate 
(Nakagomi et al., 2013), progression to fulfilment of 1987 ACR RA criteria (Salaffi et 
al., 2010; Filer et al., 2011) and radiographic progression (Funck-Brentano et al., 
2013). However, these studies have largely been conducted in heterogeneous 
patient groups, including patients without any clinical evidence of joint swelling 
(Freeston et al., 2010; Kawashiri et al., 2013; Nakagomi et al., 2013; Pratt et al., 
2013) and patients with various types of IA including those with non-RA diagnoses 
(Filer et al., 2011). Furthermore, outcomes such as disease progression to 
fulfilment of the1987 RA criteria and radiographic progression may be insufficiently 
sensitive in early disease (Banal et al., 2009). Other limitations of these existing 
studies have been discussed in section 2.3.2.1.  
 
Evidence for the prognostic validity of ultrasound erosions, or the predictors of 
progression in ultrasound-detectable erosive damage, is especially lacking (section 
2.3.2.3). To date, knowledge of the predictors of new ultrasound erosions is limited 
to a small study of single joint ultrasound in patients with established RA only 
(Reynolds et al., 2009). 
 
In particular, the preceding Chapter (Chapter 6) described two characteristics of 
disease, discernible by ultrasound, which warrant further exploration in terms of 
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determining their prognostic significance. These include fulfilment of the 2010 
ACR/EULAR RA classification criteria using ultrasound in the determination of joint 
involvement, and presence of ‘active’ ultrasound erosions.  
  
7.2 Aims and Objectives 
 To determine the one year outcomes of patients with new-onset, DMARD-naïve 
IA (specifically UA or RA, classified according to the 2010 ACR/EULAR RA 
criteria). 
 To include the presence of severe and/or persistent IA, progression to RA in 
patients with UA, need for triple DMARD or biologic therapy in patients with RA 
and progression in ultrasound erosive change at one year. 
 To determine the clinical and imaging features of disease which may be useful 
in predicting these outcomes, including the following features of disease 
measureable by ultrasound: fulfilment of the 2010 RA criteria with joint 
involvement determined by ultrasound, ultrasound erosions and ‘active’ 
erosions.  
 
7.3 Methods  
A prospective, observational study was conducted in patients with new-onset, UA 
and RA presenting to the Leeds EAC as previously described (Chapter 4). 
 
7.3.1 Assessments 
Clinical and imaging assessments were defined as per sections 4.2 and 4.3. 
Reclassification of patients using ultrasound synovitis alone to determine the score 
for joint involvement in the application of the 2010 ACR/EULAR RA criteria was 
ascertained as per section 6.3.1. The reclassification of UA patients according to 
fulfilment of the 2010 RA criteria considering both clinical and ultrasound signs of 
synovitis (UA→UAclinical+US or UA→RAclinical+US) was not assessed here due to the 
small number of patients receiving a revised diagnosis by this approach in the total 
cohort (section 6.4.6). 
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7.3.2 Outcomes 
These have been described in section 4.5. 
 
7.3.3 Statistics 
In order to assess the utility of clinical and imaging parameters in the prediction of 
clinical outcomes, univariable logistic regression analyses were conducted in 
patients grouped according to clinical fulfilment of the 2010 ACR/EULAR RA 
classification criteria. As follow-up imaging data was available in a smaller number 
of patients, analysis of imaging outcomes was conducted in all patients with IA 
(either UA or RA) at baseline (i.e. without grouping into UA and RA subgroups). The 
following baseline variables were selected due to their known or likely association 
with treatment choice, disease persistence and erosion progression: 
 Age. 
 Gender. 
 Symptom duration. 
 ACPA-positivity. 
 Duration of early morning stiffness. 
 Clinical disease activity variables: RAI, SJC44, CRP, patient VASDA and 
DAS44-CRP. These were selected over TJC28, SJC28 and DAS28-CRP 
due to their potential to be more reflective of disease activity in patients with 
UA and/or limited joint involvement. 
 HAQ score. 
 Ultrasound parameters (section 4.3):  
o total GS score,  
o total PD score,  
o number of joints with significant ultrasound synovitis (GS≥grade 2 
and/or PD≥grade 1),  
o presence of any ultrasound erosion,  
o presence of any ‘active’ ultrasound erosion,  
o fulfilment of 2010 ACR/EULAR RA classification criteria, with joint 
involvement determined by ultrasound examination, assessed as a 
dichotomous variable (rather than criteria score) to reflect its 
intended use. 
 Presence of any radiographic erosion. 
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Multivariable logistic regression analyses were conducted to assess whether 
ultrasound measures of synovitis (total GS score, total PD score and the number of 
joints with significant ultrasound synovitis) were associated with outcomes, with 
adjustment for the likely confounder clinical disease activity (as measured by 
SJC44 or DAS44-CRP). Further multivariable logistic regression analyses for 
outcomes at the patient level were not attempted, due to the inadequate number of 
patients in the outcome categories to enable inclusion of all relevant variables. 
 
To determine the implications of clinical swelling and ultrasound synovitis on the 
development of ultrasound erosion at the joint level, conditional logistic regression 
(stratifying for patient case) was conducted in joints lacking evidence of either 
radiographic or ultrasound erosion at baseline. Two models were planned; firstly, 
considering the presence of any significant ultrasound synovitis (GS≥grade 2 and/or 
PD≥grade 1) and secondly, considering the presence of significant GS (≥grade 2) 
and PD (≥grade 1) as separate variables in order to assess the independent 
contribution of either finding to the prediction of new ultrasound erosion. 
 
7.3.3.1 Missing data 
Methods for handling missing data have been described previously (section 4.6.1). 
Patients with incomplete clinical, ultrasound and/or x-ray data at baseline and 
patients lacking any clinical follow-up data (no re-attendance within 12 months) 
were excluded. In the analyses of imaging outcomes, patients lacking ultrasound 
data at 12 months were excluded. 
 
7.4 Results 
7.4.1 Patients 
Of 441 patients with suspected new-onset IA, screened for inclusion in the 
observational study, 333 patients were eligible for inclusion in these analyses 
(Figure 10). A further 95 patients were excluded due to incomplete clinical and 
imaging data at baseline and/or lack of any follow-up data. 
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Baseline characteristics are shown in Tables 20 and 21: 41 and 197 patients were 
classified as UA or RA according to 2010 RA criteria (with joint involvement score 
determined by clinical assessment). No significant differences were observed 
between all patients included in the analysis of clinical outcomes (n=238) and those 
excluded due to missing data (n=95). Whereas, patients included in the analysis of 
imaging outcomes (n=144) differed significantly (p<0.05) from those excluded due 
to missing data (n=189) in age (greater mean age was observed amongst included 
patients), measures of disease activity (incidence of significant early morning 
stiffness, RAI, DAS44-CRP, total GS score and number of joints with ultrasound 
synovitis were all lower in included patients) and HAQ score (lower in included 
patients) (Table 21).  
 
Figure 10. Disposition of patients registered in the longitudinal prospective 
observational study and included in the analysis of clinical and imaging 
outcomes. 
 
 
 
 
seline 
 
 
 
 
 
 
 
 
 
Suspected IA  
n=441 
Included in analysis of 
clinical outcomes 
n=238 
Incomplete joint assessments at baseline n=85 
- Missing ultrasound data (n=77) 
- Missing x-ray data (n=7) 
- Incomplete clinical joint examination (n=55) 
 
No clinical follow-up data available n=14 
- Enrolled in biologics clinical trial (n=11) 
- Not attending (n=2) 
- Died (n=1) 
 
Eligible for inclusion 
(new-onset UA or RA at 
baseline)  
n=333 
Included in analysis of 
imaging outcomes 
n=144 
Missing US data at one year n=94 
 
- No clinical joint swelling n=52 
- Declined consent n=18 
- Not re-attending for baseline visit n=11 
- Alternative diagnosis (diagnoses other than 
RA or UA) at baseline n=24 
- Other reason for missing all baseline data n=3 
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 Baseline characteristics of patients with new-onset UA and RA included Table 20.
in the analysis of clinical outcomes, and those excluded due to 
incomplete data.  
Values are median (IQR) or n (%) unless otherwise stated. 
 Included 
Excluded 
n=95 
All 
Included 
vs. 
Excluded 
(p value) 
 
UA 
n=41 
RA 
n=197 
All  
n=238 
Age, mean (SD) 45 (15) 56 (13) 54 (14) 52 (15) 0.1 
Female 27 (66%) 136 (69%) 163 (68%) 72 (76%) 0.2 
Symptom duration, 
months 
9 (4-18) 7 (4-13) 7 (4-14) 8 (4-13) 0.9 
ACPA positive 3 (7%) 131 (66%) 134 (56%) 57 (60%) 0.5 
Fulfilment of 2010 
ACR/EULAR RA 
criteria with joint 
involvement 
determined 
clinically
 
- 100% 197 (83%) 76 (80%) 0.6 
Early Morning 
Stiffness ≥60 min 
19 (46%) 147 (75%) 166 (70%) 72 (76%) 0.3 
RAI                                                                      
SJC44                                                                 
3 (2-6)
2 (1-5)
8 (4-10) 
5 (3-10) 
6 (3-10)  
5 (2-8) 
6 (3-11)
a
  
3 (2-8)
a 
0.6 
0.1 
CRP, mg/L 6 (0-22) 14 (0-37) 13 (0-32) 12 (0-28) 0.7 
Patient VASDA, 
mm  
45 (25-68)
b 
53 (27-73)
c
 50 (26-71)
d 
49 (25-76)
e 
0.9 
DAS44-CRP                                                    2.3 (1.8-2.9)
b 
3.1 (2.4-3.7)
c
 2.9 (2.3-3.5)
d 
2.9 (1.9-3.7)
f 
0.4 
HAQ                                                                    0.3 (0.1-0.9)
g 
1.1 (0.5-1.6)
h
 1.0 (0.4-1.6)
i 
1.0 (0.4-1.7)
j 
1.0 
US of 26 joints: 
Total GS score 
9 (5-17) 18 (11-26) 16 (9-25) 14 (12-23)
k 
1.0 
Total PD score 1 (0-2) 3 (0-8) 2 (0-6) 1 (0-4)
k
 0.2 
Number of joints  
GS≥2 and/or PD≥1 
2 (1-6) 6 (3-10) 6 (2-9) 5 (4-8)
k
 0.9 
Fulfilment of 2010 
ACR/EULAR RA 
criteria with joint 
involvement 
determined by US 
findings (RAUS) 
1 (2%) 147 (75%) 148 (62%) 10 (56%)
k 
0.6 
US erosion (PIP2-
3, MCP2-3, wrists 
or MTP2-4) 
4 (10%) 88 (45%) 92 (39%) 5 (28%)
k
 0.4 
‘Active’ US erosion 4 (10%) 58 (29%) 62 (26%) 3 (17%)
k
 0.6 
Radiographic 
erosion in the 
hands and feet                     
 
3 (7%) 31 (16%) 34 (14%) 14 (16%)
l 
0.7 
Missing data in a55, b8, c40, d48, e54 f25, g6, h33, i39, j55, k77 and l7 cases: 
percentages are number of patients/number of patients with complete data.  
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 Baseline characteristics of all patients with new-onset UA and RA Table 21.
included in the analysis of imaging outcomes, and those excluded due 
to incomplete data.  
Values are median (IQR) or n (%) unless otherwise stated. 
 Analysis of imaging outcomes 
 Included 
n=144 
Excluded 
n=189 
p 
Age, mean (SD) 56 (14) 52 (14) 0.002 
Female 103 (72%) 132 (70%) 0.7 
Symptom duration, months 7 (4-14) 7 (4-13) 0.4 
ACPA positive 91 (63%) 100 (53%) 0.06 
Fulfilment of 2010 ACR/EULAR RA criteria with 
joint involvement determined clinically
 118 (82%) 155 (82%) 1.0 
Early Morning Stiffness ≥60 min 94 (65%) 144 (76%) 0.03 
RAI                                                                      
SJC44                                                                 
6 (3-10)  
4 (2-8) 
7 (4-11)
a 
5 (3-10)
a 
0.04 
0.07 
CRP, mg/L 11 (0-28) 13 (0-33) 0.3 
Patient VASDA, mm  47 (25-69)
b 
55 (25-77)
c 
0.1 
DAS44-CRP                                                    2.7 (2.2-3.3)
b 
3.1 (2.4-3.8)
d 
0.005 
HAQ                                                                    0.9 (0.3-1.5)
e 
1.0 (0.5-1.6)
f 
0.04 
US of 26 joints:                             Total GS score 14 (8-23) 18 (12-26)
c
 0.008 
Total PD score 2 (0-6) 3 (0-7)
c
 0.3 
Number of joints  GS≥2 and/or PD≥1 5 (2-8) 6 (3-11)
c
 0.01 
Fulfilment of 2010 ACR/EULAR RA criteria with 
joint involvement determined by US (RAUS) 
89 (62%) 69 (62%)
c 
1.0 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 51 (35%) 46 (41%)
c
 0.4 
‘Active’ US erosion 31 (22%) 34 (30%)
c
 0.1 
Radiographic erosion in the hands and feet                     
 
17 (12%) 31 (17%)
g 
0.2 
Missing data in a55, b25, c77, d87, h39, e22, f72 and g7 cases: percentages are 
number of patients/number of patients with complete data.  
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7.4.2 Clinical outcomes at one year 
7.4.2.1 Methotrexate Initiation and Disease Persistence 
Clinical data were available at one year in 202 patients, and were carried forward 
from last assessments in 36. Reasons for missing data at one year in the latter 
were: non-attendance (n=17), enrolment in biologics drug trials (n=10), moving out 
of the area (n=1), pregnancy (n=1), death (n=1) or unknown (n=6).  
 
Outcomes are illustrated in Figure 11. Over one year, 18/41 (44%) patients with UA 
and 162/197 (82%) patients with RA, at baseline, ever received methotrexate. 
Persistent IA at one year was observed in 29 (71%) and 181 (92%) patients with 
UA and RA, respectively. This consisted of patients receiving DMARDs (24 [59%] 
patients with UA and 170 [86%] patients with RA), patients receiving recent or 
concurrent steroids without DMARD therapy (4 [10%] patients with UA and 11 [6%] 
patients with RA) and one patient with UA with swollen joints without concurrent use 
of DMARDs or recent steroid exposure. This latter patient had a history of 
palindromic PIP swelling, with two swollen, non-tender, PIP joints on clinical 
examination at one year. 
 
Of the remaining patients, progression to an alternative diagnosis (diagnoses other 
than UA or RA) was observed in three (7%) patients with UA and ten (5%) patients 
with RA at baseline. The alternative diagnoses were: gout (n=3), inflammatory 
osteoarthritis (n=3), psoriatic arthritis (n=2), connective tissue disease (n=2), 
ANA-associated arthralgia (n=1) and other non-inflammatory joint pain (n=1). 
Non-persistent IA at one year (i.e. absence of swollen joints without DMARD or 
corticosteroid exposure within the preceding three months) was observed in nine 
patients with UA (22%); five patients never received DMARD or corticosteroid 
treatment, one patient had received methotrexate, one had received sulfasalazine 
and two patients had received corticosteroids alone over follow-up. Amongst 
patients with RA at baseline, six had non-persistent disease (3%); three never 
received DMARD/corticosteroid treatment, one received methotrexate and two 
received corticosteroids alone over follow-up. 
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Figure 11. Outcomes at one year in patients with UA and RA at baseline. 
 
7.4.2.2 Progression to RA and Need for Triple DMARD or Biologic 
Therapy for the Treatment of RA 
Of 41 patients with UA at baseline, nine (22%) progressed to fulfil 2010 RA criteria 
over one year. Five of these patients received methotrexate (commenced prior to 
progression in three and after progression in two). Of 197 patients with RA at 
baseline, 27 (14%) required escalation to triple DMARD therapy or received biologic 
therapy over the course of one year. 
 
7.4.3 Predictors of Clinical Outcome 
7.4.3.1 Undifferentiated Arthritis 
Clinical variables which demonstrated statistically significant associations with 
outcome were patient VASDA, which associated with use of methotrexate, and RAI 
and functional disability (HAQ score) which were associated with progression to RA 
(Tables 22 and 23). 
 
The requirement for methotrexate, persistence of IA and progression to RA were all 
significantly associated with total GS score (Tables 22 and 23). Progression to RA 
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was also associated with greater number of joints with significant ultrasound 
synovitis (GS≥grade 2 and/or PD≥grade 1). These ultrasound parameters remained 
significantly associated with outcome after adjustment for swollen joint count. Only 
the association between total GS score and disease persistence lost statistical 
significance after adjustment for DAS44-CRP.  
 
All patients with x-ray erosions at baseline received methotrexate within one year 
and had persistent IA. All patients with ultrasound evidence of erosion had 
persistent IA at one year. Progression to RA did not occur in any of the three 
patients with ACPA-positivity at baseline, one of whom received methotrexate. 
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 Association between baseline characteristics and the requirement for methotrexate and persistence of IA at one year in patients with Table 22.
UA at baseline. 
Values are median (IQR) or n (%) unless otherwise stated. 
 Ever Received Methotrexate Persistent IA
 
Yes   n=18 No   n=23 OR (95%CI) p Yes   n=29 No   n=12 OR (95%CI) p 
Age, mean (SD) 46 (14) 43 (16) 1.01 (0.97-1.05) 0.6 46 (16) 41 (13) 1.02 (0.97-1.07) 0.4 
Female 12 (67%) 15 (65%) 1.07 (0.29-3.92) 0.9 19 (66%) 8 (67%) 0.95 (0.23-3.94) 0.9 
Symptom duration, months 15 (5-26) 6 (3-14) 1.06 (0.99-1.13) 0.09 13 (4-23) 5 (3-10) 1.08 (0.99-1.18) 0.1 
ACPA positive 1 (6%) 2 (9%) 0.62 (0.05-7.41) 0.7 3 (10%) 0  NA NA 
Early Morning Stiffness ≥60 min 7 (39%) 12 (52%) 0.58 (0.17-2.04) 0.4 13 (45%) 6 (50%) 0.81 (0.21-3.13) 0.8 
RAI                                                                      4 (3-6) 3 (1-6) 1.14 (0.88-1.47) 0.3 4 (3-6) 3 (1-6) 1.23 (0.91-1.67) 0.2 
SJC44                                                                 3 (1-4) 2 (1-5) 0.98 (0.75-1.28) 0.9 2 (1-4) 2 (1-8) 0.87 (0.66-1.16) 0.3 
CRP, mg/L 9 (0-28) 6 (0-17) 1.01 (0.99-1.03) 0.3 7 (0-28) 3 (0-9) 1.04 (0.98-1.11) 0.2 
Patient VASDA, mm  64 (38-74)
a 
30 (17-60)
b 
1.03 (1.00-1.07) 0.04 49 (26-71)
c 
26 (17-59)
c 
1.02 (0.98-1.05) 0.3 
DAS44-CRP                                                    2.2 (2.0-2.6)
a 
2.1 (1.5-2.7)
b 
1.90 (0.64-5.66) 0.2 2.2 (1.8-2.7)
c 
1.9 (1.6-2.5)
c 
2.21 (0.67-7.35) 0.2 
HAQ                                                                    0.5 (0.1-0.9)
b 
0.3 (0.1-0.8)
b 
1.06 (0.30-3.78) 0.9 0.5 (0.0-0.9)
d 
0.3 (0.2-0.6)
c 
1.91 (0.33-11.0) 0.5 
US synovitis:             Total GS score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
12 (9-18) 7 (2-12) 
1.13 (1.02-1.26) 
1.14 (1.02-1.26) 
1.12 (1.01-1.25) 
0.02 
0.02 
0.04 
11 (7-18) 6 (3-10) 
1.13 (1.00-1.27) 
1.14 (1.00-1.30) 
1.09 (0.96-1.23) 
0.05 
0.04 
0.2 
Total PD score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
0 (0-2) 1 (0-2) 
1.00 (0.69-1.46) 
1.00 (0.69-1.46) 
1.03 (0.67-1.61) 
1.0 
1.0 
0.9 
0 (0-2) 1 (0-2) 
1.03 (0.68-1.56) 
1.04 (0.69-1.59) 
0.94 (0.57-1.56) 
0.9 
0.8 
0.8 
Number of joints GS≥2 and/or PD≥1 (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
3 (2-7) 1 (1-4) 
1.20 (0.98-1.47) 
1.20 (0.98-1.48) 
1.23 (0.97-1.55) 
0.08 
0.08 
0.09 
3 (1-7) 1 (1-3) 
1.26 (0.95-1.67) 
1.27 (0.95-1.70) 
1.17 (0.88-1.56) 
0.1 
0.1 
0.3 
Fulfilment of 2010 ACR/EULAR RA criteria with 
joint involvement determined by US (RAUS) 
1 (6%) 0 NA NA 1 (3%) 0 NA NA 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 2 (11%) 2 (9%) 1.31 (0.17-10.4) 0.8 4 (14%) 0 NA NA 
‘Active’ US erosion 2 (11%) 2 (9%) 1.31 (0.17-10.4) 0.8 4 (14%) 0 NA NA 
Radiographic erosion in the hands and feet                     
 
3 (17%) 0 NA NA 3 (10%) 0 NA NA 
NA: logistic regression not performed. Missing data in a5, b3, c4 and d2 cases.  
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 Association between baseline characteristics and progression to RA in patients with UA at baseline. Table 23.
Values are median (IQR) or n (%) unless otherwise stated. 
 Progression to RA
 
Yes 
n=9 
No 
n=32 
OR (95%CI) p 
Age, mean (SD) 42 (15) 44 (15) 1.02 (0.97-1.07) 0.5 
Female 7 (78%) 20 (63%) 2.10 (0.37-11.8) 0.4 
Symptom duration, months 12 (5-29) 9 (4-18) 1.00 (0.97-1.04) 0.8 
ACPA positive 0 3 (9%) NA NA 
Early Morning Stiffness ≥60 min 5 (56%) 14 (44%) 1.61 (0.36-7.12) 0.5 
RAI                                                                      6 (3-8) 3 (2-6) 1.43 (1.02-2.01) 0.04 
SJC44                                                                 4 (1-6) 2 (1-4) 1.16 (0.85-1.57) 0.3 
CRP, mg/L 0 (0-10) 6 (0-22) 1.01 (0.99-1.03) 0.2 
Patient VASDA, mm  59 (33-75)
a 
45 (23-64)
b 
1.02 (0.99-1.05) 0.3 
DAS44-CRP                                                    2.8 (2.1-3.1)
a 
2.2 (1.9-2.6)
b 
3.21 (0.78-13.2) 0.1 
HAQ                                                                    0.9 (0.1-1.3) 0.3 (0.1-0.8)
c 
6.26 (1.11-35.4) 0.04 
US synovitis:             Total GS score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
16 (12-19) 8 (4-12) 
1.14 (1.02-1.27) 
1.14 (1.02-1.28) 
1.14 (1.01-1.29)  
0.02 
0.02 
0.04 
Total PD score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
0 (0-1) 1 (0-2) 
1.00 (0.64-1.57) 
0.99 (0.63-1.55) 
0.94 (0.59-1.52) 
1.0 
0.9 
0.8 
Number of joints GS≥2 and/or PD≥1 (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
7 (3-9) 1 (1-3) 
1.33 (1.05-1.68) 
1.33 (1.05-1.70) 
1.36 (1.03-1.80) 
0.02
0.02 
0.03 
Fulfilment of 2010 ACR/EULAR RA criteria with 
joint involvement determined by US  (RAUS) 
0 1 (3%) NA NA 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 2 (22%) 2 (6%) 4.29 (0.51-35.9) 0.2 
‘Active’ US erosion 2 (22%) 2 (6%) 4.29 (0.51-35.9) 0.2 
Radiographic erosion in the hands and feet                     
 
2 (22%) 1 (3%) 8.86 (0.70-112) 0.09 
NA: logistic regression not performed.   Missing data in a1, b7 and c6 cases.
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7.4.3.2 Rheumatoid Arthritis 
In patients fulfilling 2010 RA criteria (with joint involvement determined clinically) at 
baseline, ACPA-positivity was associated with methotrexate use and persistent IA 
(Table 24). Both clinical (SJC44) and ultrasound evidence of synovitis (total PD) 
were significantly associated with methotrexate use. Total PD was associated with 
methotrexate use independently of SJC44 or DAS44-CRP. Two patients with x-ray 
detectable erosions never received methotrexate; one patient was treated with 
sulfasalazine and hydroxychloroquine, in whom methotrexate was contraindicated. 
In the other, joint swelling resolved after corticosteroid therapy.  
 
Patients who demonstrated sufficient ultrasound synovitis to also fulfil the 2010 RA 
criteria with joint involvement determined solely by ultrasound examination were 
more likely to have received methotrexate and have persistent IA at one year. 
 
The requirement for triple DMARD or biologic therapy within one year was 
associated with greater disease activity at baseline as indicated by several 
measures including: significant early morning stiffness, RAI, SJC44, CRP, 
DAS44-CRP, total GS score, total PD score and number of joints with significant 
ultrasound synovitis. In line with this, greater HAQ score, fulfilment of the 2010 RA 
criteria when defining joint involvement by significant ultrasound-detectable 
synovitis and higher incidence of ‘active’ erosion were also associated with this 
outcome (Table 25). 
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 Association between baseline characteristics and the requirement for methotrexate and persistence of IA at one year in patients with Table 24.
RA at baseline. 
        Values are median (IQR) or n (%) unless otherwise stated. 
 Ever Received Methotrexate Persistent IA
 
Yes 
n=162 
No 
n=35 
OR (95%CI) p 
Yes 
n=181 
No 
n=16 
OR (95%CI) p 
Age, mean (SD) 57 (13) 56 (16) 1.00 (0.97-1.03) 0.9 57 (13) 55 (17) 1.01 (0.97-1.05) 0.6 
Female 115 (71%) 21 (60%) 1.63 (0.77-3.48) 0.2 128 (71%) 8 (50%) 2.42 (0.86-6.77) 0.09 
Symptom duration, months 6 (4-13) 9 (6-17) 0.99 (0.97-1.01) 0.2 7 (4-13) 12 (6-20) 0.99 (0.97-1.02) 0.6 
ACPA positive 116 (72%) 15 (43%) 3.36 (1.59-7.13) 0.002 126 (70%) 5 (31%) 5.04 (1.67-15.2) 0.004 
Early Morning Stiffness ≥60 min 123 (76%) 24 (69%) 1.45 (0.65-3.22) 0.4 137 (76%) 10 (63%) 1.87 (0.64-5.43) 0.3 
RAI                                                                      
SJC44                                                                 
8 (4-11) 
5 (3-11) 
7 (4-9) 
4 (2-7) 
1.04 (0.96-1.12) 
1.12 (1.02-1.23) 
0.3 
0.02 
7 (4-10) 
5 (3-10) 
8 (2-12) 
4 (2-7) 
1.01 (0.92-1.12) 
1.08 (0.96-1.22) 
0.8 
0.2 
CRP, mg/L 14 (0-39) 14 (0-27) 1.00 (0.99-1.01) 0.5 14 (0-39) 8 (0-18) 1.02 (0.99-1.04) 0.1 
Patient VASDA, mm  54 (28-74)
a 
48 (18-72)
b 
1.01 (0.99-1.02) 0.3 53 (27-72)
c 
50 (22-75)
d 
1.01 (0.99-1.03) 0.5 
DAS44-CRP                                                    3.1 (2.5-3.7)
a 
2.8 (2.3-3.4)
b 
1.50 (0.95-2.36) 0.08 3.1 (2.5-3.7)
c 
2.7 (2.2-3.7)
d 
1.51 (0.84-2.72) 0.2 
HAQ                                                                    1.1 (0.5-1.6)
e 
1 (0.4-1.7)
f 
1.07 (0.60-1.91) 0.8 1.1 (0.5-1.6)
g 
0.8 (0.4-1.3)
h 
1.79 (0.80-3.98) 0.2 
US synovitis:             Total GS score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
18 (11-26) 14 (7-24) 
1.03 (0.99-1.07) 
1.01 (0.97-1.05) 
1.38 (0.85-2.24) 
0.1 
0.5 
0.2 
18 (11-26) 15 (7-20) 
1.03 (0.98-1.08) 
1.01 (0.96-1.07) 
1.41 (0.75-2.65) 
0.3 
0.6 
0.3 
Total PD score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
4 (0-9) 2 (0-3) 
1.14 (1.03-1.26) 
1.12 (1.01-1.24) 
1.13 (1.01-1.26) 
0.009 
0.03 
0.04 
3 (0-8) 2 (0-5) 
1.07 (0.96-1.20) 
1.06 (0.94-1.19) 
1.40 (0.74-2.61) 
0.2 
0.4 
0.3 
Number of joints GS≥2 and/or PD≥1 (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
6 (3-10) 5 (1-10) 
1.07 (0.99-1.17) 
1.04 (0.95-1.14) 
1.09 (0.98-1.22) 
0.1 
0.4 
0.1 
6 (3-10) 5 (1-9) 
1.06 (0.94-1.20) 
1.06 (0.94-1.21) 
1.06 (0.93-1.22) 
0.3 
0.3 
0.4 
Fulfilment of 2010 ACR/EULAR RA criteria with joint 
involvement determined by US  (RAUS) 
129 (80%) 18 (51%) 3.69 (1.72-7.94) 0.001 140 (77%) 7 (44%) 4.39 (1.54-12.5) 0.006 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 71 (44%) 17 (49%) 0.83 (0.40-1.72) 0.6 81 (45%) 7 (44%) 1.04 (0.37-2.92) 0.9 
‘Active’ US erosion 50 (31%) 8 (23%) 1.51 (0.64-3.55) 0.3 55 (30%) 3 (19%) 1.89 (0.52-6.90) 0.3 
Radiographic erosion in the hands and feet                     
 
29 (18%) 2 (6%) 3.60 (0.82-15.8) 0.09 29 (16%) 2 (13%) 1.34 (0.29-6.19) 0.7 
Missing data in a31, b9, c38, d2, e26, f7, g32 and h1 cases.  
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 Association between baseline characteristics and the need for triple DMARD therapy or biologic therapy in patients with RA at Table 25.
baseline. 
         Values are median (IQR) or n (%) unless otherwise stated. 
 Need for Triple DMARD Therapy or Biologic Therapy
 
Yes 
n=27 
No 
n=170 
OR (95%CI) p 
Age, mean (SD) 55 (13) 57 (13) 0.99 (0.96-1.02) 0.5 
Female 21 (78%) 115 (68%) 1.67 (0.64-4.38) 0.3 
Symptom duration, months 6 (4-13) 7 (4-14) 0.99 (0.95-1.03) 0.6 
ACPA positive 22 (81%) 109 (64%) 2.46 (0.89-6.83) 0.08 
Early Morning Stiffness ≥60 min 25 (93%) 122 (72%) 4.92 (1.12-22.6) 0.04 
RAI                                                                      10 (7-15) 7 (4-10) 1.12 (1.04-1.20) 0.002 
SJC44                                                                 8 (4-16) 5 (3-9) 1.14 (1.06-1.23) 0.001 
CRP, mg/L 29 (9-92) 13 (0-32) 1.01 (1.00-1.02) 0.01 
Patient VASDA, mm  62 (47-94)
a 
50 (25-70)
b 
1.02 (1.00-1.04) 0.02 
DAS44-CRP                                                    3.7 (3.0-4.8)
a 
3.0 (2.4-3.5)
b 
2.44 (1.50-3.95) <0.001 
HAQ                                                                    1.6 (1.4-2.2)
c 
1.0 (0.4-1.5)
d 
3.91 (1.90-8.04) <0.001 
US synovitis:               Total GS score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
26 (18-36) 16 (10-25) 
1.07 (1.03-1.11)  
1.05 (1.01-1.10)  
1.07 (1.02-1.13) 
<0.001 
0.01 
0.004 
Total PD score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
7 (2-15) 3 (0-6) 
1.09 (1.04-1.15)  
1.06 (1.00-1.12)  
1.08 (1.01-1.16) 
0.001 
0.07 
0.03 
Number of joints GS≥2 and/or PD≥1 (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
10 (7-13) 6 (3-9) 
1.18 (1.08-1.29) 
1.13 (1.03-1.25) 
1.19 (1.06-1.33) 
<0.001 
0.009 
0.003 
Fulfilment of 2010 ACR/EULAR RA criteria with 
joint involvement determined by US (RAUS) 
25 (93%) 122 (72%) 4.92 (1.12-21.6) 0.04 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 13 (48%) 75 (44%) 1.18 (0.52-2.65) 0.7 
‘Active’ US erosion 13 (48%) 45 (26%) 2.58 (1.13-5.90) 0.02 
Radiographic erosion in the hands and feet                     
 
6 (22%) 25 (15%) 1.66 (0.61-4.51) 0.3 
NA: logistic regression not performed. Missing data in a4, b36, c3 and d30 cases.  
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7.4.4 Development of new ultrasound erosion at one year 
Ultrasound data was available for 144 patients at one year. Development of new 
ultrasound erosion, in at least one joint of 18 joints examined for erosions, was 
observed in 4/26 (15%) patients classified as UA and 25/118 (21%) patients 
classified as RA, clinically, at baseline. 
 
The majority of these patients developed new ultrasound erosion in only one joint 
(three patients with UA and 14 patients with RA). In patients with multiple new 
erosions, the number of joints with new erosions was as follows: 3 joints in one 
patient with UA, and 2 joints (n=9), 3 joints (n=1) and 4 joints (n=1) in patients with 
RA. At the joint level, this equated to a rate of development of ultrasound erosion, in 
joints lacking x-ray or ultrasound erosion at baseline, of 45/2469 (2%) joints. 
Additionally, new ultrasound erosions were observed in four joints with erosion 
previously visible on x-ray, but not ultrasound, at baseline; this occurred in four 
patients with RA, one of whom also demonstrated new ultrasound erosion in at 
least one other joint. 
 
7.4.4.1 Predictors of new ultrasound erosion 
 At the patient level 
Baseline characteristics of patients with or without the development of new 
ultrasound erosion are shown in Table 26. A significant difference was observed in 
age only.
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 Association between baseline characteristics and development of new ultrasound erosion at one year in patients with new-onset UA or Table 26.
RA. 
                   Values are median (IQR) or n (%) unless otherwise stated. New US Erosion 
Yes 
n=29 
No 
n=115 
OR (95%CI) p 
Age, mean (SD) 64 (14) 55 (13) 1.06 (1.02-1.09) 0.002 
Female 19 (66%) 84 (73%) 0.70 (0.29-1.67) 0.4 
Symptom duration, months 8 (4-16) 7 (4-14) 0.99 (0.96-1.03) 0.7 
ACPA positive 18 (62%) 73 (63%) 0.94 (0.41-2.18) 0.9 
Fulfilment of 2010 ACR/EULAR RA criteria with joint involvement determined clinically 25 (86%) 93 (81%) 1.48 (0.47-4.68) 0.5 
Early Morning Stiffness ≥60 min 22 (76%) 72 (63%) 1.88 (0.74-4.76) 0.2 
RAI                                                                      5 (3-8) 6 (3-10) 0.96 (0.86-1.06) 0.4 
SJC44                                                                 5 (3-9) 4 (2-7) 1.02 (0.94-1.12) 0.6 
CRP, mg/L 15 (6-41) 10 (0-27) 1.00 (0.99-1.01) 0.9 
Patient VASDA, mm  47 (27-66)
a 
48 (24-71)
b 
1.00 (0.98-1.02) 1.0 
DAS44-CRP                                                    2.6 (2.3-3.4)
a 
2.7 (2.0-3.3)
b 
1.12 (0.71-1.77) 0.6 
HAQ                                                                    0.9 (0.2-1.6)
c 
0.9 (0.3-1.4)
d 
1.01 (0.52-1.94) 1.0 
US synovitis:                                                                                Total GS score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
15 (10-23) 13 (7-23) 
1.01 (0.97-1.04) 
1.02 (0.92-1.13) 
0.99 (0.95-1.04) 
0.8 
0.7 
0.7 
Total PD score (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
5 (1-8) 1 (0-6) 
1.04 (0.98-1.11) 
0.98 (0.88-1.09) 
1.04 (0.61-1.76) 
0.2 
0.8 
0.6 
Number of joints GS≥2 and/or PD≥1 (unadjusted) 
Adjusted for SJC44 
Adjusted for DAS44-CRP 
6 (3-9) 5 (2-8) 
1.04 (0.95-1.13) 
1.01 (0.91-1.11) 
1.10 (0.67-1.82) 
0.4 
0.9 
0.7 
Fulfilment of 2010 ACR/EULAR RA criteria with joint involvement determined by US (RAUS) 22 (76%) 67 (58%) 2.25 (0.89-5.69) 0.09 
US erosion (PIP2-3, MCP2-3, wrists or MTP2-4) 10 (34%) 41 (36%) 0.95 (0.40-2.23) 0.9 
‘Active’ US erosion 7 (24%) 24 (21%) 1.21 (0.46-3.16) 0.7 
Radiographic erosion in the hands and feet                     
 
4 (14%) 13 (11%) 1.26 (0.38-4.18) 0.7 
Missing data in a1, b24, c5 and d17 cases.
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 At the joint level 
Conditional logistic regression was possible using data from the 29 patients who 
developed ultrasound erosion in at least one joint. Amongst these patients, data 
from 499 joints lacking any evidence of erosion (either on x-ray or ultrasound) at 
baseline were used in the analysis (Table 27). New ultrasound erosions were 
observed in 41 (8%) joints. After stratifying for patient case, OR (95% CI) for the 
development of new ultrasound erosion in the presence of clinical swelling or 
significant ultrasound synovitis (GS≥grade 2 and/or PD≥grade 1) at baseline were 
3.86 (1.80-8.30; p=0.006) and 1.90 (0.95-3.81; p=0.06), respectively. Considering 
the independent contributions of GS and PD (entering both variables in the 
models), PD predicted the development of new ultrasound erosion, independently 
of clinical swelling or GS; OR (95% CI) were 4.18 (1.59-11.0; p=0.004) for the 
presence of PD≥grade 1 and 1.72 (1.07-2.76; p=0.03) for PD score (grade 0-3).
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 Association of baseline measures of clinical and ultrasound synovitis with development of new ultrasound erosion, in the subgroup of Table 27.
joints lacking ultrasound or x-ray erosion at baseline (multivariable conditional logistic regression analysis, n=499 joints).  
Separate models were constructed to include: A) the presence of significant ultrasound synovitis (GS≥grade 2 and/or PD≥grade 1), 
B) the presence of significant GS (≥grade 2) and PD (≥grade 1) considered as separate categorical variables, and C) the GS and PD 
scores considered as continuous variables. 
 
A)  Association Between Ultrasound synovitis and New Erosion 
 
 
B)  Association Between GS and PD synovitis and New Erosion 
Baseline Variable OR (95% CI) p  Baseline Variable OR (95% CI) p 
Presence of clinical swelling 3.86 (1.80-8.30) 0.006  Presence of clinical swelling 2.36 (1.04-5.38) 0.04 
Presence of significant US synovitis 
(GS≥grade 2 and/or PD≥grade 1) 
2.03 (0.98-4.20) 0.06 
 Presence of GS≥grade 2 0.98 (0.41-2.34) 1.0 
 Presence of PD≥grade 1 3.76 (1.40-10.1) 0.009 
 
  
C)  Association Between Grade of GS and PD and New Erosion 
 
    
Baseline Variable OR (95% CI) p     
Presence of clinical swelling 2.39 (1.03-5.55) 0.04     
GS score (grade 0-3) 1.02 (0.67-1.57) 0.9     
PD score (grade 0-3) 1.72 (1.07-2.76) 0.03     
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7.5 Discussion 
This is the first study to demonstrate the predictive validity of ultrasound in 
DMARD-naїve UA and RA patients, defined by the 2010 ACR/EULAR RA criteria 
and treated in a contemporary clinical practice setting. It is also the first to assess 
predictors of progression to fulfilment of 2010 RA criteria and new ultrasound 
erosions on standardised ultrasound examination of several joints.  
 
Over half of patients with new-onset UA in this cohort had persistent disease. This 
is higher than that observed in patients with UA in earlier studies (Krabben et al., 
2013a), possibly reflecting the definition used for persistent disease (includes 
DMARD and/or recent corticosteroid use) and an increased awareness of the 
benefits of early therapy. A significant rate of progression to 2010 RA was also 
observed, higher than that reported in a previous UK study in which 10% of patients 
with very recent-onset UA progressed (Cader et al., 2011). This could be explained 
by the exclusion of patients with symptom durations over three months in this very 
early cohort.  
 
In patients with new-onset UA, greater GS synovitis was associated with the 
requirement for methotrexate, persistence of disease and progression to fulfilment 
of 2010 RA criteria. Progression to RA was also associated with a greater number 
of joints with significant ultrasound synovitis (GS≥grade 2 and/or PD≥grade 1). 
These associations remained statistically significant after adjustment for the burden 
of clinical synovitis. Power Doppler activity was infrequently observed in the 26-joint 
examination in this early UA cohort. When detected, it was not associated with 
outcome; the statistical power to detect a relationship being limited by the low levels 
of PD observed. Furthermore, only one patient with UA, not fulfilling RA criteria by 
clinical assessment, fulfilled the 2010 RA criteria with the use of standardised 
ultrasound assessment restricted to 26 joints (defining joint involvement by 
GS≥grade 2 and/or PD≥grade 1). Therefore, study of more extensive ultrasound 
assessments may be required to determine the most useful method for determining 
joint involvement by imaging within the 2010 RA criteria in this group. 
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The majority of patients clinically fulfilling the 2010 RA criteria in this cohort were 
treated with DMARD therapy (for the most part receiving methotrexate). This is in 
line with awareness of the benefits of early DMARD therapy in RA and knowledge 
of the 2010 criteria, which were applied prospectively in these patients. However, a 
small number of patients fulfilling the criteria demonstrated resolution of IA at one 
year or went on to receive alternative diagnoses. Total PD score (independent of 
clinical synovitis) was predictive of methotrexate initiation and fulfilment of the 2010 
criteria on ultrasound (defining joint involvement by significant ultrasound synovitis) 
was predictive of both methotrexate initiation and persistent disease, in this high 
risk group. In addition, all ultrasound measures of synovitis (total GS, total PD, 
number of joints with significant ultrasound synovitis and fulfilment of the 2010 
criteria on ultrasound) were associated with severe/refractory disease (defined by 
the need for triple DMARD or biologic therapy), independent of clinical measures of 
disease activity. 
 
Two recent studies investigating the prognostic validity of ultrasound in early IA 
patients (with at least one swollen joint) are available. Rates of progression to 
fulfilment of 1987 RA over 12-18 months were 42-50% (Salaffi et al., 2010; Filer et 
al., 2011). Independent predictors of progression included global GS and PD 
measures across 38 joints (independent of the Leiden prediction score) (van der 
Helm-vanMil et al., 2007; Filer et al., 2011) and the number of joints with 
PD≥grade 2 in the hands and wrists (independent of serological status, 
inflammatory markers and presence of early morning stiffness>30 minutes) (Salaffi 
et al., 2010). Implications for clinical practice are not immediately clear; particularly 
given the number of joints examined in calculating a global score and the use of the 
Leiden score undertaken in the former study (generally not used routinely in clinical 
practice) and that no adjustment was made for clinical evidence of synovitis in the 
latter study. Importantly, both of these studies included both patients with UA and 
RA (defined by 2010 RA criteria), therefore the predictive value of such ultrasound 
parameters over the clinical application of the 2010 criteria was not clear from their 
results. 
 
The study of imaging outcomes revealed a significant proportion of patients with 
new-onset UA and RA developed ultrasound erosion in joints previously lacking 
evidence of erosion at baseline. At the joint level, the association between new 
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ultrasound erosion and ultrasound synovitis (GS≥grade 2 and/or PD≥grade 1) did 
not reach significance with adjustment for the presence of clinical swelling. 
However, the presence of PD synovitis appeared to be a stronger predictor, being 
significantly associated with the development of ultrasound erosion independently 
of clinical swelling and GS synovitis. 
 
This is consistent with previous studies suggesting PD synovitis is predictive of 
radiographic progression amongst patients with early IA (Funck-Brentano et al., 
2013), early RA (Naredo et al., 2007; Pascual-Ramos et al., 2009; Fukae et al., 
2010) and established RA (Taylor et al., 2004; Naredo et al., 2008a; Dougados et 
al., 2013). However, several of these studies have been limited to univariable 
analyses (Taylor et al., 2004; Naredo et al., 2007; Brown et al., 2008; Fukae et al., 
2010), or have not adjusted for the burden of clinical synovitis within final prediction 
models (Naredo et al., 2008a; Foltz et al., 2012).  
 
The most convincing evidence to date is provided by a study of 59 patients with 
active RA (at least six swollen joints) requiring initiation or change of TNF-inhibitor 
therapy (Dougados et al., 2013). Both GS and PD were independently associated 
with radiographic progression at the joint level. Multivariable analyses included 
assessment of clinical synovitis and other relevant factors such as age and global 
disease activity, although not serology. The only data available in patients with early 
IA (including patients with UA and early RA defined by 2010 criteria) are from the 
ESPOIR cohort (Funck-Brentano et al., 2013). This study demonstrated 
associations between radiographic progression over one year (increase in SHS 
erosion score from baseline) and both PD (at MCPs2-5 and/or MTP5) and presence 
of ultrasound erosion (at MCP2, MCP5 and/or MTP5), at baseline. Adjustment was 
made for several relevant baseline factors including DAS28, serology and steroid 
use, although not for baseline radiographic score. Amongst joints lacking 
radiographic erosion at baseline, no association was observed with ultrasound 
measures of synovitis and new radiographic erosion on adjusted analyses. There 
was a non-significant trend towards association with ultrasound erosion at baseline. 
This may be related to the smaller number of joints examined by ultrasound in this 
study, and/or the difficulties of assessing new radiographic erosions in patients with 
early IA treated according to modern-day standards: new x-ray erosions developed 
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in only in 26/1091 (2%) joints at one year and only 13/93 (14%) patients, lacking 
x-ray erosive disease at baseline, at two years.  
 
The observational design of this study implies the results are generalisable to 
clinical practice; however, the results may be susceptible to confounding by 
indication bias. For example, presence of ultrasound synovitis (perceived by 
clinicians to be related to poor prognosis) may have affected the choice of 
treatment; greater ultrasound synovitis being expected to be associated with 
outcomes such as initiation of methotrexate and persistent IA (the definition of 
which includes DMARD use). However, the association of greater ultrasound 
synovitis with progression to RA and new ultrasound erosion supports the true 
prognostic validity of ultrasound; in patients with greater ultrasound synovitis 
DMARD use may be expected to be higher and therefore a lower rate of 
progression to RA or new ultrasound erosion may be predicted, rather than the 
higher rates that were observed. As noted in previous early arthritis inception 
cohorts, data (particularly baseline ultrasound parameters) were missing in a 
significant number of patients who were excluded from the analyses. However, 
comparing baseline characteristics between included and excluded patients for the 
main analysis of clinical outcomes did not identify any major differences between 
these groups. Differences observed between included and excluded patients for the 
analyses of imaging outcomes suggests that younger patients and those with 
greater disease activity at baseline were more likely to be excluded. This may be 
related to the proportion of patients who were subsequently referred to biologic 
DMARD clinical trials or received biologic DMARDs with follow-up in 
biologic-monitoring clinic in which standardised ultrasound did not form part of 
routine assessments. Excluding patients with greater disease activity suggests the 
rate of development of new ultrasound erosions in this analysis may be an 
under-estimate; however, age is known to be associated with an increased risk of 
joint erosion. 
 
Bearing these limitations in mind, the results suggest the prognostic value of 
ultrasound in the management of patients with early IA. In particular, the degree of 
GS appears to be a sensitive indicator of disease progression in DMARD-naїve 
patients with UA, whilst PD appears to be predictive of the development of new 
ultrasound erosion. 
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 : Use of Methotrexate in Patients with Early Chapter 8
Inflammatory Arthritis in Clinical Practice.  
Does response differ according to fulfilment of 2010 
ACR/EULAR RA classification criteria or ACPA status? 
8.1 Introduction 
Methotrexate is currently recommended as the first-line therapy in the management 
of RA (Smolen, Josef S et al., 2014). For patients with RA fulfilling 1987 ACR RA 
criteria, data from randomised controlled studies suggest up to one third of 
methotrexate-naïve patients with early disease achieve remission (defined by 
DAS28) with methotrexate monotherapy (Emery et al., 2008; Emery et al., 2009).  
 
More recently, clinical trials using methotrexate have been conducted in patients 
with early IA, including patients with UA and RA defined by the 2010 RA criteria 
(section 2.4) (Wevers-de Boer, K. V. C. et al., 2012; de Jong et al., 2013; Nam et 
al., 2014b). With the recognition that patients with UA may develop persistent and 
progressive disease (albeit with a lower propensity than those who fulfil the RA 
criteria) (Cader et al., 2011; Krabben et al., 2012; Krabben et al., 2013a), the need 
to establish the efficacy of therapies, including methotrexate, in these patients has 
been identified (Emery, P et al., 2010; Wevers-de Boer et al., 2013). Furthermore, 
there is evidence that the use of methotrexate in clinical practice may be suboptimal 
(Gaujoux-Viala et al., 2012). 
 
The variable response to methotrexate which is observed may be explained, at 
least in some part, by differences between patients in their disease pathogenesis. 
Amongst patients with RA, divergence in the pathogenic mechanisms of disease is 
becoming increasingly apparent between patients with seronegative and 
seropositive disease (section 2.1.1.2) (Hill et al., 2003; Huizinga et al., 2005; 
Irigoyen et al., 2005; Verpoort et al., 2005; van der Helm-van Mil et al., 2006; 
Sigurdsson et al., 2007; van Oosterhout et al., 2008; Ding et al., 2009; Cuthbert et 
al., 2010; Stahl et al., 2010; Law et al., 2012). Currently, data suggest methotrexate 
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may improve outcomes, including delaying disease progression, in patients with 
ACPA-positive UA (Emery et al., 2015), but be less effective or have a slower onset 
of action in ACPA-negative patients (van Dongen et al., 2007; Wevers-de Boer, K. 
V. C. et al., 2012; Nam et al., 2014b) (section 2.4.2.4). Further research is required 
to investigate this. 
 
8.2 Aims and Objectives 
To determine clinical response to methotrexate in patients with new-onset, 
DMARD-naive IA in clinical practice. In particular, to establish whether there is any 
difference in response according to serological status or fulfilment of the 2010 
ACR/EULAR RA classification criteria. 
 
8.3 Methods 
A prospective, observational study was conducted in patients with new-onset UA 
and RA (Chapter 4). Additional criteria for inclusion in these analyses were the 
commencement of methotrexate monotherapy as a first-line DMARD regimen within 
three months of baseline, presence of at least low disease activity at baseline 
(defined by DAS28-CRP based on 3 variables SJC28, TJC28 and CRP 
[DAS28-CRP3v≥2.6]) and continued use of methotrexate monotherapy for at least 
six weeks. Due to the frequency of missing SJC44, RAI and patient VASDA data at 
baseline, the eligibility for inclusion was based on DAS28-CRP3v to maximise the 
study population. A minimum of six weeks of therapy was considered necessary to 
assess response. Patients receiving an alternative non-RA diagnosis within six 
months were excluded.  
 
8.3.1 Outcomes 
The primary outcomes assessed were remission (DAS28-CRP3v<2.6) and EULAR 
response (based on DAS28-CRP3v) at six months after the commencement of 
methotrexate. The EULAR response was calculated from the level of disease 
activity at either baseline or the time of commencement of methotrexate, whichever 
time-point demonstrated the highest DAS28-CRP3v. This was deemed appropriate 
to allow for an expected reduction in disease activity with use of corticosteroids 
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which may have been administered prior to methotrexate in the instance of a delay 
in the commencement of methotrexate. Outcomes based on DAS28-CRP3v were 
selected over those based on disease activity scores using more extensive joint 
counts and patient VASDA measurements in order to minimise potential bias due to 
the frequency of missing data for these variables. 
 
Secondary outcomes at six months after the commencement of methotrexate were 
DAS28-CRP3v low disease activity (DAS28-CRP3v<3.2), Boolean remission 
(SJC44≤1, TJC53≤1, CRP≤10mg/dL and patient VASDA≤10mm) and change from 
baseline (or time of commencement of methotrexate, whichever time-point 
demonstrated the highest DAS28-CRP3v) in: swollen joint counts (SJC28 and 
SJC44), tender joint counts (TJC28 and RAI), CRP, DAS28-CRP3v, patient VASDA 
and HAQ score. 
 
8.3.2 Statistics 
Patients were grouped in two-ways, as follows: into UA and RA groups (according 
to clinical fulfilment of 2010 RA criteria) and into ACPA-negative and ACPA-positive 
IA groups. Differences between these groups, in baseline and treatment variables, 
were assessed using Chi-Squared or Fisher’s exact tests for categorical variables 
(as appropriate for numbers of expected values) or t-tests for continuous variables 
following a normal distribution. For non-parametric data Mann-Whitney-U testing 
was carried out. The differences in outcomes between the groups were evaluated 
using univariable logistic regression analysis. Wilcoxon signed-ranks tests for 
paired data were also used to determine whether there was any significant 
improvement in the secondary outcome measures from baseline. 
 
For primary outcomes, multivariable logistic regression models were also 
constructed. The following variables were entered into models due to their expected 
association with methotrexate response (Wevers-de Boer, K. V. C. et al., 2012): 
age, gender, symptom duration, baseline DAS28-CRP3v and either fulfilment of 
2010 RA criteria or ACPA status. Due to the high weighting of serological status 
within the 2010 RA criteria, separate models were constructed for fulfilment of the 
criteria and ACPA status to avoid errors that may be introduced by the inclusion of 
overlapping variables.  
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On the basis of clinical trial data suggesting approximately one third of patients may 
achieve DAS28 remission with methotrexate monotherapy (Emery et al., 2008; 
Emery et al., 2009; Wevers-de Boer, K. V. C. et al., 2012; de Jong et al., 2013), a 
sample of 150 patients was expected to be required to ensure these models were 
robust (i.e. 50 expected events, with 5 variables per model). Two sensitivity 
analyses were planned. Firstly, RF status was considered within the definition of 
seropositivity in the model, defining seropositivity as positivity for either ACPA or 
RF, or both. Secondly, patients receiving concomitant hydroxychloroquine were 
also included, due to the frequent use of methotrexate and hydroxychloroquine 
combination therapy in local clinical practice. 
 
8.3.3 Missing data 
For patients in whom primary outcome data were not available at six months after 
the commencement of methotrexate, data collected at the closest assessment 
within the preceding or following three months were used. Patients who were lost to 
follow-up were excluded. In the instance of either an adverse event necessitating 
the cessation of methotrexate or an inadequate response requiring the escalation of 
therapy, observations were carried forward from the time of cessation/escalation of 
therapy. 
 
8.4 Results 
8.4.1 Patients 
Of 333 DMARD-naïve patients with new-onset UA or RA identified in the 
observational study (Figure 3, section 6.4.1), 163 met the inclusion criteria for this 
analysis. Two further patients were excluded due to loss to follow-up (Figure 12). 
Characteristics at baseline are shown in Table 28.  
 
Patients with UA (n=19) differed significantly (p<0.05) from those with RA (n=142), 
at baseline. Age, rates of seropositivity, clinical disease activity measures and 
prevalence of radiographic erosion were all lower in patients with UA. At least one 
feature of SpA was also more likely to be recorded in patients with UA. Significant 
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differences were also identified between patients with ACPA-negative IA (n=57) 
and ACPA-positive patients (n=104). Positivity for ACPA was associated with an 
increased rate of RF-positivity, fulfilment of RA classification criteria and worse 
physical function (greater HAQ score). 
 
 
Figure 12. Disposition of patients registered in the longitudinal prospective 
observational study and included in the analysis of the efficacy of 
methotrexate. 
 
 
 
 
 
 
 
 
 
 
 
Eligible for inclusion 
n=163 
 
Exclusions n=170 
- Commenced alternative DMARD or  
  combination DMARD therapy first-line n=53 
- No DMARD commenced within 3 months of 
baseline n=42 
- Referred to biologic clinical trial n=17 
- Received alternative diagnosis within 6 
  months n=12 
- Baseline DAS28-CRP3v<2.6 n=16 
- Baseline DAS28-CRP3v not known n=2 
- Duration of MTX monotherapy <6 wks n=28 
 
New-onset UA or RA at 
baseline  
n=333 
Included in analysis  
n=161 
 
Loss to follow-up n=2 
- Died n=1 
- Not attending n=1 
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 Baseline characteristics of patients with UA and RA receiving methotrexate monotherapy first-line, with grouping according to fulfilment Table 28.
of 2010 ACR/EULAR RA criteria and ACPA status.  
                   Values are median (IQR) or n (%),  
                   unless otherwise stated. 
All patients 
n=161 
Grouped by fulfilment of 2010 RA criteria Grouped by ACPA status 
UA 
n=19 
RA 
n=142 
p 
Negative 
n=57 
Positive 
n=104 
p 
Age, mean (SD) 55 (15) 45 (14) 56 (15) 0.002 53 (15) 56 (15) 0.3 
Female 114 (71%) 11 (58%) 103 (73%) 0.2 37 (65%) 77 (74%) 0.2 
Symptom duration, months 7 (4-13) 9 (4-17) 7 (4-13) 0.3 7 (4-13) 7 (4-13) 0.9 
Current/previous smoker                                89 (56%)
a 
12 (67%)
b 
77 (55%)
b 
0.3 29 (52%)
b 
60 (58%)
b 
0.4 
Number of comorbidities:                                           1 
2 
3 
≥4 
49 (30%) 
29 (18%) 
19 (12%) 
8 (5%) 
4 (21%) 
2 (11%) 
3 (16%) 
1 (5%) 
45 (32%) 
27 (19%) 
16 (11%) 
7 (5%) 
0.5 
17 (30%) 
11 (19%) 
6 (11%) 
2 (4%) 
32 (31%) 
18 (17%) 
13 (13%) 
6 (6%) 
0.6 
History/current evidence of coexistent osteoarthritis 60 (37%) 4 (21%) 56 (39%) 0.1 21 (37%) 39 (38%) 0.9 
≥1 feature of SpA 12 (7%) 4 (21%) 8 (6%) 0.04 6 (11%) 6 (6%) 0.3 
RF positive 
ACPA positive 
102 (63%) 
104 (65%) 
2 (11%) 
1 (5%) 
100 (70%) 
103 (73%) 
<0.001 
<0.001 
15 (26%) 
- 
87 (84%) 
- 
<0.001 
- 
Fulfilment of RA classification criteria:  1987 ACR RA 
2010 ACR/EULAR RA
 
107 (66%) 
142 (88%) 
5 (26%) 
- 
102 (72%) 
- 
<0.001 
- 
32 (56%) 
39 (68%) 
75 (72%) 
103 (99%) 
0.04 
<0.001 
Early Morning Stiffness ≥60 min 126 (78%) 12 (63%) 114 (80%) 0.2 44 (77%) 82 (79%) 0.5 
TJC28 
SJC28 
8 (4-14)  
5 (2-9) 
4 (3-5)  
2 (1-4) 
8 (4-15)  
5 (3-10) 
<0.001 
<0.001 
8 (4-15)  
4 (2-8) 
8 (4-14)  
5 (3-9) 
1.0 
0.2 
RAI                                                                      
SJC44                                                                 
8 (4-11)
c
  
5 (3-11)
c 
5 (3-7)
d
  
2 (2-4)
d 
8 (4-11)
e
  
6 (3-12)
e 
0.04 
0.001 
8 (4-12)
f
  
5 (3-10)
f 
8 (4-10)
g
  
6 (3-12)
g 
0.7 
0.5 
Patient VASDA, mm 56 (30-79) 49 (28-69) 60 (31-80) 0.8 55 (26-71) 58 (33-80)
 
0.6 
CRP, mg/L 14 (0-38)
h 
14 (0-28)
i 
14 (0-39)
j 
0.5 18 (4-36)
k 
13 (0-43)
c 
0.4 
DAS28-CRP3v                                                    4.5 (3.7-5.5) 4.0 (3.1-4.5) 4.6 (3.7-5.7) 0.002 4.5 (3.8-5.5) 4.5 (3.6-5.5) 0.9 
DAS44-CRP3v 3.0 (2.3-3.6)
c 2.5 (2.2-2.8)
d 
3.1 (2.3-3.7)
e 
0.03 3.1 (2.3-3.7)
f 
3.0 (2.2-3.6)
g 
0.8 
HAQ                                                                    1.0 (0.5-1.6)
l 
0.9 (0.1-1.1)
l 
1.1 (0.5-1.6)
m 
0.07 0.9 (0.3-1.3)
k 
1.1 (0.5-1.8)
n 
0.03 
Radiographic erosion in the hands and feet                     
 
28 (18%)
o 1 (<1%)
b 
28 (20%)
a 
0.04 7 (13%)
a 
21 (20%)
b 
0.2 
Missing data in a2, b1, c38, d9, e29, f14, g24, h59, i10, j49, k21, l57, m47, n36 and o3 cases. 
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8.4.2 Management 
The majority of patients (134/161, 83%) commenced methotrexate at baseline 
(Table 29). Amongst the remaining patients (n=27) commencing methotrexate 
between one and three months after baseline, DAS28-CRP3v was greater at 
baseline than at methotrexate commencement (likely due to the use of 
corticosteroids) in all but two patients with ACPA-positive RA. For these two 
patients, variables at commencement of methotrexate, rather than baseline, were 
used in the determination of response. 
 
Cessation of methotrexate or escalation to combination DMARD therapy occurred 
in 67 patients at a median (IQR) time of 13 (10-16) weeks. Fourteen patients 
stopped methotrexate due to intolerance or an adverse event. The reasons 
reported were: nausea and/or vomiting (n=3), subjective breathlessness (n=2), 
diarrhoea, mouth ulcers, hair loss, rash, lower respiratory tract infection, general 
malaise, headache and visual disturbance (each n=1) or were unknown (n=1).  
 
Data were missing for DAS28-CRP3v assessment at six months in 14 patients, in 
whom data from the closest assessment between three and nine months were 
used. This gave a median (IQR) time on methotrexate monotherapy at outcome 
assessment for the total sample of 22 (14-26) weeks. 
 
A significantly greater number of patients with ACPA-positive IA escalated therapy 
in comparison to ACPA-negative patients. No other statistically significant 
differences in treatment were identified between patients with UA and RA, or 
ACPA-negative and ACPA-positive patients.
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 Management over six months in patients with UA and RA commencing methotrexate monotherapy first-line. Table 29.
Patients are grouped according to fulfilment of 2010 ACR/EULAR RA criteria and ACPA status. Values are median (IQR) or n (%). 
 All 
patients 
n=161 
Fulfilment of 2010 RA criteria ACPA status 
 UA 
n=19 
RA 
n=142 
p 
Negative 
n=57 
Positive 
n=104 
p 
Time from baseline to MTX commencement, months:  0  
1 
2 
3 
134 (83%) 
18 (11%) 
6 (4%) 
3 (2%) 
14 (74%) 
5 (26%) 
0 
0 
120 (85%) 
13 (9%) 
6 (4%) 
3 (2%) 
0.3 
45 (79%) 
9 (16%) 
0 
3 (5%) 
89 (86%) 
9 (9%) 
6 (6%) 
0 
0.3 
Stopping MTX due to adverse event  
Escalating treatment 
14 (9%) 
53 (33%) 
2 (11%) 
3 (16%) 
12 (8%) 
50 (35%) 
0.7 
0.09 
6 (11%) 
12 (21%) 
8 (8%) 
41 (39%) 
0.6 
0.02 
Time on MTX monotherapy at outcome assessment, 
weeks 
22 (14-26) 23 (13-29) 22 (14-26) 0.4 23 (15-26) 21 (13-26) 0.3 
Average weekly dose of MTX, mg 19 (15-20) 17 (15-20) 19 (15-20) 0.6 19 (15-20) 19 (15-20) 0.9 
Receiving significant total steroid dose:   
≥120mg methylprednisolone 
 ≥150mg prednisolone  
≥80mg triamcinolone 
 
110 (68%) 
37 (23%) 
11 (7%) 
 
12 (63%) 
3 (16%) 
0 
 
98 (69%) 
34 (24%) 
11 (8%) 
 
0.6 
0.6 
0.4 
 
42 (74%) 
10 (18%) 
5 (9%) 
 
68 (65%) 
27 (26%) 
6 (6%) 
 
0.3 
0.2 
0.5 
Total methylprednisolone dose, mg 120 (0-240) 120 (0-240) 120 (38-240) 0.5 120 (80-240) 120 (0-240) 0.4 
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8.4.3 Outcomes  
At a median (IQR) time of 22 (14-26) weeks on methotrexate, a total of 56 (35%) 
patients achieved DAS28-CRP3v remission, 66 (41%) achieved a good EULAR 
response and 111 (69%) achieved at least a moderate EULAR response. 
Remission, defined by DAS28-CRP3v<2.6, was observed in 8/19 (42%) patients 
with UA versus 48/142 (34%) patients with RA (p=0.5). Rates of good and 
moderate EULAR response were 7/19 (37%) and 11/19 (58%) in patients with UA, 
versus 59/142 (42%) and 100/142 (70%) in patients with RA (p=0.3 and p=0.7 
comparing rates of good and moderate EULAR responses, respectively). 
 
With grouping according to ACPA status, DAS28-CRP3v remission was achieved in 
16/57 (28%) patients with ACPA-negative disease versus 40/104 (38%) patients 
who were ACPA-positive (p=0.2). Good and moderate EULAR responses were 
observed in 21/57 (37%) and 37/57 (65%) patients with ACPA-negative disease 
versus 45/104 (43%) and 74/104 (71%) patients who were ACPA-positive (p=0.4 
comparing the rates of both good and moderate responses).  
 
Secondary outcomes are shown in Table 30. Change in SJC28 was statistically 
significantly lower in patients with UA versus patients with RA (p=0.04), however 
SJC28 at baseline was also lower amongst these patients. No statistically 
significant differences were identified in outcomes between ACPA-negative and 
ACPA-positive patients.  
 
Figures 13 to 16 illustrate improvement from baseline in the majority of outcome 
measures across the patient groups. No statistically significant improvement from 
baseline was observed in RAI and patient VASDA amongst patients with UA or 
patients with ACPA-negative disease. A significant improvement in HAQ score was 
also only observed in patients with RA. Of note, missing data precluded analysis of 
these outcomes in a subset of patients.  
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 Outcomes in patients receiving methotrexate monotherapy at follow-up (median 22, IQR 14-26 weeks) according to fulfilment of 2010 Table 30.
ACR/EULAR RA criteria and ACPA status (univariable logistic regression analyses).  
Values are median (IQR) and n (%). 
 
All patients 
n=161 
Fulfilment of 2010 RA criteria ACPA status 
 UA 
n=19 
RA 
n=142 
OR (95% CI) p 
Negative 
n=57 
Positive 
n=104 
OR (95% CI) p 
DAS28-CRP3v 
Remission 
(DAS28-CRP3v<2.6) 
56 (35%) 8 (42%) 48 (34%) 0.70 (0.26-1.86) 0.5 16 (28%) 40 (38%) 1.60 (0.80-3.22) 0.2 
DAS28-CRP3v Low 
Disease Activity 
(DAS28-CRP3v<3.2) 
85 (53%) 12 (63%) 73 (51%) 0.62 (0.23-1.66) 0.3 29 (51%) 56 (54%) 1.13 (0.59-2.15) 0.7 
EULAR Response 
(based on 
DAS28-CRP3v):   Good 
Moderate 
 
 
66 (41%) 
111 (69%) 
 
 
7 (37%) 
11 (58%) 
 
 
59 (42%) 
100 (70%) 
 
 
1.22 (0.45-3.28) 
1.73 (0.65-4.61) 
 
 
0.7 
0.3 
 
 
21 (37%) 
37 (65%) 
 
 
45 (43%) 
74 (71%) 
 
 
1.31 (0.67-2.54) 
1.33 (0.67-2.66) 
 
 
0.4 
0.4 
Boolean Remission 
(SJC44≤1, TJC53≤1, 
CRP≤10mg/dL, 
VASDA≤10mm)           
9 (8%)
a 
2 (17%)
b 
7 (7%)
c 
0.39 (0.07-2.16) 0.3 3 (8%)
d 
6 (9%)
e 
1.14 (0.27-4.85) 0.9 
Change from baseline:           
SJC28 
 
3 (1-6) 
 
1 (1-3) 
 
3 (1-7) 
 
1.12 (1.00-1.26) 
 
0.04 
 
3 (1-5) 
 
3 (1-6) 
 
1.01 (0.95-1.09) 
 
0.7 
TJC28 3 (0-9) 2 (0-4) 4 (0-10) 1.06 (0.99-1.13) 0.1 3 (0-10) 4 (0-8) 1.00 (0.96-1.04) 0.9 
SJC44 3 (1-7)
f 
2 (1-3)
g 
3 (1-8)
h 
1.10 (0.97-1.26) 0.1 3 (1-9)
i 
3 (1-6)
j 
0.99 (0.92-1.07) 0.9 
RAI 2 (-1-6)
f 
2 (0-3)
g 
2 (-1-6)
h 
1.03 (0.91-1.16) 0.7 1 (-3-6)
i 
2 (0-6)
j 
1.02 (0.95-1.10) 0.6 
CRP, mg/dL 8 (0-29) 7 (0-21) 8 (0-30) 1.01 (0.99-1.02) 0.5 8 (0-28) 8 (0-30) 1.00 (0.99-1.01) 0.7 
Patient VASDA, mm 8 (-10-33)
k 
-2 (-16-18)
l 
8 (-6-38)
m 
1.01 (0.99-1.04) 0.3 15 (-15-26)
n 
6 (-5-41)
o 
1.00 (0.99-1.02) 0.6 
HAQ score 0.1 (-0.1-0.4)
p 
0.3 (-0.6-0.7)
l 
0.1 (-0.1-0.4)
q 
1.15 (0.37-3.58) 0.8 0.3 (-0.1-0.4)
r 
0 (-0.1-0.5)
s 
1.00 (0.51-1.97) 1.0 
Missing data in a53, b7, c46, d18, e35, f52, g9, h43, i16, j36, k82, l13, m69, n31, o51, p90, q77, r34 and s56 cases. 
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Figure 13. Boxplots of: A) SJC28, B) TJC28, C) SJC44, and D) RAI, at baseline and follow-up (median 22, IQR 14-26 weeks) in patients grouped 
according to fulfilment of 2010 ACR/EULAR RA criteria. 
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Figure 14. Boxplots of: A) CRP level, B) DAS28-CRP3v, C) patient VASDA and D) HAQ score, at baseline and follow-up (median 22, IQR 14-26 
weeks) in patients grouped according to fulfilment of 2010 ACR/EULAR RA criteria. 
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Figure 15. Boxplots of: A) SJC28, B) TJC28, C) SJC44, and D) RAI, at baseline and follow-up (median 22, IQR 14-26 weeks) in patients grouped 
according to according to ACPA status. 
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Figure 16. Boxplots of: A) CRP level, B) DAS28-CRP3v, C) patient VASDA and D) HAQ score, at baseline and follow-up (median 22, IQR 14-26 
weeks) in patients grouped according to according to ACPA status. 
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8.4.4 Multivariable Analyses 
After adjustment for age, gender, symptom duration and baseline DAS28-CRP3v, 
neither fulfilment of 2010 ACR/EULAR RA criteria nor ACPA-positivity were 
associated with the primary outcomes, DAS28-CRP3v remission or EULAR 
response at follow-up (Table 31). 
 
 Odds ratios for DAS28-CRP3v remission and EULAR response, in Table 31.
patients receiving methotrexate monotherapy, according to fulfilment of 
2010 ACR/EULAR RA criteria or ACPA status, with adjustment for age, 
gender, symptom duration and baseline DAS28-CRP3v (multivariable 
logistic regression analyses). 
Response Outcome Baseline Variable 
OR (95% CI)  
for Response 
p 
DAS28-CRP3v 
Remission 
(DAS28-CRP3v<2.6) 
Age 1.01 (0.98-1.04) 0.5 
Female 0.43 (0.19-0.95) 0.04 
Symptom duration, months 0.92 (0.87-0.98) 0.01 
Baseline DAS28-CRP3v 0.44 (0.31-0.64) <0.001 
Fulfilling 2010 RA criteria 1.02 (0.31-3.31) 1.0 
DAS28-CRP3v 
Remission 
(DAS28-CRP3v<2.6) 
Age 1.01 (0.98-1.03) 0.6 
Female 0.40 (0.18-0.88) 0.02 
Symptom duration, months 0.92 (0.87-0.98) 0.01 
Baseline DAS28-CRP3v 0.45 (0.31-0.65) <0.001 
 ACPA-positive 1.76 (0.79-3.91) 0.2 
EULAR Response 
(at least Moderate) 
Age 1.01 (0.99-1.03) 0.4 
Female 0.89 (0.39-2.01) 0.8 
Symptom duration, months 0.98 (0.96-1.01) 0.2 
Baseline DAS28-CRP3v 1.86 (1.32-2.63) <0.001 
Fulfilling 2010 RA criteria 0.85 (0.28-2.59) 0.8 
EULAR Response 
(at least Moderate) 
Age 1.01 (0.98-1.03) 0.5 
Female 0.84 (0.37-1.88) 0.7 
Symptom duration, months 0.98 (0.96-1.01) 0.3 
Baseline DAS28-CRP3v 1.86 (1.32-2.62) <0.001 
 ACPA-positive 1.32 (0.63-2.80) 0.5 
 
 
8.4.5 Sensitivity Analyses 
Substituting ACPA-positivity with seropositivity for ACPA and/or RF) did not affect 
the conclusion. Odds ratios (95% CI) were 0.91 (0.38-2.18) and 1.33 (0.53-3.29) for 
achieving DAS28-CRP3v remission and a moderate EULAR response, 
respectively, on multivariable analyses.  
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For analyses of response to methotrexate with or without hydroxychloroquine, a 
total of 167 patients with complete outcome data were identified. These were 
patients who commenced methotrexate either alone or in combination with 
hydroxychloroquine, and either remained on methotrexate monotherapy or 
escalated from first-line methotrexate monotherapy to combination treatment with 
hydroxychloroquine. Outcomes were assessed at six months after commencement 
of methotrexate (with/without hydroxychloroquine) or carried forward from the last 
assessment in patients either stopping methotrexate due to an adverse 
event/intolerance or escalating therapy to receive an alternative or additional 
DMARD (other than hydroxychloroquine) or biologic therapy (provided they had 
received at least six weeks of methotrexate). This gave a median (IQR) duration of 
methotrexate (with/without hydroxychloroquine) at outcome assessment of 25 (19-
27) weeks. Outcomes were: DAS28-CRP3v remission in 65/167 (39%) patients and 
EULAR response (at least moderate) in 121/167 (72%) patients. Neither fulfilment 
of 2010 ACR/EULAR RA classification criteria, nor ACPA-positivity, were 
independently associated with either outcome; OR (95% CI) for achievement of 
DAS28-CRP3v remission with fulfilment of 2010 RA criteria were 1.20 (0.37-3.84) 
and with ACPA-positivity were 1.98 (0.93-4.24), and for achievement of at least a 
moderate EULAR response were 1.43 (0.48-4.23) and 1.27 (0.58-2.77), 
respectively.  
 
8.5 Discussion 
This study is the first to report remission rates achieved with methotrexate in 
patients with early UA and RA, defined according to 2010 RA criteria, in a clinical 
setting. In ESPOIR, clinical response to methotrexate was assessed using mean 
DAS28 levels at six months (Gaujoux-Viala et al., 2012). Notably, suboptimal 
dosing of methotrexate was identified, whereas the majority of patients in our study 
in Leeds were treated with methotrexate doses above 15mg weekly. 
 
Approximately one third of all IA patients (42% of patients with UA and 34% of 
patients with RA) in our study achieved DAS28-CRP3v remission at follow-up. This 
is lower than that observed in the methotrexate arm of the double-blind randomised 
controlled trial, EMPIRE. In EMPIRE, DAS28-CRP remission was achieved in 44% 
of patients at 12 weeks and 49% of patients at 26 weeks (Nam et al., 2014b). All 
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patients were seropositive (presence of at least one of ACPA, RF or the shared 
epitope) with at least one swollen and tender joint; only 7 (6%) patients did not fulfil 
2010 RA criteria at baseline, in comparison to the 19 (12%) patients in our 
observational study. Explanations for a lower rate of response in our observational 
Leeds cohort include differences in patient characteristics, differences in inclusion 
criteria and likely differences in management approach. Patients studied in the 
context of a clinical trial may be expected to be more homogeneous in terms of the 
nature of their disease (with more restrictive, defined criteria for inclusion/exclusion) 
and their treatment (with perhaps greater adherence to more protocollised 
treatment regimens). Other plausible explanations include the potential 
underestimation of the efficacy of methotrexate in our observational study. 
Approximately half of patients discontinued or stepped up to combination therapy at 
a time that may have been too early to assess full response. Bias may also have 
been generated through non-attendance of the least symptomatic patients. 
 
Other clinical trials in early IA (not restricted to patients with RA) have reported 
rates of DAS44 remission with methotrexate monotherapy in combination with oral 
corticosteroids. In IMPROVED, 291/479 (61%) of patients with RA (defined by 2010 
RA criteria) and 79/122 (65%) of UA patients (not fulfilling 2010 RA criteria) 
achieved DAS44 remission at four months (Wevers-de Boer, K. V. C. et al., 2012). 
In tREACH, the rate was 28/90 (31%) amongst patients assessed at three months 
(de Jong et al., 2013). The tREACH study included a similar proportion of patients 
with UA, not fulfilling 2010 criteria, to our study (12%), although response was not 
reported amongst this important subgroup. 
 
Whilst no statistically significant differences in response were identified between 
patients with UA and RA, and patients with ACPA-negative and ACPA-positive 
disease in the primary outcome measures, the use of DAS28-CRP3v may not be 
ideal for patients with predominant disease in the feet. Unfortunately, the number of 
patients with complete data for analyses based on DAS44-CRP was not sufficient in 
order to achieve an adequate sample size to allow adjustment for the selected 
variables. Secondary outcomes show that significant improvement in SJC44 was 
observed in all groups, although changes in RAI, VASDA and HAQ were not 
significant in patients with UA or ACPA-negative IA. Contributory factors may be the 
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low baseline levels of some of these variables, particularly HAQ (median scores 
0.9), and small patient numbers due to missing data.  
 
Controlling for corticosteroids and determining the speed of response was not 
possible within the observational study design. The sample size did not permit 
adjustment for further variables such as steroid exposure, or fitting treatment 
duration as an interaction term, within the multivariable analyses. Importantly, no 
significant differences were detected in the use of steroids or duration of 
methotrexate between the groups.  
 
Research to date remains inconclusive regarding possible superior or more rapid 
response to methotrexate in ACPA-positive patients, in comparison to 
ACPA-negative patients, with early IA. Multivariable analysis of the IMPROVED 
study identified ACPA-positivity amongst independent predictors for DAS44-ESR 
remission after four months with adjustment for baseline DAS44-ESR, but not with 
adjustment for the number of involved small and large joints (Wevers-de Boer, K. V. 
C. et al., 2012). At one year (after four months of methotrexate followed by a 
DAS44-steered treatment regimen), no significant difference was observed 
between the rates of DAS44-ESR remission achieved amongst ACPA-positive and 
ACPA-negative patients (Wevers-de Boer, K.V.C. et al., 2012). In the PROMPT 
study, methotrexate monotherapy significantly delayed progression to RA in 
comparison to placebo only amongst ACPA-positive patients. Radiographic 
progression was also significantly lower with methotrexate only amongst 
ACPA-positive patients. However this was based on a subgroup analysis in a study 
powered to detect a treatment difference in the whole patient group and the majority 
of ACPA-negative patients did not show any progression (van Dongen et al., 2007). 
The EMPIRE study also indicates a trend towards earlier clinical response to 
methotrexate in ACPA-positive patients, with significant differences in response 
observed at week two and 26, but not at week 12 or 52, after adjustment for 
confounders (Nam et al., 2014b). 
 
These results support the ongoing first-line use of methotrexate in patients with 
early IA, including those with UA and ACPA-negative disease. Step-up to 
combination DMARD therapy may be required in up to two-thirds of patients, in the 
context of treatment-to-target guidelines for the management of early RA, in clinical 
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practice (Smolen et al., 2010). To delineate subtle differences in response 
according to fulfilment of the 2010 criteria or ACPA status further studies are 
required, ideally within the context of a trial controlling for the use of steroids. 
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 : Evaluation of a Treat-To-Target Management Chapter 9
Strategy in Patients with Early RA in a Clinical Practice 
Setting. 
Discordance between the predictors of clinical and imaging 
remission. 
9.1 Introduction 
Randomised controlled trials reveal patients with early RA may achieve superior 
outcomes with treatment-to-target strategies in comparison to conventional care 
(section 2.4.1) (Grigor et al., 2004; Verstappen et al., 2007; Knevel et al., 2010). 
Guidelines, first published in 2010 by EULAR, recommend this approach (Smolen 
et al., 2010; Smolen, Josef S et al., 2014; Smolen et al., 2017). Monitoring of 
disease activity, using a validated composite measure, is recommended at least 
every three months, with optimisation of treatment to achieve a pre-defined target, 
primarily remission. In 2011, ACR/EULAR remission criteria were developed for use 
in clinical trials (Felson et al., 2011) and are now recommended as the optimal 
target for treatment (Smolen, Josef S et al., 2014; Smolen et al., 2017). Two 
alternative definitions are proposed, based on either the simplified disease activity 
index (SDAI≤3.3) or that developed using a Boolean approach: swollen joint count, 
tender joint count, CRP (mg/dl), and patient global self-assessment (0 to 10 scale) 
all less than or equal to one.  
 
There is evidence, however, that such clinical definitions of remission are imperfect 
in delineating patients with a true absence of any inflammatory disease activity 
(section 2.4.1.5). Data from randomised trials indicates approximately half of 
patients achieving SDAI remission and one third of patients achieving Boolean 
remission (using a 28-joint count), after 12 months of treatment with methotrexate, 
experience worsening radiographic scores and/or a decrease in physical 
functioning over the following 12 months (Felson et al., 2011). Observational data 
confirms over half of patients with early RA achieving SDAI or Boolean remission 
experience a deterioration in radiographic and/or HAQ scores over the following 12-
24 months (Zhang et al., 2012). This highlights the need for ongoing monitoring.  
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Imaging studies in patients with established RA confirm that despite achievement of 
a clinical remission state, subclinical inflammatory disease activity may persist. In 
patients achieving 2011 ACR/EULAR Boolean remission, PD on ultrasound 
examination has been demonstrated in up to approximately half of patients within 
the hands and wrists (Saleem et al., 2011; Geng et al., 2014) and one third of 
patients within 22 joints including the hands, wrists, elbows and knees (Zufferey et 
al., 2014). The relevance of PD in clinical remission and low disease activity states 
is evident from its relationship with radiographic progression (Brown et al., 2008; 
Foltz et al., 2012) and future disease flare (Scirè et al., 2009; Foltz et al., 2012; 
Saleem et al., 2012) (section 2.3.2.1). Conversely, studies suggest the clinical 
remission criteria may be too stringent in a subset of patients, notably those with 
comorbidities (Thiele et al., 2013).  
 
Ultrasound, by directly assessing the pathology of RA, may enable a more 
comprehensive approach to defining remission and could therefore guide 
therapeutic decisions. Indeed, imaging remission has been proposed as a future 
goal for therapy (van der Heijde, 2012). Recent interventional studies have failed to 
demonstrate superiority of targeting disease activity evident on ultrasound in 
comparison to clinical targets in terms of primary outcomes assessed, however 
deficiencies in study methods imply further investigations are needed in order to 
determine the value of targeting imaging remission (Dale et al., 2016; 
Haavardsholm et al., 2016; D'Agostino et al., 2017) (section 2.4.1.5). Further 
studies have been proposed (Wakefield et al., 2012). 
 
Further data are needed to inform the use of the 2011 ACR/EULAR remission 
criteria and ultrasound in clinical practice. Evidence of success of treat-to-target 
strategies in unselected patients with early RA in clinical practice remains limited 
(van Hulst et al., 2010; Bosello et al., 2011; Vermeer et al., 2011; Vermeer et al., 
2012; Gremese et al., 2013; Farman et al., 2015). In addition, data regarding the 
relationship between clinical and imaging remission in early disease, in particular 
with respect to the new 2011 ACR/EULAR Boolean criteria, are limited (Scirè et al., 
2009; Balsa et al., 2010; Sakellariou, Garifallia et al., 2013) (section 2.4.1.5). 
Several studies have examined predictors of clinical remission in observational, 
open-label and randomised controlled studies (Möttönen et al., 2002; Gossec et al., 
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2004; Bosello et al., 2011; Contreras-Yanez et al., 2012; Ma et al., 2012; Wevers-
de Boer, K. V. C. et al., 2012; Gremese et al., 2013) (see Tables 5 and 6, section 
2.2). However, less is understood regarding the predictors of clinical and imaging 
remission in daily practice which may ultimately facilitate decisions regarding choice 
of first-line therapy or treatment strategy for individual patients. 
 
9.2 Aims and Objectives 
To assess how the EULAR treat-to-target guidelines and the paradigm for targeting 
clinical remission in early RA translate into clinical practice, particularly in relation to 
ultrasound imaging. Specific objectives were to evaluate:  
 Adherence to the EULAR treat-to-target guidelines and identify potential 
barriers to adherence in clinical practice. 
 The rates of DAS28 remission, DAS44 remission, 2011 ACR/EULAR 
Boolean remission and imaging remission. 
 Agreement between these clinical remission states and imaging remission.  
 Predictors of achievement of these clinical and imaging remission 
outcomes. 
 
9.3 Methods 
A prospective, observational study was conducted in patients with new-onset, 
DMARD-naïve IA (Chapter 4). Patients were selected from this cohort according to 
the following criteria: (i) fulfilment of RA criteria (1987 ACR and/or 2010 
ACR/EULAR RA classification criteria) at baseline, (ii) active disease at baseline or 
time of commencement of DMARD (DAS28-CRP≥2.6, or in the instance of missing 
patient VASDA, DAS28-CRP3v≥2.6), and (iii) commencement of DMARD therapy 
within three months of baseline. Patients receiving an alternative non-RA diagnosis 
within the following 12 months or with incomplete 12-month outcome data were 
excluded. 
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9.3.1 Assessments 
Clinical disease activity and ultrasound assessments are described in sections 4.2 
and 4.3.  
 
9.3.1.1 Outcomes 
 Adherence to guidelines 
Adherence to guidelines was assessed by calculating the proportion of patients in 
whom DAS28-CRP was recorded at least every three months until achievement of 
the target (DAS28-CRP<2.6), and DMARD or corticosteroid treatment was 
escalated at least every three months if the target was not met. Escalation in 
DMARD treatment was defined as addition or switch of synthetic DMARD 
(methotrexate, sulfasalazine, hydroxychloroquine, leflunomide or other) or biologic 
DMARD, or an increase in dose of DMARD. Corticosteroid treatment escalation 
was defined as either the initiation, or increase in dose of oral prednisolone, or 
administration of intramuscular, intra-articular or intravenous methylprednisolone, or 
intramuscular triamcinolone. 
 
 Clinical outcomes 
The clinical outcomes were DAS28-CRP remission (DAS28-CRP<2.6) and low 
disease activity (DAS28-CRP<3.2), DAS44-CRP remission (DAS44-CRP<1.6) and 
low disease activity (DAS44-CRP<2.4), and 2011 ACR/EULAR Boolean remission 
(SJC44≤1, TJC53≤1, CRP≤10mg/dL and patient VASDA ≤10mm).  
 
 Imaging outcomes 
Imaging outcomes were defined using the sum of the semi-quantitative scores for 
PD assessed in 26 joints (maximum total score 78). Absence of PD was defined as 
a total score of zero. In order to allow for low-level PD which may be observed, 
particularly at the wrist and first MTPs in healthy individuals (Terslev et al., 2004; 
Hameed et al., 2008; Millot et al., 2011; Carotti et al., 2012; Kitchen and Kane, 2015) 
and/or patients with osteoarthritis (Keen et al., 2008; Mathiessen et al., 2016), two 
alternative definitions of absent/minimal PD were also considered. These were: 
(i) total PD score≤1 (i.e. presence of a maximum of grade 1 PD in a maximum  of 
any one of the 26 joints), and (ii) PD≤grade 1 at any or all of the wrists and first 
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MTPs and up to one other joint examined, with absence of PD (grade 0) in the 
remaining 21 joints (i.e. allowing for a maximum total PD score=5, comprising 
PD=grade1 in both wrists and first MTPs and any one of the other joints examined: 
elbow, MCP2-3, PIP2-3, knee, ankle or MTP2-5 joints).  
 
9.3.2 Statistics 
Prevalence and bias adjusted kappa (PABAK) statistics were calculated to examine 
the relationship between the clinical remission endpoints and imaging outcomes. 
Univariable logistic regression was conducted to investigate factors associated with 
the clinical remission and imaging outcomes. Multivariable logistic regression 
analysis was also planned, entering baseline variables demonstrating statistical 
significance (p<0.05) on univariable analysis. 
 
9.4 Results 
9.4.1 Patients 
Between June 2010 and September 2012, 217 patients fulfilling RA criteria were 
eligible for inclusion in the analysis. Patient disposition is displayed in Figure 17 and 
baseline characteristics are shown in Table 32. No significant difference was 
observed between baseline DAS28-CRP scores, DAS44-CRP scores or ultrasound 
parameters in patients included in the analyses (n=105) and those who were lost to 
follow-up or in whom follow-up data was incomplete (n=112). However, they 
differed significantly (p<0.05) in the following manner: mean age was higher and 
SJC28, TJC28, SJC44 and RAI were generally lower amongst included patients. 
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Figure 17. Disposition of patients included in the analysis of outcomes of patients 
with RA receiving DMARDs according to a treatment-to-target strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Suspected IA  
n=441 
Eligible for inclusion 
n=217 
 
Exclusions n=160 
- No swelling n=52 
- Declined consent n=18 
- Not attending n=11 
- Alternative diagnosis (not fulfilling 2010 
ACR/EULAR and/or 1987 ACR RA 
classification criteria) n=76 
- Other n=3 
Other exclusions n=64 
- No DMARD within 3 months n=18  
- DAS28-CRP<2.6 (or DAS28-CRP3v<2.6 if 
VASDA missing) at baseline or time of 
commencement of DMARD n=17 
- Referred to biologic clinical trial n=16 
- Alternative non-RA diagnosis within 12 
months follow-up n=11 
- DAS28-CRP3v at baseline not known n=2 
 
RA at baseline 
n=281 
12 Months  
n=105 
Loss to follow-up n=25 
- Did not attend n=14 
- Biologic clinical trial n=6 
- Died n=3 
- Moved out of area n=1 
- Reason unknown n=1 
 
Incomplete outcome data n=87 
- Clinical data incomplete n=67 
- Ultrasound data incomplete n=71 
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 Baseline characteristics of patients with new-onset RA receiving Table 32.
DMARDs according to a treatment-to-target strategy.  
Values are median (IQR) and n (%), unless otherwise stated. 
 Included in analysis Excluded due to 
missing follow-up 
data p 
 
(n=105) 
Missing 
Values 
(n=112) 
Missing 
Values 
Age, mean (SD) 59 (13) - 53 (15) - 0.002 
Female 79 (75%) - 80 (71%) - 0.5 
BMI, mean (SD) 27 (5) 13 29 (6) 12 0.1 
Symptom duration, months 6 (4-13) - 7 (4-13) - 0.5 
Current/previous smoker                                65 (62%) - 67 (60%) 1 0.8 
Number of comorbidities:          1 
2 
3 
≥4 
34 (32%) 
19 (18%) 
15 (14%) 
7 (7%) 
- 
25 (22%) 
31 (28%) 
14 (13%) 
7 (6%) 
- 0.9 
History/current evidence of 
coexistent osteoarthritis 
46 (44%) - 37 (33%) - 0.1 
RF positive 
ACPA positive 
78 (74%) 
81 (77%) 
- 
- 
72 (64%) 
73 (65%) 
- 
- 
0.1 
0.05 
Fulfilment of RA classification 
criteria:                 1987 ACR RA 
2010 ACR/EULAR RA
 
 
73 (70%) 
101 (96%) 
 
- 
- 
 
83 (74%) 
109 (97%) 
 
- 
- 
 
0.5 
0.7 
TJC28                                                                 
SJC28                                                                 
7 (3-13) 
4 (2-8)
- 
- 
10 (5-17) 
6 (3-10) 
- 
- 
0.003 
0.03 
RAI                                                                      
SJC44                                                                 
7 (4-10)
5 (3-9)
17 
17 
9 (5-13) 
7 (4-13) 
24 
24 
0.01 
0.01 
CRP, mg/L 21 (7-45) - 13 (0-40) - 0.2 
Patient VASDA, mm  50 (31-77) 27 61 (35-82) 44 0.3 
DAS28-CRP3v 
DAS28-CRP                                                    
4.5(3.8-5.2) 
4.9(4.0-5.5) 
- 
27 
4.7(3.7-5.8) 
5.1(3.9-6.1) 
- 
44 
0.1 
0.5 
DAS44-CRP                                                    3.1(2.6-3.6) 34 3.4(2.6-4.0) 46 0.1 
HAQ                                                                    1.3(0.8-1.9) 30 1.4(0.5-1.8) 40 0.9 
Ultrasound of 26 joints: 
Total GS score
 
Total PD score
 
Absence of PD (total PD=0) 
Absent/minimal PD (total PD≤1)
 
 
17 (10-25) 
3 (0-8) 
23 (27%) 
34 (40%) 
 
21 
21 
21 
21 
 
19 (12-26) 
3 (0-9) 
55 (28%) 
61 (35%) 
 
33 
33 
33 
33 
 
0.2 
0.9 
0.9 
0.5 
Radiographic erosion in the 
hands and feet:                     Any 
1987 ACR definition  
2010 ACR/EULAR definition
 
 
18 (17%) 
11 (10%) 
9 (9%) 
- 
 
20 (18%) 
16 (14%) 
9 (8%) 
 
2 
2 
2 
 
0.8 
0.4 
0.9 
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9.4.2 Management 
The majority of patients commenced DMARDs at baseline (72%) or within four 
weeks of baseline (15%). Choice of first DMARD was methotrexate monotherapy in 
86%, hydroxychloroquine monotherapy in 10% and sulfasalazine monotherapy in 
4% of patients. Methotrexate in combination with another DMARD was commenced 
in the remaining 1%. A contraindication to early commencement of methotrexate 
was recorded in 5% of patients, comprising chronic obstructive airways disease, 
recent or concurrent infection and deranged liver function tests. Over 12 months, 
9 (9%) and 20 (19%) patients failed treatment with methotrexate or an alternative 
DMARD, respectively, due to intolerance or an adverse event. Table 33 provides 
further details of patient management. 
  
 Management of patients with new-onset RA receiving DMARDs Table 33.
according to a treatment-to-target strategy over 12 months. 
Values are median (IQR) and n (%). 
 RA 
n=105 
Ongoing Treatment at 12 months:                               MTX monotherapy 
SSZ monotherapy 
HCQ monotherapy 
MTX + other DMARD 
2 DMARDs (excluding MTX) 
MTX + SSZ + HCQ 
Biologic therapy 
Referred to Biologics Clinical Trial 
Other DMARD  
Steroid alone 
None 
38 (36%) 
3 (3%) 
5 (5%) 
36 (34%) 
1 (1%) 
8 (8%) 
5 (5%) 
2 (2%) 
2 (2%) 
4 (4%) 
1 (1%) 
Ongoing MTX use at 12 months:                                Administered orally 
Administered subcutaneously 
Weekly dose, mg 
75 (76%) 
14 (13%) 
25 (20-25) 
Receiving significant total steroid dose over 12 months: 
                                      ≥80mg triamcinolone 
≥150mg prednisolone 
≥120mg methylprednisolone                               
 
10 (10%) 
30 (29%) 
84 (80%)
Total methylprednisolone dose over 12 months, mg 240 (120-360) 
Adherence to treatment-to-target guidelines: 
- Clinical assessment at least every 3 months until the target for 
treatment (DAS28-CRP <2.6) was met  
- DAS28-CRP available at least every 3 months until the target 
for treatment (DAS28-CRP <2.6) was met 
- DAS28-CRP available at least every 3 months and DMARD 
therapy escalated if the target was not met 
- DAS28-CRP available at least every 3 months and DMARD or 
corticosteroid therapy escalated if the target was not met 
 
97 (92%) 
 
76 (72%) 
 
53 (51%) 
 
61 (58%) 
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9.4.3 Adherence to treat-to-target guidelines 
The DAS28-CRP score was recorded at least every three months up to 12 months, 
or until the target was met, in 76 (72%) patients. Appropriate escalation of DMARDs 
(excluding corticosteroids), i.e. at least every three months if DAS28-CRP≥2.6, was 
observed in 53/76 (70%) of these patients. In a further eight (10%) patients, 
corticosteroid therapy was increased or administered without a change in DMARD. 
Amongst the remaining 15 patients in whom treatment was not escalated despite 
awareness of DAS28-CRP≥2.6, reasons throughout the 12 months were: awaiting 
effect of previous treatment escalation (n=6), physician impression of 
non-inflammatory symptoms only (n=4, simultaneous ultrasound assessments 
revealed total PD scores ranging between zero and three), physician judgement of 
acceptable disease control (n=4, simultaneous ultrasound assessments were 
available in n=3 cases with total PD scores ranging between one and three), 
contraindication to treatment escalation (n=2), patient declining (n=2), considering 
biologic clinical trial (n=2) and isolated flare (n=1).  
 
As the target DAS28-CRP<2.6 allows the presence of clinical swelling (Mäkinen et 
al., 2005), there is still a role for clinical assessment as recommended within 
EULAR guidelines. In fact, out of 121 visits at which DAS28-CRP<2.6 was 
observed, treatment was escalated (including steroid administration) due to a 
clinician impression of ongoing inflammatory disease activity at 44 (36%) visits. 
Standardised ultrasound examination of 26 joints was conducted at 31/44 of these 
visits, confirming presence of PD in 22/31 (71%) cases. This compares to the 
availability of ultrasound at 43/77 visits at which DAS28-CRP<2.6 and treatment 
was not escalated, with PD confirmed in 18/43 (42%) of these cases. 
 
9.4.4 Clinical outcomes 
At 12 months, rates of DAS28-CRP remission and low disease activity were 45/105 
(43%) and 63/105 (60%). Rates of DAS44-CRP remission and low disease activity 
were 41/105 (39%) and 77/105 (73%). The rate of 2011 ACR/EULAR Boolean 
remission was 15/105 (14%). The thirty patients achieving DAS28-CRP<2.6 but not 
meeting the Boolean definition of remission missed the latter due to patient 
VASDA>10mm (n=23), TJC53>1 (n=9), SJC44>1 (n=6) and/or CRP>10mg/L (n=6). 
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Amongst 70 patients attaining DAS28-CRP remission at least once over the 
12 month period, the median (IQR) time to first achievement of DAS28-CRP<2.6 
was 6 (3-9) months. In patients achieving DAS28-CRP remission prior to 
month 12 (n=61), first DAS28-CRP remission was sustained over the remaining 
follow-up in 27 (44%) patients. The majority of these patients achieved DAS28-CRP 
remission within the first six months; 41% achieved remission within the first three 
months and 70% had achieved remission by six months. 
 
9.4.5 Imaging outcomes 
Absence of PD (total PD score=0) was observed in 42 (40%) patients at 12 months. 
Absent/minimal PD, defined by (i) total PD score≤1, was observed in 60 (57%) 
patients. Absent/minimal PD, defined by (ii) PD≤grade 1 at any or all of the wrists 
and first MTPs and up to one other joint examined and PD=grade 0 in all other 
joints (i.e. accepting low-grade PD at the wrists and/or first MTP joints and one 
other joint), was observed in seven additional patients; a total of 67 (64%) patients. 
 
9.4.6 Agreement between clinical and imaging outcomes 
Poor agreement was demonstrated between clinical and imaging outcomes 
(Table 34). In patients achieving clinical remission at 12 months, absence of PD 
(total PD score=0) was observed in 19/45 (42%) patients achieving 
DAS28-CRP<2.6, 18/41 (44%) patients achieving DAS44-CRP<1.6, and 
6/15 (40%) patients achieving Boolean remission. Absent/minimal PD, defined by 
(i) total PD score≤1, was observed in 28/45 (62%), 27/41 (66%) and 10/15 (67%) 
patients, respectively. The less stringent definition for absent/minimal PD, (ii), was 
observed in slightly more patients achieving DAS28-CRP and DAS44-CRP 
remission (rates were 31/45 (69%) and 29/41 (71%), respectively), whilst the rate 
amongst patients achieving Boolean remission was unchanged. 
 
In patients achieving DAS28-CRP<2.6 with ongoing imaging evidence of synovitis 
(n=26), PD was observed at the following sites: wrists (n=16), MCPs2-3 (n=13), 
MTP1 (n=4), MTPs2-5 (n=4), PIP2-3 (n=4), elbows (n=2) and the knee (n=1). In 
patients achieving Boolean remission, PD affected the following joint regions: 
MCPs2-3 (n=5), wrists (n=4), MTPs2-5 (n=1), PIP2-3 (n=1), and elbows (n=1). 
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In patients lacking any PD, but with active disease as indicated by DAS28-CRP≥2.6 
(n=23), median (IQR) values for the DAS28 component variables were 
TJC28 5 (2-9), SJC28 1 (0-2), patient VASDA 57 (40-57) mm and 
CRP 9 (0-18) mg/dL. Amongst 36 patients lacking any PD but not achieving 
Boolean remission, patient VASDA>10mm was the most frequent preclusion to 
fulfilment of the Boolean criteria (n=32), followed by TJC53>1 (n=24), 
CRP>10mg/dL (n=15) and SJC44>1 (n=9). 
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 Agreement between clinical remission outcomes and; A) absence of power Doppler activity and B) absent/minimal power Doppler Table 34.
activity, at 12 months in patients with new-onset RA receiving DMARDs according to a treatment-to-target strategy. 
Values are n (%), unless otherwise stated. 
 
A)  Agreement between Clinical Remission and Absence of PD. 
 
 
B)  Agreement between Clinical Remission and Absent/Minimal PD. 
Clinical Outcomes 
Absent/minimal PD in 26 joints 
(i) Total PD score≤1 
(ii) PD≤grade1 at any or all of the wrists and first MTPs and 
up to one other joint examined, PD=grade 0 all other joints 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical 
nor 
imaging 
outcome 
PABAK 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical nor 
imaging 
outcome 
PABAK 
DAS28-CRP remission  
(DAS28-CRP<2.6) 
28 (27%) 17 (16%) 32 (30%) 28 (27%) 0.07 31 (30%) 14 (13%) 36 (34%) 24 (23%) 0.05 
DAS44-CRP remission 
(DAS44-CRP<1.6) 
27 (26%) 14 (13%) 33 (31%) 31 (30%) 0.10 29 (28%) 12 (11%) 38 (36%) 26 (25%) 0.05 
Boolean remission
 
10 (10%) 5 (5%) 50 (48%) 40 (38%) -0.05 10 (10%) 5 (5%) 57 (54%) 33 (31%) -0.18 
Clinical Outcomes 
Absence of PD in 26 joints (total PD score=0) 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical 
nor 
imaging 
outcome 
PABAK 
DAS28-CRP remission  
(DAS28-CRP<2.6) 
19 (18%) 26 (25%) 23 (22%) 37 (35%) 0.07 
DAS44-CRP remission 
(DAS44-CRP<1.6) 
18 (17%) 23 (22%) 24 (23%) 40 (38%) 0.10 
Boolean remission
 
6 (6%) 9 (9%) 36 (34%) 54 (51%) 0.14 
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9.4.7 Predictors of clinical and imaging outcomes 
Univariable analyses demonstrated achievement of the various clinical remission 
outcomes was significantly associated with being male and having a shorter 
duration of symptoms, fewer tender joints and lower HAQ score at baseline 
(Table 35). In comparison, the baseline parameters predictive of achievement of 
good imaging outcomes were lack of coexistent osteoarthritis, seronegativity, fewer 
swollen joints, lower CRP and lower total PD score. A lower DAS28-CRP score at 
baseline was also significantly associated with all outcomes. Using the less 
stringent definition for the outcome absent/minimal PD, (ii) PD≤grade 1 at any or all 
of the wrists and first MTPs and up to one other joint examined, did not reveal any 
differences in the results, in comparison to the alternative definition, (i) total 
PD score≤1 amongst all 26 joints. Therefore, only results for total PD score≤1 
amongst all 26 joints are presented.  
 
Results of multivariable analyses, entering baseline variables demonstrating 
statistical significance (p<0.05) on univariable analyses, are shown in Table 36. The 
composite score (DAS28-CRP) was assessed in univariable analyses, but not in 
multivariable analysis, because of overlap with its component variables. 
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 Baseline variables predictive of achievement of clinical and imaging outcomes at 12 months in patients with new-onset RA receiving Table 35.
DMARDs according to a treatment-to-target strategy (univariable logistic regression analyses). 
 
DAS28-CRP<2.6 DAS44-CRP<1.6 Boolean Remission
 Absence of PD 
(Total PD score=0) 
Absent/minimal PD 
(Total PD score≤1) 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Age 1.01(0.98-1.04) NS 1.01(0.98-1.04) NS 1.01(0.96-1.05) NS 0.98(0.95-1.01) NS 0.98(0.95-1.01) NS 
Female 0.45(0.18-1.11) NS 0.36(0.15-0.89) 0.03 0.31(0.10-0.95) 0.04 0.58(0.24-1.42) NS 0.63(0.25-1.59) NS 
BMI
a 
0.94(0.87-1.02) NS 0.96(0.88-1.04) NS 0.94(0.82-1.07) NS 1.01(0.93-1.09) NS 1.00(0.93-1.09) NS 
Symptom duration, 
months 
0.92(0.86-0.99) 0.03 0.93(0.87-1.00) 0.05 1.00(0.92-1.08) NS 0.99(0.94-1.05) NS 1.03(0.97-1.10) NS 
Current or previous 
smoker 
0.63(0.28-1.39) NS 0.94(0.42-2.1) NS 0.66(0.22-1.99) NS 1.41(0.62-3.17) NS 1.15(0.52-2.55) NS 
Number of comorbidities 0.86(0.63-1.16) NS 1.02(0.76-1.37) NS 0.67(0.40-1.13) NS 1.01(0.75-1.36) NS 0.89(0.67-1.20) NS 
History or current 
evidence of concurrent 
osteoarthritis 
0.76(0.35-1.67) NS 0.73(0.33-1.61) NS 0.83(0.27-2.54) NS 0.41(0.18-0.93) 0.03 0.70(0.32-1.52) NS 
RF positive 1.38(0.56-3.40) NS 1.12(0.45-2.77) NS 0.94(0.27-3.26) NS 0.52(0.21-1.26) NS 0.37(0.14-0.97) 0.04 
ACPA positive 1.68(0.65-4.37) NS 1.76(0.66-4.7) NS 2.10(0.44-10.05) NS 0.73(0.29-1.84) NS 0.36(0.13-1.00) 0.05 
SJC28  0.98(0.89-1.08) NS 0.97(0.87-1.07) NS 1.00(0.87-1.14) NS 0.85(0.75-0.96) 0.009 0.88(0.79-0.98) 0.02 
TJC28 0.93(0.86-0.99) 0.03 0.90(0.83-0.97) 0.006 0.87(0.77-0.99) 0.04 0.96(0.90-1.03) NS 0.97(0.91-1.03) NS 
CRP, mg/L 0.99(0.98-1.00) NS 0.99(0.98-1.00) NS 0.99(0.98-1.01) NS 0.99(0.97-1.00) NS 0.99(0.98-1.00) 0.03 
Patient VAS global 
disease assessment, mm
b 
0.98(0.96-1.00) 0.02 0.98(0.97-1.00) NS 0.98(0.96-1.00) NS 0.99(0.97-1.01) NS 0.98(0.97-1.00) NS 
DAS28-CRP3v 0.66(0.45-0.97) 0.03 0.57(0.38-0.86) 0.008 0.53(0.30-0.95) 0.03 0.66(0.45-0.97) 0.04 0.59(0.40-0.87) 0.008 
HAQ score
c 0.46(0.23-0.93) 0.03 0.46(0.23-0.95) 0.04 0.28(0.10-0.79) 0.02 0.65(0.33-1.29) NS 0.49(0.24-1.01) NS 
Total GS score on US
d 
1.00(0.96-1.04) NS 0.98(0.94-1.02) NS 1.00(0.95-1.05) NS 0.96(0.92-1.01) NS 0.97(0.93-1.01) NS 
Total PD score on US
d 
0.98(0.92-1.05) NS 0.97(0.91-1.04) NS 0.98(0.89-1.07) NS 0.89(0.81-0.97) 0.01 0.87(0.80-0.95) 0.002 
Radiographic erosions 0.82(0.29-2.32) NS 1.31(0.47-3.65) NS 1.97(0.55-7.09) NS 0.37(0.11-1.21) NS 0.41(0.14-1.16) NS 
NS: Not Significant (p≥0.05). Missing data in a13, b27, c30 and d21 cases. 
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 Baseline variables predictive of achievement of clinical and imaging outcomes at 12 months in patients with new-onset RA receiving Table 36.
DMARDs according to a treatment-to-target strategy (multivariable logistic regression analyses). 
Outcome at 12 
months 
Baseline Variable OR (95% CI) p 
Missing 
Cases 
DAS28-CRP<2.6 
Symptom duration, months 0.90(0.81-0.99) 0.04 
37 
TJC28 0.93(0.85-1.02) NS 
Patient VASDA, mm 0.98(0.95-1.00) NS 
HAQ 0.71(0.26-1.93) NS 
DAS44-CRP<1.6 
Female 0.22(0.06-0.77) 0.02 
30 
Symptom duration, months 0.93(0.85-1.02) NS 
TJC28 0.88(0.79-0.98) 0.02 
HAQ 0.53(0.23-1.26) NS 
Boolean Remission 
Female 0.35(0.08-1.50) NS 
30 TJC28 0.91(0.79-1.05) NS 
HAQ 0.33(0.11-0.98) 0.05 
Absence of PD 
(Total PD score=0) 
History or current evidence of concurrent osteoarthritis
 0.35(0.13-0.93) 0.04 
21 SJC28 0.89(0.77-1.03) NS 
Total PD score
 
0.92(0.83-1.02) NS 
Absent/minimal PD 
(Total PD score≤1) 
RF-positivity 0.59(0.15-2.29) NS 
21 
ACPA-positivity 0.54(0.14-2.07) NS 
SJC28 0.99(0.86-1.13) NS 
CRP 0.99(0.98-1.01) NS 
Total PD score
 0.89(0.81-0.98) 0.01 
NS: Not Significant (p>0.05). 
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9.5 Discussion  
This study reveals that almost half of patients with new-onset RA were achieving 
the clinical target (DAS28-CRP remission) at 12 months, in daily practice using 
EULAR treatment-to-target recommendations as a guide to management. The rate 
of 2011 ACR/EULAR Boolean remission was significantly lower. In patients 
achieving a state of clinical remission, regardless of the outcome measure used to 
define remission (either DAS28, DAS44 or even 2011 ACR/EULAR Boolean 
remission), any PD (total PD score>0) was observed in at least half and significant 
PD (total PD score>1) was apparent in approximately one third of patients. 
 
These rates of clinical remission are consistent with other observational 
treat-to-target RA cohorts. In an Italian EAC, the rate of DAS44 remission was 
reported as 46% (Bosello et al., 2011). In the multicentre Dutch Rheumatoid 
Arthritis Monitoring (DREAM) cohort, DAS28 remission and 2011 ACR/EULAR 
Boolean remission were observed in 58% (Vermeer et al., 2011) and 21% of 
patients (Vermeer et al., 2013), respectively. Methods of assessment in the DREAM 
study included 28 joint examination and patient assessment of general health, and 
it is not clear whether more extensive joint examination or patients’ global disease 
assessments were available in determining 2011 ACR/EULAR Boolean remission. 
In DREAM, intensification of treatment in appropriate patients was not adhered to at 
35% of visits, with the most frequent reasons being a physician impression of 
clinical remission, followed by side-effects (Vermeer et al., 2012); comparable to 
our findings. 
 
This is the first study to demonstrate the discordance between DAS28 remission, or 
the more stringent 2011 ACR/EULAR Boolean definition of remission, and imaging 
remission in an early RA ‘treat-to-target’ cohort. Previous reports of ultrasound 
findings in DAS28 and Boolean remission states in patients with early RA are 
limited to an Italian inception cohort study (Sakellariou, Garifallia et al., 2013). 
Rates of sustained absence of PD were 43/56 (77%) and 21/22 (95%) amongst 
patients achieving DAS28 and Boolean remission at one year, respectively. 
However, this analysis was restricted to a subgroup of patients fulfilling 1987 ACR 
RA criteria, responding to methotrexate (DAS44<2.4 over one year), with complete 
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data (167 of 267 patients with early IA commencing DMARDs). The ultrasound 
assessment was also limited to 12 joints (MCPs and wrists).  
 
The findings of persistent PD in patients achieving DAS44 remission are similar to 
two smaller studies of patients with early RA (Scirè et al., 2009; Peluso et al., 
2011). In these studies patients were treated according to a DAS44-steered 
treatment protocol (including methotrexate and TNF-inhibitors). Persistence of any 
PD was identified in 42% of 48 patients amongst 10 joints (wrists, MCPs2-3 and 
PIPs2-3) (Peluso et al., 2011), and 41% of 43 patients using a 44-joint ultrasound 
assessment (Scirè et al., 2009). Other groups have reported ongoing PD in patients 
with established RA across various definitions of clinical remission (see section 
2.4.1.5). 
 
A significant proportion of patients with absent or absent/minimal PD demonstrated 
evidence of clinical disease activity as measured by DAS28-CRP, DAS44-CRP and 
non-fulfilment of 2011 ACR/EULAR Boolean remission criteria. It is likely, at least 
for a subset of these patients, that the standardised 26-joint ultrasound assessment 
missed active joint inflammation in other joints (e.g. hips, shoulders, MCPs3-5, 
PIPs3-5). However, reduced ultrasound joint assessments including the elbows, 
wrists, second and third MCPs, knees, ankles and second to fifth MTPs have 
previously been shown to correlate well with ultrasound assessment of 44 joints in 
both patients in clinical remission (Naredo et al., 2013b) and those with active 
disease (Naredo et al., 2008b). Moreover, the likelihood that the presence of tender 
joints and a high patient global assessment, which may be influenced by a complex 
interaction of factors other than active synovitis (such as chronic pain, side-effects 
of treatment and the presence of comorbidity), is also relevant. This is supported by 
data, given the characteristics which were evident in these patients.  
 
Baseline predictors of clinical remission outcomes were male gender, shorter 
symptom duration, fewer tender joints, and lower patient VASDA and HAQ scores. 
In contrast, lack of osteoarthritis and objective signs of less severe disease (RF- 
and ACPA-negativity, fewer clinically swollen joints, and lower CRP and 
baseline PD) were associated with favourable imaging outcomes. The latter 
parameters are arguably more reflective of the primary pathology, active synovitis. 
Therefore, logically, they should warrant aggressive treatment or treatment 
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escalation if present or if increased above normal levels. These findings, therefore, 
support current and future research into the use of imaging within the management 
of early RA. 
 
The significantly higher SJC28, TJC28 and RAI of patients with missing follow-up 
data in comparison to patients included in the analyses may be related to the 
proportion of patients who were subsequently referred to biological DMARD clinical 
trials or received biologic DMARDs with follow-up in biologic-monitoring clinic in 
which standardised ultrasound does not form part of routine assessments. Loss to 
follow-up of patients with more severe disease may have falsely elevated the 
remission rates observed. 
 
This study provides insights into the translation of treat-to-target within clinical 
practice. It again highlights the challenges in data collection and adherence to 
treat-to-target guidelines in a clinical setting and identifies room for improving the 
outcomes of patients with early RA. A clinically significant proportion of patients 
achieving DAS28, DAS44 or 2011 ACR/EULAR Boolean remission (now 
recommended for use as a target for treatment by EULAR) demonstrate PD on 
ultrasound. More accurate measurement of inflammatory activity by ultrasound 
should perhaps be a key determinant in guiding treatment escalation and assessing 
true absence of disease activity. The differences observed between the disease 
characteristics at baseline which predicted clinical and imaging remission provide 
further support for the ongoing investigation into the use of imaging within a 
treat-to-target strategy; patients with unfavourable subjective factors were less likely 
to achieve the clinical remission outcomes, whereas factors more directly indicative 
of inflammatory disease activity predicted persistent active disease on imaging. 
Failure to achieve absent or minimal PD was associated with higher PD at baseline. 
As persistence of PD in clinical remission is associated with poor outcomes (Brown 
et al., 2008; Foltz et al., 2012; Saleem et al., 2012) the baseline PD is a warning. 
Ultrasound may therefore prove to be a useful tool in discerning an individual’s 
prognosis at diagnosis as well as assessing inflammation on treatment.  
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 : Discussion Chapter 10
Aspects of the clinical phenotype of IA may be used to stratify patients according to 
their risk of severe, progressive disease. These include features of disease which 
are now contained within the new 2010 ACR/EULAR RA classification criteria, such 
as the pattern of joint involvement and ACPA status. However, knowledge of how 
these criteria perform in a modern-day clinic setting, and how the imaging 
phenotype of IA may be best interpreted, alongside the criteria, remains incomplete. 
Hence, a greater understanding of the clinical and imaging phenotypes of patients 
with UA and RA (defined by today’s standard of the 2010 RA criteria), and the 
prognostic implications of such, may aid in the risk stratification of patients and 
directing early therapy in order to optimise patient outcomes. Other strategies for 
improving the management of patients with early IA which have previously been 
adopted include the implementation of EACs and the treatment-to-target 
management of RA. The impact of targeting ultrasound-detectable disease activity 
on disease outcomes, particularly in the long-term, is yet to be fully established. 
 
For the purposes of better understanding the clinical and imaging phenotype of 
patients with early IA, identifying deficiencies in their management and potential 
ways to resolve these in contemporary clinical practice, a clinical audit and 
observational prospective cohort study were conducted in the Leeds EAC. Areas for 
improvement identified included the necessity to expedite the initial assessment 
and treatment of patients, as well as the need to optimise their management within 
treat-to-target regimens. The results of the observational study support the 
predictive utility of ultrasound which may help in addressing these needs in the 
future. 
 
The audit of the Leeds EAC identified that one of the main factors limiting early 
initiation of DMARDs was the time lag between symptom onset and referral to a 
specialist. Unfortunately, from retrospective data, it was not possible to distinguish 
whether delay was mainly due to the patient or the GP. Nevertheless, room for 
improvement post-referral was also highlighted. Approaches to enable the 
prioritisation of IA referrals and prompt treatment initiation were recommended. 
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The observational cohort study of patients with suspected new-onset IA enabled the 
determination of the clinical and imaging phenotypes of patients with UA or RA, 
defined by the 2010 ACR/EULAR RA criteria. The prevalence of both subclinical 
synovitis and ultrasound erosions in the absence of radiographic erosions was 
confirmed. These findings are a development from existing evidence owing to the 
contemporary definitions of IA employed. Patients were classified as UA or RA with 
use of the recently published consensus definition of radiographic change for use in 
conjunction with the 2010 ACR/EULAR RA criteria (van der Heijde et al., 2013). A 
more extensive ultrasound examination for erosions was also carried out in 
comparison to previous studies in patients with early IA (Funck-Brentano et al., 
2009; Sheane et al., 2009). Other novel aspects of this research include the 
reporting of the incidence and distribution of ‘active’ ultrasound erosions in patients 
with early IA. 
 
Longitudinal, prospective data collection in this cohort allowed investigation of the 
significance of these and other aspects of disease phenotype in respect to their 
outcomes and responses to treatments. Greater synovitis detected by ultrasound, 
at baseline, was associated with a higher rate of methotrexate use and persistence 
of IA. In addition, GS synovitis predicted progression to RA in the subgroup of 
patients with UA at baseline. This appeared to be independent of clinical synovitis 
measures. At the joint level, PD synovitis also predicted the development of new 
ultrasound erosion, with adjustment for patient factors and clinical swelling. These 
findings are developments from existing studies, the limitations of which have been 
discussed (section 2.3.2.1) (Freeston et al., 2010; Salaffi et al., 2010; Filer et al., 
2011; Dougados et al., 2013; Funck-Brentano et al., 2013; Kawashiri et al., 2013; 
Nakagomi et al., 2013; Pratt et al., 2013). 
 
A further aim of this research was to determine the efficacy of methotrexate in 
patients with seronegative versus seropositive IA, due to evidence for a divergence 
in disease mechanisms, and possibly response to treatment, between these 
groups. Efficacy of methotrexate was also compared between patients with UA and 
RA (defined according to 2010 RA criteria) in view of the relative shortage of 
intervention studies in the former disease group. No significant differences in 
response to methotrexate were observed between patients according to serological 
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status or fulfilment of 2010 RA criteria, although the number of patients limited the 
number of potential confounding factors which could be accounted for in the 
analyses. 
 
Analysis of adherence to treatment-to-target guidelines and outcomes in the 
subgroup of patients with early RA highlighted room for improvement in achieving 
the optimal treatment goal, remission. The rate of clinical remission was, however, 
consistent with other observational studies (Bosello et al., 2011; Vermeer et al., 
2011; Vermeer et al., 2013). Power Doppler was demonstrated in a significant 
proportion of patients achieving clinical remission, similar to previous studies 
conducted in patients with established RA (Brown et al., 2006; Balsa et al., 2010; 
Peluso et al., 2011; Saleem et al., 2011; Foltz et al., 2012; Naredo et al., 2013b; 
Geng et al., 2014; Zufferey et al., 2014). This is of potential clinical relevance given 
the prognostic validity of PD synovitis identified in this and other studies (section 
2.3.2.1) (Taylor et al., 2004; Naredo et al., 2007; Naredo et al., 2008a; Pascual-
Ramos et al., 2009; Fukae et al., 2010; Dougados et al., 2013; Funck-Brentano et 
al., 2013). The argument for inclusion of the absence of significant PD synovitis 
within a definition of remission, to be utilised as a treatment target, is also 
strengthened by the association of favourable objective baseline measures of 
disease severity with achievement of imaging remission, in comparison to 
subjective parameters which were predictive of clinical remission.  
 
10.1  Strengths 
The observational, longitudinal study was conducted in a well-defined cohort of 
patients with early IA, defined according to the 2010 ACR/EULAR RA criteria. It is a 
considerable size for a single-centre study. All assessors were trained, supervised 
and working within one clinic with consensus treatment algorithms, limiting undue 
variation in prescribing behaviour. Management and data collection conducted in an 
out-patient clinic setting and the absence of strict inclusion criteria afford a degree 
of generalisability to daily practice. Of note, the prevalence of comorbidities was 
significant. In the subgroup of patients receiving treat to target management, 
greater than one in ten patients had a contraindication to commencement of 
methotrexate or intolerance to it necessitating cessation. In addition, one in five 
patients failed an alternative DMARD to methotrexate due to side-effects.  
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Whilst clinical features predictive of the course of disease have been extensively 
reported in the literature, novel aspects of this research are the inclusion of patients 
managed in the knowledge of the 2010 ACR/EULAR RA classification criteria. In 
addition, the innovative outcome measures (progression to RA according to 2010 
criteria, new ultrasound erosion and imaging remission) are relevant to patients 
treated early and aggressively according to modern-day standards. The use of a 
standardised ultrasound examination of 26 joints also permitted the exploration of 
the predictive validity of ultrasound over and above prevailing clinical features of 
disease, including clinical examination and fulfilment of the 2010 RA criteria.  
 
10.2  Limitations 
The audit sample was a small sample of the target population, patients presenting 
with possible IA to the Leeds EAC. Consecutive sampling was employed as this 
was felt to be the most practical method for data collection in view of the logistical 
difficulties that may arise in obtaining clinical notes for a large number of patients. It 
is feasible that patients presenting within the audit period may not be representative 
of patients presenting throughout the course of a year. However, the shortcomings 
identified in the clinical pathway of patients with new IA here are important findings 
relevant to improving patient management that should be acknowledged. The 
prospective observational cohort study provided a larger sample of patients with 
suspected IA, presenting over the course of a two-year period. 
 
Observational study design was selected as the objective was that the findings 
reflect real-life clinical practice. However, patients judged to have more severe 
disease are more likely to have received aggressive treatment; a key source of 
bias, integral to observational study design. Attempts to minimise this were made 
through adjustment for major prognostic factors. Due to sample size, it was not 
possible to include an unlimited number of variables within multivariable analyses 
and unidentified confounders may also have affected results. Where possible, 
conditional logistic regression (a statistical method of analysis for paired data) was 
employed to explore the predictive validity of ultrasound findings at the joint level, 
controlling for patient-related confounding factors. 
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The intention was for the cohort study to be generalisable to patients with early IA, 
being inclusive of all patients newly-presenting with either UA or RA, i.e. prior to 
provision of any treatment. The proposed inclusion criteria were broad: clinical 
swelling of at least one joint and provision of informed consent. As the study was 
reflective of best clinical practice, only 18 of 441 patients recorded on the study 
screening log declined to participate. It is possible that a small number of eligible 
patients were never recorded on the study screening log, for example if they 
refused consent when initially approached or were otherwise not considered 
suitable (e.g. frailty affecting ability to attend out-patient appointments, planning to 
move out of area).  
 
It may be argued that exclusion of patients lacking any joint swelling (as determined 
by a rheumatologist) may have excluded patients presenting with early palindromic 
disease or those with a very insidious onset of IA. However, such patients who 
developed joint swelling subsequently were later included, with their baseline 
assessments taken at the time of the first documented joint swelling. Furthermore, 
including patients lacking objective signs of synovitis may have introduced difficulty 
in the interpretation of results (for example, potentially preventing the inclusion of 
patients receiving a later diagnosis of fibromyalgia after the exclusion of IA).  
 
No restriction was made to the duration of symptoms in order to achieve a study 
sample reflective of patients presenting in clinical practice. As observed in the 
clinical audit, a number of patients may present late in practice. This should be 
borne in mind when considering treatment outcomes, including comparisons with 
other early IA cohort studies that have restricted patients to those with short 
symptom durations. 
 
Unfortunately, baseline data (particularly ultrasound data) were missing in a 
significant number of patients who were excluded from the analyses. A contributing 
factor appeared to be the requirement to provide patients with 24 hours to consider 
study information before giving their consent; eligible patients were provided with 
this at their first consultation and returned for consent at the next opportunity, at 
which time baseline assessments were recorded in an electronic case report form. 
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A proportion of patients received corticosteroids either before or at the first 
consultation, i.e. prior to consent. This included patients receiving treatment in 
primary care as well as those for whom it was deemed clinically unethical to delay 
such treatment in the out-patient clinic. In this instance, the baseline data recorded 
was that which was obtained on the basis of its clinical relevance, prior to 
treatment, i.e. retrospectively from clinical notes. In many cases this included full 
clinical and ultrasound assessments, perhaps attributable to use of a clinical pro 
forma in the EAC. In some cases this data was incomplete. Comparisons of 
baseline characteristics between included and excluded patients for the relevant 
analyses were conducted in order to establish any major differences between these 
groups. Where relevant, implications for the interpretation of results have been 
discussed within individual chapters (sections 6.5, 7.5, 8.5 and 9.5). 
 
The volume of missing follow-up data highlights the challenges of obtaining 
research data in clinical practice. Missing clinical outcome data has been dealt with 
using a deterministic method, with observations from last assessments carried 
forward. Therefore, final estimates are likely to be less precise than if data was 
more complete. Results are perhaps more likely to be an overestimation of disease 
persistence/severity rather than an underestimate, as patients with more severe 
symptoms are conceivably more likely to attend for follow-up than those who are 
less severely affected. Other methods of imputation of missing data were not 
deemed appropriate due to the volume of data that was missing.  
 
With respect to imaging outcomes, patients who were missing ultrasound follow-up 
were excluded. In these analyses, baseline characteristics of excluded patients 
indicated they might have had more severe disease. Plausible explanations include 
referral to specialist biologic clinics which did not include standardised ultrasound 
follow-up, necessity to attend a different location from clinical visits (although the 
ultrasound department was in reasonably close proximity to the clinic), and 
occasionally the need to re-attend on a different date (although attempt was made 
to minimise this, see section 4.3.2). 
 
Certain outcomes in the study were susceptible to bias, such as initiation of 
methotrexate (relevance to the validity of results is discussed in section 7.5). Other 
outcomes were more objective, such as imaging remission. Ultrasonographers 
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were blinded to clinical assessments and treatment, although it was not possible to 
fully blind examiners to the time of assessment (i.e. whether the examination was at 
baseline or follow-up, due to the real-time nature of ultrasound). Ultrasound was 
performed by one of several assessors. Whilst this provides a realistic and 
pragmatic aspect to the study, as any proposed use for ultrasound in clinical 
practice would need to be considered in this context, the lack of formal evaluation of 
inter-reader reliability is a potential limitation of this study (Wakefield et al., 2003; 
D'Agostino et al., 2005; Joshua et al., 2005; Koski et al., 2006b; Strunk et al., 2006; 
Torp-Pedersen and Terslev, 2008; Ellegaard et al., 2009; Lee et al., 2009). All 
assessors were trained by an experienced EULAR teacher and consultant 
rheumatologist. 
 
With respect to the duration of follow-up, six month outcomes with methotrexate 
treatment and one year remission outcomes in patients with RA treated according 
to treatment-to-target principles are very relevant to patients. Considerations in 
selecting these time-points were the relatively slow onset of action of the majority of 
DMARD therapies, as well as the significance of the early achievement of remission 
in determining a good outcome in the long-term (Table 5, section 2.2).  
 
Modern-day treatment practices entail a tendency towards the early treatment of 
patients who are perceived to be at risk of persistent or aggressive IA (Combe et 
al., 2017). This implies that the outcome disease persistence at one year (defined 
here as the use of DMARDs/concurrent steroids and/or persistence of joint 
swelling) may be an imperfect outcome measure. A proportion of these patients 
may have experienced resolution of disease over time or with initial steroid therapy 
alone. The long-term outcomes for these patients, for example assessment of 
disease persistence at five years will give further insight in the future.  
 
10.3  Future Directions 
Progression of three key aspects of this work is desirable in order to further develop 
and distil the optimal management strategy for patients with early IA, and the role of 
ultrasound within it. Firstly, working to improve the identification of patients ‘at risk’ 
of aggressive/severe disease, with the aim of preventing progression to, or ‘curing’, 
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disease classifiable as RA with early treatment. Secondly, aiming to determine the 
optimal therapeutic regimen in patients with early IA; for example, in patients with 
early UA, not fulfilling 2010 RA criteria, further randomised trials are desirable to 
establish the optimal strategy for treatment. Inclusion of an initial placebo-controlled 
phase in such studies, as well as a long follow-up period, may help to determine 
whether early therapy can alter the disease course in such patients. Furthermore, it 
may prove possible to determine in whom first-line methotrexate is appropriate and 
in whom biologic therapy would be preferable. This is in the context of maximising 
the cost-effectiveness of biologic therapies and the evolving ambition to achieve 
drug-free remission in patients with IA. Thirdly, tools to assess the achievement of 
remission within a treatment-to-target regimen, such as ultrasound, require further 
investigation to establish whether altering treatment accordingly affects the rate of 
early and sustained remission, in addition to longer-term outcomes such as 
prevention of joint damage and drug-free remission. This is the focus of ongoing 
studies (Wakefield et al., 2012; Bruyn et al., 2015). In particular, the location and 
number of joints to be examined, and the ideal definition for imaging remission form 
an important part of the research agenda. For example, what is the added value of 
achieving a complete absence of PD in the context of a treatment-to-target 
management strategy employing DMARDs and the biologic therapies which are 
currently available?   
 
Poor prognostic clinical factors are currently recognised and are of use in clinical 
practice (Tables 2 to 6, section 2.2). The additional predictive value of ultrasound is 
now emerging and is supported by this work (Chapter 7). Nevertheless, ongoing 
research to ascertain more sensitive and specific biomarkers is needed in order to 
predict, with greater reliability, individuals ‘at risk’ of severe disease in whom early 
aggressive treatment, perhaps with biologic therapy, may be justified. With 
advances in methods of genetic analysis, several polymorphisms have been 
identified as being potentially useful in the prediction of response to certain 
therapies, such as methotrexate (Kurzawski et al., 2007; Wessels et al., 2007; 
James et al., 2008), TNF-inhibitors (Plant et al., 2011; Mirkov et al., 2013) or 
tocilizumab (Wang et al., 2013). However, results have not been consistently 
replicated across cohorts (Stamp and Roberts, 2011; Márquez et al., 2014) and the 
value of genetic biomarkers alongside other clinical and imaging prognostic factors 
is yet to be established. The translation of immunological biomarkers in the 
predication of response is another emerging field of interest (Ponchel et al., 2014).  
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There is increasing data suggesting the presence of a window of opportunity when 
significantly greater benefits can be attained with early biologic intervention in 
particular (Quinn, M. A. et al., 2005; Emery, P. et al., 2010; Saleem et al., 2010). 
Hence, applying biologic therapy relatively early, especially in poor prognosis 
patients, is encouraged (Smolen et al., 2017). The ability of TNF-inhibitors to induce 
sustained remission, with biologic-free and even drug-free remission achievable in 
a proportion of patients, portrays an emerging treatment goal. However, the optimal 
application of such expensive therapies in publically-funded healthcare systems 
remains an area of continued research.  
 
Even earlier in the disease spectrum, there is increasing research in the area of 
preclinical IA (Gerlag et al., 2012). It is now known that immunological abnormalities 
may pre-date the onset of clinical synovitis for several years, including development 
of ACPAs (Sokolove et al., 2012) and T cell abnormalities (Cuthbert et al., 2010). In 
ACPA-positive individuals with symptoms of arthralgia, but without joint swelling, 
subclinical synovitis may invariably be present (Krabben et al., 2013b; Nam et al., 
2016). Synovial studies indicate histological change may precede clinical synovitis, 
with changes demonstrated in asymptomatic joints of patients with early RA (Kraan 
et al., 1998), however histological abnormalities have not been observed in synovial 
studies prior to the development of synovitis (with the caveat that these studies 
were conducted in knee joints rather than small joint which are more commonly 
affected in early disease) (van de Sande et al., 2011). The premise that intervention 
in these patients may lead to a ‘cure’ for RA is an intriguing basis for future 
research. 
 
Further research in the use of ultrasound is underway, including further evaluation 
of the EULAR-OMERACT global synovitis score  (D’Agostino et al., 2017). Such a 
score, if validated, may be of use as an objective outcome measure of response in 
future clinical studies. Advanced ultrasound techniques, as yet confined to 
research, may also prove to be of clinical value in the future, including the use of 
contrast (Klauser et al., 2002; Terslev et al., 2005; Klauser et al., 2010; Rednic et 
al., 2011) and 3-dimensional imaging systems (Strunk and Lange, 2004; 
Szkudlarek et al., 2016). 
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10.4  Significance for Clinical Practice 
This work demonstrates that most patients who fulfil the 2010 ACR/EULAR RA 
classification criteria in current clinical practice receive DMARD therapy, with the 
majority receiving methotrexate first-line. Furthermore, a significant proportion of 
patients with UA (not yet fulfilling the criteria) may progress to RA, and over half 
may be judged to require DMARDs. 
 
This research improves our understanding of the clinical and imaging phenotype of 
patients with new-onset UA and RA defined by the 2010 RA criteria. Aspects of the 
phenotype of disease were identified as being predictive of outcome and response 
to treatment. In particular, the prognostic value of ultrasound in the evaluation of 
synovitis was confirmed, supporting its use in clinical practice as a guide for the 
commencement of treatment. In regards to therapeutic options, this research 
provides evidence of the efficacy of methotrexate in clinical practice, including 
efficacy in seronegative patients and patients with UA (not fulfilling 2010 RA criteria) 
in whom there has been limited data to date. Data in patients with early RA 
suggests ultrasound may also be of use in monitoring patients on treatment. The 
significant rate of subclinical synovitis in clinical remission and the disparity 
between the predictors of clinical and imaging remission which were identified 
suggests ultrasound may be of value in guiding the escalation of therapy within a 
treatment-to-target strategy in these patients. 
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List of Abbreviations 
ACPA Anti-cyclic Citrullinated Peptide Antibody 
ACR American College of Rheumatology 
ANA Anti-Nuclear Antibody 
AUC Area Under the receiver operating characteristic Curve 
BMI Body Mass Index 
CDAI Clinical Disease Activity Index 
CI Confidence Interval 
CMC Carpometacarpal joint 
CRP C-Reactive Protein 
CT Computed Tomography 
DAS28-CRP  Disease Activity Score using 4 variables (SJC28, TJC28, CRP 
and patient VASDA) 
DAS28-CRP3v Disease activity score using 3 variables (SJC28, TJC28 and CRP) 
DAS44-CRP Disease activity score using 4 variables (SJC44, RAI, CRP and 
patient VASDA) 
DAS44-CRP3v Disease activity score using 3 variables (SJC44, RAI and CRP) 
DIP Distal Inter-Phalangeal joint 
DMARD Disease-Modifying Anti-Rheumatic Drug 
EAC Early Arthritis Clinic 
EMS Early Morning Stiffness 
ESR Erythrocyte Sedimentation Rate 
EULAR European League Against Rheumatism 
GS Grey Scale synovitis 
GP General Practitioner 
HAQ Health Assessment Questionnaire 
HCQ Hydroxychloroquine 
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HR Hazard Ratio 
IA Inflammatory Arthritis/Intra-Articular 
IM Intra-Muscular 
IQR  Interquartile Range 
MCP Metacarpophalangeal joint 
MRI Magnetic Resonance Imaging 
MTP Metatarsophalangeal joint 
MTX Methotrexate 
NA Not Applicable 
NICE The National Institute for Health and Care Excellence 
NS Not Significant 
NSAID Non-Steroidal Anti-Inflammatory Drug 
OR Odds Ratio 
PABAK Prevalence And Bias Adjusted Kappa 
PD Power Doppler activity 
PIP Proximal Inter-Phalangeal joint 
RA Rheumatoid Arthritis 
RAI Ritchie Articular Index 
RCT Randomised Controlled Trial 
RF Rheumatoid Factor 
ROC Receiver Operating Characteristic curve 
ROM Range Of Movement 
SD Standard Deviation 
SDAI Simplified Disease Activity Index 
SEM Standard Error of the Mean 
SHS Sharp/van der Heijde Score (total score unless otherwise 
specified) 
SJC Swollen Joint Count 
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SpA Spondyloarthropathy 
SSZ Sulfasalazine 
TJC Tender Joint Count 
TNF Tumour Necrosis Factor 
UA Undifferentiated Arthritis 
US Ultrasound 
VAS Visual Analogue Scale 
VASDA Visual Analogue Scale of global Disease Activity 
 
 
